US 20090191159A1

(19) **United States**

(12) **Patent Application Publication**

Sakurada et al.

(10) **Pub. No.: US 2009/0191159 A1**

(43) **Pub. Date: Jul. 30, 2009**

(54) **MULTIPOTENT/PLURIPOTENT CELLS AND METHODS**

(76) Inventors: **Kazuhiro Sakurada**, Yokohama (JP); **Hideki Masaki**, Akita (JP); **Tetsuya Ishikawa**, Chuo-Ku (JP); **Shunichi Takahashi**, Kobe (JP)

Correspondence Address:
WILSON SONSINI GOODRICH & ROSATI
650 PAGE MILL ROAD
PALO ALTO, CA 94304-1050 (US)

(21) Appl. No.: **12/157,967**

(22) Filed: **Jun. 13, 2008**

Related U.S. Application Data

(60) Provisional application No. 61/040,646, filed on Mar. 28, 2008.

(30) **Foreign Application Priority Data**

Jun. 15, 2007 (JP) 2007-159382
Nov. 20, 2007 (EP) PCT/EP2007/010019

Publication Classification

(51) **Int. Cl.**

A61K 45/00	(2006.01)
C12N 5/08	(2006.01)
C12Q 1/68	(2006.01)
G01N 33/53	(2006.01)
A61P 25/28	(2006.01)
A61P 3/10	(2006.01)

(52) **U.S. Cl.** **424/93.7**; 435/372; 435/377; 435/6; 435/7.1

(57) **ABSTRACT**

Described herein are multipotent stem cells, e.g., human and other mammalian pluripotent stem cells, and related methods.

Fig. 1


100
Collection of Cells
(from a donor or third party)
140
Storage
110
Induction
(e.g., by forced expression of Oct3/4, Sox2, Klf4, & c-Myc)
120
Identification
of Induced Multipotent or Pluripotent Stem Cells
130
Isolation
of Induced Multipotent or Pluripotent Stem Cells
140
Storage
150
Therapeutics/
Other Uses

Fig. 2


Human adult bone marrow-derived cell
human Nanog
human TERT
Amount of gene expressed (Relative value)
2.5
2.0
1.5
1.0
0.5
0.0
Mesenchymal stem cell
Non-colony forming cell
ALP positive colony forming cell
Non-introduction group
4 gene introduction group

Fig. 3


Neonatal skin fibroblasts
human Nanog
human TERT
Amount of gene expressed (Relative value)
1.2
1.0
0.8
0.6
0.4
0.2
0.0
Mesenchymal stem cell
Neonatal skin fibroblast
Non-colony forming cell
ALP positive colony forming cell
Non-introduction group
4 gene introduction group

Fig. 4

Amount of Nanog expressed after 3 gene introduction and HDAC inhibitor treatment in mouse adult bone marrow derived cells



Fig. 5

Morphology and expansion culture of human iPS clone 1-8



Fig. 6

Surface antigen and gene expression analysis of clone 1-8



Fig. 7

Gene expression analysis by RT-PCR in clone 1-8



Fig. 8

Global gene expression analysis – scatter plot



Fig. 9

Global gene expression analysis – gene tree (1)



Fig. 10

Global gene expression analysis – gene tree (2)



Fig. 11

Methylation analysis of promoter regions in human IPS 1-8



Fig. 12

Teratoma formation (1)



(T1, 56 d.p.i)

Fig. 13

Teratoma formation (2)



Fig. 14

Teratoma formation (3)



Fig. 15

Southern blot analysis



Fig. 16

hES marker gene expression in ALP positive colonies



c

	n	number of expressed hES cell maker genes									experimental conditions	
		0	1	2	3	4	5	6	7	8	donor	infected cells (cells in 20cm^2)
Exp. #1	42	1	0	2	2	5	12	11	7	0	5F0416	$2x10^4$
Exp. #2	49	1	0	2	2	7	12	13	9	3	5F0416	$2x10^5$
Exp. #3	32	0	1	2	7	9	8	5	1	0	5F0474	$2x10^4$
Exp. #4	40	0	1	5	4	7	11	10	2	1	5F0474	$2x10^5$
Total	163	2	2	11	15	28	43	39	19	4		

d



Fig. 17

Morphologies of analyzed ALP positive colonies (1)



Fig. 18

Morphologies of analyzed ALP positive colonies (2)



Fig. 19

Morphologies of analyzed ALP positive colonies (3)



Fig. 20

Morphologies of analyzed ALP positive colonies (4)



Fig. 21

Morphologies of analyzed ALP positive colonies (5)



Fig. 22

Morphologies of analyzed ALP positive colonies (6)



Fig. 23

Morphologies of analyzed ALP negative colonies



Fig. 24

Human Oct 3/4 Predicted Mutation Tolerance Map



Fig. 25

Human Sox2 Predicted Mutation Tolerance Map



Fig. 26

Human Klf4 Predicted Mutation Tolerance Map



Fig. 27

Human c-Myc Predicted Mutation Tolerance Map



Fig. 28

Analysis of ALP Positive Colonies
Mouse Embryonic Fibroblasts



Fig. 29

Analysis of ALP Positive Colonies
Adult Neural Stem Cells



Fig. 30

Analysis of ALP Positive Colonies
Bone Marrow Derived Cells



Day 9 Day 15 →

Figure 30

Fig. 31

Analysis of ALP Positive Colonies
Bone Marrow Derived Cells



MULTIPOTENT/PLURIPOTENT CELLS AND METHODS

CROSS-REFERENCE

[0001] This application claims the benefit of Japanese Patent Application, JPO 2007-159382, filed Jun. 15, 2007, PCT/EP2007/010019, filed Nov. 20, 2007, and U.S. Provisional Application 61/040,646, filed Mar. 28, 2008, the contents of all three of which are incorporated by reference herein in their entirety.

BACKGROUND OF THE INVENTION

[0002] The field of regenerative medicine encompasses therapies designed to aid the repair, replacement, or regeneration of damaged cells, tissues, or organs. One branch of regenerative medicine includes cell therapies that rely on embryonic stem cells (ES), which have the potential to give rise to a diverse range of cell types. ES-based cell therapies have the promise of treating a variety of health conditions including Alzheimer's Disease, Parkinson's Disease, stroke, spinal injuries, heart attack, renal failure, osteoporosis, type I diabetes, multiple sclerosis, rheumatoid arthritis, burns, and wounds. However, the progress of such therapies has been hindered by a range of factors including the possibility of immune rejection of ES cells derived from a donor who is immunologically incompatible with the recipient.

SUMMARY OF THE INVENTION

[0003] This disclosure encompasses human stem cells that in some cases are pluripotent and in some cases are multipotent. The disclosure further encompasses methods for generating such human stem cells, methods for using such stem cells, and related compositions.

[0004] Accordingly, in one aspect provided herein are human stem cells that are pluripotent, somatic, non-embryonic, and have the property of long-term self renewal. In some embodiments, such human stem cells comprise exogenous genes including a first exogenous gene encoding an Oct3/4 polypeptide, a second exogenous gene encoding a Sox2 polypeptide, and a third exogenous gene encoding a Klf4 polypeptide. In one embodiment, the human stem cells comprising exogenous genes comprise three and only three exogenous genes, where a first exogenous gene encodes an Oct3/4 polypeptide, a second exogenous gene encodes a Sox2 polypeptide, and a third exogenous gene encodes a Klf4 polypeptide. In a further embodiment, the exogenous genes consist essentially of the just-mentioned first, second, and third exogenous genes. In another embodiment, the exogenous genes comprise a first exogenous gene encoding an Oct3/4 polypeptide, a second exogenous gene encoding a Sox2 polypeptide, a third exogenous gene encoding a Klf4 polypeptide, and a fourth exogenous gene encoding the amino acid sequence of the mouse-derived cationic amino acid transporter (mCAT) (e.g. mCAT1). In another embodiment, the human stem cells comprising exogenous genes comprise four and only four exogenous genes, where a first exogenous gene encodes an Oct3/4 polypeptide, a second exogenous gene encodes a Sox2 polypeptide, a third exogenous gene encodes a Klf4 polypeptide, and a fourth exogenous gene encodes a c-Myc polypeptide. In a further embodiment, the exogenous genes consist essentially of the just-mentioned first, second, third, and fourth exogenous genes. In some embodiments, the exogenous genes do not include a gene encoding a c-Myc polypeptide. In further embodiments, the human stem cell comprising the exogenous genes, does not comprise an exogenous c-Myc polypeptide. In other embodiments, the exogenous genes include a gene encoding a c-Myc polypeptide. In one embodiment, where the exogenous genes include a gene encoding the c-Myc polypeptide, the exogenous genes include a fifth exogenous gene encoding the amino acid sequence of the mouse-derived cationic amino acid transporter (mCAT). In some embodiments, the exogenous genes do not include a gene encoding a TERT polypeptide. In some embodiments, the exogenous genes do not include a gene encoding an HPV16 E6 polypeptide or an HPV16E7 polypeptide. In further embodiments, the exogenous genes do not include a gene encoding any of a TERT polypeptide, an SV40 Large T antigen polypeptide, an HPV16 E6 polypeptide, or a Bmi 1 polypeptide. In yet other embodiments, the human stem cells comprising the exogenous genes do not comprise an exogenous gene capable of inducing cancer. In yet other embodiments, the human stem cells comprise exogenous genes encoding three or more of the following: an Oct3/4 polypeptide, a Sox2 polypeptide, a Klf4 polypeptide, and a c-Myc polypeptide.

[0005] In another aspect provided herein are stem cells that are somatic, non-embryonic, positive for alkaline phosphatase, and express two or more of the genes TDGF 1, Dnmt3b, FoxD3, GDF3, Cyp26a1, TERT, zfp42, Sox2, Oct3/4, and Nanog. In some embodiments, such stem cells are pluripotent.

[0006] In a related aspect provided herein are human stem cells that, compared to human embryonic stem cells have a higher level of gene expression in 1 to 1000 genes (e.g., in 1 to 700 genes, 1 to 500 genes, 1 to 300 genes, 1 to 200 genes, 1 to 100 genes, 1 to 50 genes, 3 to 20 genes, 5 to 20 genes, 5 to 50 genes, 10 to 50 genes, 20 to 50 genes, 30 to 100 genes, or 50 to 100 genes). In some embodiments, such human stems cells are alkaline phosphatase positive, and express two or more (e.g., 3, 4, 5, 6, 7, 8, 9, or 10) genes selected from TDGF1, Dnmt3b, FoxD3, GDF3, Cyp26a1, Tert, zfp42, Sox2, Oct3/4, and Nanog.

[0007] In another aspect provided herein are human stem cells that compared to human embryonic stem cells have a higher level of gene expression in two or more (e.g., 3 or more, 4 or more, 5 or more, 10 or more, 15 or more, 25 or more, 50 or more, 75 or more, 100 or more, or 200 or more) of the genes listed in Tables 13, 15, or 16 provided herein. In some embodiments, such human stems cells are alkaline phosphatase positive, and express two or more (e.g., 3, 4, 5, 6, 7, 8, 9, or 10) genes selected from TDGF1, Dnmt3b, FoxD3, GDF3, Cyp26a1, Tert, zfp42, Sox2, Oct3/4, and Nanog.

[0008] In a further aspect provided herein are human stem cells that compared to human embryonic stem cells have a lower level of gene expression in two or more (e.g., 3 or more, 4 or more, 5 or more, 10 or more, 15 or more, 25 or more, 50 or more, 75 or more, 100 or more, or 200 or more) of the genes listed in Table 14 provided herein. In some embodiments, such human stems cells are alkaline phosphatase positive, and express two or more genes (e.g., 3, 4, 5, 6, 7, 8, 9, or 10) selected from TDGF1, Dnmt3b, FoxD3, GDF3, Cyp26a1, Tert, zfp42, Sox2, Oct3/4, and Nanog.

[0009] In another aspect provided herein are human stem cells that compared to human embryonic stem cells have a lower level of gene expression in 1 to 1000 genes (e.g., in 1 to 300 genes, or 1 to 50 genes). In some embodiments, such human stems cells are alkaline phosphatase positive, and

express two or more genes (e.g., 3, 4, 5, 6, 7, 8, 9, or 10) selected from TDGF1, Dnmt3b, FoxD3, GDF3, Cyp26a1, Tert, zfp42, Sox2, Oct3/4, and Nanog.

[0010] In a further aspect provided herein are human stem cells in which the expression levels of 1 to 100 genes is closer to the expression levels in human fibroblasts than in human embryonic stem cells. In some embodiments, such human stems cells are alkaline phosphatase positive, and express two or more genes (e.g., 3, 4, 5, 6, 7, 8, 9, or 10) selected from TDGF1, Dnmt3b, FoxD3, GDF3, Cyp26a1, Tert, zfp42, Sox2, Oct3/4, and Nanog.

[0011] In yet another aspect provided herein is a method for generating an autologous stem cell by forcing expression of an Oct3/4 polypeptide, a Sox2 polypeptide, and a Klf4 polypeptide in a cultured population of non-embryonic postnatal cells from the human subject. In some embodiments, the autologous stem cells generated by this method are capable of forming a teratoma. In one embodiment, the autologous stem cells so generated are pluripotent.

[0012] In a further aspect provided herein are human stem cells generated by a method comprising forcing the expression of an Oct3/4 polypeptide, a Sox2 polypeptide, and a Klf4 polypeptide in human postnatal cells to obtain one or more colonies of cells that have a high nucleus to cytoplasm ratio and are smaller in size than cells surrounding the one or more colonies, and isolating at least one of the one or more colonies. In some embodiments, the human stem cells generated by the just-mentioned method are pluripotent human stem cells. In some embodiments, forced expression of the Oct3/4, Sox2, and Klf4 polypeptides is achieved by introducing into the human postnatal cells one or more expression vectors, e.g., retroviral expression vectors, lentiviral expression vectors, adeno-associated viral expression vectors, adenoviral expression vectors, recombinant retroviruses, or nucleic acid expression vectors such as plasmid expression vectors. In one embodiment, the above-mentioned method does not include forcing expression of a c-Myc polypeptide in the human postnatal cells. In another embodiment, the method does not include forcing expression of an exogenous gene encoding a c-Myc polypeptide in the human postnatal cells. In a further embodiment, the method further includes forcing expression of a c-Myc polypeptide in the human postnatal cells. In some embodiments, where the method further includes forcing expression of the c-Myc polypeptide, the method comprises forcing expression of four and only four exogenous genes encoding induction factors, where the exogenous genes encode an Oct3/4 polypeptide, a Sox2 polypeptide, a Klf4 polypeptide, and a c-Myc polypeptide. In one embodiment, the method comprises forcing expression of four exogenous genes encoding induction factors, where the four exogenous genes encode an Oct3/4 polypeptide, a Sox2 polypeptide, a Klf4 polypeptide, and a c-Myc polypeptide. In yet another embodiment, the method includes forcing the expression of a set of polypeptides consisting essentially of an Oct3/4 polypeptide, a Sox2 polypeptide, a Klf4 polypeptide, and a c-Myc polypeptide. In another embodiment, the method includes forcing the expression of three and only three exogenous genes encoding induction factors, where the exogenous genes encode an Oct3/4 polypeptide, a Sox2 polypeptide, and a Klf4 polypeptide. In another embodiment, the method includes forcing the expression of a set of polypeptides consisting essentially of an Oct3/4 polypeptide, a Sox2 polypeptide, and a Klf4 polypeptide. In yet another embodiment, the above-mentioned method for generating the human stem cells also includes contacting the human postnatal cells with a histone deacetylase inhibitor. In other embodiments, the above-mentioned method comprises forcing expression of the Oct3/4, Sox2, and Klf4 polypeptides by introducing into the human postnatal cells: (i) a first purified polypeptide comprising the amino acid sequence of the Oct3/4 polypeptide; (ii) a second purified polypeptide comprising the amino acid sequence of the Sox2 polypeptide; and (iii) a third purified polypeptide comprising the amino acid sequence of the Klf4 polypeptide. In some embodiments, at least one of the first, second, and third purified polypeptides, further comprises a protein transduction domain.

[0013] In some embodiments, the human stem cells disclosed herein have one or more of the following properties: pluripotency; multipotency; capability to form a teratoma; a normal diploid karyotype; progeny that can be passaged at least about 30 times to at least about 100 times; shorter telomeres than human embryonic stem cells; ability to proliferate with an undifferentiated phenotype under atmospheric oxygen conditions (e.g. greater than 5% oxygen to about 21% oxygen); proliferation in colonies; induction from human somatic or postnatal that had been passaged four or fewer times after preparation from a biological sample; induction from fetal human somatic cells; induction from adult human somatic cells; induction from a population of cells comprising any of: adult human skin fibroblasts, adult peripheral blood mononuclear cells, adult human bone marrow-derived mononuclear cells, neonatal human skin fibroblasts, human umbilical vein endothelial cells, human umbilical artery smooth muscle cells, human postnatal skeletal muscle cells, human postnatal adipose cells, human postnatal peripheral blood mononuclear cells, or human cord blood mononuclear cells; induction from the foregoing population of cells, where the population was prepared from a composition of cells that had been stored frozen and was then thawed before the preparation.

[0014] A number of aspects provided herein relate to any of the above-described human stem cells. Such aspects include: a purified population of the human stem cells; cells differentiated from the human stem cells (e.g., purified populations of differentiated cells). Such differentiated stem cells include, but are not limited to, pancreatic beta cells, neural stem cells, cortical neurons, dopaminergic neurons, oligodendrocytes or oligodendrocyte progenitor cells, hepatocytes or hepatocyte stem cells, or cardiac muscle cells. Other related aspects include methods: a method for storing the human stem cells by suspending them in a cryopreservation medium and freezing the resulting suspension; a method for generating differentiated cells (including any of the foregoing differentiated cells) by differentiating the human stem cells; a method for introducing differentiated cells (e.g., differentiated cells substantially free of other cell types) into a human subject, where the differentiated cells share the same genome as the subject or are immunocompatible with the subject. Further related aspects include: a composition comprising the human stem cells and a cryopreservation medium; a composition comprising the human stem cells and a medium comprising a purified growth factor (e.g., at a concentration of about 4 ng/ml to about 100 ng/ml). In various embodiments, such growth factors may include one or more of bFGF, FGF-2, PDGF, EGF, IGF, insulin, TGFb-1, activin A, Noggin, BDNF, NGF, NT-1, NT-2, or NT-3, IGF, IGFI, IGFII, or a member of the FGF family of growth factors.

[0015] In yet another aspect provided herein is a composition comprising at least one of the following components:

[0016] i. a purified polypeptide comprising the amino acid sequence of a protein transduction domain and an Oct3/4 polypeptide;

[0017] ii. a carrier reagent and a purified Oct3/4 polypeptide;

[0018] iii. a purified polypeptide comprising the amino acid sequence of a protein transduction and a Sox2 polypeptide;

[0019] iv. a carrier reagent and a purified Sox2 polypeptide;

[0020] v. a purified polypeptide comprising the amino acid sequence of a protein transduction domain and a Klf4 polypeptide;

[0021] vi. a carrier reagent and a purified Klf4 polypeptide;

[0022] vii. a purified polypeptide comprising the amino acid sequence of a protein transduction domain and a c-Myc polypeptide;

[0023] viii. a carrier reagent and a purified c-Myc; or

any combination of (i) to (viii).

[0024] In some embodiments, the above-mentioned composition contains at least two, three, or four of components (i) to (viii). In a further aspect provided herein is a method for generating human stem cells by forcing expression of polypeptides in human postnatal cells, wherein the polypeptides comprise an Oct3/4 polypeptide, a Sox2 polypeptide, and a Klf4 polypeptide. In some embodiments, the human postnatal cells used in the method were passaged four or fewer times after preparation from a biological sample. In some embodiments, the human postnatal cells were prepared from a composition comprising human postnatal cells that had been stored frozen and were then thawed. In one embodiment, the human postnatal cells are from an adult. In some embodiments, the human postnatal cells to be used in the method comprise adult human bone marrow-derived mononuclear cells, neonatal human skin fibroblasts, umbilical vein endothelial cells, umbilical artery smooth muscle cells, postnatal skeletal muscle cells, postnatal adipose cells, postnatal peripheral blood mononuclear cells, cord blood mononuclear cells, or placental cells. In some embodiments, the human postnatal cells used in this method have been passaged four or fewer times after preparation from a biological sample. In some embodiments, the postnatal human cells are cultured at a density of about 10^3 cells/cm^2 to about 10^4 cells/cm^2 prior to the forced expression. In some embodiments, the human postnatal cells are cultured in the presence of a serum concentration of 5% or less (e.g., 2% or less). In some embodiments, the human postnatal cells are cultured in the presence of one or more of bFGF, FGF-2, PDGF, EGF, IGF, insulin, TGFb-1, activin A, Noggin, BDNF, NGF, NT-1, NT-2, NT-3, or an FGF-growth factor family member prior to the forced expression.

[0025] In some embodiments, forcing expression of the Oct3/4, Sox2, and Klf4 polypeptides is carried out by introducing into the human postnatal cells one or more expression vectors encoding the Oct3/4, Sox2, and Klf4 polypeptides. Such vectors include, e.g., recombinant retroviruses, lentiviruses, or adenoviruses; retroviral expression vectors, lentiviral expression vectors, nucleic acid expression vectors, or plasmid expression vectors. In other embodiments, where recombinant retroviruses are used for forced expression, the method includes introducing into the population of cultured human cells an expression vector for expression of a mouse-derived cationic amino acid transporter (mCAT) polypeptide prior to introducing the one or more retroviral vectors encoding the Oct 3/4, Sox2, and Klf4 polypeptides.

[0026] In some embodiments, this method does not include forcing the expression of a c-Myc polypeptide. In other embodiments, the method includes forcing expression of a c-Myc polypeptide. In one embodiment, the method does not include forcing expression of a TERT polypeptide.

[0027] In some embodiments, this method also includes contacting the postnatal human cells with a histone deacetylase inhibitor.

[0028] In some embodiments, forcing expression of the Oct3/4, Sox2, and Klf4 polypeptides, comprises introducing into the human postnatal cells one or more expression vectors In some embodiments, the above method for generating human stem cells also includes isolating, after the forced expression, one or more colonies of cells smaller in size than surrounding cells, and identifying at least one of the one or more colonies that expresses alkaline phosphatase, nanog, TDGF1, Dnmt3b, FoxD3, GDF3, CYP26A1, TERT, and zfp4.

[0029] In some embodiments, the method comprises forcing expression of the Oct ¾, Sox2, and Klf4 polypeptides, by introducing into a culture of the human postnatal cells: (i) a first purified polypeptide comprising the amino acid sequence of the Oct3/4 polypeptide; (ii) a second purified polypeptide comprising the amino acid sequence of the Sox2 polypeptide, and (iii) a third purified polypeptide comprising the amino acid sequence of the Klf4 polypeptide. In one embodiment, at least one of the just-mentioned polypeptides further comprises a protein transduction domain.

[0030] In other embodiments, forcing expression of the Oct 3/4, Sox2, and Klf4 polypeptides in the human postnatal cells is done by contacting them with at least one of:

[0031] i. a purified polypeptide comprising the amino acid sequence of a protein transduction domain and an Oct3/4 polypeptide;

[0032] ii. a carrier reagent and a purified Oct3/4 polypeptide;

[0033] iii. a purified polypeptide comprising the amino acid sequence of a protein transduction and a Sox2 polypeptide;

[0034] iv. a carrier reagent and a purified Sox2 polypeptide;

[0035] v. a purified polypeptide comprising the amino acid sequence of a protein transduction domain and a Klf4 polypeptide;

[0036] vi. a carrier reagent and a purified Klf4 polypeptide;

[0037] vii. a purified polypeptide comprising the amino acid sequence of a protein transduction domain and a c-Myc polypeptide; or

any combination of (i) to (vii).

[0038] In some embodiments, the human stem cells generated by this method are capable of forming a teratoma. In some embodiments, the human stem cells generated by this method are pluripotency, and thus capable of generating ectoderm, mesoderm, and endoderm.

[0039] In another aspect provided herein is a method for identifying an agent that stimulates pluripotency or multipotency in human somatic cells (e.g., postnatal human somatic cells) comprising:

[0040] (i) providing first and second cultured human somatic cells;

[0041] (ii) contacting the first cultured human somatic cell with a test agent;

[0042] (iii) contacting the second cultured human somatic cell with a negative control agent;

[0043] (iv) determining expression levels of an embryonic stem cell marker gene in the contacted first and second cultured cells; and

[0044] (v) comparing the expression levels determined in step (iii) and indicating that the test agent stimulates pluripotency or multipotency if the embryonic stem cell marker gene expression level in the contacted first cultured cell is greater than that determined in the contacted second cultured cell, and indicating that the test agent fails to stimulate multipotency or pluripotency if the expression level of the embryonic stem cell marker gene in the contacted first cultured cell is the same or less than that determined in the contacted second cultured cell, wherein determining the expression levels of the embryonic stem cell marker gene comprises determining the expression levels of Tert or Cyp26A1.

[0045] comparing the expression levels determined in step (iii) and indicating that the test agent stimulates pluripotency or multipotency if the embryonic stem cell marker gene expression level in the contacted first cultured cell is greater than that determined in the contacted second cultured cell, and indicating that the test agent fails to stimulate multipotency or pluripotency if the expression level of the embryonic stem cell marker gene in the contacted first cultured cell is the same or less than that determined in the contacted second cultured cell, wherein embryonic stem cell marker gene comprises Tert or Cyp26A1.

[0046] In a further aspect provided herein is a method for performing cell transplantation in a subject in need thereof, comprising:

[0047] (i) identifying a donor that is immunocompatible with the subject;

[0048] (ii) generating an induced pluripotent stem cell line from postnatal cells of the donor; and

[0049] (iii) transplanting one or more cells differentiated from the induced pluripotent stem cell line into the subject. In some embodiments, the donor is identified as immunocompatible if the HLA genotype matches the HLA genotype of the recipient. In one embodiment, the immunocompatible donor is identified by genotyping a blood sample from the immunocompatible donor. In some embodiments, the induced pluripotent stem cell line is induced from a mononuclear blood cell.

[0050] In some embodiments of the human stem cells, compositions, and methods described herein, an Oct3/4 polypeptide comprises an amino acid sequence at least 70% identical (e.g., 75%, 80%, 85%, 90%, 95%, or 100%) identical to SEQ ID NO:7, the Sox2 polypeptide comprises an amino acid sequence least 70% identical (e.g., 75%, 80%, 85%, 90%, 95%, or 100%) to SEQ ID NO:9, the Klf4 polypeptide comprises an amino acid at least 70% (e.g., 75%, 80%, 85%, 90%, 95%, or 100%) identical to SEQ ID NO:11, or a c-Myc polypeptide at least 70% (e.g., 75%, 80%, 85%, 90%, 95%, or 100%) identical to SEQ ID NO: 13. In other embodiments, an Oct3/4 polypeptide comprises an amino acid sequence at least 70% identical (e.g., 75%, 80%, 85%, 90%, 95%, or 100%) identical to SEQ ID NO:6, the Sox2 polypeptide comprises an amino acid sequence least 70% identical (e.g., 75%, 80%, 85%, 90%, 95%, or 100%) to SEQ ID NO:8, the Klf4 polypeptide comprises an amino acid at least 70% (e.g., 75%, 80%, 85%, 90%, 95%, or 100%) identical to SEQ ID NO: 10, or a c-Myc polypeptide at least 70% (e.g., 75%, 80%, 85%, 90%, 95%, or 100%) identical to SEQ ID NO:12. In some embodiments, the Oct3/4 polypeptide comprises the amino acid sequence of human Oct3/4 or mouse Oct3/4 polypeptide, the Sox2 polypeptide comprises the amino acid sequence of human Sox2 or mouse Sox2; and the Klf4 polypeptide comprises the amino acid sequence of human Klf4 or mouse Klf4. In some embodiments, the Oct3/4 polypeptide is an Oct family member other than Oct3/4, the Sox2 polypeptide is a Sox family member other than Sox2, the Klf4 polypeptide is a Klf family member other than Klf4, and the c-Myc polypeptide is a c-Myc family member other than c-Myc. In some embodiments, the c-Myc polypeptide has inducible activity. In one embodiment, the c-Myc polypeptide is a c-Myc-estrogen receptor (c-Myc-ER) fusion polypeptide.

INCORPORATION BY REFERENCE

[0051] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.

BRIEF DESCRIPTION OF THE DRAWINGS

[0052] The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:

[0053] FIG. **1** is an overview of an approach to the induction process and uses of cells.

[0054] FIG. **2** shows the relative expression of Nanog and Tert genes in human adult bone-marrow derived cells following introduction of four genes. Oct3/4, Sox2, Klf4 and c-Myc were introduced into cells established from mononuclear cells derived from human adult bone marrow under low serum conditions. RNA was extracted from the colonies obtained, and the expression of human Nanog and human Tert genes was demonstrated by quantitative PCR. Fibroblasts and mesenchymal stem cells in which the four genes were not introduced were used as controls in the experiment. The amount of gene expression is provided as a relative value in which the amount of expression was normalized by the amount of expression of the human hypoxanthine phosphoribosyltransferase (HPRT) gene, and by setting as one the amount of HPRT gene expression in Alkaline Phosphatase (ALP)-positive colonies induced from a neonatal skin fibroblast. It was confirmed that the expression of Nanog and Tert was significantly higher in colonies in which four genes (Oct3/4, Sox2, Klf4 and c-Myc) were introduced and which were positive for ALP.

[0055] FIG. **3** shows the relative expression of Nanog and Tert genes in neonatal fibroblasts following introduction of four genes. Oct3/4, Sox2, Klf4 and c-Myc, were introduced into primary culture fibroblasts derived from neonatal skin; RNA was extracted from the colonies obtained; and the amount expressed of the human Nanog and human Tert genes was determined by quantitative PCR. Parental fibroblasts and mesenchymal stem cells in which four genes were not intro-

duced were used as controls in the experiment. Gene expression was normalized using the same procedure outlined in FIG. **2**. It was confirmed that the expression of Nanog and Tert was significantly high in colonies in which four genes were introduced and which were positive for ALP.

[0056] FIG. **4** shows the relative expression of Nanog and Tert genes in mouse adult bone-marrow-derived cells following introduction of three genes and treatment with histone deacetylase (HDAC) inhibitor. Three genes (Oct3/4, Sox2, and Klf4) were introduced into mouse bone marrow-derived cells established under low serum conditions. The cells were also treated with MS-275 (0.1 or 1.0 μM), an HDAC inhibitor. RNA was extracted from the colonies obtained, and the amount of Nanog expression was determined by quantitative PCR. From the cells in which three genes were introduced and which were treated with a histone deacetylase inhibitor, ALP-positive cell group (colonies) were formed, and it was confirmed that the expression of Nanog in these colonies was significantly higher than the ALP-negative colonies. In the figure, W1, W2, W3, W4, W5 and W6 represent the designation of each well of the 6-well plate used in Example 12.

[0057] FIG. **5** shows the characterization of human iPS clone 1-8. The morphology of its parental fibroblast (lot. 5F0438) is shown in Panel a; the morphology human iPS clone 1-8 cells cultured on murine embryonic fibroblast (MEF) feeder cells is shown in Panel b; the morphology of human iPS clone 1-8 cells in mTeSR1 medium is shown in Panel c; clone 2-4 cells in mTeSR1 medium are shown in Panel d; and clone 3-2 cells in mTeSR1 medium are shown in Panel e. The growth curve of clone 1-8 is shown in Panels f and g. Arrows indicate the dates of examinations. The square indicates the period for counting cell numbers to estimate cell proliferation rate. Panel h is a multicolor karyogram image indicating a normal karyotype of iPS clone 1-8 derived cell at day 101.

[0058] FIG. **6** shows the characterization of transcription factors, cell surface antigens and ALP activity in human iPS clone 1-8. Human iPS cells (clone 1-8) were stained for Nanog (Panel a), SSEA-3 (Panel b), SSEA4 (Panel c), TRA-1-60 (Panel d), TRA-1-81 (Panel e), CD9 (Panel f), CD24 (Panel g), Thy-1 (also called CD90) (Panel h). Green fluorescent staining indicates that human iPS clone 1-8 expresses all of these surface antigens. ALP staining indicates that iPS clone 1-8 is ALP positive. Arrows illustrate regions of green fluorescent staining.

[0059] FIG. **7** shows the RT-PCR analysis of gene expression of human iPS clone 1-8 cells. Panel a depicts a RT-PCR analysis of hES marker gene expression in clone 1-8 and its parental fibroblast (NeoFB). Genes were detected at 30 cycles except for CYP26A1 (35 cycles). Panel b depicts the silencing of four transgenes in clone 1-8. Crude fibroblasts obtained 17 days after gene transduction were used as control. "Exo" primer sets selectively detected the expression of the exogenous genes; and "total" primer sets detected both endogenous and exogenous gene expression.

[0060] FIG. **8** shows a scatter plot analysis of the global gene expression of human iPS clone 1-8 cells. The scatter plots show a comparison of global gene expression between human iPS clone-1-8 cells cultured in mTeSR1 and H14 hES cells with MEFs (GSM151741 from public database GEO) (Panel a), or between clones 1-8 and their parental fibroblasts (Panel b). Symbols of ES cell specific genes were pointed with lines in both scatter plots. Expression intensity was shown in colorimetric order from red (high) to green (low). Arrows indicate representative regions of color.

[0061] FIG. **9** shows global gene expression of different cell lines and gene trees based on global gene expression analysis. Cells were clustered in the gene tree based on a set of genes identified by the International Stem Cell Initiative (see Table 21). Samples were designated "1-8 mTeSR" for clone-1-8 cultured in mTeSR; "1-8CM" for clone 1-8 cultured in MEF-conditioned medium; "I-8 mTeSR(f&t)" for clone 1-8 cultured in mTeSR after freeze-thaw treatment; "1-8MEF" for clone 1-8 cultured on MEF; "24 mTeSr" for clone 24 cultured in mTeSR medium; "24MEF" for clone 24 cultured on MEF; "3-2 mTeSR" for clone 3-2 cultured in mTeSR medium; "5F0438" or "5F0416" for the parental fibroblasts; "hES1," "hES2," "hES3" (GSM194307, GSM194308, GSM194309, respectively) for Sheff 4 line cultured on MEF; "hES4," or "hES5" (GSM194313, GSM194314, respectively) for Sheff 4 line cultured on matrigel; "hES6," or "hES7" (GSM151739, GSM151741) for H14 line cultured on MEF; "Fibroblasts1" for GSM96262; "Fibroblasts2" for GSM96263, and "Fibroblasts3" for GSM96264, respectively. Expression intensity was shown in colorimetric order from red (high) to green (low).

[0062] FIG. **10** shows global gene expression of different cell lines and gene trees based on the global gene expression analysis. Cells were clustered in the gene tree based on a set of genes correlated with Nanog gene expression in human ES cells (seven GEO data) between the ratio of 0.99 and 1 when compared with fibroblasts (three GEO data). Samples were designated "1-8 mTeSR" for clone-1-8 cultured in mTeSR; "1-8CM" for clone 1-8 cultured in MEF-conditioned medium, "5F0438" for the parental fibroblasts, "hES1," "hES2," "hES3" (GSM194307, GSM194308, GSM194309, respectively) for Sheff4 line cultured on MEF; "hES4," "hES5" (GSM194313, GSM194314, respectively) for Sheff4 line cultured on matrigel" "hES6," "hES7" (GSM151739, GSM151741, respectively) for H14 line cultured on MEF; "Fibroblasts1" for GSM96262, "Fibroblasts2" for GSM96263, and "Fibroblasts3" for GSM96264, respectively. Expression intensity was shown in colorimetric order from red (high) to green (low).

[0063] FIG. **11** shows the methylation analysis of promoters in human iPS 1-8. The Oct3/4 promoter (including the distal enhancer (Oct3/4-Z1) and the proximal promoter region (Oct3/4-Z2)) and parts of the Nanog promoter (including the proximal promoter region (Nanog-Z1, -Z2)), were analyzed for the methylation of CpG (Panel a). Panel b depicts the ratio of methylation on CpG shown by circles, as indicated by the percentage.

[0064] FIG. **12** shows the teratoma-formation ability of cells derived from human iPS-1-8 mTeSR cells cultured for 94 days. Human iPS-1-8 mTeSR cells were injected into SCID mouse testes and analyzed 56 days after injection. Panel a depicts HE and alcian blue staining of formaldehyde-fixed teratoma tissues. The teratomas contained tissues representative of the three germ layers; ne: neural epithelium, ca: cartilage, et: endodermal tract. Tissues originated from transplant were distinguished from host tissues by HuNu staining (Panels b-d). Nestin-expressing neural epithelium is depicted in Panel b; Collagen II expressing chondrocyte is depicted in Panel c; alpha-fetoprotein expressing endodermal tract is depicted in Panel d. Arrows indicate representative regions of staining.

[0065] FIG. **13** shows the teratoma-formation ability of cells that had been cultured under varying conditions. Teratoma 1 (Panel T-1) was derived from human iPS-1-8 mTeSR cells cultured for 94 days. The human iPS-1-8 mTeSR cells were injected into SCID mouse testes and analyzed 56 days after injection. Teratoma 2 (Panel T-2) was derived from human iPS-1-8 mTeSR cells cultured for 102 days. The human iPS-1-8 mTeSR cells were injected into SCID mouse testes and analyzed 48 days after injection. In teratoma-1 (Panel T-1), smooth muscle cells (positive for α-SMA) and secretary epithelium (positive for MUC-1) were observed in addition to three germ layers observed in FIG. **12**. Arrows indicate representative regions of staining.

[0066] FIG. **14** shows the teratoma-formation ability of cells that had been cultured under varying conditions. Teratoma 3 (Panel T3) was derived from human iPS-1-8 mTeSR cells cultured for 114 days. Human iPS-1-8 mTeSR cells were injected into SCID mouse testis and analyzed 42 days after injection. Three germ layers similar to FIGS. **12** and **13** were observed. T-F1 and F2 figure shows teratoma that were derived from freeze-thawed iPS-1-8 mTeSR cells cultured for 134 days (passage 19). Human iPS-1-8 mTeSR cells were injected into SCID mouse testes and analyzed 46 days (Panel T-F1) and 48 days (Panel T-F2) after injection. Tissues consisting of three germ layers were observed. Melanocytes were also observed in T-F2 experiment. Pluripotency was maintained even after freezing and thawing. Arrows indicate representative regions of staining.

[0067] FIG. **15** shows Southern blot and PCR analyses of transgenes detected in human iPS clone 1-8. Oct3/4, Sox2, and Klf4 transgenes were detected by Southern blot analysis. Human iPS clone-1-8 was estimated to have approximately ten copies of both Oct3/4 transgenes and Sox2 transgenes, and a single copy of Klf4 transgene. For the c-Myc transgene, genomic PCR analysis was performed. The primer set was designed to include the entire second intron. Black arrows indicate the position of the transgene of interest. The white arrow indicates the position of endogenous c-Myc.

[0068] FIG. **16** shows hES maker gene expression profile in ALP positive colonies induced by four genes (Oct4, Sox2, Klf4 and c-Myc). Colonies were stained for ALP at 17 days after 4 gene transduction. All ALP(+) colonies were dissected and evaluated for hES marker gene expression. Panel a shows the number of colonies expressing Nanog, TDGF1, Dnmt3b, Zfp42, FoxD3, TERT, CYP26A1, and GDF3. Panel b shows the morphologies of octa-positive colonies. Panels c-d show the number of hES cell marker genes categorized by individual experiments.

[0069] FIG. **17**-FIG. **23** show morphologies of four gene (Oct4, Sox2, Klf4 and c-Myc) induced colonies categorized by gene expression profile of ES cell related 8 genes (Nanog, TDGF1, Dnmt3b, Zfp42, FoxD3, TERT, CYP26A1, and GDF3) as well as ALP activity. Circles indicate the picked-up colony.

[0070] FIG. **24** is a graphic representation of the human Oct3/4 predicted mutation tolerance map.

[0071] FIG. **25** is a graphic representation of the human Sox2 predicted mutation tolerance map.

[0072] FIG. **26** is a graphic representation of the human Klf4 predicted mutation tolerance map.

[0073] FIG. **27** is a graphic representation of the human c-Myc predicted mutation tolerance map.

[0074] FIG. **28** shows the use of transgenes to induce ALP positive colonies from mouse embryonic fibroblasts. The gene combination of (Sox2, c-Myc, and Klf4), and (Oct4, Sox2 and c-Myc) can induce ALP colonies on day 12.

[0075] FIG. **29** shows the use of transgenes to induce ALP positive colonies from Mouse adult neural stem cells. In comparison to MEF cells, adult neural stem cells do not require expression of exogenous Sox2 to induce ALP colonies.

[0076] FIG. **30** shows the use of three or four transgenes to induce ALP positive colonies from mouse bone marrow derived cells. ALP colonies can be induced without c-Myc or Klf4.

[0077] FIG. **31** shows the use of two or four transgenes to induce ALP positive colonies from mouse bone marrow derived cells. The combination of Sox2 and cMyc can induce ALP colonies.

[0078]

DETAILED DESCRIPTION OF THE INVENTION
Table of Contents

I. OVERVIEW

[0079] The present disclosure features induced multipotent and pluripotent stem cells and related methods and compositions. Pluripotent stem cells have the ability to differentiate into cells of all three germ layers (ectoderm, mesoderm and endoderm); in contrast, multipotent stem cells can give rise to one or more cell-types of a particular germ layer(s), but not necessarily all three.

[0080] The process of inducing cells to become multipotent or pluripotent is based on forcing the expression of polypeptides, particularly proteins that play a role in maintaining or regulating self-renewal and/or pluripotency of ES cells. Examples of such proteins are the Oct3/4, Sox2, Klf4, and c-Myc transcription factors, all of which are highly expressed in ES cells. Forced expression may include introducing expression vectors encoding polypeptides of interest into cells, transduction of cells with recombinant viruses, intro-

ducing exogenous purified polypeptides of interest into cells, contacting cells with a non-naturally occurring reagent that induces expression of an endogenous gene encoding a polypeptide of interest (e.g., Oct3/4, Sox2, Klf4, or c-Myc), or any other biological, chemical, or physical means to induce expression of a gene encoding a polypeptide of interest (e.g., an endogenous gene Oct3/4, Sox2, Klf4, or c-Myc). Some basic steps to induce the cells are shown in FIG. **1**. These steps may involve: collection of cells from a donor, e.g., a human donor, or a third party (100); induction of the cells, e.g., by forcing expression of polypeptides such as Oct3/4, Sox2, Klf4, and c-Myc (110); identifying multipotent or pluripotent stem cells (120); isolating colonies (130); and optionally, storing the cells (140). Interspersed between all of these steps are steps to maintain the cells, including culturing or expanding the cells. In addition, storage of the cells can occur after many steps in the process. Cells may later be used in many contexts, such as therapeutics or other uses.(150).

[0081] Embryonic stem (ES) cells are both self-renewing and pluripotent. The induced cells may also be self-renewing and pluripotent. However, in contrast to ES cells, the induced cells can be derived from a wide range of cells and tissue, including non-embryonic tissue.

[0082] The induced cells (e.g., induced multipotent or pluripotent stem cells) have many uses. They may be subjected to conditions that enable them to generate differentiated cells, e.g., neurons, hepatocytes, or cardiomyocytes. They may also give rise to other types of stem cells, e.g., neural stem cells, hepatic stem cells, or cardiac stem cells, that have the ability differentiate into other cells of a specific lineage. The induced cells, and cells differentiated from them, are also useful for medical therapies such as cell replacement therapies. Since the induced cells can be induced from non-embryonic cells, a cell therapy can involve providing a subject with cells derived from his or her own tissue, thereby lessening the possibility of immune rejection.

[0083] This disclosure describes induced multipotent and pluripotent stem cells, their preparation, and their storage. The disclosure further describes cells differentiated from the induced multipotent and pluripotent stem cells, their preparation, and their storage. Also described are the use of the induced cells, or of cells differentiated from them, for cell therapies. Analytical methods and methods of cell banking are also provided.

II. PREPARATION OF CELLS

[0084] A. Description of Cells that can be Induced

[0085] The multipotent or pluripotent cells may be induced from a wide variety of mammalian cells. Examples of suitable populations of mammalian cells include those that include, but are not limited to: fibroblasts, bone marrow-derived mononuclear cells, skeletal muscle cells, adipose cells, peripheral blood mononuclear cells, macrophages, hepatocytes, keratinocytes, oral keratinocytes, hair follicle dermal cells, gastric epithelial cells, lung epithelial cells, synovial cells, kidney cells, skin epithelial cells or osteoblasts.

[0086] The cells can also originate from many different types of tissue, e.g., bone marrow, skin (e.g., dermis, epidermis), muscle, adipose tissue, peripheral blood, foreskin, skeletal muscle, or smooth muscle. The cells can also be derived from neonatal tissue, including, but not limited to: umbilical cord tissues (e.g., the umbilical cord, cord blood, cord blood vessels), the amnion, the placenta, or other various neonatal tissues (e.g., bone marrow fluid, muscle, adipose tissue, peripheral blood, skin, skeletal muscle etc.).

[0087] The cells can be derived from neonatal or post-natal tissue collected from a subject within the period from birth, including cesarean birth, to death. For example, the tissue may be from a subject who is >10 minutes old, >1 hour old, >1 day old, >1 month old, >2 months old, >6 months old, >1 year old, >2 years old, >5 years old, >10 years old, >15 years old, >18 years old, >25 years old, >35 years old, >45 years old, >55 years old, >65 years old, >80 years old, <80 years old, <70 years old, <60 years old, <50 years old, <40 years old, <30 years old, <20 years old or <10 years old. The subject may be a neonatal infant. In some cases, the subject is a child or an adult. In some examples, the tissue is from a human of age 2, 5, 10 or 20 hours. In other examples, the tissue is from a human of age 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 9 months or 12 months. In some cases, the tissue is from a human of age 1 year, 2 years, 3 years, 4 years, 5 years, 18 years, 20 years, 21 years, 23 years, 24 years, 25 years, 28 years, 29 years, 31 years, 33 years, 34 years, 35 years, 37 years, 38 years, 40 years, 41 years, 42 years, 43 years, 44 years, 47 years, 51 years, 55 years, 61 years, 63 years, 65 years, 70 years, 77 years, or 85 years old.

[0088] The cells may be from non-embryonic tissue, e.g., at a stage of development later than the embryonic stage. In other cases, the cells may be derived from an embryo. In some cases, the cells may be from tissue at a stage of development later than the fetal stage. In other cases, the cells may be derived from a fetus.

[0089] The cells are preferably from a human subject but can also be derived from non-human subjects, e.g., non-human mammals. Examples of non-human mammals include, but are not limited to, non-human primates (e.g., apes, monkeys, gorillas), rodents (e.g., mice, rats), cows, pigs, sheep, horses, dogs, cats, or rabbits.

[0090] The cells may be collected from subjects with a variety of disease statuses. The cells can be collected from a subject who is free of an adverse health condition. In other cases, the subject is suffering from, or at high risk of suffering from, a disease or disorder, e.g., a chronic health condition such as cardiovascular disease, eye disease (e.g., macular degeneration), auditory disease, (e.g., deafness), diabetes, cognitive impairment, schizophrenia, depression, bipolar disorder, dementia, neurodegenerative disease, Alzheimer's Disease, Parkinson's Disease, multiple sclerosis, osteoporosis, liver disease, kidney disease, autoimmune disease, arthritis, or a proliferative disorder (e.g., a cancer). In other cases, the subject is suffering from, or at high risk of suffering from, an acute health condition, e.g., stroke, spinal cord injury, burn, or a wound. In certain cases, a subject provides cells for his or her future use (e.g., an autologous therapy), or for the use of another subject who may need treatment or therapy (e.g., an allogeneic therapy). In some cases, the donor and the recipient are immunohistologically compatible or HLA-matched.

[0091] The cells to be induced can be obtained from a single cell or a population of cells. The population may be homogeneous or heterogeneous. The cells may be a population of cells found in a human cellular sample, e.g., a biopsy or blood sample. Often, the cells are somatic cells. The cells may be a cell line. In some cases, the cells are derived from cells fused to other cells. In some cases, the cells are not derived from cells fused to other cells. In some cases, the cells are not derived from cells artificially fused to other cells. In some

cases, the cells are not a cell that has undergone the procedure known as somatic cell nuclear transfer (SCNT) or a cell descended from a cell that underwent SCNT.

[0092] The cellular population may include both differentiated and undifferentiated cells. In some cases, the population primarily contains differentiated cells. In other cases, the population primarily contains undifferentiated cells, e.g., undifferentiated stem cells. The undifferentiated cells within the population may be induced to become pluripotent or multipotent. In some cases, differentiated cells within the cellular population are induced to become pluripotent or multipotent.

[0093] The cellular population may include undifferentiated stem cells or naïve stem cells. In some cases, the undifferentiated stem cells are stem cells that have not undergone epigenetic inactivating modification by heterochromatin formation due to DNA methylation or histone modification of at least four genes, at least three genes, at least two genes, at least one gene, or none of the following: Nanog, Oct3/4, Sox2 and Tert. Activation, or expression of such genes, e.g., Tert, Nanog, Oct3/4 or Sox2, may occur when human pluripotent stem cells are induced from undifferentiated stem cells present in a human postnatal tissue.

[0094] B. Collection of Cells

[0095] Methods for obtaining human somatic cells are well established, as described in, e.g., Schantz and Ng (2004), *A Manual for Primary Human Cell Culture*, World Scientific Publishing Co., Pte, Ltd. In some cases, the methods include obtaining a cellular sample, e.g., by a biopsy (e.g., a skin sample), blood draw, or alveolar or other pulmonary lavage. It is to be understood that initial plating densities from of cells prepared from a tissue may be varied based on such variable as expected viability or adherence of cells from that particular tissue. Methods for obtaining various types of human somatic cells include, but are not limited to, the following exemplary methods:

[0096] 1. Bone Marrow

[0097] The donor is given a general anesthetic and placed in a prone position. From the posterior border of the ilium, a collection needle is inserted directly into the skin and through the iliac surface to the bone marrow, and liquid from the bone marrow is aspirated into a syringe. The somatic stem cells are enriched by isolating bone marrow cells from an osteogenic zone of bone marrow. A mononuclear cell fraction is then prepared from the aspirate by density gradient centrifugation. The collected crude mononuclear cell fraction is then cultured prior to use in the methods described herein for induction.

[0098] 2. Postnatal Skin

[0099] Skin tissue containing the dermis is harvested, for example, from the back of a knee or buttock. The skin tissue is then incubated for 30 minutes at 37° C. in 0.6% trypsin/Dulbecco's Modified Eagle's Medium (DMEM)/F-12 with 1% antibiotics/antimycotics, with the inner side of the skin facing downward.

[0100] After the skin tissue is turned over, tweezers are used to lightly scrub the inner side of the skin. The skin tissue is finely cut into 1 mm^2 sections using scissors and is then centrifuged at 1200 rpm and room temperature for 10 minutes. The supernatant is removed, and 25 ml of 0.1% trypsin/DMEM/F-12/1% antibiotics, antimycotics, is added to the tissue precipitate. The mixture is stirred at 200-300 rpm using a stirrer. at 37° C. for 40 minutes. After confirming that the tissue precipitate is fully digested, 3 ml fetal bovine serum (FBS) (manufactured by JRH) is added, and filtered sequentially with gauze (Type I manufactured by PIP), a 100 μm nylon filter (manufactured by FALCON) and a 40 μm nylon filter (manufactured by FALCON). After centrifuging the resulting filtrate at 1200 rpm and room temperature for 10 minutes to remove the supernatant, DMEM/F-12/1% antibiotics, antimycotics is added to wash the precipitate, and then centrifuged at 1200 rpm and room temperature for 10 minutes. The cell fraction thus obtained is then cultured prior to induction.

[0101] Dermal stem cells can be enriched by isolating dermal papilla from scalp tissue. Human scalp tissues (0.5-2 cm or less) are rinsed, trimmed to remove excess adipose tissues, and cut into small pieces. These tissue pieces are enzymatically digested in 12.5 mg/ml dispase (Invitrogen, Carlsbad, Calif.) in DMEM for 24 hours at 4° C. After the enzymatic treatment, the epidermis is peeled off from the dermis; and hair follicles are pulled out from the dermis. Hair follicles are washed with phosphate-buffered saline (PBS); and the epidermis and dermis are removed. A microscope may be used for this procedure. Single dermal papilla derived cells are generated by culturing the explanted papilla on a plastic tissue culture dish in the medium containing DMEM and 10% FCS for 1 week. When single dermal papilla cells are generated, these cells are removed and cultured in FBM supplemented with FGM-2 SingleQuots (Lonza) or cultured in the presence of 20 ng/ml EGF, 40 ng/ml FGF-2, and B27 without serum.

[0102] Epidermal stem cells can be also enriched from human scalp tissues (0.5-2 cm^2 or less). Human scalp issues is rinsed, trimmed to remove excess adipose tissues, and cut into small pieces. These tissue pieces are enzymatically digested in 12.5 mg/ml dispase (Invitrogen, Carlsbad, Calif.) in Dulbecco's modified Eagle's medium (DMEM) for 24 hours at 4° C. After the enzymatic treatment, the epidermis is peeled off from the dermis; and hair follicles are pulled out from the dermis. The bulb and intact outer root sheath (ORS) are dissected under the microscope. After the wash, the follicles are transferred into a plastic dish. Then the bulge region is dissected from the upper follicle using a fine needle. After the wash, the bulge is transferred into a new dish and cultured in medium containing DMEM/F12 and 10% FBS. After the cells are identified, culture medium is changed to the EpiLife™ Extended-Lifespan Serum-FreeMedium (Sigma).

[0103] 3. Postnatal Skeletal Muscle

[0104] After the epidermis of a connective tissue containing muscle such as the lateral head of the biceps brachii muscle or the sartorius muscle of the leg is cut and the muscle tissue is excised, it is sutured. The whole muscle obtained is minced with scissors or a scalpel, and then suspended in DMEM (high glucose) containing 0.06% collagenase type IA and 10% FBS, and incubated at 37° C. for 2 hours.

[0105] Cells are collected by centrifugation from the minced muscle, and suspended in DMEM (high glucose) containing 10% FBS. After passing the suspension through a microfilter with a pore size of 40 μm and then a microfilter with a pore size of 20 μm, the cell fraction obtained may be cultured as crude purified cells containing undifferentiated stem cells, and used for the induction of human pluripotent stem cells as described herein.

[0106] 4. Postnatal Adipose Tissue

[0107] Cells derived from adipose tissue for use in the present invention may be isolated by various methods known to a person skilled in the art. For example, such a method is described in U.S. Pat. No. 6,153,432, which is incorporated

herein in its entirety. A preferred source of adipose tissue is omental adipose tissue. In humans, adipose cells are typically isolated by fat aspiration.

[0108] In one method of isolating cells derived from adipose cells, adipose tissue is treated with 0.01% to 0.5%, e.g., 0.04% to 0.2%, 0.1% collagenase; 0.01% to 0.5%, e.g., 0.04%, or 0.2% trypsin; and/or 0.5 ng/ml to 10 ng/ml dispase, or an effective amount of hyaluronidase or DNase (DNA digesting enzyme), and about 0.01 to about 2.0 mM, e.g., about 0.1 to about 1.0 mM, or 0.53 mM ethylenediaminetetraacetic acid (EDTA) at 25 to 50° C., e.g., 33 to 40° C., or 37° C. for 10 minutes to 3 hours, e.g., 30 minutes to 1 hour, or 45 minutes.

[0109] Cells are passed through nylon or a cheese cloth mesh filter of 20 microns to 800 microns, more preferably 40 microns to 400 microns, and most preferably 70 microns. Then the cells in the culture medium are subjected to differential centrifugation directly or using Ficoll or Percoll or another particle gradient. The cells are centrifuged at 100 to 3000×g, more preferably 200 to 1500×g, most preferably 500×g for 1 minute to 1 hours, more preferably 2 to 15 minutes and most preferably 5 minutes, at 4 to 50° C., preferably 20 to 40° C. and more preferably about 25° C.

[0110] The adipose tissue-derived cell fraction thus obtained may be cultured according to the method described herein as crude purified cells containing undifferentiated stem cells, and used for the induction of human pluripotent or multipotent stem cells.

[0111] 5. Blood

[0112] About 50 ml to about 500 ml vein blood or cord blood is collected, and a mononuclear cell fraction is obtained by the Ficoll-Hypaque method, as described in, e.g., Kanof et al., (1993), *Current Protocols in Immunology* (J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevack, and W. Strober, eds.), ch. 7.1.1.-7.1.5, John Wiley & Sons, New York).

[0113] After isolation of the mononuclear cell fraction, approximately 1×10^7 to 1×10^8 human peripheral blood mononuclear cells are suspended in a RPMI 1640 medium containing 10% fetal bovine serum, 100 μg/ml streptomycin and 100 units/ml penicillin, and after washing twice, the cells are recovered. The recovered cells are resuspended in RPMI 1640 medium and then plated in a 100 mm plastic petri dish at a density of about 1×10^7 cells/dish, and incubated in a 37° C. incubator at 8% CO_2. After 10 minutes, cells remaining in suspension are removed and adherent cells are harvested by pipetting. The resulting adherent mononuclear cell fraction is then cultured prior to the induction period as described herein. In some cases, the peripheral blood-derived or cord blood-derived adherent cell fraction thus obtained may be cultured according to the method described herein as crude purified cells containing undifferentiated stem cells, and used for the induction of human pluripotent or multipotent stem cells.

[0114] Macrophages in the peripheral blood can be enriched by culturing the mononuclear cell fraction in low-glucose DMEM supplemented with 10% heat-inactivated fetal bovine serum (FBS; JRH Biosciences, Lenexa, Kans.), 2 mM L-glutamine, 50 U/ml penicillin, and 50 μg/ml streptomycin. In order to expand macrophages, peripheral blood mononuclear cells are spread at a density of 2×10^6/ml on plastic plates that have been treated with 10 μg/ml FN (Sigma, St. Louis, Mo.) overnight at 4° C. The cells are then cultured without any additional growth factors at 37° C. and 5% CO_2 in a humidified atmosphere. The medium containing floating cells is changed every 3 days. Macrophages with observable fibroblastic features may be used for the induction experiments.

[0115] In some cases, a cell fraction from peripheral blood, cord blood, or bone marrow is expanded, as described in U.S. patent application Ser. No. 11/885,112, and then used in the induction methods described herein.

III. INDUCTION

[0116] A. Overview

[0117] During the induction process, forced expression of certain polypeptides is carried out in cultured cells for a period of time, after which the induced cells are screened for a number of properties that characterize multipotent and pluripotent stem cells (e.g., morphological, gene expression). Induced cells that meet these screening criteria may then be subcloned and expanded. In some cases, the cells to be induced may be cultured for a period of time prior to the induction procedure. Alternatively, the cells to be induced may be used directly in the induction process without a prior culture period. In some cases, different cell culture media are used at different points prior to, during, and after the induction process. For example, one type of culture medium may be used after collection of tissue and/or directly before the induction process, while a second type of media is used during and/or after the induction process. At times, a third type of culture medium is used during and/or after the induction process.

[0118] B. Cell Culture

[0119] After collection, tissue or cellular samples can be cultured in any medium suitable for the specific cells or tissue collected. Some representative media that the tissue or cells can be cultured in include but are not limited to: multipotent adult progenitor cell (MAPC) medium; FBM (manufactured by Lonza); Embryonic Stem cell (ES) ES medium; Mesenchymal Stem Cell Growth Medium (MSCGM) (manufactured by Lonza); MCDB202 modified medium; Endothelial Cell Medium kit-2 (EBM2) (manufactured by Lonza); Iscove's Modified Dulbecco's Medium (IMDM) (Sigma); Dulbecco's Modified Eagle Medium (DMEM); MEF-conditioned ES (MC-ES); and mTeSR (available, e.g., from StemCell Technologies, Vancouver, Canada), See, e.g., Ludwig et al., (2006), *Nat. Biotechnol.,* 24(2):185-187. In other cases, alternative culture conditions for growth of human ES cells are used, as described in, e.g., Skottman et al., (2006), *Reproduction,* 132(5):691-698.

[0120] MAPC (2% FBS) medium may comprise: 60% Dulbecco's Modified Eagle's Medium-low glucose, 40% MCDB 201, Insulin Transferrin Selenium supplement, (0.01 mg/ml insulin; 0.0055 mg/ml transferrin; 0.005 μg/ml sodium selenite), 1× linolenic acid albumin (1 mg/mL albumin; 2 moles linoneic acid/mole albumin), 1 nM dexamethasone, 2% fetal bovine serum, 1 nM dexamethasone, 10^{-4} M ascorbic acid, and 10 μg/ml gentamycin

[0121] FBM (2% FBS) medium may comprise: MCDB202 modified medium, 2% fetal bovine serum, 5 μg/ml insulin, 50 mg/ml gentamycin, and 50 ng/ml amphotericin-B.

[0122] ES medium may comprise: 40% Dulbecco's Modified Eagle's Medium (DMEM) 40% F12 medium, 2 mM L-glutamine, 1× non-essential amino acids (Sigma, Inc., St. Louis, Mo.), 20% Knockout Serum Replacement™ (Invitrogen, Inc., Carlsbad, Calif.), and 10 μg/ml gentamycin.

[0123] MC-ES medium may be prepared as follows. ES medium is conditioned on mitomycin C-treated murine embryonic fibroblasts (MEFs), for 20 to 24 hours, harvested, filtered through a 0.45-1M filter, and supplemented with about 0.1 mM 13-mercaptoethanol, about 10 ng/ml bFGF or FGF-2, and, optionally, about 10 ng/ml activin A. In some cases, irradiated MEFs are used in place of the mitomycin C-treated MEFs. In other cases, STO (ATCC) or human fibroblast cells are used in place of the MEFs.

[0124] Cells may be cultured in medium supplemented with a particular serum. In some embodiments, the serum is fetal bovine serum (FBS). The serum can also be fetal calf serum (FCS). In some cases, the serum may be human serum (e.g., human AB serum). Mixtures of serum may also be used, e.g. mixture of FBS and Human AB, FBS and FCS, or FCS and Human AB.

[0125] After collection of tissue and preparation of cells, it may be useful to promote the expansion of tissue stem cells or progenitor cells that may be present among the prepared cells by use of suitable culture conditions. In some cases, a low-serum culture or serum-free medium (as described herein) may facilitate the expansion of tissue stem cells or progenitor cells. Suitable culture media include, but are not limited to, MAPC, FBM, or MSCGM.

[0126] Primary culture ordinarily occurs immediately after the cells are isolated from a donor, e.g., human. The cells can also be sub-cultured after the primary culture. A "second" subculture describes primary culture cells subcultured once, a "third" subculture describes primary cultures subcultured twice, a "fourth" subculture describes primary cells subcultured three times, etc. In some cases, the primary cells are subjected to a second subculture, a third subculture, or a fourth subculture. In some cases, the primary cells are subjected to less than four subcultures. The culture techniques described herein may generally include culturing from the period between the primary culture and the fourth subculture, but other culture periods may also be employed. Preferably, cells are cultured from the primary culture to the second subculture. In some cases, the cells may be cultured for about 1 to about 12 days e.g., 2 days, 3 days, 4.5 days, 5 days, 6.5 days, 7 days, 8 days, 9 days, 10 days, or any other number of days from about 1 day to about 12 days prior to undergoing the induction methods described herein. In other cases, the cells may be cultured for more than 12 days, e.g. from about 12 days to about 20 days; from about 12 days to about 30 days; or from about 12 days to about 40 days. In some embodiments, the cells to be induced are passaged four or fewer times (e.g., 3, 2, 1, or 0 times) prior to induction.

[0127] In some cases, prior to induction cells are cultured at a low density, e.g., from about 1×10^3 cells/cm^2 to about 1×10^4 cells/cm^2. In other cases, prior to induction (e.g., just prior to induction), cells are cultured at a density of about 1×10^3 cells/cm^2 to about 3×10^4 cells/cm^2; or from about 1×10^4 cells/cm^2 to about 3×10^4 cells/cm^2.

[0128] Often the cells and/or tissue are cultured in a first medium, as described above, prior to and/or during the introduction of induction factors to the cells; and then the cells are cultured in a second or third medium during and/or after the introduction of the induction factors to the cells. The second or third medium may be MEF-Conditioned (MC)-ES, mTeSR1 medium, or other ES cell medium, as described in, e.g., Skottman et al., (2006), *Reproduction,* 132(5):691-698.

[0129] In many examples, the cells are cultured in MAPC, FBM or MSCGM medium prior to the initiation of forced expression of genes or polypeptides in the cells (e.g., immediately after a retroviral infection period); and then, following the initiation of the forced expression, the cells are cultured in MC-ES medium, mTeSR1™ medium, or other ES cell medium as described herein.

[0130] Culture of cells may be carried out under low serum culture conditions prior to, during, or following the introduction of induction factors. A "low serum culture condition" refers to the use of a cell culture medium containing a concentration of serum ranging from 0% (v/v) (i.e., serum-free) to about 5% (v/v), e.g., 0% to 2%, 0% to 2.5%, 0% to 3%, 0% to 4%, 0% to 5%, 0.1% to 2%, 0.1% to 5%, 0%, 0.1%, 0.5%, 1%, 1.2%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, or 5%. In some embodiments, a low serum concentration is from about 0% (v/v) to about 2% (v/v). In some cases, the serum concentration is about 2%. In other embodiments, cells are cultured under a "high serum condition," i.e., greater than 5% (v/v) serum to about 20% (v/v) serum, e.g., 6%, 7%, 8%, 10%, 12%, 15%, or 20%. Culturing under high serum conditions may occur prior to, during, and/or after the introduction of induction factors. Media with low concentrations of serum may be particularly useful to enrich undifferentiated stem cells. For example, MSCs are often obtained by isolating the non-hematopoietic cells (e.g., interstitial cells) adhering to a plastic culture dish when tissue, e.g., bone marrow, fat, muscle, or skin etc., is cultured in a culture medium containing a high-concentration serum (5% or more). However, even under these culture conditions, a very small number of undifferentiated cells can be maintained, especially if the cells were passaged under certain culture conditions (e.g., low passage number, low-density culturing or low oxygen).

[0131] When either low or high serum conditions are used for culturing the cells, one or more growth factors such as fibroblast growth factor (FGF)-2; basic FGF (bFGF); platelet-derived growth factor (PDGF), epidermal growth factor (EGF); insulin-like growth factor (IGF); IGF II; or insulin can be included in the culture medium. Other growth factors that can be used to supplement cell culture media include, but are not limited to one or more: Transforming Growth Factor β-1 (TGF β-1), Activin A, Noggin, Brain-derived Neurotrophic Factor (BDNF), Nerve Growth Factor (NGF), Neurotrophin (NT)-1, NT-2, or NT-3. In some cases, one or more of such factors is used in place of the bFGF or FGF-2 in the MC-ES medium or other cell culture medium.

[0132] The concentration of growth factor(s) (e.g., FGF-2, bFGF, PDGF, EGF, IGF, insulin, IGF II, TGF β-1, Activin A, Noggin, BDNF, NGF, NT-1, NT-2, NT-3) in the culture media described herein (e.g., MAPC, FBM, MC-ES, MSCGM, IMDM, mTeSR1™) may be from about 4 ng/ml to about 50 ng/ml, e.g., about 2 ng/ml, 3 ng/ml, 4 ng/ml, 5 ng/ml, 6 ng/ml, 7 ng/ml, 8 ng/ml, 10 ng/ml, 12 ng/ml, 14 ng/ml, 15 ng/ml, 17 ng/ml, 20 ng/ml, 25 ng/ml, 30 ng/ml, 35 ng/ml, 40 ng/ml, 45 ng/ml, or 50 ng/ml. The concentration of growth factors may also be from about 4 ng/ml to about 10 ng/ml; from about 4 ng/ml to about 20 ng/ml; from about 10 ng/ml to about 30 ng/ml; from about 5 ng/ml to about 40 ng/ml; or from about 10 ng/ml to about 50 ng/ml. In other cases, higher concentrations of growth factors may be used, e.g., from about 50 ng/ml to about 100 ng/ml; or from about 50 ng/ml to about 75 ng/ml.

[0133] The growth factors may be used alone or in combination. For example, FGF-2 may be added alone to the medium; in another example, both PDGF and EGF are added to the culture medium. Often, growth factors appropriate for a particular cell type may be used. For example, dermal cells may be cultured in the presence of about 20 ng/ml EGF and/or about 40 ng/ml FGF-2, while epidermal cells may be cultured in the presence of about 50 ng/ml EGF and/or 5 ug/ml Insulin.

[0134] The induced cells may be maintained in the presence of a rho, or rho-associated, protein kinase (ROCK) inhibitor to reduce apoptosis. A ROCK inhibitor may be particularly useful when the cells are subjected to a harsh treatment, such as an enzymatic treatment. For example, the addition of Y-27632 (Calbiochem; water soluble) or Fasudil

(HA1077: Calbiochem), an inhibitor of Rho associated kinase (Rho associated coiled coil-containing protein kinase) may be used to culture the human pluripotent and multipotent stem cells of the present invention. In some cases the concentration of Y-27632 or Fasudil, is from about 2.5 μM to about 20 μM, e.g., about 2.5 μM, 5 μM, 10 μM, 15 μM, or 20 μM.

[0135] The induced cells may be cultured in a maintenance culture medium in a 37° C., 5% CO_2 incubator (e.g., under an atmospheric oxygen level), with medium changes preferably every day. In some embodiments, in order to culture and grow human pluripotent stem cells induced from the undifferentiated stem cells of the present invention present in a human postnatal tissue, it is preferred that the cells are subcultured every 5 to 7 days in a culture medium containing the additives described herein on a MEF-covered plastic culture dish or a matrigel-coated plastic culture dish. Examples of maintenance culture media for induced cells include any and all complete ES cell media (e.g., MC-ES). The maintenance culture medium may be supplemented with b-FGF or FGF2. In some cases, the maintenance culture medium is supplemented with other factors, e.g., IGF-II, Activin A or other growth factor described herein, see, e.g., Bendall et al., (2007), *Nature,* 30:448(7157):1015-21. In some embodiments, the induced cells are cultured and observed for about 14 days to about 40 days, e.g., 15, 16, 17, 18, 19, 20, 23, 24, 27, 28, 29, 30, 31, 33, 34, 35, 36, 37, 38 days, or other period from about 14 days to about 40 days, prior to identifying and selecting candidate multipotent or pluripotent stem cell colonies based on morphological characteristics.

[0136] Morphological characteristics for identifying candidate multipotent or pluripotent stem cell colonies include, but are not limited to, a rounder, smaller cell size relative to surrounding cells and a high nucleus-to-cytoplasm ratio. The size of the candidate induced cell may be from about 5 μm to about 10 μm; from about 5 μm to about 15 μm; from about 5 μm to about 30 μm; from about 10 μm to about 30 μm; or from about 20 μm to about 30 μm. A high nucleus-to-cytoplasm ratio may be from about 1.5:1 to about 10:1, e.g., about 1.5:1; about 2:1; about 3:1; about 4:1; about 5:1; about 7:1; about 8:1; about 9.5:1; or about 10:1. In some cases, the induced cell clones display a flattened morphology relative to mouse ES cells. For example, candidate induced cells derived from peripheral blood cells or from cells cultured in feeder-free media may exhibit a flattened morphology compared to surrounding cells. Another morphological characteristic for identifying induced cell clones is the formation of small monolayer colonies within the space between parental cells (e.g., between fibroblasts).

[0137] The induced cells can be plated and cultured directly on tissue culture-grade plastic. Alternatively, cells are plated and cultured on a coated substrate, e.g., a substrate coated with fibronectin, gelatin, matrigeltm (BD Bioscience), collagen, or laminin. In some cases, untreated petri-dishes may be used. Suitable cell culture vessels include, e.g., 35 mm, 60 mm, 100 mm, and 150 mm cell culture dishes, 6-well cell culture plates, and other size-equivalent cell culture vessels. In some cases, the cells are cultured with feeder cells. For example, the cells may be cultured on a layer, or carpet, of MEFs (e.g., irradiated or mitomycin-treated MEFs).

[0138] Typically, the induced cells may be plated (or cultured) at a low density, which may be accomplished by splitting the cells from about 1:8 to about 1:3, e.g., about 1:8; about 1:6; about 1:5; about 1:4; or about 1:3. Cells may be plated at a density of from about 10^3 cells/cm^2 to about 10^4 cells/cm^2. In some examples, the cells may be plated at a density of from about 1.5×10^3 cells/cm^2 to about 10^4 cells/cm^2; from about 2×10^3 cells/cm^2 to about 10^4 cells/cm^2; from about 3×10^3 cells/cm^2 to about 10^4 cells/cm^2; from about 4×10^3 cells/cm^2 to about 10^4 cells/cm^2; or from about 10^3 cells/cm^2 to about 9×10^3 cells/cm^2. In some embodiments, the cells may be plated at a density greater than 10^4 cells/cm^2, e.g., from about 1.25×10^4 cells/cm^2 to about 3×10^4 cells/cm^2.

[0139] C. Induction Factors

[0140] Inducing a cell to become multipotent or pluripotent can be accomplished in a number of ways.

[0141] In some embodiments, the methods for induction of pluripotency or multipotency in one or more cells include forcing expression of a set of induction factors. Forced expression may include introducing expression vectors encoding polypeptides of interest into cells, introducing exogenous purified polypeptides of interest into cells, or contacting cells with a non-naturally occurring reagent that induces expression of an endogenous gene encoding a polypeptide of interest.

[0142] In some cases, the set of IFs includes one or more: an Oct3/4 polypeptide, a Sox2 polypeptide, a Klf4 polypeptide, or a c-Myc polypeptide. In some cases, the set does not include a c-Myc polypeptide. For example, the set of IFs can include one or more of: an Oct3/4 polypeptide, a Sox2 polypeptide, and a Klf4 polypeptide, but not a c-Myc polypeptide. In some cases, the set of IFs does not include polypeptides that might increase the risk of cell transformation or the risk of inducing cancer. The ability of c-Myc to induce cell transformation has been described, see, e.g., Adhikary et al., (2005), *Nat. Rev. Mol. Cell. Biol.,* 6(8):635-645.

[0143] In some cases, the set includes a c-Myc polypeptide. In certain cases, the c-Myc polypeptide is a constitutively active variant of c-Myc. In some instances, the set includes a c-Myc polypeptide capable of inducible activity, e.g., a c-Myc-ER polypeptide, see, e.g., Littlewood, et al., (1995), *Nucleic Acid Res.,* 23(10): 1686-90.

[0144] In other cases, the set of IFs includes: an Oct3/4 polypeptide, a Sox2 polypeptide, and a Klf4 polypeptide, but not a TERT polypeptide, a SV40 Large T antigen polypeptide, HPV16 E6 polypeptide, a HPV16 E7 polypeptide, or a Bmi1 polypeptide. In some cases, the set of IFs does not include a TERT polypeptide. In some cases, the set of IFs does not include a SV40 Large T antigen. In other cases, the set of IFS does not include a HPV16 E6 polypeptide or a HPV16 E7 polypeptide.

[0145] In some cases, the set of IFs includes three IFs, wherein two of the three IFs are an Oct3/4 polypeptide and a Sox2 polypeptide. In other cases, the set of IFs includes two IFs, e.g., a c-Myc polypeptide and a Sox2 polypeptide or an Oct3/4 and a Klf4 polypeptide. In some cases, the set of IFs is limited to Oct 3/4, Sox2, and Klf4 polypeptides. In other cases, the set of IFs may be limited to a set of four IFs: an Oct3/4 polypeptide, a Sox2 polypeptide, a Klf4 polypeptide, and a c-Myc polypeptide.

[0146] A set of IFs may include IFs in addition to an Oct 3/4, a Sox2, and a Klf4 polypeptide. Such additional IFs include, but are not limited to Nanog, TERT, LIN28, CYP26A1, GDF3, FoxD3, Zfp42, Dnmt3b, Ecat1, and Tcl1 polypeptides. In some cases, the set of additional IFs does not include a c-Myc polypeptide. In some cases, the set of additional IFs does not include polypeptides that might increase the risk of cell transformation or of inducing cancer.

[0147] Forced expression of IFs may be maintained for a period of at least about 7 days to at least about 40 days, e.g., 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 25 days, 30 days, 33 days, or 37 days.

[0148] The efficiency of inducing pluripotency in cells of a human population of cells is from at least about 0.001% to at least about 0.1% of the total number of parental cells cultured initially, e.g., 0.002%, 0.0034%, 0.004%, 0.005%, 0.0065%, 0.007%, 0.008%, 0.01%, 0.04%, 0.06%, 0.08%, or 0.09%. At times, depending on the age of the donor, the origin of the tissue, or the culture conditions, higher efficiencies may be achieved.

[0149] D. HDAC Inhibitor

[0150] Induction of the cells may be accomplished by combining histone deacetylase (HDAC) inhibitor treatment with forced expression of sets of IFs. The cells to be induced may be undifferentiated stem cells present in a human postnatal tissue. In other cases, the cells to be induced are differentiated cells or are a mixture of differentiated and undifferentiated cells.

[0151] The HDAC may be combined with the forced expression of a specific set of IFs, e.g., Oct3/4, Sox2, and Klf4. For example, a human somatic cell is induced to become pluripotent after HDAC inhibitor treatment is combined with forced expression of Oct3/4, Sox2 and Klf4 or forced expression of Oct3/4, Sox2, Klf4, and c-Myc. In some cases, human pluripotent stem cells can be induced by introducing three genes (e.g., Oct3/4, Sox2 and Klf4) or three genes (e.g., Oct3/4, Sox2 and Klf4) plus the c-Myc gene or a HDAC inhibitor into undifferentiated stem cells present in a human postnatal tissue in which each gene of Tert, Nanog, Oct3/4 and Sox2 has not undergone epigenetic inactivation. In still other cases, human pluripotent stem cells are induced by introducing three genes (e.g., Oct3/4, Sox2 and Klf4) or three genes (e.g., Oct3/4, Sox2 and Klf4) plus the c-Myc gene or a histone deacetylase inhibitor into undifferentiated stem cells after the undifferentiated stem cells were amplified by a primary culture or a second subculture, or a subculture in a low density and subculturing in a culture medium comprising a low-concentration serum.

[0152] Cells may be treated with one or more HDACs for about 2 hours to about 5 days, e.g., 3 hours, 6 hours, 12 hours, 14 hours, 18 hours, 1 day, 2 days, 3 days, or 4 days. Treatment with HDAC inhibitor may be initiated prior to beginning forced expression of IFs in the cells. In some cases, HDAC inhibitor treatment begins during or after forced expression of IFs in the cells. In other cases, HDAC inhibitor treatment begins prior to forced expression and is maintained during forced expression.

[0153] Suitable concentrations of an HDAC inhibitor range from about 0.001 nM to about 10 mM, depending on the particular HDAC inhibitor to be used, but are selected so as to not significantly decrease cell survival in the treated cells. The HDAC concentration may range from 0.01 nM, to 1000 nM. In some embodiments, the HDAC concentration ranges from about 0.01 nM to about 1000 nM, e.g., about 0.05 nM, 0.1 nM, 0.5 nM, 0.75 nM, 1.0 nM, 1.5 nM, 10 nM, 20 nM, 40 nM, 50 nM, 100 nM, 200 nM, 300 nM, 500 nM, 600 nM, 700 nM, 800 nM, or other concentration from about 0.01 nM to about 1000 nM. Cells are exposed for 1 to 5 days or 1 to 3 days. For example, cells are exposed 1 day, 2 days, 3 days, 4 days or 5 days.

[0154] Multiple varieties of HDAC inhibitors can be used for the induction experiments. In a preferred embodiment, the HDAC inhibitor MS-275 is used. Examples of suitable HDAC inhibitors include, but are not limited to, any the following:

[0155] A. Trichostatin A and its analogs, for example: trichostatin A (TSA); and trichostatin C (Koghe et al., (1998), *Biochem. Pharmacol.,* 56:1359-1364).

[0156] B. Peptides, for example: oxamflatin [(2E)-5-[3-[(phenylsulfonyl)aminophenyl]-pent-2-ene-4-inohydroxamic acid (Kim et al., (1999), *Oncogene,* 18:2461-2470); Trapoxin A (cyclo-(L-phenylalanyl-L-phenylalanyl-D-pipecolinyl-L-2-amino-8-oxo-9,10-epoxy-decanoyl) (Kijima et al., (1993), *J. Biol. Chem.,* 268:22429-22435); FR901228, depsipeptide (Nakajima et al., (1998). *Ex. Cell Res.,* 241:126-133); FR225497, cyclic tetrapeptide (H. Mori et al., (2000), PCT International Patent Publication WO 00/08048); apicidin, cyclic tetrapeptide [cyclo-(N—O-methyl-L-tryptophanyl-L-isoleucinyl-D-pipecolinyl-L-2-amino-8-oxodecanoyl)] (Darkin-Rattray et al., (1996), *Proc. Natl. Acad. Sci. U.S.A.,* 93:13143-13147; apicidin Ia, apicidin Ib, apicidin Ic, apicidin Ia, and apicidin IIb (P. Dulski et al., PCT International Patent Publication WO 97/11366); HC-toxin, cyclic tetrapeptide (Bosch et al., (1995), *Plant Cell,* 7:1941-1950); WF27082, cyclic tetrapeptide (PCT International Patent Publication WO 98/48825); and chlamydocin (Bosch et al., supra).

[0157] C. Hybrid polar compounds (HPC) based on hydroxamic acid, for example: salicyl hydroxamic acid (SBHA) (Andrews et al., (2000), *International J. Parasitology,* 30:761-8); suberoylanilide hydroxamic acid (SAHA) (Richon et al., (1998), *Proc. Natl. Acad. Sci. U.S.A.,* 95:3003-7); azelaic bishydroxamic acid (ABHA) (Andrews et al., supra); azelaic-1-hydroxamate-9-anilide (AAHA) (Qiu et al., (2000), *Mol. Biol. Cell,* 11:2069-83); M-carboxy cinnamic acid bishydroxamide (CBHA) (Ricon et al., supra); 6-(3-chlorophenylureido) carpoic hydroxamic acid, 3-Cl-UCHA) (Richon et al., supra); MW2796 (Andrews et al., supra); and MW2996 (Andrews et al., supra).

[0158] D. Short chain fatty acid (SCFA) compounds, for example: sodium butyrate (Cousens et al., (1979), *J. Biol. Chem.,* 254:1716-23); isovalerate (McBain et al., (1997), *Biochem. Pharm.,* 53:1357-68); valproic acid; valerate (McBain et al., supra); 4-phenyl butyric acid (4-PBA) (Lea and Tulsyan, (1995), *Anticancer Research,* 15:879-3); phenyl butyric acid (PB) (Wang et al., (1999), Cancer Research 59:2766-99); propinate (McBain et al., supra); butylamide (Lea and Tulsyan, supra); isobutylamide (Lea and Tulsyan, supra); phenyl acetate (Lea and Tulsyan, supra); 3-bromopropionate (Lea and Tulsyan, supra); tributyrin (Guan et al., (2000), *Cancer Research,* 60:749-55); arginine butyrate; isobutyl amide; and valproate.

[0159] E. Benzamide derivatives, for example: MS-275 [N-(2-aminophenyl)-4-[N-(pyridine-3-yl-methoxycarbonyl) aminomethyl]benzamide] (Saito et al., (1999), *Proc. Natl. Acad. Sci. U.S.A.,* 96:4592-7); and a 3'-amino derivative of MS-275 (Saito et al., supra); and CI-994.

[0160] A histone deacetylase inhibitor treatment may be carried out, for example, as follows. The concentration of the HDAC inhibitor may depend on a particular inhibitor, but is preferably 0.001 nM to about 10 mM, and more preferably about 0.01 nM to about 1000 nM. The effective amount or the dosage of a histone deacetylase inhibitor is defined as the amount of the histone deacetylase inhibitor that does not

significantly decrease the survival rate of cells, specifically undifferentiated stem cells. Cells are exposed for 1 to 5 days or 1 to 3 days. The exposure period may be less than one day. In a specific embodiment, cells are cultured for about 1 to 5 days, and then exposed to an effective amount of a histone deacetylase inhibitor. However, the histone deacetylase inhibitor may be added at the start of culturing. Within such a time frame, a gene-carrying vehicle such as a vector containing a nucleic acid encoding three genes (Oct3/4, Sox2 and Klf4) is introduced into cultured cells by a known method.

[0161] E. IF Expression Vectors

[0162] Forced expression of the IFs may comprise introducing one or more mammalian expression vectors encoding an Oct3/4, a Sox2, and a Klf4 polypeptide to a population of cells. The IFs may be introduced into the cells as exogenous genes. In some cases, the exogenous genes are integrated into the genome of a host cell and its progeny. In other cases, the exogenous genes persist in an episomal state in the host cell and its progeny. Exogenous genes are genes that are introduced to the cell from an external source. A gene as used herein is a nucleic acid that normally includes an open reading frame encoding a polypeptide of interest, e.g., an IF. The gene preferably includes a promoter operably linked to an open reading frame. In some cases, a natural version of the gene may already exist in the cell but an additional "exogenous gene" is added to the cell to induce polypeptide expression.

[0163] The one or more mammalian expression vectors may be introduced into greater than 20% of the total population of cells, e.g., 25%, 30%, 35%, 40%, 44%, 50%, 57%, 62%, 70%, 74%, 75%, 80%, 90%, or other percent of cells greater than 20%. A single mammalian expression vector may contain two or more of the just-mentioned IFs. In other cases, one or more expression vectors encoding an Oct 3/4, Sox2, Klf4, and c-Myc polypeptide are used. In some embodiments, each of the IFs to be expressed is encoded on a separate mammalian expression vector.

[0164] In some cases, the IFs are genetically fused in frame with a transport protein amino acid sequence, e.g., that of a VP22 polypeptide as described in, e.g., U.S. Pat. Nos. 6,773,920, 6,521,455, 6,251,398, and 6,017,735. In particular, VP22 polypeptide encompasses polypeptides corresponding to amino acids 60-301 and 159-301 of the full HSV1 VP22 sequence (1-301), whose sequence is disclosed in FIG. 4 in WO 97/05265. Homologous proteins and fragments based on sequences of VP22 protein homologues from other herpes viruses are described in U.S. Pat. No. 6,017,735. Such VP22 sequences confer intercellular transport of VP22 fusion polypeptides from cells that have been transfected with a VP22 fusion polypeptide expression vector to neighboring cells that have not been transfected or transduced. See, e.g., Lemken et al., (2007), *Mol. Ther.*, 15(2):310-319. Accordingly, the use of vectors encoding IF-VP22 fusion polypeptides can significantly increase the functional efficiency of transfected mammalian expression vectors in the induction methods described herein.

[0165] Examples of suitable mammalian expression vectors include, but are not limited to: recombinant viruses, nucleic acid vectors, such as plasmids, bacterial artificial chromosomes, yeast artificial chromosomes, human artificial chromosomes, cDNA, cRNA, and PCR product expression cassettes. Examples of suitable promoters for driving expression of IFs include, but are not limited to, retroviral LTR elements; constitutive promoters such as CMV, HSV1-TK, SV40, EF-1α, β-actin; PGK, and inducible promoters, such as those containing Tet-operator elements. In some cases, one or more of the mammalian expression vectors encodes, in addition to an IF, a marker gene that facilitates identification or selection of cells that have been transfected or infected. Examples of marker genes include, but are not limited to, genes encoding fluorescent proteins, e.g., EGFP, DS-Red, YFP, and CFP; genes encoding proteins conferring resistance to a selection agent, e.g., the neo^R gene, and the blasticidin resistance gene.

[0166] 1. Recombinant Viruses

[0167] Forced expression of an IF may be accomplished by introducing a recombinant virus carrying DNA or RNA encoding an IF to one or more cells. For ease of reference, at times a virus will be referred to herein by the IF it is encoding. For example, a virus encoding an Oct3/4 polypeptide, may be described as an "Oct3/4 virus." In certain cases, a virus may encode more than one copy of an IF or may encode more than one IF, e.g., two IFs, at a time.

[0168] Combinations or sets of recombinant viruses may be introduced to the cells for force expression of various sets of IFs. In some cases, the set of IFs expressed by the recombinant viruses includes one or more: an Oct3/4 polypeptide, a Sox2 polypeptide, a Klf4 polypeptide, or a c-Myc polypeptide. In some cases, the set does not include a c-Myc polypeptide. For example, the set of IFs can include: an Oct3/4 polypeptide, a Sox2 polypeptide, and a Klf4 polypeptide, but not a c-Myc polypeptide. In some cases, the set of IFs does not include polypeptides that might increase the risk of cell transformation or the risk of inducing cancer. The ability of c-Myc to induce cell transformation has been described, see, e.g., Adhikary et al., (2005), *Nat. Rev. Mol. Cell. Biol.*, 6(8):635-645.

[0169] In some cases, the set of IFs to be expressed includes a c-Myc polypeptide. In certain cases, the c-Myc polypeptide is a constitutively active variant of c-Myc. In some instances, the set includes a c-Myc polypeptide capable of inducible activity, e.g., a c-Myc-ER polypeptide, see, e.g., Littlewood, et al., (1995), *Nucleic Acid Res.*, 23(10):1686-90.

[0170] In other cases, the set of IFs to be expressed includes: an Oct3/4 polypeptide, a Sox2 polypeptide, and a Klf4 polypeptide, but not a TERT polypeptide, a SV40 Large T antigen polypeptide, HPV16 E6 polypeptide, a HPV16 E7 polypeptide, or a Bmi1 polypeptide. In some cases, the set of IFs does not include a TERT polypeptide. In some cases, the set of IFs does not include a SV40 Large T antigen. In other cases, the set of IFS does not include a HPV16 E6 polypeptide or a HPV16 E7 polypeptide.

[0171] In some cases, the set of IFs includes three IFs, wherein two of the three IFs are an Oct3/4 polypeptide and a Sox2 polypeptide. In other cases, the set of IFs includes two IFs, wherein the two polypeptides are a c-Myc polypeptide and a Sox2 polypeptide. In some cases, the set of IFs is limited to Oct 3/4, Sox2, and Klf4 polypeptides. In other cases, the set of IFs may be limited to a set of four IFs: an Oct3/4 polypeptide, a Sox2 polypeptide, a Klf4 polypeptide, and a c-Myc polypeptide.

[0172] A set of IFs may include IFs in addition to an Oct 3/4, a Sox2, and a Klf4 polypeptide. Such additional IFs include, but are not limited to Nanog, TERT, LIN28, CYP26A1, GDF3, FoxD3, Zfp42, Dnmt3b, Ecat1, and Tcl1 polypeptides. In some cases, the set of additional IFs does not include a c-Myc polypeptide. In some cases, the set of additional IFs does not include polypeptides that might increase the risk of cell transformation or of inducing cancer.

[0173] Individual viruses may be added to the cells sequentially in time or simultaneously. In some cases, at least one virus, e.g., an Oct3/4 virus, a Sox2 virus, a Klf4 virus, or a c-Myc virus, is added to the cells at a time different from the time when one or more other viruses are added. In some examples, the Oct3/4 virus, Sox2 virus and KlF4 virus are added to the cells simultaneously, or very close in time, and the c-Myc virus is added at a time different from the time when the other viruses are added.

[0174] At least two recombinant viruses may be added to the cells simultaneously or very close in time. In some examples, Oct3/4 virus and Sox2 virus are added simultaneously, or very close in time, and the Klf4 virus or c-Myc virus is added at a different time. In some examples, Oct3/4 virus and Sox2 virus; Oct3/4 virus and Klf4 virus; Oct3/4 virus and c-Myc virus; Sox2 virus and Klf4 virus; Sox2 virus and c-Myc virus; or Klf4 and c-Myc virus are added simultaneously or very close in time.

[0175] In some cases, at least three viruses, e.g., an Oct3/4 virus, a Sox2 virus, and a Klf4 virus, are added to the cells simultaneously or very close in time. In other instances, at least four viruses, e.g., Oct3/4 virus, Sox2 virus, Klf4 virus, and c-Myc virus are added to the cells simultaneously or very close in time.

[0176] At times, the efficiency of viral infection can be improved by repetitive treatment with the same virus. In some cases, one or more Oct3/4 virus, Sox2 virus, Klf4 virus, or c-Myc virus is added to the cells at least two, at least three, or at least four separate times.

[0177] Examples of recombinant viruses include, but are not limited, to retroviruses (including lentiviruses); adenoviruses; and adeno-associated viruses. Often, the recombinant retrovirus is murine moloney leukemia virus (MMLV), but other recombinant retroviruses may also be used, e.g., Avian Leukosis Virus, Bovine Leukemia Virus, Murine Leukemia Virus (MLV), Mink-Cell focus-Inducing Virus, Murine Sarcoma Virus, Reticuloendotheliosis virus, Gibbon Abe Leukemia Virus, Mason Pfizer Monkey Virus, or Rous Sarcoma Virus, see, e.g., U.S. Pat. No. 6,333,195.

[0178] In other cases, the recombinant retrovirus is a lentivirus (e.g., Human Immunodeficiency Virus-1 (HIV-1); Simian Immunodeficiency Virus (SIV); or Feline Immunodeficiency Virus (FIV)), See, e.g., Johnston et al., (1999), *Journal of Virology,* 73(6):4991-5000 (FIV); Nègre D et al., (2002), *Current Topics in Microbiology and Immunology,* 261:53-74 (SIV); Naldini et al., (1996), *Science,* 272:263-267 (HIV).

[0179] The recombinant retrovirus may comprise a viral polypeptide (e.g., retroviral env) to aid entry into the target cell. Such viral polypeptides are well-established in the art, see, e.g., U.S. Pat. No. 5,449,614. The viral polypeptide may be an amphotropic viral polypeptide, e.g., amphotropic env, that aids entry into cells derived from multiple species, including cells outside of the original host species. See, e.g., id. The viral polypeptide may be a xenotropic viral polypeptide that aids entry into cells outside of the original host species. See, e.g., id. In some embodiments, the viral polypeptide is an ecotropic viral polypeptide, e.g., ecotropic env, that aids entry into cells of the original host species. See, e.g., id.

[0180] Examples of viral polypeptides capable of aiding entry of retroviruses into cells include but are not limited to: MMLV amphotropic env, MMLV ecotropic env, MMLV xenotropic env, vesicular stomatitis virus-g protein (VSV-g), HIV-1 env, Gibbon Ape Leukemia Virus (GALV) env, RD114, FeLV-C, FeLV-B, MLV 10A1 env gene, and variants thereof, including chimeras. See e.g., Yee et al., (1994), *Methods Cell Biol., Pt A:*99-112 (VSV-G); U.S. Pat. No. 5,449,614. In some cases, the viral polypeptide is genetically modified to promote expression or enhanced binding to a receptor.

[0181] In general, a recombinant virus is produced by introducing a viral DNA or RNA construct into a producer cell. In some cases, the producer cell does not express exogenous genes. In other cases, the producer cell is a "packaging cell" comprising one or more exogenous genes, e.g., genes encoding one or more gag, pol, or env polypeptides and/or one or more retroviral gag, pol, or env polypeptides. The retroviral packaging cell may comprise a gene encoding a viral polypeptide, e.g., VSV-g that aids entry into target cells. In some cases, the packaging cell comprises genes encoding one or more lentiviral proteins, e.g., gag, pol, env, vpr, vpu, vpx, vif, tat, rev, or nef. In some cases, the packaging cell comprises genes encoding adenovirus proteins such as E1A or E1B or other adenoviral proteins. For example, proteins supplied by packaging cells may be retrovirus-derived proteins such as gag, pol, and env; lentivirus-derived proteins such as gag, pol, env, vpr, vpu, vpx, vif, tat, rev, and nef; and adenovirus-derived proteins such as E1A and E1B. In many examples, the packaging cells supply proteins derived from a virus that differs from the virus from which the viral vector derives.

[0182] Packaging cell lines include but are not limited to any easily-transfectable cell line. Packaging cell lines can be based on 293T cells, NIH3T3, COS or HeLa cell lines. Packaging cells are often used to package virus vector plasmids deficient in at least one gene encoding a protein required for virus packaging. Any cells that can supply a protein or polypeptide lacking from the proteins encoded by such virus vector plasmid may be used as packaging cells. Examples of packaging cell lines include but are not limited to: Platinum-E (Plat-E); Platinum-A (Plat-A); BOSC 23 (ATCC CRL 11554); and Bing (ATCC CRL 11270), see, e.g., Morita et al., (2000), *Gene Therapy,* 7:1063-1066; Onishi et al., (1996), *Experimental Hematology,* 24:324-329; U.S. Pat. No. 6,995,009. Commercial packaging lines are also useful, e.g., Ampho-Pak 293 cell line, Eco-Pak 2-293 cell line, RetroPack PT67 cell line, and Retro-X Universal Packaging System (all available from Clontech).

[0183] The retroviral construct may be derived from a range of retroviruses, e.g., MMLV, HIV-1, SIV, FIV, or other retrovirus described herein. The retroviral construct may encode all viral polypeptides necessary for more than one cycle of replication of a specific virus. In some cases, the efficiency of viral entry is improved by the addition of other factors or other viral polypeptides. In other cases, the viral polypeptides encoded by the retroviral construct do not support more than one cycle of replication, e.g., U.S. Pat. No. 6,872,528. In such circumstances, the addition of other factors or other viral polypeptides can help facilitate viral entry. In an exemplary embodiment, the recombinant retrovirus is HIV-1 virus comprising a VSV-g polypeptide but not comprising a HIV-1 env polypeptide.

[0184] The retroviral construct may comprise: a promoter, a multi-cloning site, and/or a resistance gene. Examples of promoters include but are not limited to CMV, SV40, EF1α, β-actin; retroviral LTR promoters, and inducible promoters. The retroviral construct may also comprise a packaging signal (e.g., a packaging signal derived from the MFG vector; a

psi packaging signal). Examples of some retroviral constructs known in the art include but are not limited to: pMX, pBabeX or derivatives thereof. See e.g., Onishi et al., (1996), *Experimental Hematology,* 24:324-329. In some cases, the retroviral construct is a self-inactivating lentiviral vector (SIN) vector, see, e.g., Miyoshi et al., (1998), *J. Virol.,* 72(10):8150-8157. In some cases, the retroviral construct is LL-CG, LS-CG, CL-CG, CS-CG, CLG or MFG. Miyoshi et al., (1998), *J. Virol.,* 72(10):8150-8157; Onishi et al., (1996), *Experimental Hematology,* 24:324-329; Riviere et al., (1995), *PNAS,* 92:6733-6737. Virus vector plasmids (or constructs), include: pMXs, pMxs-IB, pMXs-puro, pMXs-neo (pMXs-IB is a vector carrying the blasticidin-resistant gene in stead of the puromycin-resistant gene of pMXs-puro) Kimatura et al., (2003), *Experimental Hematology,* 31: 1007-1014; MFG Riviere et al., (1995), *Proc. Natl. Acad. Sci. U.S.A.,* 92:6733-6737; pBabePuro; Morgenstern et al., (1990), *Nucleic Acids Research,* 18:3587-3596; LL-CG, CL-CG, CS-CG, CLG Miyoshi et al., (1998), *Journal of Virology,* 72:8150-8157 and the like as the retrovirus system, and pAdex1 Kanegae et al., (1995), *Nucleic Acids Research,* 23:3816-3821 and the like as the adenovirus system. In exemplary embodiments, the retroviral construct comprises blasticidin (e.g., pMXs-IB), puromycin (e.g., pMXs-puro, pBabePuro); or neomycin (e.g., pMXs-neo). See, e.g., Morgenstern et al., (1990), *Nucleic Acids Research,* 18:3587-3596.

[0185] The retroviral construct may encode one or more IFs. In an exemplary embodiment, pMX vectors encoding Oct3/4, Sox2, Klf4, or c-Myc polypeptides, or variants thereof, are generated or obtained. For example, Oct3/4 is inserted into pMXs-puro to create pMX-Oct3/4; Sox2 is inserted into pMXs-neo to create pMX-Sox2; Klf4 is inserted into pMXs-IB to create pMX-Klf4; and c-Myc is inserted into pMXs-IB to create pMX-c-Myc.

[0186] Methods of producing recombinant viruses from packaging cells and their uses are well-established, see, e.g, U.S. Pat. Nos. 5,834,256; 6,910,434; 5,591,624; 5,817,491; 7,070,994; and 6,995,009, incorporated herein by reference. Many methods begin with the introduction of a viral construct into a packaging cell line. The viral construct may be introduced by any method known in the art, including but not limited to: the calcium phosphate method (see, e.g., Kokai, Japanese Unexamined Patent Publication No. 2-227075, the lipofection method Felgner et al., (1987), *Proc. Natl. Acad. Sci. U.S.A.,* 84:7413-7417, the electroporation method, microinjection, Fugene transfection, and the like, and any method described herein.

[0187] In one example, pMX-Oct3/4, pMX-Sox2, pMX-Klf4 or pMX-c-Myc is introduced into PlatE cells by Fugene HD (Roche) transfection. The cell culture medium may be replaced with fresh medium comprising FBM (Lonza) supplemented with FGM-2 Single Quots (Lonza). In some embodiments, the medium is replaced from about 12 to about 60 hours following the introduction of the viral construct, e.g., from about 12 to about 18 hours; about 18 to about 24; about 24 to about 30; about 30 to about 36; about 36 to about 42; about 42 to about 48; about 48 to about 54; or about 54 to about 60 hours following introduction of the viral construct to the producer cells. The medium may be replaced from about 24 to about 48 hours after introduction of the viral construct to the producer cells. The supernatant can be recovered from about 4 to about 24 hours following the addition of fresh media, e.g., about 4 hours. In some cases, the supernatant may be recovered about every 4 hours following the addition of fresh media. The recovered supernatant may be passed through a 0.45 uM filter (Millipore). In some cases, the recovered supernatant comprises retrovirus derived from one or more: pMX-Oct3/4, pMX-Sox2, pMX-Klf4 or pMX-c-Myc.

[0188] Adenoviral transduction may be used to force expression of the sets of IFs. Methods for generating adenoviruses and their use are well established as described in, e.g., Straus, The Adenovirus, Plenum Press (NY 1984), 451 496; Rosenfeld, et al., (1991), *Science,* 252:431-434; U.S. Pat. Nos. 6,203,975, 5,707,618, and 5,637,456. In other cases, adenoviral-associated viral transduction is used to force expression of the sets of IFs. Methods for preparing adeno-associated viruses and their use are well established as described in, e.g., U.S. Pat. Nos. 6,660,514 and 6,146,874.

[0189] In an exemplary embodiment, an adenoviral construct is obtained or generated, wherein the adenoviral construct, e.g., Adeno-X, comprises DNA encoding Oct3/4, Sox2, Klf4, or c-Myc. An adenoviral construct may be introduced by any method known in the art, e.g., Lipofectamine 2000 (Invitrogen) or Fugene HD (Roche), into HEK 293 cells. In some cases, the method further comprises (1) collecting the cells when they exhibit a cytopathic effect (CPE), such effect occurring from about 10 to about 20 days, e.g., about 11, 13, 14, 15, 18, or 20 days after transfection (2) subjecting the cells to from about 2 to about 5 freeze-thaw cycles, e.g., about 3, (3) collecting the resulting virus-containing liquid; (4) purifying the virus using an adenovirus purification kit (Clontech) and (5) storing the virus at −80° C. In some cases, the titer, or plaque-forming unit (PFU), of the adenoviral stocks is determined using an Adeno-X rapid titer kit (Clontech), as described herein.

[0190] The cells may be infected with a recombinant retrovirus that naturally targets a different cell type or cells originating from a different host. To aid infection efficiency, an exogenous receptor may be first introduced into the human cells. For example, an exogenous mouse receptor may be added to human cells, e.g., postnatal dermal fibroblasts, in order help entry of murine moloney leukemia virus (MMLV). The exogenous receptor may improve infection efficiency by facilitating viral entry, especially if the receptor recognizes a viral polypeptide, e.g., MMLV env, or HIV env. Examples of exogenous receptors include but are not limited to any receptor recognized by a specific retrovirus or lentivirus known in the art. For example, a murine receptor, mCAT1, GenBank Accession No NM_007513 protein is used in order to aid MMLV infection of a human target cell.

[0191] The exogenous receptor may be introduced by methods described herein. Methods of introducing the exogenous receptor include but are not limited to: calcium phosphate transfection, Lipofectamine transfection, Fugene transfection, microinjection, or electroporation. In exemplary embodiments, a virus, e.g., recombinant adenovirus or retrovirus (including lentivirus), is used to introduce the exogenous receptor to the target cell. In a further exemplary embodiment, a recombinant adenovirus is used to introduce mCAT1 to human cells and then a recombinant retrovirus, e.g., MMLV, is used to introduce the IF genes, e.g., Oct 3/4, a Sox2, a Klf4, or c-Myc, to the cells.

[0192] In some cases, a solution of adenovirus comprising DNA encoding the mCAT1 protein, e.g., an adenovirus generated by using a pADEX-mCAT1 construct, is generated or obtained. The adenovirus solution can comprise Hanks' balanced salt solution. In exemplary embodiments, infection of cells is accomplished by: (1) contacting the p-ADEX-mCAT1

adenovirus solution with cells, e.g., human, non-embryonic fibroblasts, at a multiplicity of infection (m.o.i.) (virus to cell ratio) from about 1 m.o.i. to about 50 m.o.i., e.g., about 1 m.o.i., about 5 m.o.i., about 7.5; m.o.i., about 10 m.o.i., about 15 m.o.i., about 20 m.o.i., about 30 m.o.i., about 40 m.o.i., or about 50 m.o.i.; (2) incubating the cells with the adenovirus solution at room temperature from about 15 minutes to about 2 hours, e.g., about 15 minutes, about 30 minutes, about 45 minutes, about 1 hour, about 1.25 hours, about 1.5 hours, about 1.75 hours, or about 2 hours; and (3) culturing the somatic cell population in culture medium from about 24 hours to about 60 hours, e.g., about 24 hours, about 30 hours, about 36 hours, about 42 hours, about 48 hours, about 54 hours, or about 60 hours.

[0193] The cells can be infected using a wide variety of methods. In some cases, the infection of cells occurs by (1) combining one or more, two or more, three or more, or all four: pMX-Oct3/4 retrovirus, pMX-Sox2 retrovirus, pMX-Klf4, or pMX-c-Myc to obtain a retrovirus solution (2) supplementing the retrovirus solution with from about 2 ug/ml to about 15 ug/ml Polybrene, e.g., about 2 ug/ml, about 3 ug/ml, about 5 ug/ml, about 7 ug/ml, about 10 ug/ml, about 12 ug/ml, or about 15 ug/ml Polybrene; (3) contacting the retroviral solution with the somatic cells, at a m.o.i. (virus-to-cell ratio) of from about 0.5 m.o.i. to about 10 m.o.i., e.g., about 0.5 m.o.i., about 1 m.o.i., about 2 m.o.i., about 5 m.o.i., about 7.5 m.o.i., or about 10 m.o.i.; (4) allowing the contacting of step (3) to continue at 37° C. from about 2 hours to about 24 hours, e.g., about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, or about 24 hours; (5) soon after the contacting of step (4), changing the medium to MC-ES medium, as described herein; and (6) changing the MC-ES medium with fresh medium every 1 to 2 days. In some cases, infection of somatic cells occurs by following steps (1) through (6) described herein, with the added step of pre-incubating the somatic cells for a length of time, e.g., about 48 hours, prior to contacting the cells with the retroviral solution. Such pre-incubation may be necessary when the somatic cell expresses an exogenous receptor that was introduced by viral transduction, transfection, or other method. Thus, in some embodiments, if an adenovirus or lentivirus is used to introduce an exogenous receptor, e.g., mCAT1, to the somatic cell; such cells may need to be cultured for a length of time from at least about 30 hours to at least about 60 hours, e.g., about 30, about 35, about 40, about 48, about 52, about 55, or about 60 hours.

[0194] The infection of cells may be accomplished by any method known in the art. e.g., Palsson, B., et al., (1995), WO95/10619; Morling, F. J. et al., (1995), *Gene Therapy,* 2:504-508; Gopp et al., (2006), *Methods Enzymol,* 420:64-81. For example, the infection may be accomplished by spin-infection or "spinoculation" methods that involve subjecting the cells to centrifugation during the period closely following the addition of virus to the cells. In some cases, virus may be concentrated prior to the infection, e.g., by ultracentrifugation. In some cases, other technologies may be used to aid or improve entry of retroviruses into the target cell. For example, the retrovirus may be contacted with a liposome or immunoliposome to aid or direct entry into a specific cell type. See, e.g., Tan et al., (2007), *Mol. Med.* 13(34):216-226.

[0195] The methods of infecting cells described herein may be used to infect cells expressing an exogenous receptor, e.g., mCAT1 or other exogenous receptor described herein. Depending on how the exogenous receptor was introduced, the preincubation period of the cells prior to infection may need to be varied. In some cases, cells that do not express an exogenous receptor are used. Some recombinant retroviruses, e.g., VSV-G pseudotyped recombinant retroviruses, may not need the aid of an exogenous receptor in order to efficiently enter cells. In some examples, VSV-G pseudotyped recombinant retrovirus is introduced to cells following the method described herein, except that the timing of the preculturing of the cells may vary.

[0196] 2. Nucleic Acid Vectors

[0197] Nucleic acid vector transfection (e.g., transient transfection) methods may be used to introduce IFs into human cells. Methods for preparation of transfection-grade nucleic acid expression vectors and transfection methods are well established. See, e.g., Sambrook and Russell (2001), "Molecular Cloning: A Laboratory Manual," 3rd ed, (CSHL Press); and Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (2005), 9.1-9.14. Examples of high efficiency transfection efficiency methods include "nucleofection," as described in, e.g., Trompeter (2003), *J Immunol. Methods,* 274(1-2):245-256, and in international patent application publications WO2002086134, WO200200871, and WO2002086129, transfection with lipid-based transfection reagents such as Fugene® 6 and Fugene® HD(Roche), DOTAP, and Lipofectamine™ LTX in combination with the PLUS™ (Invitrogen, Carlsbad, Calif.), Dreamfect™ (OZ Biosciences, Marseille, France), GeneJuice™ (Novagen, Madison, Wis.), polyethylenimine (see, e.g., Lungwitz et al., (2005), *Eur. J Pharm. Biopharm.,* 60(2):247-266), and GeneJammer™ (Stratagene, La Jolla, Calif.), and nanoparticle transfection reagents as described in, e.g., U.S. patent application Ser. No. 11/195,066.

[0198] 3. Protein Transduction

[0199] The induction methods may use protein transduction to introduce at least one of the IFs directly into cells. In some cases, protein transduction method includes contacting cells with a composition containing a carrier agent and at least one purified polypeptide comprising the amino acid sequence of one of the above-mentioned IFs. Examples of suitable carrier agents and methods for their use include, but are not limited to, commercially available reagents such as Chariot™ (Active Motif, Inc., Carlsbad, Calif.) described in U.S. Pat. No. 6,841,535; Bioport® (Gene Therapy Systems, Inc., San Diego, Calif.), GenomeONE (Cosmo Bio Co., Ltd., Tokyo, Japan), and ProteoJuice™ (Novagen, Madison, Wis.), or nanoparticle protein transduction reagents as described in, e.g., in U.S. patent application Ser. No. 10/138,593.

[0200] The protein transduction method may comprise contacting a cells with at least one purified polypeptide comprising the amino acid sequence of one of the above-mentioned IFs fused to a protein transduction domain (PTD) sequence (IF-PTD fusion polypeptide). The PTD domain may be fused to the amino terminal of an IF sequence; or, the PTD domain may be fused to the carboxy terminal of an IF sequence. In some cases, the iF-PTD fusion polypeptide is added to cells as a denatured polypeptide, which may facilitate its transport into cells where it is then renatured. Generation of PTD fusion proteins and methods for their use are established in the art as described in, e.g., U.S. Pat. Nos. 5,674,980, 5,652,122, and 6,881,825. See also, Becker-

Hapak et al., (2003), *Curr Protocols in Cell Biol*, John Wiley & Sons, Inc. Exemplary PTD domain amino acid sequences include, but are not limited to, any of the following: YGRKKRRQRRR (SEQ ID NO:1); RKKRRQRR (SEQ ID NO:2); YARAAARQARA (SEQ ID NO:3); THRL-PRRRRRR (SEQ ID NO:4); and GGRRARRRRRR (SEQ ID NO:5).

[0201] In some cases, individual purified IF polypeptides are added to cells sequentially at different times. In other embodiments, a set of at least three purified IF polypeptides, but not a purified c-Myc polypeptide, e.g., an Oct3/4 polypeptide, a Sox2 polypeptide, and a Klf4 polypeptide are added to cells. In some embodiments, a set of four purified IF polypeptides, e.g., purified Oct3/4, Sox2, Klf4, and c-Myc polypeptides are added to cells. In some embodiments, the purified IF polypeptides are added to cells as one composition (i.e., a composition containing a mixture of the IF polypeptides). In some embodiments, cells are incubated in the presence of a purified IF polypeptide for about 30 minutes to about 24 hours, e.g., 1 hours, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 12 hours, 16 hours, 18 hours, 20 hours, or any other period from about 30 minutes to about 24 hours. In some embodiments, protein transduction of cells is repeated with a frequency of about every day to about every 4 days, e.g., every 1.5 days, every 2 days, every 3 days, or any other frequency from about every day to about every four days with the same or different IF polypeptides.

[0202] In some cases, the methods described herein utilize protein transduction and expression vector transduction/transfection in any combination to force expression of a set of IFs as described herein. In some embodiments, retroviral expression vectors are used to force expression of Oct 3/4, a Sox2, and a Klf4 polypeptides in cells, and purified c-Myc purified polypeptide is introduced into cells by protein transduction as described herein. HDAC inhibitor treatment can be used in addition to the purified IF polypeptide. In some cases, a set of at least three purified IF polypeptides, but not a purified c-Myc polypeptide, e.g., an 3/4Oct3/4 polypeptide, a Sox2 polypeptide, and a Klf4 polypeptide are added to cells which are also subjected to HDAC inhibitor treatment.

[0203] F. Induction Factor Sequences

[0204] Described herein are polypeptides comprising the amino acid sequences of IFs used in the induction methods described herein, and exogenous genes encoding such polypeptides. In some embodiments, an IF amino acid sequence is a naturally occurring amino acid sequence, e.g., that of: human or mouse Oct 3/4, human or mouse Sox2, human or mouse Klf4, or human or mouse c-Myc polypeptides. In other embodiments, the amino acid sequence of an IF is a non-naturally occurring amino acid sequence variant of an IF that is, nevertheless, functionally or structurally homologous to an IF amino acid sequence, as described herein.

[0205] Evaluating the structural and functional homology of two or polypeptides generally includes determining the percent identity of their amino acid sequences to each other. Sequence identity between two or more amino acid sequences is determined by conventional methods. See, for example, Altschul et al., (1997), *Nucleic Acids Research,* 25(17):3389-3402; and Henikoff and Henikoff (1982), *Proc. Natl. Acad. Sci. USA,* 89:10915 (1992). Briefly, two amino acid sequences are aligned to optimize the alignment scores using a gap opening penalty of 10, a gap extension penalty of 1, and the "BLOSUM62" scoring matrix of Henikoff and Henikoff (ibid.). The percent identity is then calculated as: ([Total number of identical matches]/[length of the longer sequence plus the number of gaps introduced into the longer sequence in order to align the two sequences])(100).

[0206] Those skilled in the art will appreciate that there are many established algorithms available to align two amino acid sequences. The "FASTA" similarity search algorithm of Pearson and Lipman is a suitable protein alignment method for examining the level of identity shared by an amino acid sequence disclosed herein and the amino acid sequence of another peptide. The FASTA algorithm is described by Pearson and Lipman (1988), *Proc. Nat'l Acad. Sci. USA,* 85:2444, and by Pearson (1990), *Meth. Enzymol.,* 183:63. Briefly, FASTA first characterizes sequence similarity by identifying regions shared by the query sequence (e.g., any of SEQ ID NOs:6-13) and a test sequence that have either the highest density of identities (if the ktup variable is 1) or pairs of identities (if ktup=2), without considering conservative amino acid substitutions, insertions, or deletions. The ten regions with the highest density of identities are then rescored by comparing the similarity of all paired amino acids using an amino acid substitution matrix, and the ends of the regions are "trimmed" to include only those residues that contribute to the highest score. If there are several regions with scores greater than the "cutoff" value (calculated by a predetermined formula based upon the length of the sequence and the ktup value), then the trimmed initial regions are examined to determine whether the regions can be joined to form an approximate alignment with gaps. Finally, the highest scoring regions of the two amino acid sequences are aligned using a modification of the Needleman-Wunsch-Sellers algorithm (Needleman and Wunsch (1970), *J. Mol. Biol.,* 48:444-453; Sellers (1974), *SIAM J. Appl. Math.,* 26:787), which allows for amino acid insertions and deletions. Illustrative parameters for FASTA analysis are: ktup=1, gap opening penalty=10, gap extension penalty=1, and substitution matrix=BLOSUM62. These parameters can be introduced into a FASTA program by modifying the scoring matrix file ("SMATRIX"), as explained in Appendix 2 of Pearson (1990), *Meth. Enzymol.,* 183:63.

[0207] Also described herein are nucleic acids (e.g., exogenous genes) encoding Oct3/4, Sox2, Klf4, or c-Myc polypeptides, as described herein, that hybridize specifically under low, medium, or high stringency conditions to a probe of at least 100 nucleotides from a nucleic acid encoding the amino acid sequence any of SEQ ID NOs:6-13. Low stringency hybridization conditions include, e.g., hybridization with a 100 nucleotide probe of about 40% to about 70% GC content; at 42° C. in 2×SSC and 0.1% SDS. Medium stringency hybridization conditions include, e.g., at 50° C. in 0.5×SSC and 0.1% SDS. High stringency hybridization conditions include, e.g., hybridization with the above-mentioned probe at 65° C. in 0.2×SSC and 0.1% SDS. Under these conditions, as the hybridization temperature is elevated, a nucleic acid with a higher homology can be obtained. Such nucleic acids encoding Oct 3/4, Sox2, Klf4, or c-Myc polypeptides are useful in the forced expression of these IFs as described herein.

[0208] A number of considerations are useful to the skilled artisan in determining if a particular amino acid sequence variant of an IF is suitable for use in the methods described herein. These considerations include, but are not limited to: (1) known structure-function relationships for the IF, e.g., the

presence of modular domains such as a DNA binding domain or a transactivation domain, which, in many cases, have been shown to be functionally discrete and capable of independent function; (2) the presence of amino acid sequence conservation among naturally occurring homologs (e.g., in paralogs and orthologs) of the IF, as revealed by sequence alignment algorithms as described herein. Notably, a number of bioinformatic algorithms are known in the art that successfully predict the functional effect, i.e., "tolerance" of particular amino substitutions in the amino acid sequence of a protein on its function. Such algorithms include, e.g., pMUT, SIFT, PolyPhen, and SNPs3D. For a review see, e.g., Ng and Henikoff (2006), *Ann Rev Genomics Hum Genet.,* 7:61-80. For example, pMUT predicts with a high degree of accuracy (about 84% overall) whether a particular amino acid substitution at a given sequence position affects a protein's function based on sequence homology. See Ferrer-Costa et al., (2005), *Bioinformatics,* 21(14):3176-3178; Ferrer-Costa et al., (2004), *Proteins,* 57(4):811-819; and Ferrer-Costa et al., (2002), *J Mol Biol,* 315:771-786. The PMUT algorithm server is publicly available on the world wide web at: //mmb2.pcb.ub.es:8080/PMut/. Thus, for any IF polypeptide amino acid sequence, an "amino acid substitution matrix" can be generated that provides the predicted neutrality or deleteriousness of any given amino acid substitution on IF polypeptide function.

[0209] Non-naturally occurring sequence variants can be generated by a number of known methods. Such methods include, but are not limited to, "Gene Shuffling," as described in U.S. Pat. No. 6,521,453; "RNA mutagenesis," as described in Kopsidas et al., (2007), *BMC Biotechnology,* 7:18-29; and "error-prone PCR methods." Error prone PCR methods can be divided into (a) methods that reduce the fidelity of the polymerase by unbalancing nucleotides concentrations and/or adding of chemical compounds such as manganese chloride (see, e.g., Lin-Goerke et al., (1997), *Biotechniques,* 23:409-412), (b) methods that employ nucleotide analogs (see, e.g., U.S. Pat. No. 6,153,745), (c) methods that utilize 'mutagenic' polymerases (see, e.g., Cline, J. and Hogrefe, H. H. (2000), *Strategies* (Stratagene Newsletter), 13:157-161 and (d) combined methods (see, e.g., Xu et al., (1999), *Biotechniques,* 27:1102-1108. Other PCR-based mutagenesis methods include those, e.g., described by Osuna et al., (2004), *Nucleic Acids Res.,* 32(17):e136 and Wong et al., (2004), *Nucleic Acids Res.,* 10; 32(3):e26), and others known in the art.

[0210] Confirmation of the retention, loss, or gain of function of the amino acid sequence variants of an IF can be determined in various types of assays according to the protein function being assessed. For example, where the IF is a transcriptional activator, e.g., an Oct3/4, function is readily assessed using cell-based, promoter-reporter assays, where the reporter construct comprises one or more cognate target elements for the transactivator polypeptide to be assayed. Methods for generating promoter-reporter constructs, introducing them into cells, and assaying various reporter polypeptide activities, can be found in detail in, e.g., *Current Protocols in Molecular Biology*, John Wiley & Sons, N.Y. (2005), 3.16-3.17 and 9.1-9.14, respectively). Promoter activity can be quantified by measuring a property of the reporter polypeptide (e.g., enzymatic activity or fluorescence), reporter polypeptide expression (e.g., by an ELISA assay), or reporter mRNA expression (e.g., by a fluorescent hybridization technique). Suitable reporter polypeptides include, e.g., firefly luciferase, *Renilla* luciferase, fluorescent proteins (e.g., enhanced green fluorescent protein), β-galactosidase, β lactamase, ALP, and horseradish peroxidase.

[0211] For example, luciferase activity can be detected by providing an appropriate luminogenic substrate, e.g., firefly luciferin for firefly luciferase or coelenterazine for *Renilla* luciferase. Luciferase activity in the presence of an appropriate substrate can be quantified by a number of standard techniques, e.g., luminometry. See, e.g., U.S. Pat. No. 5,744,320. Fluorescent polypeptides (e.g., EGFP) can be detected and quantified in live cells by a number of detection methods known in the art (e.g., fluorimetry or fluorescence microscopy). Details of reporter assay screens in live cells using fluorescent polypeptides, including high-throughput screening methods, can be found, e.g., in U.S. Pat. No. 6,875,578.

[0212] Described herein are a number of IFs that are transcriptional activators, i.e., polypeptides that transactivate promoters containing specific target elements to which the transcriptional activator binds as a monomer, a multimer, or in a heteromeric complex with other polypeptides. Naturally occurring transcriptional activators, e.g., Klf4, are modular proteins minimally composed of two domains as follows: a DNA binding domain that dictates the genes to be targeted and an activation domain that governs the nature and the extent of the transcriptional response through interactions with the transcriptional machinery. The two domains typically operate in an independent fashion such that the DNA binding domain of one transcriptional activator, e.g., the DNA binding domain Sox2, can be attached to the transactivation domain of another transcriptional activator, e.g., Herpes VP16, to generate a fully functional, "chimeric" transcriptional activator, e.g., a chimeric Sox2 transcriptional activator as described in, e.g., Kamachi et al., (1999), *Mol Cell Biol.,* 19(1): 107-120.

[0213] In view of the guidance provided herein, a broad range of IF sequence variants (e.g., Oct3/4, Sox2, Klf4, or c-Myc sequence variants), operable in the methods described herein, can readily be identified by those of ordinary skill in the art without undue effort.

Oct3/4 Polypeptide

[0214] As referred to herein, an "Oct3/4 polypeptide" includes human Oct 3/4, mouse Oct 3/4, or any polypeptide that:

(i) includes a DNA binding domain (DBD) that binds to the human nanog gene Octamer element:

```
5'-TTTTGCAT-3'; and
```

(ii) is capable of transactivating a promoter comprising one or more nanog Octamer elements. See, e.g., Kuroda et al., (2005), *Mol and Cell Biol.,* 25(6):2475-2485.

[0215] In some embodiments, an Oct3/4 is a polypeptide having the above-mentioned functional properties, and comprising an amino acid sequence at least 70% identical to SEQ ID NO:6 corresponding to the amino acid sequence of human Oct 3/4, also known as *Homo sapiens* POU class 5 homeobox 1 (POU5F1; GenBank Accession No. NP_002692), e.g., 75%, 80%, 85%, 90%, 91%, 92%, 95%, 97%, 99%, or any other percent identical from at least 70% to 100% identical to SEQ ID NO:6. In some embodiments, an Oct3/4 is a polypeptide having the above-mentioned functional properties, and comprising an amino acid sequence from at least 70% to less

than 100% identical (e.g., 75%, 80%, 85%, 90%, 91%, 92%, 95%, 97%, 99% identical) to SEQ ID NO:6, e.g., SEQ ID NO: 6 with at least one amin amino acid substitution, deletion, or insertion. In other embodiments, an Oct-3/4 is a polypeptide having the above-mentioned functional properties comprising the amino acid sequence of SEQ ID NO:6 with up to a total of 30 amino acid substitutions, deletions, insertions, or any combination thereof, e.g., SEQ ID NO:6 with 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 15, 20, 25, or any other number of amino acid substitutions, deletions, insertions, or any combination thereof, from 0 to 30.

SEQ ID NO:6 (Human Oct 3/4):
MAGHLASDFAFSPPPGGGGDGPGGPEPGWVDPRTWLSFQGPPGGPGIGPG

VGPGSEVWGIPPCPPPYEFCGGMAYCGPQVGVGLVPQGGLETSQPEGEAG

VGVESNSDGASPEPCTVTPGAVKLEKEKLEQNPEESQDIKALQKELEQFA

KLLKQKRITLGYTQADVGLTLGVLFGKVFSQTTICRFEALQLSFKNMCKL

RPLLQKWVEEADNNENLQEICKAETLVQARKRKRTSIENRVRGNLENLFL

QCPKPTLQQISHIAQQLGLEKDVVRVWFCNRRQKGKRSSSDYAQREDFEA

AGSPFSGGPVSFPLAPGPHFGTPGYGSPHFTALYSSVPFPEGEAFPPVSV

TTLGSPMHSN

[0216] In some embodiments, an Oct3/4 is a polypeptide having the above-mentioned functional properties, and comprising an amino acid sequence at least 70% identical to SEQ ID NO:7, e.g., 75%, 80%, 85%, 90%, 91%, 92%, 95%, 97%, 99%, or any other percent identical from at least 70% to 100% identical to SEQ ID NO:7, corresponding to amino acids 138-290 of Human Oct3/4 comprising the highly conserved POU DNA binding domain. In some embodiments, an Oct3/4 is a polypeptide having the above-mentioned functional properties, and comprising an amino acid sequence from at least 70% to less than 100% identical (e.g., 75%, 80%, 85%, 90%, 91%, 92%, 95%, 97%, 99% identical) to SEQ ID NO:7, e.g., SEQ ID NO: 7 with at least one amino acid substitution, deletion, or insertion (e.g., 1 to 10 amino acid substitutions, deletions, or insertions).

(POU/DNA BindinG Domain of Human Oct 3/4)
SEQ ID NO:7
DIKALQKELEQFAKLLKQKRITLGYTQADVGLTLGVLFGKVFSQTTICRF

EALQLSFKNMCKLRPLLQKWVEEADNNENLQEICKAETLVQARKRKRTSI

ENRVRGNLENLFLQCPKPTLQQISHIAQQLGLEKDVVRVWFCNRRQKGKR

SSS

[0217] Oct3/4 polypeptides, as described herein, may include naturally occurring or non-naturally occurring homologs of human Oct 3/4. Examples of naturally occurring homologs of human Oct3/4 include, but are not limited to, those listed under GenBank Accession Nos: NP_002692; NP_001108427; NP_001093427; NP_001009178; and NP_038661, or any other Oct family members that meet the above-mentioned structural and functional criteria.

[0218] Examples of non-naturally occurring homologs of human Oct 3/4, include, but are not limited to those described in, e.g., Niwa et al., (2002), *Mol Cell Biol.,* 22(5):1526-1536; and Lunde et al., (2004), *Curr. Biol.,* 14(1):48-55.

[0219] pMUT analysis of the human Oct3/4 amino acid sequence (SEQ ID NO:6) based on a PSI-BLAST multiple alignment encompassing 250 sequences yields an amino acid substitution matrix (ASM) as shown in Table 17. For each wild-type amino acid position in the human Oct3/4 amino acid sequence, Table 17 shows which amino acid substitutions (of 20 possible amino acids) are predicted to be deleterious (bold and underlined) or neutral (plain text) to the protein's function. Functional assays for the ability of Oct3/4 polypeptides to bind to the cognate nanog gene octamer element (described above) and to transactivate a promoter containing one or more nanog target elements are known in the art as described in, e.g., Kuroda et al., (supra); and Loh et al., (2006), *Nat. Genet.,* 39(4):431-440.

Sox2 Polypeptide

[0220] As referred to herein, a "Sox2 polypeptide" includes human Sox2, mouse Sox2, or any polypeptide that:

(i) includes a DNA binding domain (DBD) that binds to the human nanog gene Sox element:

5'-TACAATG-3'; and

(ii) is capable of transactivating a promoter comprising one or more nanog gene promoter Sox elements. See, e.g., Kuroda et al., (2005), *Mol and Cell Biol.,* 25(6):2475-2485.

[0221] In some embodiments, a Sox2 polypeptide is a polypeptide having the above-mentioned functional properties, and comprising the amino acid sequence at least 70% identical to SEQ ID NO:8 corresponding to the amino acid sequence of human Sox2, i.e., sex-determining region Y-box 2 protein (GenBank Accession No. NP_003097), e.g., 75%, 80%, 85%, 90%, 91%, 92%, 95%, 97%, 99%, or any other percent identical from at least 70% to 100% identical to SEQ ID NO:8. In some embodiments, a Sox2 polypeptide is a polypeptide having the above-mentioned functional properties, and comprising an amino acid sequence from at least 70% to less than 100% identical (e.g., 75%, 80%, 85%, 90%, 91%, 92%, 95%, 97%, 99% identical) to SEQ ID NO:8, e.g., SEQ ID NO: 8 with at least one amino acid substitution, deletion, or insertion (e.g., 1 to 10 amino acid substitutions, deletions, or insertions).

[0222] In other embodiments, a Sox2 polypeptide is a polypeptide having the above-mentioned functional properties, and comprising the amino acid sequence of SEQ ID NO:8 with up to a total of 30 amino acid substitutions, deletions, insertions, or any combination thereof, e.g., SEQ ID NO:8 with 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 15, 20, 25, or any other number of amino acid substitutions, deletions, insertions, or any combination thereof, from 0 to 30.

SEQ ID NO:8 (Human Sox2):
MYNMMETELKPPGPQQTSGGGGGNSTAAAAGGNQKNSPDRVKRPMNAFMV

WSRGQRRKMAQENPKMHNSEISKRLGAEWKLLSETEKRPFIDEAKRLRAL

HMKEHPDYKYRPRRKTKTLMKKDKYTLPGGLLAPGGNSMASGVGVGAGLG

AGVNQRMDSYAHMNGWSNGSYSMMQDQLGYPQHPGLNAHGAAQMQPMHRY

DVSALQYNSMTSSQTYMNGSPTYSMSYSQQGTPGMALGSMGSVVKSEASS

SPPVVTSSSHSRAPCQAGDLRDMISMYLPGAEVPEPAAPSRLHMSQHYQS

GPVPGTAINGTLPLSHM

[0223] In some embodiments, a Sox2 polypeptide is a polypeptide having the above-mentioned functional properties, and comprising an amino acid sequence at least 70% identical to SEQ ID NO:9, e.g., 75%, 80%, 85%, 90%, 91%, 92%, 95%, 97%, 99%, or any other percent identical from at least 70% to 100% identical to SEQ ID NO:9, amino acids 40-115 of Human Sox2 comprising the highly conserved High Mobility Group-Sox-TCF (HMG-Sox-TCF) motif DNA binding domain (DBD). In some embodiments, a Sox2 polypeptide is a polypeptide having the above-mentioned functional properties, and comprising an amino acid sequence from at least 70% to less than 100% identical (e.g., 75%, 80%, 85%, 90%, 91%, 92%, 95%, 97%, 99% identical) to SEQ ID NO:9, e.g., SEQ ID NO: 9 with at least one amino acid substitution, deletion, or insertion (e.g., 1 to 5 amino acid substitutions, deletions, or insertions).

SEQ ID NO:9 (HMG-Sox2-TCF DBD)
RVKRPMNAFMVWSRGQRRKMAQENPKMHNSEISKRLGAEWKLLSETEKRP

FDEAKRLRALHMKEHPDYKYRPRRK

[0224] Sox2 polypeptides, as described herein, may include naturally occurring or non-naturally occurring homologs of human Sox2. Examples of naturally occurring homologs of human Sox2 include, but are not limited to, those listed under GenBank Accession Nos: NP_001098933; NP_035573, ACA58281; BAA09168; NP_001032751; and NP_648694, or any other Sox family members that meet the above-mentioned structural and functional criteria.

[0225] Examples of non-naturally occurring homologs of human Sox2, include, but are not limited to those described in, e.g., Kamachi et al., (1999), *Mol Cell Biol.,* 19(1):107-120.

[0226] pMUT analysis (described above) of the human Sox2 amino acid sequence (SEQ ID NO:8) based on a PSI-BLAST multiple alignment encompassing 250 sequences yields an ASM (Table 18) showing amino acid substitutions predicted to be deleterious or neutral to the protein's function. Functional assays for the ability of Sox2 polypeptides to bind to the nanog gene Sox element and to transactivate a promoter containing one or more nanog Sox elements are known in the art as described in, e.g., Kuroda et al., (supra).

Klf4 Polypeptide

[0227] As referred to herein, a "Klf4 polypeptide" includes human Klf4, mouse Klf4, or any polypeptide that:
(i) includes a zinc-finger DNA binding domain (DBD) that binds to a Klf target element, e.g.,

5'-GAGGTCC-3' OR 5'-GGGGTGT-3'; and

(ii) is capable of transactivating a promoter comprising one or more of the above-mentioned target elements. See, e.g., Nakatake et al., (2006), *Mol Cell Biol.,* 24(20):7772-7782.

[0228] In some embodiments, a Klf4 polypeptide is a polypeptide having the above-mentioned functional properties, and comprising the amino acid sequence at least 70% identical to SEQ ID NO:10 corresponding to the amino acid sequence of human Klf4, i.e., Kruppel-Like Factor 4 (GenBank Accession No. NP_004226), e.g., 75%, 80%, 85%, 90%, 91%, 92%, 95%, 97%, 99%, or any other percent identical from at least 70% to 100% identical to SEQ ID NO:10. In some embodiments, a Klf4 polypeptide is a polypeptide having the above-mentioned functional properties, and comprising an amino acid sequence from at least 70% to less than 100% identical (e.g., 75%, 80%, 85%, 90%, 91%, 92%, 95%, 97%, 99% identical) to SEQ ID NO:10, e.g., SEQ ID NO:10 with at least one amino acid substitution, deletion, or insertion (e.g., 1 to 10 amino acid substitutions, deletions, or insertions).

[0229] In other embodiments, a Klf polypeptide is a polypeptide having the above-mentioned functional properties, and comprising the amino acid sequence of SEQ ID NO:10 with up to a total of 30 amino acid substitutions, deletions, insertions, or any combination thereof, e.g., SEQ ID NO:10 with 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 15, 20, 25, or any other number of amino acid substitutions, deletions, insertions, or any combination thereof, from 0 to 30.

SEQ ID NO:10 (Human Klf4):
MAVSDALLPSFSTFASGPAGREKTLRQAGAPNNRWREELSHMKRLPPVLP

GRPYDLAAATVATDLESGGAGAACGGSNLAPLPRRETEEFNDLLDLDFIL

SNSLTHYPESVAATVSSSASASSSSSPSSSGPASAPSTCSFTYPIRAGND

PGVAPGGTGGGLLYGRESAPPPTAPFNLADINDVSPSGGFVAELLRPELD

PVYWPPQQPQPPGGGLMGKFVLKASLSAPGSEYGSPSVISVSKGSPDGSH

PVVVAPYNGGPPRTCPKIKQEAVSSCTHLGAGPPLSNGHRPAAHDFPLGR

QLPSRTTPTLGLEEVLSSRDCHPALPLPPGFHPHPGPNYPSFLPDQMQPQ

VPPLHYQELMPPGSCMPEEPKPKRGRRSWPRKRTATHTCDYAGCGKTYTK

SSHLKAHLRTHTGEKPYHCDWDGCGWKFARSDELTRHYRKHTGHRPFQGQ

KGDRAFSRSDHLALHMKRHF

[0230] In some embodiments, a Klf4 polypeptide is a polypeptide having the above-mentioned functional properties, and comprising an amino acid sequence at least 70% identical to SEQ ID NO:11, e.g., 75%, 80%, 85%, 90%, 91%, 92%, 95%, 97%, 99%, or any other percent identical from at least 70% to 100% identical to SEQ ID NO:11, amino acids 382-469 of Human Klf4 comprising the highly conserved Zinc Finger motif DNA binding domain (ZF-DBD). In some embodiments, a Klf4 polypeptide is a polypeptide having the above-mentioned functional properties, and comprising an amino acid sequence from at least 70% to less than 100% identical (e.g., 75%, 80%, 85%, 90%, 91%, 92%, 95%, 97%, 99% identical) to SEQ ID NO:11, e.g., SEQ ID NO:11 with at least one amino acid substitution, deletion, or insertion (e.g., 1 to 5 amino acid substitutions, deletions, or insertions).

SEQ ID NO:11 (Human Klf4-ZF-DBD)
KRTATHTCDYAGCGKTYTKSSHLKAHLRTHTGEKPYHCDWDGCGWKFARS

DELTRHYRKHTGHRPFQCQKGDRAFSRSDHLALHMKRH

[0231] Klf4 polypeptides, as described herein, may include naturally occurring or non-naturally occurring homologs of human Klf4. Examples of naturally occurring homologs of human Klf4 include, but are not limited to, those listed under listed under GenBank Accession Nos: NP_001017280, NP_057354 (Klf2); AAP36222 (Klf5); NP_034767; and NP_446165, or any other Klf family members that meet the above-mentioned structural and functional criteria. Examples of non-naturally occurring Klf4 polypeptides include, but are not limited to, those having the above-mentioned functional properties and comprising an amino acid sequence at least 70%, e.g., 75%, 80%, 85%, 90%, or a percent from 70% to 100% identical to SEQ ID NO:10 or SEQ ID NO:11.

[0232] In some embodiments, a Klf4 polypeptide is a non-naturally occurring polypeptide having the above-mentioned functional properties.

[0233] pMUT analysis (described above) of the human Klf4 amino acid sequence (SEQ ID NO:10) based on a PSI-BLAST multiple alignment encompassing 136 sequences yields an ASM (Table 19) showing amino acid substitutions predicted to be deleterious or neutral to the protein's function. Functional assays for the ability of Klf4 polypeptides to bind to any of the above-mentioned target elements and to transactivate a promoter containing one or more of the target elements are known in the art as described in, e.g., Nakatake et al., (supra).

c-Myc Polypeptide

[0234] As referred to herein, a "c-Myc polypeptide" includes human c-Myc, mouse c-Myc, or any polypeptide that:

(i) includes a basic helix-loop-helix leucine zipper domain and binds to a target element comprising the sequence: 5'-CACGTG-3'; or 5'-C/GACCACGTGGTG/C-3' and

(ii) is capable of transactivating a promoter comprising one or more of the above-mentioned target elements. See, e.g., Cowling et al., (2006), *Seminars in Canc. Biol.,* 16:242-252.

[0235] In some embodiments, a c-Myc polypeptide is a polypeptide having the above-mentioned functional properties, and comprising an amino acid sequence at least 70% identical to SEQ ID NO:12 corresponding to the amino acid sequence of human c-Myc, i.e., myelocytomatosis viral oncogene homolog (GenBank Accession No. NP_002458), e.g., 75%, 80%, 85%, 90%, 91%, 92%, 95%, 97%, 99%, or any other percent identical from at least 70% to 100% identical to SEQ ID NO:12. In some embodiments, a c-Myc polypeptide is a polypeptide having the above-mentioned functional properties, and comprising an amino acid sequence from at least 70% to less than 100% identical (e.g., 75%, 80%, 85%, 90%, 91%, 92%, 95%, 97%, 99% identical) to SEQ ID NO:12, e.g., SEQ ID NO:12 with at least one amino acid substitution, deletion, or insertion (e.g., 1 to 10 amino acid substitutions, deletions, or insertions).

[0236] In other embodiments, a c-Myc polypeptide is a polypeptide having the above-mentioned functional properties, and comprising the amino acid sequence of SEQ ID NO:12 with up to a total of 30 amino acid substitutions, deletions, insertions, or any combination thereof, e.g., SEQ ID NO:12 with 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 15, 20, 25, or any other number of amino acid substitutions, deletions, insertions, or any combination thereof, from 0 to 30.

SEQ ID NO:12 (Human c-Myc):
MDFFRVVENQQPPATMPLNVSFTNRNYDLDYDSVQPYFYCDEEENFYQQ

QQQSELQPPAPSEDIWKKFELLPTPPLSPSRRSGLCSPSYVAVTPFSLR

GDNDGGGGSFSTADQLEMVTELLGGDMVNQSFICDPDDETFIKNIIIQD

CMWSGFSAAAKLVSEKLASYQAARKDSGSPNPARGHSVCSTSSLYLQDL

SAAASECIDPSVVFPYPLNDSSSPKSCASQDSSAFSPSSDSLLSSTESS

PQGSPEPLVLHEETPPTTSSDSEEEQEDEEEIDVVSVEKRQAPGKRSES

GSPSAGGHSKPPHSPLVLKRCHVSTHQHNYAAPPSTRKDYPAAKRVKLD

SVRVLRQISNNRKCTSPRSSDTEENVKRRTHNVLERQRRNELKRSFFAL

RDQIPELENNEKAPKVVILKKATAYILSVQAEEQKLISEEDLLRKRREQ

LKHKLEQLRNSCA

[0237] In some embodiments, a c-Myc polypeptide is a polypeptide having the above-mentioned functional properties, and comprising an amino acid sequence at least 70% identical to SEQ ID NO:13, e.g., 75%, 80%, 85%, 90%, 91%, 92%, 95%, 97%, 99%, or any other percent identical from at least 70% to 100% identical to SEQ ID NO:13, amino acids 370-454 of Human c-Myc comprising the highly conserved basic helix-loop-helix (bHLH)-leucine zipper (LZ) DNA binding domain. In some embodiments, a Klf4 polypeptide is a polypeptide having the above-mentioned functional properties, and comprising an amino acid sequence from at least 70% to less than 100% identical (e.g., 75%, 80%, 85%, 90%, 91%, 92%, 95%, 97%, 99% identical) to SEQ ID NO:13, e.g., SEQ ID NO:13 with at least one amino acid substitution, deletion, or insertion (e.g., 1 to 5 amino acid substitutions, deletions, or insertions).

SEQ ID NO:13 (Human c-Myc bHLH-LZ domain)
KRRTHNVLERQRRNELKRSFFALRDQIPELENNEKAPKVVILKKATAYI

LSVQAEEQKLISEEDLLRKRREQLKHKLEQLRNSCA

[0238] c-Myc polypeptides, as described herein, may include naturally occurring or non-naturally occurring homologs of human c-Myc. Examples of naturally occurring homologs of human c-Myc include, but are not limited to, those listed under listed under GenBank Accession Nos: NP_001005154, NP_036735, NP_034979, P0C0N9, and NP_001026123, or any other c-Myc family members that meet the above-mentioned structural and functional criteria. Examples of non-naturally occurring homologs of human c-Myc include, but are not limited to, those described in, e.g., Chang et al., (2000), *Mol Cell Biol.,* 20:4309-4319.

[0239] pMUT analysis (described above) of the human c-Myc amino acid sequence (SEQ ID NO:12) based on a PSI-BLAST multiple alignment encompassing 250 sequences yields an ASM (Table 20) showing amino acid substitutions predicted to be deleterious or neutral to the protein's function. Functional assays for the ability of c-Myc polypeptides to bind to any of the above-mentioned target elements and to transactivate a promoter containing one or more of the target elements are known in the art as described in, e.g., Gu et al., (1993), *Proc. Natl. Acad. Sci. USA,* 90:2935-2939.

[0240] In some cases, any of the Oct3/4, Sox2, Klf4, or c-Myc polypeptide DNA binding domains are fused to the Herpes VP16 transactivation domain to generate chimeric fusion proteins that can be used as induction factors in the induction methods described herein. In one embodiment the Herpes VP16 transactivation domain comprises the following amino acid sequence:

TKTLMKKDKYTLPGGLLAPGGNSMASGVGVGAGLGAGVNQRMDSYAHMN

GWSNGSYSMMQDQLGYPQHSTTAPITDVSLGDELRLDGEEVDMTPADAL

DDFDLEMLGDVESPSPGMTHDPVSYGALDVDDFEFEQMFTDALGIDDF

GG

[0241] In some embodiments, any of the Oct 3/4, Sox2, Klf4, or c-Myc polypeptides, or combinations thereof are provided as polypeptide transduction compositions for use in the induction methods described herein. Such compositions contain at least one of the following:

(i) a purified 3/4Oct3/4 polypeptide comprising a protein transduction domain at the amino or carboxy terminus;

(ii) a carrier reagent and a purified 3/4Oct3/4 polypeptide;

(iii) a purified Sox2 polypeptide comprising a protein transduction domain and the amino acid sequence of a Sox2 polypeptide;

(iv) a carrier reagent and a purified Sox2 polypeptide;
(v) a purified Klf4 polypeptide comprising a protein transduction domain;
(vi) a carrier reagent and a purified Klf4 polypeptide;
(vii) a purified c-Myc polypeptide comprising a protein transduction domain
(viii) a carrier reagent and a purified c-Myc-polypeptide
(ix) any combination of (i) to (vi) where the composition is substantially free of a purified polypeptide comprising the amino acid of a c-Myc polypeptide.

[0242] In some embodiments, the protein transduction domain is fused to the amino terminal of an IF sequence. In other embodiments, the PTD domain is fused to the carboxy terminal of an IF sequence. In some embodiments, the IF-PTD fusion polypeptide is added to cells as a denatured polypeptide, which may facilitate its transport into cells where it is then renatured. The generation of PTD fusion proteins and methods for their use are known the art as described in, e.g., U.S. Pat. Nos. 5,674,980, 5,652,122, 6,881,825. See also, Becker-Hapak et al., (2003), *Curr. Protocols in Cell Biol*., John Wiley & Sons, Inc. Exemplary PTD domain amino acid sequences include, but are not limited to, any of the following:

YGRKKRRQRRR;	(SEQ ID NO:1)
RKKRRQRR;	(SEQ ID NO:2)
YARAAARQARA;	(SEQ ID NO:3)
THRLPRRRRRR;	(SEQ ID NO:4)
and	
GGRRARRRRRR.	(SEQ ID NO:5)

[0243] Examples of suitable carrier agents and methods for their use include, but are not limited to those described in U.S. Pat. No. 6,841,535.

[0244] G. Subcloning Induced Cell Colonies

[0245] Cell colonies may be subcloned, by any method known in the art, to obtain a pure population of human stem cells, which contains a higher proportion of the generated human stem cells relative to the total cell population than that found in the total cell population before purification. In some cases, the induced cells are cultured and observed for about 14 days to about 40 days, e.g., 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 23 days, 24 days, 27 days, 28 days, 29 days, 30 days, 31 days, 33 days, 34 days, 35 days, 36 days, 37 days, 38 days, or other period from about 14 days to about 40 days prior to identifying and selecting clones comprising "induced cells" based on morphological characteristics, as described herein. The induced cells may be cultured in a maintenance culture medium in a 37° C., 5% CO_2 incubator, with medium changes about every 1 to 2 days, preferably every day. Examples of maintenance culture media include any and all complete ES media (e.g., MC-ES). The maintenance culture medium may be supplemented with b-FGF or FGF2. In some cases, the maintenance culture medium is supplemented with other factors, e.g., IGF-II or Activin A.

[0246] After washing cell cultures with a physiological buffer, e.g., Hank's balanced salt solution, colonies displaying the morphological characteristics of interest are surrounded by a cloning ring coated with silicone grease on the bottom side. About 100 μl (or 50 μl to 150 μl) of "Detachment Medium For Primate ES Cells" (manufactured by ReproCELL, Tokyo Japan) may be then added to the cloning ring and incubated at 37° C. for about 20 minutes to form a cell suspension. The cell suspension in the ring containing the detached colonies may be added to about 2 ml of MC-ES medium (or other medium described herein), and plated in one well of a MEF-coated 24-well plate or other cell culture vessel of equivalent surface area. After culturing the colony-derived cells in a 5% CO_2 (atmospheric O_2) cell culture incubator at 37° C. for about 14 hours, the medium is replaced. Subsequently, the medium is replaced about every two days until about 8 days later when a second subculture is carried out.

[0247] In some embodiments, in the first subculture, the medium is removed, the cells are washed with Hank's balanced salt solution, and Detachment Medium For Primate ES Cells (ReproCell, Tokyo, Japan) is then added to the cells and incubated at 37° C. for 10 minutes. After the incubation, MC-ES medium (2 ml) is added to the resulting cell suspension to quench the activity of the Detachment Medium. The cell suspension is then transferred to a centrifuge tube, and centrifuged at 200×g at 4° C. for 5 minutes. The supernatant is removed, the cell pellet is resuspended in MC-ES medium, and the resuspended cells are plated on four wells of a MEF-coated 24-well plate and cultured for about seven days until a second subculture is prepared.

[0248] In the second subculture, prepared by the method described above, cells are plated on a 60 mm cell culture dish coated with Matrigel™ at a concentration of 20 μg/cm2. About eight days later (approximately 5 weeks after initiating forced expression of IFs), a third subculture is prepared in which cells are plated on two Matrigel™-coated 60 mm cell culture dishes, one of which can subsequently be used for gene expression analysis and the other for continued passaging as described below. One of the subcultures is used for gene expression analysis, as described herein, and the other is passaged as needed to maintain a cell line derived from the induced cell clone.

[0249] H. Passaging and Maintaining Induced Cells

[0250] After subcloning, the induced cells may be subcultured about every 5 to 7 days. In some cases, the cells are washed with Hank's balanced salt solution, and dispase or Detachment Medium For Primate ES Cells is added, and incubated at 37° C. for 5 to 10 minutes. When approximately more than half of the colonies are detached, MC-ES medium is added to quench enzymatic activity of the detachment medium, and the resulting cell/colony suspension is transferred to a centrifuge tube. Colonies in the suspension are allowed to settle on the bottom of the tube, the supernatant is carefully removed, and MC-ES medium is then added to resuspend the colonies. After examining the size of the colonies, any extremely large ones are broken up into smaller sizes by slow up and down pipetting. Appropriately sized colonies are plated on a matrigel-coated plastic culture dish with a base area of about 3 to 6 times that before subculture. For example, the cells may be split from about 1:6 to about 1:3, e.g., about 1:6, 1:5, 1:4, or 1:3.

[0251] Examples of culture media useful for culturing human pluripotent stem cells induced from undifferentiated stem cells present in a human postnatal tissue of the present invention include, but are not limited to, the ES medium, and a culture medium suitable for culturing human ES cells such as MEF-conditioned ES medium (MC-ES) or other medium

described herein, e.g., mTeSR1™. In some examples, the cells are maintained in the presence of a ROCK inhibitor, as described herein.

IV. ANALYSIS OF INDUCED CELLS

[0252] Cell colonies subcultured from those initially identified on the basis of morphological characteristics may be assayed for any of a number of properties associated with pluripotent stem cells, including, but not limited to, expression of ALP activity, expression of ES cell marker genes, expression of protein markers, hypomethylation of Oct3/4 and Nanog promoters relative to a parental cells, long term self-renewal, normal diploid karyotype, and the ability to form a teratoma comprising ectodermal, mesodermal, and endodermal tissues.

[0253] A number of assays and reagents for detecting ALP activity in cells (e.g., in fixed cells or in living cells) are known in the art. In an exemplary embodiment, colonies to be analyzed are fixed with a 10% formalin neutral buffer solution at room temperature for about 5 minutes, e.g., for 2 to 5 minutes, and then washed with PBS. A chromogenic substrate of ALP, 1 step BCIP (5-Bromo-4-Chloro-3'-Indolyphosphate p-Toluidine Salt) and NBT (Nitro-Blue Tetrazolium Chloride) manufactured by Pierce (Rockford, Ill.) is then added and reacted at room temperature for 20 to 30 minutes. Cells having ALP activity are stained blue-violet.

[0254] Putative iPS cell colonies tested for ALP activity may then be assayed for expression of a series of human embryonic stem cell marker (ESCM) genes including, but not limited to, Nanog, TDGF1, Dnmt3b, Zfp42, FoxD3, GDF3, CYP26A1, TERT, Oct 3/4, Sox2, Sal14, and HPRT. See, e.g., Assou et al., (2007), *Stem Cells,* 25:961-973. Many methods for gene expression analysis are known in the art. See, e.g., Lorkowski et al., (2003), *Analysing Gene Expression, A Handbook of Methods: Possibilities and Pitfalls*, Wiley-VCH. Examples of suitable nucleic acid-based gene expression assays include, but are not limited to, quantitative RT-PCR (qRT-PCR), microarray hybridization, dot blotting, RNA blotting, RNAse protection, and SAGE.

[0255] In some embodiments, levels of ESCM gene mRNA expression levels in putative iPS cell colonies are determined by qRT-PCR. Putative iPS cell colonies are harvested, and total RNA is extracted using the "Recoverall total nucleic acid isolation kit for formaldehyde- or paraformaldehyde-fixed, paraffin-embedded (FFPE) tissues" (manufactured by Ambion, Austin, Tex.). In some instances, the colonies used for RNA extraction are fixed colonies, e.g., colonies that have been tested for ALP activity. The colonies can be used directly for RNA extraction, i.e., without prior fixation. In an exemplary embodiment, after synthesizing cDNA from the extracted RNA, the target gene is amplified using the TaqMan® PreAmp mastermix (manufactured by Applied Biosystems, Foster City, Calif.). Real-time quantitative PCR is performed using an ABI Prism 7900HT using the following PCR primer sets (from Applied Biosystems) for detecting mRNA of the above-mentioned ESCM genes: Nanog, Hs02387400_g1, Dnmt3b, Hs00171876_m1, FoxD3, Hs00255287_s1, Zfp42, Hs01938187_s1, TDGF1, Hs02339499_g1, TERT, Hs00162669_m1, GDF3, Hs00220998_m1, CYP26A1, Hs00175627_m1, GAPDH, Hs99999905_m1).

[0256] Putative iPS cell colonies may be assayed by an immunocytochemistry method for expression of protein markers including, but not limited to, SSEA-3, SSEA4, TRA-1-60, TRA-1-81, CD9, CD24, Thy-1, and Nanog. A wide range of immunocytochemistry assays, e.g., fluorescence immunocytochemistry assays, are known as described in, e.g., Harlow et al., (1988), *Antibodies: A Laboratory Manual* 353-355, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., and see also, *The Handbook—A Guide to Fluorescent Probes and Labeling Technologies* (2004), Molecular Probes, Inc., Eugene, Oreg.

[0257] In an exemplary embodiment, expression of one or more of the above-mentioned protein markers in putative iPS cell colonies is assayed as follows. Cultured cells are fixed with 10% formaldehyde for 10 min and blocked with 0.1% gelatin/PBS at room temperature for about an hour. The cells are incubated overnight at 4° C. with primary antibodies against SSEA-3 (MC-631; Chemicon), SSEA-4 (MC813-70; Chemicon), TRA-1-60 (ab16288; abcam), TRA-1-81 (ab16289; abcam), CD9 (M-L13; R&D systems), CD24 (ALB9; abcam), Thy1 (5E10; BD Bioscience), or Nanog (MAB1997; R&D Systems). For Nanog staining, cells are permeabilized with 0.1% Triton X-100/PBS before blocking. The cell colonies are washed with PBS three times, then incubated with AlexaFluor 488-conjugated secondary antibodies (Molecular Probes) and Hoechst 33258 (Nacalai) at room temperature for 1 h. After further washing, fluorescence is detected with a fluorescence microscope, e.g., Axiovert 200M microscope (Carl Zeiss).

A. Methylation Analysis

[0258] In some embodiments, a characteristic of the induced cells is reduced methylation of the genomic promoters of Oct3/4 and Nanog relative to those of their parental cells. Suitable Oct3/4 promoter regions to be analyzed include, but are not limited to, the Oct3/4 proximal promoter including conserved region 1 (CR1) and the Oct3/4 promoter distal enhancer including CR4. Suitable Nanog promoter regions to be analyzed include, but are not limited to, the Nanog proximal promoter including the Oct3/4 and Sox2 binding sites. See, e.g., Rodda et al., (2005), *J. Biol. Chem.,* 280:24731-24737 and Yang et al., (2005), *J Cell Biochem.,* 96:821-830. A number of methods for the quantitative analysis of genomic DNA are known as described in, e.g., Brena et al., (2006), *J Mol. Med.,* 84(5):365-377. In an exemplary embodiment, genomic DNA isolated from putative induced cells and cells used for a comparison is isolated and treated with bisulfite. Bisulfite-treated genomic DNA is then PCR-amplified with primers containing a T7 promoter sequence. Afterwards, RNA transcripts are generated using T7 polymerase and then treated with RNAse A to generate methylation-specific cleavage products. Methylation of individual CpG sites is assessed by MALDI-TOF mass spectrometry of the cleavage products. A detailed description of the method is provided in, e.g., Ehich et al., (2005), *Proc. Natl. Acad. Sci. USA,* 102:15785-15790.

B. Self-Renewal Assay

[0259] One of the characteristics of stem cells is their ability to proliferate continuously without undergoing senescence. Accordingly, induced cells are assessed for their ability to be passaged continuously in vitro. In some cases, the induced cells are assayed for their ability to be passaged for at least about 30 to at least about 100 times in vitro, e.g., about

33, 35, 40, 45, 51, 56, 60, 68, 75, 80, 90, 93, 100, or any other number of passages from at least about 30 to at least about 100 passages.

[0260] In another evaluation, induced cells are assayed for their ability to proliferate for a period of about 30 days to about 500 days from initiation of forced expression of IFs in parental cells, e.g., 40 days, 50 days, 60 days, 70 days, 80 days, 100 days, 150 days, 180 days, 200 days, 250 days, 300 days, 400 days, 450 days or any other period from about 30 days to about 500 days from initiation of forced expression of IFs in the parental cells. In some embodiments, long-term self-renewal of induced cells is determined when the cells are passaged in a defined medium (e.g., mTeSR1 medium) and in the absence of feeder cells, e.g., mTeSR1 medium as described herein. In other embodiments, cells are passaged in MC-ES medium as described herein.

C. Karyotype Analysis

[0261] As another possible analysis, induced cells are assessed for diploidy and a normal, stable karyotype, e.g., stable after the cells of have been passaged for at least one year in vitro. A number of karotype analysis methods are known in the art. In some embodiments, the karyotype analysis method is multicolor FISH as described in, e.g., Bayani et al., (2004), *Curr. Protoc. Cell Biol., Chapter* 22:Unit 22.5. In other embodiments, the karyotype analysis includes a molecular karyotype analysis as described in, e.g., Vermeesch et al., (2007), *Eur. J. Hum. Genet.,* 15(11):1105-1114. In an exemplary embodiment, induced cells are pretreated with 0.02 μg/ml colecemid for about 2 to about 3 hours, incubated with about 0.06 to about 0.075M KCl for about 20 minutes, and then fixed with Carnoy's fixative. Afterwards, for multicolor FISH analysis, cells are hybridized with multicolor FISH probes, e.g., those in the Star*FISH® Human Multicolour FISH (M-FISH) Kit from Cambio, Ltd (Cambridge, UK).

D. Teratoma Analysis

[0262] It is generally believed that pluripotent stem cells have the ability to form a teratoma, comprising ectodermal, mesodermal, and endodermal tissues, when injected into an immunocompromised animal. Induced cells or induced pluripotent stem cells (iPS) or ES cell-like pluripotent stem cells may refer to cells having an in vitro long-term self-renewal ability and the pluripotency of differentiating into three germ layers, and said pluripotent stem cells may form a teratoma when transplanted into a test animal such as mouse.

[0263] The induced cells may be assessed for pluripotency in a teratoma formation assay in an immunocompromised animal model. The immunocompromised animal may be a rodent that is administered an immunosuppressive agent, e.g., cyclosporin or FK-506. For example, the immunocompromised animal model may be a SCID mouse. About 0.5×10^6 to about 2.0×10^6, e.g., 0.6×10^6, 0.8×10^6, 1.0×10^6, 1.2×10^6, 1.5×10^6, 1.7×10^6, or other number of induced cells from about 0.5×10^6 to about 2.0×10^6 induced cells/mouse may be injected into the medulla of a testis of a 7- to 8-week-old immunocompromised animal. After about 6 to about 8 weeks, the teratomas are excised after perfusing the animal with PBS followed by 10% buffered formalin. The excised teratomas are then subjected to immunohistological analysis. One method of distinguishing human teratoma tissue from host (e.g., rodent) tissue includes immunostaining for the human-specific nuclear marker HuNu. Immunohistological analysis includes determining the presence of ectodermal (e.g., neuroectodermal), mesodermal, and endodermal tissues. Protein markers for ectodermal tissue include, but are not limited to, nestin, GFAP, and integrin β1. Protein markers for mesodermal tissue include, but are not limited to, collagen II, Brachyury, and osteocalcin. Protein markers for endodermal tissue include, but are not limited to, α-fetoprotein (α-FP) and HNF3beta.

E. Gene Expression

[0264] In some embodiments, gene expression analysis is performed on putative iPS cell colonies. Such gene expression analysis may include a comparison of gene expression profiles from a putative iPS cell colony with those of one or more cell types, including but not limited to, (i) parental cells, i.e., one or more cells from which the putative iPS cell colony was induced; (ii) a human ES cell line; or (iii) an established iPS cell line. As known in the art, gene expression data for human ES cell lines are available through public sources, e.g., on the world wide web in the NCBI "Gene Expression Omnibus" database. See, e.g., Barrett et al., (2007), Nuc. Acids Research, D760-D765. Thus, in some embodiments, comparison of gene expression profiles from a putative iPS colony to those of an ES cell line entails comparison experimentally obtained data from a putative iPS cell colony with gene expression data available through public databases. Examples of human ES cell lines for which gene expression data are publicly available include, but are not limited to, hE14 (GEO data set accession numbers GSM151739 and GSM151741), Sheff4 (GEO Accession Nos GSM194307, GSM194308, and GSM193409), h_ES 01 (GEO Accession No. GSM194390), h_ES H9 (GEO Accession No. GSM194392), and h_ES BG03 (GEO Accession No. GSM194391).

[0265] It is also possible to accomplish gene expression by analyzing the total RNA isolated from one or more iPS cell lines by a nucleic acid microarray hybridization assay. Examples of suitable microarray platforms for global gene expression analysis include, but are not limited to, the Human Genome U133 plus 2.0 microarray (Affymetrix) and the Whole Human Genome Oligo Micoarray (Agilent). A number of analytical methods for comparison of gene expression profiles are known as described in, e.g., Suarez-Farinas et al., (2007), *Methods Mol. Biol.,* 377:139-152, Hardin et al., (2007), *BMC Bioinformatics,* 8:220-232, Troyanskaya et al., (2002), *Bioinformatics,* 18(11): 1454-1461, and Knudsen (2002), *A Biologist's Guide to Analysis of DNA Microarray Data*, John Wiley & Sons. In some embodiments, gene expression data from cells produced by the methods described herein are compared to those obtained from other cell types including, but not limited to, human ES cell lines, parental cells, and multipotent stem cell lines. Suitable statistical analytical metrics and methods include, but are not limited to, the Pearson Correlation, Euclidean Distance, Hierarchical Clustering (See, e.g., Eisen et al., (1998), *Proc. Natl. Acad. Sci. USA,* 95(25):14863-14868), and Self Organizing Maps (See, e.g., Tamayo et al., (1999), *Proc. Natl. Acad. Sci. USA,* 96(6):2907-2912.

V. DESCRIPTION OF INDUCED CELLS

[0266] The induced cells may share certain properties associated with pluripotent or multipotent stem cells, including,

but not limited to: expression of ALP activity, expression of ES cell marker genes, expression of protein markers, higher or lower expression of genetic markers compared to ES cells or parental cells, hypomethylation of certain promoters (e.g., Oct3/4 and Nanog) relative to parental cells, long-term self-renewal ability, normal diploid karyotype, morphological characteristics and the ability to form a teratoma comprising ectodermal, mesodermal, and endodermal tissue. The compositions of induced cells may include the cells and another component such as a supplement to culture medium.

[0267] The induced cells may be positive for alkaline phosphatase (ALP) activity. They may express ALP and express from 2 to 10 (e.g., 3, 4, 5, 6, 7, 8, 9, or 10) of the following ES cell marker genes: TDGF1, Dnmt3b, FoxD3, GDF3, Cyp26a1, TERT, zfp42, Sox2, Oct ¾, and Nanog. In some cases, the induced cells express Tert or Cyp26a1. In some cases, the induced cells express both Tert and Cyp26a1. In some cases, the induced cells are positive for ALP activity, and express all of the foregoing ES-cell marker genes. In some cases, the induced cells are positive for ALP activity and express Nanog. In some cases, the induced cells are positive for ALP activity and express one or more: TERT, CYP26A1, or GDF3. In some cases, the induced cells are positive for ALP activity and express one or more: Nanog, TDGF, and Dnmt3b

[0268] The induced cells may express two or more of the following marker proteins: SSEA-3, SSEA4, TRA-1-60, TRA-1-81, CD9, CD24, or Thy-1. In some cases, the induced cells express all of the foregoing marker proteins. In exemplary embodiments, the human pluripotent stem cells express cell surface antigens SSEA-3, SSEA-4, TRA-1-60, TRA-1-81, CD9, CD24, and CD90, and ES cell marker genes Nanog, Oct3/4, TDGF1, Dnmt3b, GABRB3, GDF3, Zfp42, ALP, CD9, and Thy-1.

[0269] The induced cells may exhibit a difference in the expression level, e.g., a higher or lower expression level, of one or more genes (e.g., endogenous genes), compared to the expression levels of those genes in one or more embryonic stem cells, e.g., a human embryonic stem cell. Preferably, differences in gene expression are statistically significant by one or more statistical tests (e.g., Student's t-test or other parametric or non-parametric tests). For example, the difference in expression may have a p value of less than or equal to 0.05, less than or equal to 0.01, or less or equal to 0.001.

[0270] The number of genes exhibiting different expression levels in the induced cells and embryonic stem cells, can be, e.g., 1 to 1000 genes, 1 to 700 genes, 1 to 500 genes, 1 to 300 genes, 1 to 200 genes, 1 to 100 genes, 1 to 50 genes, 3 to 20 genes, 5 to 20 genes, 5 to 50 genes, 10 to 50 genes, 20 to 50 genes, 30 to 100 genes, or 50 to 100 genes, 1 or more genes, 2 or more genes, 3 or more genes, 5 or more genes, 10 or more genes, 15 or more genes, 20 or more genes, 50 or more genes, 70 or more genes, or 100 or more genes, 500 or more genes, 1000 or more genes, 9 genes, 12 genes, 42 genes, 70 genes, or 100 genes. The differences in gene expression levels may be at least 2 fold, e.g., at least 3 fold, 4 fold, 5 fold, 6 fold, 7 fold, 10 fold, 2 to 50 fold, 2 to 30 fold, 2 to 20 fold, 2 to 10 fold, or 2 to 5 fold.

[0271] In some cases, the genes exhibiting different expression levels in the induced cells and embryonic stem cells exhibit a higher level of expression in the induced cells than in human embryonic stem cells. In some cases, the genes expressing the higher level of expression in the induced cells are 1 or more, 2 or more, 3 or more, 4 or more, 5 or more, 10 or more, 15 or more, 25 or more, 50 or more, 75 or more, 100 or more, or 200 or more of the genes listed in Tables 13, 15, or 16. In some cases, the genes exhibiting a different expression level from in the induced cells compared to the embryonic stem cells are expressed at a higher level in human embryonic stem cells compared to the induced cells. In some cases, the genes expressed at a higher level in human embryonic stem cells are a 1 or more, 2 or more, 3 or more, 4 or more, 5 or more, 10 or more, 15 or more, 25 or more, 50 or more, 75 or more, 100 or more, or 200 or more of the genes listed in Table 14.

[0272] In certain cases, a gene or a set of genes exhibits a higher expression level in the induced cells when compared to embryonic stem cells and when compared to the parental cells, e.g., fibroblasts. For example, the genes exhibiting higher expression in the induced cells than in both embryonic stem cells and parental cells are 1 or more, 2 or more, 3 or more, 4 or more, 5 or more, 10 or more, 15 or more, 25 or more, 50 or more, 75 or more, 100 or more, or 200 or more of the genes listed in Table 15.

[0273] A gene or set of genes may be expressed in the induced cells at a level that is closer to the expression level in parental cells (e.g., fibroblasts) than its expression level in embryonic stem cells. A gene or set of genes may, for example, exhibit a higher expression level in the induced cells when compared to embryonic stem cells but not when compared to parental cells, e.g., fibroblasts. Genes. exhibiting higher expression level in the induced cells than in embryonic cells but not the parental cells may be 1 or more, 2 or more, 3 or more, 4 or more, 5 or more, 10 or more, 15 or more, 25 or more, 50 or more, 75 or more, 100 or more, or 200 or more of the genes listed in Table 16.

[0274] The lengths of the telomeres within the induced cells may be shorter than that of telomeres at the ends of chromosomes within embryonic stem cells. In some cases, the telomeres in the induced cells are at least 0.1 kB, at least 0.25 kB, at least 0.5 kB, at least 1 kB, at least 2 kB, at least 3 kB, at least 4 kB, or at least 5 kB shorter than telomeres within embryonic stem cell lines. In certain instances, the induced cells have telomeres that are shorter than at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 8, at least 10, or at least 15 embryonic stem cell lines.

[0275] The induced cells may comprise exogenous genes (or transgenes) encoding IFs. The induced cells may comprise exogenous genes encoding any set of IFs described herein. For example, the induced cells may comprise four exogenous genes encoding Oct 3/4, Sox2, Klf4, and c-Myc polypeptides. In some cases, the induced cells comprise four exogenous genes encoding Oct 3/4, Sox2, Klf4, and c-Myc polypeptides, but not other exogenous genes encoding induction factors. In other cases, the induced cells may comprise exogenous genes encoding Oct 3/4, Sox2, and Klf4 polypeptides, but not an exogenous gene encoding a c-Myc polypeptide. In some cases, the induced cells contain exogenous genes consisting essentially of three genes encoding Oct 3/4, Sox2, and Klf4 polypeptides. In some cases, the human pluripotent stem cells carry at least a single copy of exogenous genes encoding Oct3/4, Sox2, Klf4, and c-Myc. In some cases, any of the induced cells containing exogenous genes also contain an exogenous gene encoding a polypeptide comprising the amino acid sequence of mouse-derived cationic transporter 1 (mCAT-1), a receptor for ecotropic retroviruses.

[0276] At some point after introduction of exogenous genes, one or more of the exogenous genes may be silenced.

In some cases, the Oct3/4 exogenous gene is silenced; the Klf4 exogenous gene is silenced; the Sox2 exogenous gene is silenced; or the c-Myc transgene is silenced. In some cases, all four exogenous genes (e.g., Oct3/4; Sox2; Klf4; and c-Myc) are silenced. In some cases, all three exogenous genes (e.g., Oct3/4; Sox2; and Klf4) are silenced.

[0277] The induced cells may share all of the identifying characteristics of induced pluripotent stem (iPS) cell lines: 1-8; 24; or 3-2, described herein. Cell line iPS1-8 is deposited with the International Patent Organism Depositary (IPOD) in compliance with the terms of the Budapest Treaty. The certificate number for the deposit is FERM BP-10956. The address of IPOD is as follows:

International Patent Organism Depositary (IPOD)

AIST Tsukuba Central 6

[0278] 1-1, Higashi 1-chome

Tsukuba-shi, Ibaraki-Ken 305-8566

Japan

[0279] In some cases, human pluripotent or multipotent stem cells are induced from undifferentiated stem cells present in a human postnatal tissue in which the Tert, Nanog, Oct3/4 and Sox2 genes have not undergone epigenetic inactivation. In some cases, the cells are induced from differentiated cells present in tissue or from a combination of differentiated and undifferentiated cells present in tissue.

[0280] The promoter regions of Nanog and Oct3/4 in the induced cells may be hypo- or de-methylated compared to the parental fibroblasts. The induced cells may be stem cells that have long-term self-renewal ability when cultured under human ES cell-culture conditions.

[0281] One of the characteristics of stem cells is their ability to proliferate continuously without undergoing senescence. Accordingly, induced cells may be passaged continuously in vitro. In some cases, the induced cells are able to be passaged for at least about 30 to at least about 100 times in vitro, e.g., about 33, 35, 40, 45, 51, 56, 60, 68, 75, 80, 90, 93, 100, or other number of passages from at least about 30 to at least about 100 passages. The induced cells may be able to proliferate for a period of about 30 days to about 500 days from initiation of forced expression of IFs in parental cells, e.g., 40 days, 50 days, 60 days, 70 days, 80 days, 100 days, 150 days, 180 days, 200 days, 250 days, 300 days, 400 days, 450 days, or other number of days from about 30 to about 500 days. In some embodiments, the induced cells proliferate for greater than 500 days.

[0282] Typically, the induced cells are able to proliferate with an undifferentiated phenotype under atmospheric oxygen conditions, (e.g., about 21% oxygen). In other cases, the induced cells proliferate as undifferentiated cells under oxygen conditions ranging from greater than 5% oxygen to about 21% oxygen. Generally, the induced cells proliferate in colonies.

[0283] The induced cells may have in vitro pluripotency capabilities, such as the ability to differentiate into ectoderm, mesoderm and endoderm under conditions for inducing in vitro differentiation of human ES cells; and such cells may further have a potential of differentiating into primordial germ cells (e.g., sperm, oocytes).

[0284] In some cases, the induced human pluripotent stem cells and the parental cells (e.g., undifferentiated stem cells present in a human postnatal tissue) have identical or almost identical SNP genotypes. In some cases, the induced cells and the parental cells have the same HLA type (e.g., HLA-A, B, Cw, DR, DQ, DP, and Bw).

[0285] The compositions provided herein may include other components in addition to the induced cells, or in addition to the cells differentiated from the induced cells. In some cases, the composition comprises such cells and a cryopreservative agent, e.g., a cryopreservation medium described in, U.S. patent application Ser. Nos. 10/902,571; 11/142,651; or in Ha et al., (2005), *Hum. Reprod.*, 20(7):1779-1785.

[0286] The composition may comprise such cells and a culture medium, e.g., human ES culture medium. In some cases, the culture medium is a medium comprised of one or more growth factors, for example: FGF-2, bFGF, PDGF, EGF, IGF, or derivatives thereof. In some examples, the composition comprises human induced pluripotent or multipotent stem cells and a medium comprising FGF-2 or bFGF or derivatives thereof. In other instances, the composition comprises human induced pluripotent or multipotent stem cells and a medium comprising human ES culture medium and FGF-2 or bFGF, or derivatives thereof. In still another example, the composition comprises human induced pluripotent or multipotent stem cells and MC-ES medium described herein.

[0287] In some cases, the concentration of bFGF or FGF2 in the culture medium is from 2 ng/ml to about 50 ng/ml, e.g., about 2 ng/ml, 3 ng/ml, 4 ng/ml, 5 ng/ml, 6 ng/ml, 7 ng/ml, 8 ng/ml, 10 ng/ml, 12 ng/ml, 14 ng/ml, 15 ng/ml, 17 ng/ml, 20 ng/ml, 25 ng/ml, 30 ng/ml, 35 ng/ml, 40 ng/ml, 45 ng/ml, 50 ng/ml. The concentration of bFGF or FGF2 may also be from about 4 ng/ml to about 10 ng/ml; from about 4 ng/ml to about 20 ng/ml; from about 10 ng/ml to about 30 ng/ml; from about 5 ng/ml to about 40 ng/ml; or from about 10 ng/ml to about 50 ng/ml. In other cases, higher concentrations of bFGF or FGF2 may be used, e.g., from about 50 ng/ml to about 100 ng/ml; from about 50 ng/ml to about 75 ng/ml. Similarly, the culture medium can contain growth factors other than bFGF or FGF2 that are concentrations from about 2 ng/ml to about 100 ng/ml, as described herein.

VI. CELL DIFFERENTIATION

[0288] The induced cells may be differentiated into cell-types of various lineages. Examples of differentiated cells include any differentiated cells from ectodermal (e.g., neurons and fibroblasts), mesodermal (e.g., cardiomyocytes), or endodermal (e.g., pancreatic cells) lineages. The differentiated cells may be one or more: pancreatic beta cells, neural stem cells, neurons (e.g., dopaminergic neurons), oligodendrocytes, oligodendrocyte progenitor cells, hepatocytes, hepatic stem cells, astrocytes, myocytes, hematopoietic cells, or cardiomyocytes.

[0289] The differentiated cells derived from the induced cells may be terminally differentiated cells, or they may be capable of giving rise to cells of a specific lineage. For example, induced cells can be differentiated into a variety of multipotent cell types, e.g., neural stem cells, cardiac stem cells, or hepatic stem cells. The stem cells may then be further differentiated into new cell types, e.g., neural stem cells may be differentiated into neurons; cardiac stem cells may be differentiated into cardiomyocytes; and hepatic stem cells may be differentiated into hepatocytes.

[0290] There are numerous methods of differentiating the induced cells into a more specialized cell type. Methods of

differentiating induced cells may be similar to those used to differentiate stem cells, particularly ES cells, MSCs, MAPCs, MIAMI, hematopoietic stem cells (HSCs). In some cases, the differentiation occurs ex vivo; in some cases the differentiation occurs in vivo.

[0291] Any known method of generating neural stem cells from ES cells may be used to generate neural stem cells from induced cells, See, e.g., Reubinoff et al., (2001), *Nat, Biotechnol.,* 19(12): 1134-40. For example, neural stem cells may be generated by culturing the induced cells as floating aggregates in the presence of noggin, or other bone morphogenetic protein antagonist, see e.g., Itsykson et al., (2005), *Mol, Cell Neurosci.,* 30(1):24-36. In another example, neural stem cells may be generated by culturing the induced cells in suspension to form aggregates in the presence of growth factors, e.g., FGF-2, Zhang et al., (2001), *Nat. Biotech.*, (19): 1129-1133. In some cases, the aggregates are cultured in serum-free medium containing FGF-2. In another example, the induced cells are co-cultured with a mouse stromal cell line, e.g., PA6 in the presence of serum-free medium comprising FGF-2. In yet another example, the induced cells are directly transferred to serum-free medium containing FGF-2 to directly induce differentiation.

[0292] Neural stems derived from the induced cells may be differentiated into neurons, oligodendrocytes, or astrocytes. Often, the conditions used to generate neural stem cells can also be used to generate neurons, oligodendrocytes, or astrocytes.

[0293] Dopaminergic neurons play a central role in Parkinson's Disease and other neurodegenerative diseases and are thus of particular interest. In order to promote differentiation into dopaminergic neurons, induced cells may be co-cultured with a PA6 mouse stromal cell line under serum-free conditions, see, e.g., Kawasaki et al., (2000) *Neuron,* 28(1):3140. Other methods have also been described, see, e.g., Pomp et al., (2005), *Stem Cells* 23(7):923-30; U.S. Pat. No. 6,395,546, e.g., Lee et al., (2000), *Nature Biotechnol.,* 18:675-679

[0294] Oligodendrocytes may also be generated from the induced cells. Differentiation of the induced cells into oligodendrocytes may be accomplished by known methods for differentiating ES cells or neural stem cells into oligodendrocytes. For example, oligodendrocytes may be generated by co-culturing induced cells or neural stem cells with stromal cells, e.g., Hermann et al. (2004), *J Cell Sci.* 117(Pt 19):4411-22. In another example, oligodendrocytes may be generated by culturing the induced cells or neural stem cells in the presence of a fusion protein, in which the Interleukin (IL)-6 receptor, or derivative, is linked to the IL-6 cytokine, or derivative thereof. Oligodendrocytes can also be generated from the induced cells by other methods known in the art, see, e.g. Kang et al., (2007) *Stem Cells* 25, 419-424.

[0295] Astrocytes may also be produced from the induced cells. Astrocytes may be generated by culturing induced cells or neural stem cells in the presence of neurogenic medium with bFGF and EGF, see e.g., Brustle et al., (1999), *Science,* 285:754-756.

[0296] Induced cells may be differentiated into pancreatic beta cells by methods known in the art, e.g., Lumelsky et al., (2001) *Science,* 292:1389-1394; Assady et al., (2001), *Diabetes,* 50:1691-1697; D'Amour et al., (2006), *Nat. Biotechnol.,* 24:1392-1401; D'Amour et al., (2005), *Nat. Biotechnol.* 23:1534-1541. The method may comprise culturing the induced cells in serum-free medium supplemented with Activin A, followed by culturing in the presence of serum-free medium supplemented with all-trans retinoic acid, followed by culturing in the presence of serum-free medium supplemented with bFGF and nicotinamide, e.g., Jiang et al., (2007), *Cell Res.,* 4:333-444. In other examples, the method comprises culturing the induced cells in the presence of serum-free medium, activin A, and Wnt protein from about 0.5 to about 6 days, e.g., about 0.5, 1, 2, 3, 4, 5, 6, days; followed by culturing in the presence of from about 0.1% to about 2%, e.g., 0.2%, FBS and activin A from about 1 to about 4 days, e.g., about 1, 2, 3, or 4 days; followed by culturing in the presence of 2% FBS, FGF-10, and KAAD-cyclopamine (keto-N-aminoethylaminocaproyl dihydro cinnamoylcyclopamine) and retinoic acid from about 1 to about 5 days, e.g., 1, 2, 3, 4, or 5 days; followed by culturing with 1% B27, gamma secretase inhibitor and extendin-4 from about 1 to about 4 days, e.g., 1, 2, 3, or 4 days; and finally culturing in the presence of 1% B27, extendin-4, IGF-1, and HGF for from about 1 to about 4 days, e.g., 1, 2, 3, or 4 days.

[0297] Hepatic cells or hepatic stem cells may be differentiated from the induced cells. For example, culturing the induced cells in the presence of sodium butyrate may generate hepatocytes, see e.g., Rambhatla et al., (2003), *Cell Transplant,* 12:1-11. In another example, hepatocytes may be produced by culturing the induced cells in serum-free medium in the presence of Activin A, followed by culturing the cells in fibroblast growth factor-4 and bone morphogenetic protein-2, e.g., Cai et al., (2007), *Hepatology,* 45(5): 1229-39. In an exemplary embodiment, the induced cells are differentiated into hepatic cells or hepatic stem cells by culturing the induced cells in the presence of Activin A from about 2 to about 6 days, e.g., about 2, about 3, about 4, about 5, or about 6 days, and then culturing the induced cells in the presence of hepatocyte growth factor (HGF) for from about 5 days to about 10 days, e.g., about 5, about 6, about 7, about 8, about 9, or about 10 days.

[0298] The induced cells may also be differentiated into cardiac muscle cells. Inhibition of bone morphogenetic protein (BMP) signaling may result in the generation of cardiac muscle cells (or cardiomyocytes), see, e.g., Yuasa et al., (2005), *Nat. Biotechnol.,* 23(5):607-11. Thus, in an exemplary embodiment, the induced cells are cultured in the presence of noggin for from about two to about six days, e.g., about 2, about 3, about 4, about 5, or about 6 days, prior to allowing formation of an embryoid body, and culturing the embryoid body for from about 1 week to about 4 weeks, e.g., about 1, about 2, about 3, or about 4 weeks.

[0299] In other examples, cardiomyocytes may be generated by culturing the induced cells in the presence of leukemia inhibitory factor (LIF), or by subjecting them to other methods known in the art to generate cardiomyocytes from ES cells, e.g., Bader et al., (2000), *Circ. Res.,* 86:787-794, Kehat et al., (2001), *J. Clin. Invest.,* 108:407-414; Mummery et al., (2003), *Circulation,* 107:2733-2740.

[0300] Examples of methods to generate other cell-types from induced cells include: (1) culturing induced cells in the presence of retinoic acid, leukemia inhibitory factor (LIF), thyroid hormone (T3), and insulin in order to generate adipocytes, e.g., Dani et al., (1997), *J. Cell Sci.,* 110:1279-1285; (2) culturing induced cells in the presence of BMP-2 or BMP4 to generate chondrocytes, e.g., Kramer et al., (2000), *Mech. Dev.,* 92:193-205; (3) culturing the induced cells under conditions to generate smooth muscle, e.g., Yamashita et al., (2000), *Nature,* 408:92-96; (4) culturing the induced cells in the presence of beta-1 integrin to generate keratinocytes, e.g.,

Bagutti et al., (1996), *Dev. Biol.,* 179:184-196; (5) culturing the induced cells in the presence of Interleukin-3 (IL-3) and macrophage colony stimulating factor to generate macrophages, e.g., Lieschke and Dunn (1995), *Exp. Hemat.,* 23:328-334; (6) culturing the induced cells in the presence of IL-3 and stem cell factor to generate mast cells, e.g., Tsai et al., (2000), *Proc. Natl. Acad. Sci. USA,* 97:9186-9190; (7) culturing the induced cells in the presence of dexamethasone and stromal cell layer, steel factor to generate melanocytes, e.g., Yamane et al., (1999), *Dev. Dyn.,* 216:450-458; (8) co-culturing the induced cells with fetal mouse osteoblasts in the presence of dexamethasone, retinoic acid, ascorbic acid, beta-glycerophosphate to generate osteoblasts, e.g., Buttery et al., (2001), *Tissue Eng.,* 7:89-99; (9) culturing the induced cells in the presence of osteogenic factors to generate osteoblasts, e.g., Sottile et al., (2003), *Cloning Stem Cells,* 5:149-155; (10) overexpressing insulin-like growth factor-2 in the induced cells and culturing the cells in the presence of dimethyl sulfoxide to generate skeletal muscle cells, e.g., Prelle et al., (2000), *Biochem. Biophys. Res. Commun.,* 277:631-638; (11) subjecting the induced cells to conditions for generating white blood cells; or (12) culturing the induced cells in the presence of BMP4 and one or more: SCF, FLT3, IL-3, IL-6, and GCSF to generate hematopoietic progenitor cells, e.g., Chadwick et al., (2003), *Blood,* 102:906-915.

[0301] In some cases, sub-populations of differentiated cells may be purified or isolated. In some cases, one or more monoclonal antibodies specific to the desired cell type are incubated with the cell population and those bound cells are isolated. In other cases, the desired subpopulation of cells expresses a reporter gene that is under the control of a cell type specific promoter.

[0302] In a specific embodiment, the hygromycin B phosphotransferase-EGFP fusion protein is expressed in a cell type specific manner. The method of purifying comprises sorting the cells to select green fluorescent cells and reiterating the sorting as necessary, in order to obtain a population of cells enriched for cells expressing the construct (e.g., hygromycin B phosphotransferase-EGFP) in a cell-type-dependent manner. Selection of desired sub-populations of cells may also be accomplished by negative selection of proliferating cells with the herpes simplex virus thymidine kinase/ganciclovir (HSVtk/GCV) suicide gene system or by positive selection of cells expressing a bicistronic reporter, e.g., Anderson et al. (2007) *Mol. Ther.* (11):2027-2036.

VII. CELL THERAPIES

[0303] The induced cells, or cells differentiated from the induced cells, may be used as a therapy to treat disease (e.g., a genetic defect). The therapy may be directed at treating the cause of the disease; or alternatively, the therapy may be to treat the effects of the disease or condition. The induced cells may be transferred to, or close to, an injured site in a subject; or the cells can be introduced to the subject in a manner allowing the cells to migrate, or home, to the injured site. The transferred cells may advantageously replace the damaged or injured cells and allow improvement in the overall condition of the subject. In some instances, the transferred cells may stimulate tissue regeneration or repair.

[0304] The transferred cells may be cells differentiated from induced cells. The transferred cells also may be multipotent stem cells differentiated from the induced cells. In some cases, the transferred cells may be induced cells that have not been differentiated.

[0305] The number of administrations of treatment to a subject may vary. Introducing the induced and/or differentiated cells into the subject may be a one-time event; but in certain situations, such treament may elicit improvement for a limited period of time and require an on-going series of repeated treatments. In other situations, multiple administrations of the cells may be required before an effect is observed. The exact protocols depend upon the disease or condition, the stage of the disease and parameters of the individual subject being treated.

[0306] The cells may be introduced to the subject via any of the following routes: parenteral, intravenous, intraarterial, intramuscular, subcutaneous, transdermal, intratracheal, intraperitoneal, or into spinal fluid.

[0307] The induced cells may be differentiated into cells and then transferred to subjects suffering from a wide range of diseases or disorders. Subjects suffering from neurological diseases or disorders could especially benefit from stem cell therapies. In some approaches, the induced cells may be differentiated into neural stem cells or neural cells and then transplanted to an injured site to treat a neurological condition, e.g., Alzheimer's disease, Parkinson's disease, multiple sclerosis, cerebral infarction, spinal cord injury, or other central nervous system disorder, see, e.g., Morizane et al., (2008), *Cell Tissue Res.,* 331(1):323-326; Coutts and Keirstead (2008), *Exp. Neurol.,* 209(2):368-377; Goswami and Rao (2007), *Drugs,* 10(10):713-719.

[0308] For the treatment of Parkinson's disease, the induced cells may be differentiated into dopamine-acting neurons and then transplanted into the striate body of a subject with Parkinson's disease. For the treatment of multiple sclerosis, neural stem cells may be differentiated into oligodendrocytes or progenitors of oligodendrocytes, which are then transferred to a subject suffering from MS.

[0309] For the treatment of any neurologic disease or disorder, a successful approach may be to introduce neural stem cells to the subject. For example, in order to treat Alzheimer's disease, cerebral infarction or a spinal injury, the induced cells may be differentiated into neural stem cells followed by transplantation into the injured site. The induced cells may also be engineered to respond to cues that can target their migration into lesions for brain and spinal cord repair, e.g., Chen et al., (2007), *Stem Cell Rev.,* 3(4):280-288.

[0310] Diseases other then neurological disorders may also be treated by a stem cell therapy that uses cells differentiated from induced cells, e.g., induced multipotent or pluripotent stem cells. Degenerative heart diseases such as ischemic cardiomyopathy, conduction disease, and congenital defects could benefit from stem cell therapies, see, e.g. Janssens et al., (2006), *Lancet,* 367:113-121.

[0311] Pancreatic islet cells (or primary cells of the islets of Langerhans) may be transplanted into a subject suffering from diabetes (e.g., diabetes mellitus, type 1), see e.g., Burns et al., (2006) *Curr. Stem Cell Res. Ther.,* 2:255-266. In some embodiments, pancreatic beta cells derived from induced cells may be transplanted into a subject suffering from diabetes (e.g., diabetes mellitus, type 1).

[0312] In other examples, hepatic cells or hepatic stem cells derived from induced cells are transplanted into a subject suffering from a liver disease, e.g., hepatitis, cirrhosis, or liver failure.

[0313] Hematopoietic cells or hematopoietic stem cells (HSCs) derived from induced cells may be transplanted into a subject suffering from cancer of the blood, or other blood or

immune disorder. Examples of cancers of the blood that are potentially treated by hematopoietic cells or HSCs include: acute lymphoblastic leukemia, acute myeloblastic leukemia, chronic myelogenous leukemia (CML), Hodgkin's disease, multiple myeloma, and non-Hodgkin's lymphoma. Often, a subject suffering from such disease must undergo radiation and/or chemotherapeutic treatment in order to kill rapidly dividing blood cells. Introducing HSCs derived from induced cells to these subjects may help to repopulate depleted reservoirs of cells.

[0314] In some cases, hematopoietic cells or HSCs derived from induced cells may also be used to directly fight cancer. For example, transplantation of allogeneic HSCs has shown promise in the treatment of kidney cancer, see, e.g., Childs et al., (2000), *N. Engl. J. Med.,* 343:750-758. In some embodiments, allogeneic, or even autologous, HSCs derived from induced cells may be introduced into a subject in order to treat kidney or other cancers.

[0315] Hematopoietic cells or HSCs derived from induced cells may also be introduced into a subject in order to generate or repair cells or tissue other than blood cells, e.g., muscle, blood vessels, or bone. Such treatments may be useful for a multitude of disorders.

[0316] In some cases, the induced cells are transferred into an immunocompromised animal, e.g., SCID mouse, and allowed to differentiate. The transplanted cells may form a mixture of differentiated cell types and tumor cells. The specific differentiated cell types of interest can be selected and purified away from the tumor cells by use of lineage specific markers, e.g., by fluorescent activated cell sorting (FACS) or other sorting method, e.g., magnetic activated cell sorting (MACS). The differentiated cells may then be transplanted into a subject (e.g., an autologous subject, HLA-matched subject) to treat a disease or condition. The disease or condition may be a hematopoietic disorder, an endocrine deficiency, degenerative neurologic disorder, hair loss, or other disease or condition described herein.

VIII. ANALYTICAL METHODS

[0317] Also described herein are assay methods for identifying an agent capable of inducing pluripotency alone or in combination with other agents, such as the induction factors described herein, in primary somatic cells (e.g., skin cells, mononuclear blood cells, or bone marrow cells) or a cell line (e.g., HEK293 cells, Hela cells, a multipotent stem cell line, or an adult stem cell line). The methods may also include methods for identifying agents that increase the ability of induction factors to induce pluripotency (e.g., the efficiency of inducing pluripotency). In some embodiments, cells to be used in the assay methods have not undergone epigenetic inactivation of Tert, Nanog, Oct3/4 or Sox2.

[0318] In some embodiments, the ability of a test agent to induce pluripotency or multipotency is assessed in a primary screen endpoint by determining the test agent's ability to induce the expression of one or more of: alkaline phosphatase (ALP), ES marker genes, or protein markers. In some cases, such determination is made by comparing the test agent's inducing ability with that of a negative control agent (e.g., an agent with limited or non-existent ability to induce the subject gene or protein markers). In most instances, prior to and during incubation with a test agent or control agent, cells are cultivated in a cell culture medium suited to the particular cell type being cultured, e.g., any of the cell culture media for culturing cells as described herein, although it is possible to take a sample and utilize it directly in an assay without prior culturing steps. In some cases, after a test agent incubation period, cells are cultured in MC-ES medium as described herein.

[0319] Examples of ES marker genes suitable for a screening assay include, but are not limited to, Tert, Cyp26A1, Nanog, Oct3/4, or Sox2. The expression of a marker may be determined by detecting or quantifying mRNA levels or protein levels by a standard method, e.g., any of the methods mentioned herein, such as qPCR. In other embodiments, a reporter construct containing one or more elements from an ES marker gene promoter is introduced into the cells to be assayed prior to contacting the cells with a test agent. Methods for generating promoter-reporter constructs, introducing them into cells, and assaying various reporter polypeptide activities, can be found in detail in, e.g., *Current Protocols in Molecular Biology*, John Wiley & Sons, N.Y. (2005), 3.16-3.17 and 9.1-9.14, respectively). Where a particular cell type is difficult to transfect by conventional methods, viral transduction can be used, e.g., as described herein, to introduce a viral promoter-reporter construct. Promoter activity can be quantified by measuring a property of the reporter polypeptide (e.g., enzymatic activity or fluorescence), reporter polypeptide expression (e.g., by an ELISA assay), or reporter mRNA expression (e.g., by a fluorescent hybridization technique). Suitable reporter polypeptides include, e.g., firefly luciferase, *Renilla* luciferase, fluorescent proteins (e.g., enhanced green fluorescent protein), β-galactosidase, β lactamase, and horseradish peroxidase. Exemplary promoter-reporter constructs for detecting induction of Nanog, Sox2, Oct 3/4, TERT, or Cyp26A1 promoter activation are described in Kuroda et al., (2005), *Mol. Cell. Biol.,* 25(6):2475-2485 (for Nanog); Zhan et al., (2005), *Cell Biochem. Biophys.,* 43(3):379-405 (for Oct3/4 and Sox2); and Tzukerman et al., (2000), *Mol. Biol. Cell,* 11(12):4381-4391 (for hTert), and Loudig et al., (2005), *Biochem. J.,* 392(Pt 1):241-248. In some embodiments, the presence of ALP activity in assayed cells is used as a preliminary test for inducing activity of a test agent. A positive result in any of the foregoing assays, such as a significantly higher level of activity for a test agent than for a control agent, is taken as a preliminary indication that a test agent has inducing activity. Such candidate inducing agents may be further screened by testing the cells contacted with the test agent in the primary. screen in any of the assays described herein for determining pluripotency or multipotency, including, but not limited, determining the expression of a panel of ES marker genes, protein markers, long term self renewal, hypomethylation of Oct3/4, Sox2, and Nanog promoters, ability to form teratomas, and the ability to differentiate into cell types of ectodermal, mesodermal, or endodermal lineage ex vivo.

[0320] The conditions for the assays may vary and depend upon the nature of the assay protocol being utilized and the cells and agent being employed. For such assays, the cell culture period prior to an endpoint assay may vary from at least about 3 days to at least about 40 days, e.g., 5, 6, 9, 10, 12, 14, 20, 21, 25, 26, 27, 30, 32, 34, 36, 38, or other period from at least about 3 days to at least about 40 days. Additionally, in most cases the time for the test agent incubation ranges from at least about 30 minutes to about 40 days, e.g., 1 hour, 2 hours, 12 hours, 18 hours, 1 day, 3 days, 5 days, 7 days, 14 days, 21 days, 25 days, 30 days, 34 days, or any other period from at least about 30 minutes to at least about 40 days.

[0321] In some embodiments, the agent to be tested is an siRNA, including, but not limited to, a double stranded RNA

that comprises about 19 base pairs of a target gene sequence and is capable of inhibiting target gene expression of RNA interference. See, e.g., Scherr et al., (2007), *Cell Cycle,* 6(4): 444-449. In some embodiments, the siRNAs to be assayed include, but are not limited to, whole-genome siRNA libraries, as described in, e.g., Miyagishi et al., (2003), Oligonucleotides, 13(5):325-333; and Huesken et al., (2005), *Nat. Biotechnol.,* 8:995-1001. Suitable whole genome siRNA libraries, e.g., arrayed siRNA libraries that are commercially available include, the "Human Whole Genome siRNA Set V4.0" from Qiagen (Valencia, Calif.); the "Human siGENOME siRNA Library—Genome" from Dharmacon, Inc. (Lafayette, Colo.); and the Silencer® Human Genome siRNA Library from Ambion (Austin, Tex.). Methods and reagents for introducing siRNAs include, but are not limited to, commercial reagents such as Lipofectamine™ RNAiMAX (Invitrogen, Carlsbad, Calif.), TransMessenger Transfection Reagent (Qiagen, Valencia, Calif.), or Dharma FECT® (Dharmacon, Lafayette, Colo.). See, e.g., Krausz (2007), *Mol. Biosyst.,* 3(4):232-240. In some embodiments, a viral RNAi library is used as described in, e.g., Root et al., (2006), *Nat. Methods,* 3(9):715-719.

[0322] Optionally, the induction test agents to be screened are small molecules. The test molecules may be individual small molecules of choice or in some cases, the small molecule test agents to be screened come from a combinatorial library, i.e., a collection of diverse chemical compounds generated by either chemical synthesis or biological synthesis by combining a number of chemical "building blocks." For example, a linear combinatorial chemical library such as a polypeptide library is formed by combining a set of chemical building blocks called amino acids in every possible way for a given compound length (i.e., the number of amino acids in a polypeptide compound). Millions of chemical compounds can be synthesized through such combinatorial mixing of chemical building blocks. Indeed, theoretically, the systematic, combinatorial mixing of 100 interchangeable chemical building blocks results in the synthesis of 100 million tetrameric compounds or 10 billion pentameric compounds. See, e.g., Gallop et al., (1994), *J. Med. Chem.,* 37(9), 1233-1251. Preparation and screening of combinatorial chemical libraries are well known in the art. Combinatorial chemical libraries include, but are not limited to: diversomers such as hydantoins, benzodiazepines, and dipeptides, as described in, e.g., Hobbs et al., (1993), *Proc. Natl. Acad. Sci. U.S.A.,* 90:6909-6913; analogous organic syntheses of small compound libraries, as described in Chen et al., (1994), *J. Amer. Chem. Soc.,* 116:2661-2662; Oligocarbamates, as described in Cho, et al., (1993), *Science,* 261:1303-1305; peptidyl phosphonates, as described in Campbell et al., (1994), *J. Org. Chem.,* 59: 658-660; and small organic molecule libraries containing, e.g., thiazolidinones and metathiazanones (U.S. Pat. No. 5,549,974), pyrrolidines (U.S. Pat. Nos. 5,525,735 and 5,519,134), benzodiazepines (U.S. Pat. No. 5,288,514).

[0323] Numerous combinatorial libraries are commercially available from, e.g., ComGenex (Princeton, N.J.); Asinex (Moscow, Russia); Tripos, Inc. (St. Louis, Mo.); ChemStar, Ltd. (Moscow, Russia); 3D Pharmaceuticals (Exton, Pa.); and Martek Biosciences (Columbia, Md.)/

[0324] In some cases, test agents to be screened for inducing activity may be used in combination with one or more induction factors (e.g., Oct3/4, Sox2, Klf4, or c-Myc) described herein, e.g., 1, 2, 3, or 4 of the induction factors described herein. In some cases, a test agent is screened in combination with one induction factor, e.g., with Oct3/4, Sox2, Klf4, or c-Myc. In other cases, the test agent is screened in combination with two induction factors, e.g., Oct3/4 and Sox2; Oct3/4 and Klf4; Oct3/4 and c-Myc; Sox2 and Klf4; Sox2 and c-Myc; or Klf4- and c-Myc. In some embodiments, the test agent is screened in combination with three induction factors, e.g., Oct3/4, Sox2, and Klf4; Oct3/4, Klf4, and c-Myc; Oct3/4, Sox2, and c-Myc; or Sox2, Klf4, and c-Myc. Test agents may also be assayed for their ability to increase the efficiency of pluripotency induction by a set of induction factors, e.g., a combination of Oct3/4, Sox2, Klf4, and c-Myc.

IX. Storage of Cells

[0325] The harvested tissue, the cells, the induced cells, the induced pluripotent cells, the induced multipotent cells, cells differentiated from the harvested tissue, or other cells described herein may be stored. Thus, cells or materials from any point during the processes may be stored for future completion of the process or modification for use.

[0326] The methods of storage may be any method including the methods described herein, e.g., using cryopreservation medium. Some exemplary cryopreservation media include the "Cryopreservation Medium For Primate ES Cells" (ReproCELL, Tokyo, Japan) or mFreSR™ (StemCell Technologies, Vancouver, Calif.). The cells preferably are rapidly frozen in liquid nitrogen, and stored in a liquid nitrogen storage vessel. Other suitable cryopreservation media and methods for cryopreservation/thawing of cells generated by the methods described herein are provided in, e.g., U.S. patent application Ser. Nos. 10/902,571 and 11/142,651. See also, Ha et al., (2005), *Hum. Reprod.,* 20(7):1779-1785.

X. EXAMPLES

[0327] The following specific examples are to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever. Without further elaboration, it is believed that one skilled in the art can, based on the description herein, utilize the present invention to its fullest extent. All publications cited herein are hereby incorporated by reference in their entirety. Where reference is made to a URL or other such identifier or address, it is understood that such identifiers can change and particular information on the internet can come and go, but equivalent information can be found by searching the internet. Reference thereto evidences the availability and public dissemination of such information.

Example 1

Preparation of Retrovirus Vector

[0328] Retrovirus vector plasmids for four genes (Oct3/4-pMx, Sox2-pMx, Klf4-pMx and c-Myc-pMx) constructed as in Table 1 were introduced into the packaging cell line Plat-E [Experimental Hematology, 2003, 31 (11): 1007-1014], using Fugene HD (manufactured by Roche). About 24 to 48 hours after introduction of the retroviral vector plasmids, the medium was replaced with a medium suitable for the cell to which the gene is to be introduced. After culturing the Plat-E cells to which retrovirus vector was introduced for more than 4 hours, the supernatant was recovered and passed through a filter of 45 μm in diameter (manufactured by Millipore). Retrovirus vector solutions of the four genes (Oct3/4, Sox2, Klf4 and c-Myc) were prepared by the above procedure.

[0329] Retrovirus vector plasmids for three genes (Oct3/4-pMx, Sox2-pMx, and Klf4-pMx) were introduced into the packaging cell, the Plat-E cell, using Fugene HD (manufactured by Roche). During 24 to 48 hours after retrovirus vector introduction, the medium was replaced with a medium suitable for the cell to which gene is to be introduced. After culturing the Plat-E cell to which retrovirus vector was introduced for more than 4 hours, the supernatant was recovered and passed through a filter of 45 μm in diameter (manufactured by Millipore). Retrovirus vector solutions of the three genes (Oct3/4, Sox2 and Klf4) were prepared by the above procedure.

Example 2

Preparation of Adenovirus Vector

[0330] The use of amphotropic retroviruses presents a significant risk of infection to experimenters. This risk is of particular concern where a retrovirus encodes an oncogenic protein (e.g., c-myc). Accordingly, we utilized an ecotropic retrovirus vector that selectively recognizes a mouse receptor, mouse-derived cationic amino acid transporter 1 (mCAT1). We infected human cells with an adenovirus vector carrying the gene encoding mCAT 1, thus allowing ecotropic retroviruses to selectively infect human cells expressing the mCAT 1 receptor.

[0331] First, an adenovirus vector carrying cDNA having the sequence of coding region of the mouse-derived cationic amino acid transporter (mCAT1) gene was constructed. Specifically, Adeno-X Expression System 1 kit (manufactured by TakaraBio Clontech) was used. In Adeno-X Expression System 1 kit, based on the experimental method attached to the kit by TakaraBio, the mCAT1 gene was subcloned into the multi-cloning site of a vector called pShuttle.

[0332] Subsequently, an expression cassette was excised by the PI-Sce I site and the I-Ceu I site, cleavage sites on both ends of the expression cassette of pShuttle, and a DNA fragment containing the desired gene was inserted in between the PI-Sce I site and the I-Ceu I site in the Adeno-X Viral DNA in the above kit, which was then treated with a restriction enzyme Swa I to remove adenovirus DNA for which integration was unsuccessful. After the plasmid was transformed into an *E. coli* DH5 strain, whether the desired gene was correctly introduced into adenovirus DNA was confirmed by restriction enzyme treatment, PCR etc. The plasmid was prepared in large quantities, and cleaved with the Pac I restriction enzyme. Using the recombinant adenovirus DNA thus obtained, the gene was introduced into the HEK293 cells (MicroBix) and plated in six wells using Lipofectamin 2000 (manufactured by Invitrogen), and two weeks later when the cell exhibited a cytopathic effect (CPE), the cells were collected as they are in the medium.

[0333] Subsequently, after the cell suspension was subjected to freezing and thawing three times, the cells were disrupted, and virus particles present in the cells were allowed to release into the liquid. The virus suspension thus prepared was added to one 100 mm plastic culture dish equivalent of HEK293 cells (5×10^6 cells) to infect the cells, the virus was propagated. Furthermore, after virus was prepared in large quantities using four 150 mm plate equivalent of HEK293 cells, virus was purified using the Adenovirus Purification kit (manufactured by Clontech), and stored frozen at −80° C.

[0334] The titer (plaque forming units, PFU) of the mCAT1 adenovirus vector was determined using the Adeno-X Rapid Titer kit. On a 24-well plate, HEK293 cells were plated at a concentration of 5×10^4 cells/500 μl per well. Fifty μl of serially diluted (from 10^{-2} to 10^{-7}) virus vector was mixed with 500 μl of the medium, and then used to infect the cells. After culturing at 5% CO_2 and 37° C. for 48 hours, the medium was aspirated off, the cells were dried for 5 minutes, and then using 500 μl of cold 100% methanol the cells were fixed by allowing to stand at −20° C. for 10 minutes. After aspirating off methanol, the wells were washed three times with 500 μl of phosphate buffer containing 1% bovine serum albumin. A mouse anti-Hexon antibody was diluted 1000-fold with phosphate buffer containing 1% bovine serum albumin, and 250 μl each of it was added to wells.

[0335] After allowing to stand at 37° C. for 1 hour, the antibody solution was removed, and the wells were washed three times with 500 μl phosphate buffer containing 1% bovine serum albumin. Horseradish peroxidase-labelled rat anti-mouse immunoglobulin antibody was diluted 500-fold with phosphate buffer containing 1% bovine serum albumin, and 250 μl was added to wells. After allowing to stand at 37° C. for 1 hour, the antibody solution was removed, and washed three times with 500 μl of phosphate buffer containing 1% bovine serum albumin. 250 μl of the DAB (diaminobenzidine) solution (10-fold DAB concentrate was diluted with a stable peroxidase buffer) was added to wells, and was allowed to stand at room temperature for 10 minutes. After aspirating off DAB, 500 μl of phosphate buffer was added. Using a 20× objective lens, the number of brown positive cells in six viewing fields was counted.

Radius of a standard 20× objective lens: 0.5 mm

Area in one viewing field: 7.853×10^{-3} cm^2

Area of a well: 2 cm^2

Viewing field of a well: 2 $cm^2/7.853\times10^3$ cm^2=254.7 viewing fields

$(32/6)\times254.7/(0.55\times10^{-5})=2.5\times10^8$ ifu (infection unit)/ml

Example 3

Alkaline Phosphatase Staining

[0336] Staining for confirming alkaline phosphatase activity which is a characteristic of pluripotent stem cells was conducted in the following manner. After removing the culture medium, a 10% formalin neutral buffer solution was added to wells, and cells were fixed at room temperature for 5 minutes. After washing with a phosphate buffer etc., a chromogenic substrate of alkaline phosphatase, I step NBT/BCIP (manufactured by Pierce) was added and reacted at room temperature for 20 to 30 minutes. Cells having alkaline phosphatase activity were all stained blue violet.

Example 4

Determination Gene Expression of a Colony by Quantitative PCR

[0337] The expression of target genes in each colony including ALP-positive colonies was determined using quantitative PCR in the following manner. Colonies developed by the induction of pluripotent or multipotent stem cells were harvested, and RNA was extracted using the Recoverall total nucleic acid isolation kit for FFPE (manufactured by Ambion). After synthesizing cDNA from the extracted RNA, the target gene was amplified using the Taqman Preamp mastermix (manufactured by Applied Biosystems).

[0338] As the primers for quantitative PCR, the Taqman gene exprESsion assay (manufactured by Applied Biosystems) was used. The following shows the name of the target gene and the product code of each primer. Human Hprt: Hs99999909_m1, human Nanog: Hs02387400_g1, human Tert: Hs00162669_m1, Mouse Hprt: Mm01545399_m1, mouse Nanog: Ma02019550_s1.

[0339] As the positive control for quantitative PCR, cDNA extracted from mesenchymal stem cells established by the following manner was used.

[0340] One vial (2.5×10^7 cells) of human bone marrow-derived mononuclear cells (hBMMNCs (manufactured by Lonza), Lot 060175A: female, 21 years old, black) was thawed in a 37° C. water bath, and suspended in 10 ml of the MSCGM medium (a growth medium for mesenchymal cells) (manufactured by Lonza). In order to remove DMSO in the frozen solution, this was centrifuged at 300 g and 4° C. for seven minutes and the supernatant was removed. The cell mass thus obtained was resuspended in 10 ml of MSCGM medium, and plated on a 100 mm plate at a density of 10^5 cells/cm^2 and cultured at 37° C. Seven days later, the medium was changed. At this time, the suspended cells in the old medium were collected by centrifuging at 300 g and 4° C. for five minutes, and were returned to the cells together with the fresh medium. On day 13 when the adherent cells became confluent, the supernatant was removed, non-adherent cells were washed off with a phosphate buffer, and adherent cells were collected by detaching with a 0.05% trypsin-EDTA solution and plated at a density of 3000 cells/cm^2. RNA was collected from the cells of the third subculture, and cDNA was synthesized.

Example 5

Induction of Human Pluripotent Stem Cells from Undifferentiated Stem Cells Present in a Postnatal Human Adult Bone Marrow Tissue

[0341] From human adult bone marrow-derived cells (trade name: Human Bone Marrow-Derived Mononuclear Cell) containing undifferentiated stem cells present in a postnatal human adult bone marrow tissue, the cells were established under low serum (2%) and high serum (10%) culture conditions, and were used in the experiment for inducing pluripotent stem cells. Thus, one vial each (2.5×10^7 cells) of frozen human bone marrow-derived mononuclear cells (hBMMNCs (manufactured by Lonza), Lot 060809B: female, 20 years old, white/ and hBMMNCs (manufactured by Lonza), Lot 060470B: female, 20 years old, black) was thawed in a 37° C. water bath, and suspended in 10 ml of the MAPC medium for use in the low serum culture. In order to remove DMSO in the frozen solution, this was centrifuged at 300 g and 4° C. for seven minutes and the supernatant was removed.

[0342] The cell mass thus obtained was resuspended, and plated at a density of 10^5 cells/cm^2 on a 100 mm plate coated with 10 ng/ml fibronectin. Growth factors [10 ng/ml PDGF-BB (manufactured by Peprotech), 10 ng/ml EGF (manufactured by Peprotech), 10 ng/ml IGF-II (manufactured by Peprotech)] were added. Three days later, growth factors were only added. Seven days later, the suspended cells and the medium were collected except the adherent cells, and centrifuged at 300 g and 4° C. for five minutes. After the supernatant was removed, the cells were resuspended in a fresh medium. The cell suspension was returned to the original 10 cm dish, and growth factors were added thereto. On day 10 when the adherent cells became confluent, the supernatant was removed, non-adherent cells were washed off with a phosphate buffer, and adherent cells were collected by detaching with a 0.05% trypsin-EDTA solution, and using a cell banker (manufactured by Juji Field), the primary culture was stored frozen.

[0343] Using the human bone marrow-derived mononuclear cell of the same lot, the cells were established using a MSCGM medium (manufactured by Lonza) containing 10% FBS under the high serum condition. The Human Bone Marrow-Derived Mononuclear Cells were plated at a density of 10^5 cells/cm^2 in a 100 mm plate to which 10 ml of the MSCGM medium had been added, and cultured at 37° C. Seven days later, the suspended cells and the medium were collected except the adherent cells, and centrifuged at 300 g and 4° C. for five minutes, and after the supernatant was removed, the cells were resuspended in a fresh medium. The cell suspension was returned to the original 10 cm dish, and culturing was continued. On day 13 when the adherent cells became confluent, the supernatant was removed, non-adherent cells were washed off with a phosphate buffer. Adherent cells were collected by detaching with a 0.05% trypsin-EDTA solution, and using a cell banker (manufactured by Juji Field), the primary culture was stored frozen.

[0344] One vial each of the human bone marrow-derived primary culture cells that were established under the high serum and the low serum conditions and stored frozen was thawed in a 37° C. incubator. Two ml of the medium used for the establishment was added to the cells respectively, and the cells were plated at a density of 10^4 cells/cm^2 on a 6-well plastic culture dish the wells of which had been coated with matrigel (manufactured by BD Bioscience) at a concentration of 20 μg/cm^2 and cultured for 14 hours (a second subculture cells). Fourteen hours later, the medium was removed, and the mCAT1 adenovirus vector prepared in Example 2 at an amount equivalent to a m.o.i. of 10 in 500 μl of the Hank's balanced salt solution per well was added, and were infected at room temperature for 30 minutes.

[0345] Two ml each of the medium used for establishment was added to each well, and cultured at 37° C. Forty eight hours after the introduction of the mCAT-1 adenovirus vector, the medium of each well was replaced with 2 ml of the retrovirus vector solution (polybrene at a final concentration of 4 μg/ml was added) of four genes(Oct3/4, Sox2, Klf4, c-Myc) which were prepared in Example 1, and cultured at 37° C. for 14 hours. The virus supernatant was removed and replaced with the MEF-conditioned ES medium. Then medium change with the MEF-conditioned ES medium was continued every two days. On examining fourteen days after the introduction of the four genes, one typical colony was found in the low serum condition group of Lot 060809B that exhibits a characteristics of the induced pluripotent stem cells. Said colony was composed of markedly smaller cells than the surrounding cells. In addition to the pluripotent stem cell-like colony, a plurality of colonies were observed in both the low serum group and the high serum group, but they were not stained with alkaline phosphatase.

[0346] In order to isolate the pluripotent stem cell-like colonies, the wells were washed with the Hank's balanced salt solution, and then colonies were surrounded by a cloning ring (manufactured by Iwaki) to the bottom of which silicone grease had been applied. One hundred μl of the Detachment Medium For Primate ES Cells (manufactured by ReproCELL) was added in the ring and cultured at 37° C. for 10 to

20 minutes. The cell suspension in the ring containing the detached colony was added to 2 ml of the MEF-conditioned ES medium, and plated in one well of a MEF-coated 24-well plate. After culturing at 37° C. for 8 to 14 hours, the medium was changed, and subsequently medium change was continued every two days, and 8 days later a second subculture was carried out.

[0347] The medium was removed, washed with the Hank's balanced salt solution, the Detachment Medium For Primate ES Cells (manufactured by ReproCELL) was added, cultured at 37° C. for 10 minutes, and 2 ml of the medium was added to stop the reaction. The cell suspension was transferred to a centrifuge tube, and centrifuged at 4° C. and 200 g for 5 minutes to remove the supernatant. The cells were resuspended in the MEF-conditioned ES medium, and plated in 4 wells of MEF-coated 24-well plate. Medium change was continued every 2 days, and seven days after the second subculture, the cells were subjected to alkaline phosphatase staining, and the cloned colony-derived cells were stained blue violet.

[0348] Furthermore, by quantitative PCR, it was confirmed that Nanog and Tert were expressed by the colony of alkaline phosphatase activity-positive pluripotent stem cells. When compared to the mesenchymal stem cells established in Example 4, the amount expressed of Nanog was as much as 30-fold higher. The expression of Tert was noted only in said pluripotent stem cells, and not in the mesenchymal stem cells. FIG. **2** shows the relative expression of Nanog and Tert genes in human adult bone-marrow derived cells following introduction of four genes. Oct3/4, Sox2, Klf4 and c-Myc, were introduced into cells established from mononuclear cells derived from human adult bone marrow under low serum conditions. RNA was extracted from the colonies obtained, and the expression of human Nanog and human Tert genes was demonstrated by quantitative PCR. Fibroblasts and mesenchymal stem cells in which the four genes were not introduced were used as controls in the experiment. The amount of gene expression is provided as a relative value in which the amount of expression was normalized by the amount of expression of the human hypoxanthine phosphoribosyltransferase (HPRT) gene, and by setting as one the amount of HPRT gene expression in Alkaline Phosphatase (ALP)-positive colonies induced from a neonatal skin fibroblast. It was confirmed that the expression of Nanog and Tert was significantly high in colonies in which four genes (Oct3/4, Sox2, Klf4 and c-Myc) were introduced and which were positive for ALP. As shown in FIG. **2**, Nanog and Tert were not expressed in the cells that did not form colonies, despite the introduction of the four genes.

[0349] From the foregoing, when human adult bone marrow-derived cells were used, the pluripotent stem cells were obtained from the low serum culture group but not at all from the high serum culture group (Lot 060809B and Lot 060470B) (Table 2). Also, culturing under the low serum condition was suitable for the maintenance of the undifferentiated cells.

Example 6

Induction of Human Pluripotent Stem Cells from Undifferentiated Stem Cells Present in Human Neonatal Skin

[0350] Using cells (trade name: Neonatal Normal Human Skin Fibroblasts, primary culture) derived from a human neonatal tissue, a human tissue immediately after birth, the induction of human pluripotent stem cells from undifferentiated stem cells present in the skin of a human neonate was attempted.

[0351] One vial of the frozen Neonatal Normal Human Skin Fibroblasts (primary culture, manufactured by Lonza, Lot 5F0438) was thawed in a 37° C. incubator, and was suspended in the MCDB202 modified medium, a medium containing 2% fetal bovine serum, 5 μg/ml insulin, 50 μg/ml gentamycin, 50 ng/ml amphotericin-B (FBM medium, manufactured by Lonza) to obtain 12 ml of a cell suspension. Two ml each of the cell suspension was plated on a 6-well plastic culture dish of which bottom had been coated with matrigel (BD Biosciences) at a concentration of 20 μg/cm^2 (second subculture cells).

[0352] Fourteen hours later, the medium was removed, and the mCAT1 adenovirus vector prepared in Example 2 at an amount equivalent to a m.o.i. of 5 in 500 μl of the Hank's balanced salt solution per well was added, and was infected at room temperature for 30 minutes. To each well, 2 ml of the FBM medium was added respectively, and cultured at 37° C. Forty eight hours after the introduction of the mCAT-1 adenovirus vector, the medium of each well was replaced with 2 ml of the retrovirus vector solution (polybrene at a final concentration of 4 μg/ml was added) of the four genes (Oct3/4, Sox2, Klf4 and c-Myc) prepared in Example 1, and cultured at 37° C. for 4 hours.

[0353] The virus supernatant was removed and replaced with MEF-conditioned ES medium. Then medium change with MEF-conditioned ES medium was continued every two days, and fourteen days after the introduction of the four genes, one well of the 6-well plate was subjected to alkaline phosphatase staining. As a result, six pluripotent stem cell-like alkaline phosphatase-positive colonies were obtained. Alkaline phosphatase-positive colonies were composed of markedly smaller cells than the neonatal normal human skin fibroblasts.

[0354] Subsequently, by quantitative PCR, it was confirmed that Nanog and Tert were expressed by the colonies of alkaline phosphatase activity-positive pluripotent stem cells. FIG. **3** shows the relative expression of Nanog and Tert genes in neonatal fibroblasts following introduction of four genes. Oct3/4, Sox2, Klf4 and c-Myc, were introduced into primary culture fibroblasts derived from neonatal skin; RNA was extracted from the colonies obtained; and the amount expressed of the human Nanog and human Tert genes was determined by quantitative PCR. Parental fibroblasts and mesenchymal stem cells in which four genes were not introduced were used as controls in the experiment. Gene expression was normalized using the same procedure outlined in FIG. **2**. It was confirmed that the expression of Nanog and Tert was significantly high in colonies in which four genes were introduced and which were positive for ALP. As shown in FIG. **3**, when compared to the mesenchymal stem cells established under the high serum (10%) culture condition in Example 5, the neonatal normal human skin fibroblasts before the introduction of the four genes did not express Nanog, whereas in the case of the cells after the introduction of the four genes, 9-fold as much in the cells that are not forming colonies and 18-fold as much expression of Nanog in the alkaline phosphatase activity-positive colonies were observed (FIG. **3**). On the other hand, the expression of Tert was only noted in the alkaline phosphatase activity-positive colonies. From this, the pluripotent stem cells may bedefined

by the characteristics of alkaline phosphatase activity-positive and Nanog-positive and Tert-positive. Also, the neonatal normal human skin fibroblasts were confirmed to be the cells that have a relatively high efficiency of inducing the pluripotent stem cells and that can express Nanog by the introduction of the four genes.

[0355] Colonies of the pluripotent stem cells were isolated in the following manner. On day 17 after gene introduction, six colonies with a characteristic shape were selected from the remaining wells. After washing the wells with the Hank's balanced salt solution, colonies were surrounded by a cloning ring (manufactured by Iwaki) to the bottom of which silicone grease had been applied. One hundred μl of the Detachment Medium For Primate ES Cells (manufactured by ReproCELL) was added in the ring and cultured at 37° C. for 20 minutes. The cell suspension in the ring containing the detached colonies was added to 2 ml of MEF-conditioned ES medium, and plated in one well of a MEF-coated 24-well plate. After culturing at 37° C. for 14 hours, the medium was changed, and subsequently medium change was continued every two days, and 8 days later a second subculture was carried out. The medium was removed, the cells were washed with the Hank's balanced salt solution, the Detachment Medium For Primate ES Cells was added and cultured at 37° C. for 10 minutes, and 2 ml of the medium was added to stop the reaction.

[0356] The cell suspension was transferred to a centrifuge tube, and centrifuged at 4° C. and 200 g for 5 minutes, and the supernatant was removed. The cells were resuspended in MEF-conditioned ES medium, and plated on four wells of a MEF-coated 24-well plate. Seven days after the second subculture, in a subculturing method described below, the cells were plated on a 60 mm plastic culture dish of which bottom had been coated with matrigel at a concentration of 20 μg/cm^2. Further eight days later (37 days after the introduction of the four genes), a third subculture was conducted, and plated on two matrigel-coated 60 mm plastic culture dishes, and part of it was used in alkaline phosphatase staining and RNA extraction. The result confirmed that the cells derived from the cloned colonies are alkaline phosphatase activity-positive and are expressing Nanog and Tert at high rate, thereby endorsing that they are pluripotent stem cells.

[0357] The induced pluripotent stem cells were subcultured every 5 to 7 days for maintenance and growth. From the plastic culture dish on which subculturing is to be conducted, the medium was removed, the cells were washed with the Hank's balanced salt solution, dispase or the Detachment Medium For Primate ES Cells was added, and cultured at 37° C. for 5 to 10 minutes. When more than half of the colonies were detached, the ES medium was added to stop the reaction, and the cell suspension was transferred to a centrifuge tube. When colonies precipitated on the bottom of the tube, the supernatant was removed, and the ES medium was added again for suspension. After examining the size of the colonies, any extremely large ones were divided into appropriate sizes by slowly pipetting. Appropriately sized colonies were plated on a matrigel-coated plastic culture dish with a base area of about 3 to 6 times that before subculture.

[0358] As shown in Table 2, the Neonatal Normal Human Skin Fibroblasts in the lot (Lot 5F0474) other than the above lot 5F0438 exhibited a favorable induction of pluripotent stem cells. From comparison to Example 5, cells derived from young individuals or cells of which culturing time is short were thought to be suitable for the induction of the pluripotent stem cells.

[0359] From the above results, when cells derived from human neonatal tissue that is a human postnatal tissue containing undifferentiated cells were subjected to a second subculture in a culture medium containing 2% serum, it was possible to induce the pluripotent stem cells.

Example 7

Induction of Human Pluripotent Stem Cells from Undifferentiated Stem Cells Present in a Human Adult Skin

[0360] Then, using human adult tissue-derived cells (trade name: Adult Normal Human Skin Fibroblasts, primary culture) containing undifferentiated stem cells present in a human adult skin, the induction of pluripotent stem cells of the present invention was carried out.

[0361] One vial each of the frozen Adult Normal Human Skin Fibroblasts (primary culture, manufactured by Lonza, Lot 6F3535: 28 years old, female, white, Lot 6F4026: 39 year old, female, white) was thawed in a 37° C. incubator, suspended in the FBM medium, and 12 ml of the cell suspension was obtained, respectively. Two ml each of the cell suspensions was plated on a 6-well plastic culture dish of which bottom had been coated with matrigel at a concentration of 20 μg/cm^2 (second subculture cells).

[0362] Fourteen hours later, the medium was removed, and the mCAT1 adenovirus vector prepared in Example 2 at an amount equivalent to a m.o.i. of 5 in 500 μl of the Hank's balanced salt solution per well was added, and was infected at room temperature for 30 minutes. To each well, 2 ml of the FBM medium was added, and cultured at 37° C. Forty eight hours after the introduction of the mCAT-1 adenovirus vector, the medium of each well was replaced with 2 ml of the retrovirus vector solution (polybrene at a final concentration of 4 μg/ml was added) of the four genes (Oct3/4, Sox2, Klf4 and c-Myc) prepared in Example 1, and cultured at 37° C. for 4 hours. The virus supernatant was removed and replaced with the MEF-conditioned ES medium. Then medium change with the MEF-conditioned ES medium was continued every two days, and thirteen days after the introduction of the four genes, alkaline phosphatase staining was carried out. As a result, two pluripotent stem cell-like alkaline phosphatase-positive colonies per well were obtained from the Lot 6F3535, whereas no alkaline phosphatase-positive colonies were obtained from the Lot 6F4242 (Table 2).

[0363] From comparison to Example 6, the neonate-derived cells among the skin fibroblasts had a higher efficiency of inducing the pluripotent stem cells. Also, among the Adult Normal Human Skin Fibroblasts, cells derived from younger donors had a higher transformation efficiency. From the foregoing, it was demonstrated that the efficiency of inducing the pluripotent stem cells decreases in an age-dependent manner.

Example 8

Examination Using Neonatal Normal Human Skin Fibroblasts of the Third Subculture

[0364] One vial of frozen Neonatal Normal Human Skin Fibroblasts (primary culture, manufactured by Lonza, Lot 5F0439) was thawed in a 37° C. incubator, suspended in the FBM medium, and plated on two 100 mm plastic culture

dishes (a second subculture). After culturing for six days until a 70 to 90% confluence could be obtained, the cells were detached using a 0.025% trypsin-EDTA solution (manufactured by Lonza), centrifuged at 4° C. and 200 g for 5 minutes, and the supernatant was removed. The second subcultured cells collected were stored frozen using the cell banker. The frozen second subculture cells were thawed in a 37° C. incubator, suspended in 12 ml of the FBM medium, centrifuged at 4° C. and 200 g for 5 minutes, and the supernatant was removed. The cells were suspended, and plated at a density of 10^4 cell/cm^2 on a 100 mm plastic culture dish of which bottom had been coated with matrigel at a concentration of 20 μg/cm^2 (a third subculture). Fourteen hours later, the medium was removed, and the mCAT I adenovirus vector prepared in Example 2 at an amount equivalent to a m.o.i. of 5 in 2 ml of the Hank's balanced salt solution was added, and was infected at room temperature for 30 minutes. To each well, 10 ml of the FBM medium was added, and cultured at 37° C.

[0365] Forty eight hours after the introduction of the mCAT-1 adenovirus vector, the medium was removed, and replaced with 10 ml of the retrovirus vector solution (polybrene at a final concentration of 4 μg/ml was added) of the four genes (Oct3/4, Sox2, Klf4 and c-Myc) prepared in Example 1, and cultured at 37° C. for 4 hours. The virus supernatant was removed and replaced with the MEF-conditioned ES medium. Then medium change with the MEF-conditioned ES medium was continued every two days, and fourteen days after the introduction of the four genes, alkaline phosphatase staining was carried out. As a result, five pluripotent stem cell-like alkaline phosphatase-positive colonies were obtained. By calculating based on the area of the bottom, this indicates that 0.83 colony per well of the 6-well plate was obtained (Table 2).

[0366] From comparison to Example 6, it was demonstrated that the efficiency of inducing the pluripotent stem cells decreases with the prolonged culture period.

Example 9

Induction of Human Pluripotent Stem Cells from Undifferentiated Stem Cells Present in the Umbilical Cord (1)

[0367] Using the cells (trade name: Normal Human Umbilical Vein Endothelial Cells, primary culture) derived from a human umbilical cord, a human tissue immediately after birth, the induction of the human pluripotent stem cells of the present invention from undifferentiated stem cells present in the umbilical cord was attempted.

[0368] One vial of the frozen Normal Human Umbilical Vein Endothelial Cells (primary culture, manufactured by Lonza) was thawed in a 37° C. incubator, and suspended in the Endothelial Cell Medium kit-2 manufactured by Lonza (2% serum) (hereinafter referred to as EBM-2) to obtain 12 ml of the cell suspension. About 10^5/2 ml/well each of the cell suspension was plated to a 6-well plastic culture dish the bottom of which had been coated with matrigel at a concentration of 20 μg/cm^2 (second subculture). Six hours later, the medium was removed, and the mCAT1 adenovirus vector prepared in Example 2 at an amount equivalent to a m.o.i. of 5 in 500 μl of the Hank's balanced salt solution per well was added, and infected at room temperature for 30 minutes.

[0369] 2.5 ml each of the EBM-2 medium was added to each well, and cultured at 37° C. Forty eight hours after the introduction of the mCAT-1 adenovirus vector, the medium of each well was replaced with 2 ml each of the retrovirus vector solutions (polybrene at a final concentration of 5 μg/ml was added) of the four genes (Oct3/4, Sox2, Klf4 and c-Myc) prepared in Example 1, and cultured at 37° C. for 4 hours. The virus supernatant was removed and replaced with the MEF-conditioned ES medium. Then medium change with the MEF-conditioned ES medium was continued every two days. Twelve days after the introduction of the four genes, colonies were confirmed.

[0370] Thirteen days after the introduction of the four genes, the induced colonies were stained with alkaline phosphatase activity.

[0371] From the above results, when cells derived from human umbilical cord that is a human tissue immediately after birth containing undifferentiated cells were subjected to a second subculture in a culture medium containing 2% serum, it was possible to induce the pluripotent stem cells.

Example 10

Induction of Human Pluripotent Stem Cells from Undifferentiated Stem Cells Present in the Umbilical Cord (2)

[0372] As described below, using the cells (trade name: Normal Human Umbilical Artery Smooth Muscle Cells, the third subculture) derived from a human umbilical cord, a human tissue immediately after birth, the induction of the human pluripotent stem cells of the present invention from undifferentiated stem cells present in the umbilical cord was attempted.

[0373] One vial of the frozen Normal Human Umbilical Artery Smooth Muscle Cells (the third culture, manufactured by Lonza) was thawed in a 37° C. incubator, and suspended in the Smooth Muscle Cell Medium kit-2 manufactured by Lonza (5% serum) (hereinafter referred to as SmGM-2) to obtain 12 ml of the cell suspension. About 105/2 ml/well each of the cell suspension was plated to a 6-well plastic culture dish (manufactured by Becton Dickinson) of which bottom had been coated with matrigel (manufactured by Becton Dickinson) at a concentration of 20 μg/cm^2 (the fourth subculture). One day later, the medium was removed, and the mCAT1 adenovirus vector at an amount equivalent to a m.o.i. of 1.25 to 5 in 500 μl of the Hank's balanced salt solution per well was added, and infected at room temperature for 30 minutes. 2.5 ml each of the SmGM-2 medium was added to each well, and cultured at 37° C.

[0374] Forty eight hours after the introduction of the mCAT-1 adenovirus vector, the medium of each well was replaced with 2 ml each of the retrovirus vector solutions (polybrene at a final concentration of 5 μg/ml was added) of the four genes (Oct3/4, Sox2, Klf4 and c-Myc) prepared in Example 1, and cultured at 37° C. for 4 hours. The virus supernatant was removed and replaced with the MEF-conditioned ES medium. Then medium change with the MEF-conditioned ES medium was continued every two days. Thirteen days after the introduction of the four genes, colonies were confirmed. However, the induced colonies were not stained with alkaline phosphatase activity.

[0375] From the above results, it was revealed that though the cells derived from human umbilical cord which is a human tissue immediately after birth contains undifferentiated cells present in the umbilical cord, when the cells were

subjected to a fourth subculture in a culture medium containing 5% serum, the induction of the pluripotent stem cells is more challenging.

Example 11

Induction of Mouse Pluripotent Stem Cells from Undifferentiated Stem Cells Present in a Mouse Postnatal Tissue

[0376] Using mouse bone marrow-derived cells, a mouse postnatal tissue, the induction of pluripotent stem cells of the present invention from undifferentiated stem cells present in a mouse postnatal tissue was attempted.

[0377] Femurs and tibias were extracted from 4 to 6 week-old mice (c57BL/6N lineage, 4-week-old, female) taking utmost care not to bring in any other tissue. By soaking the collected bone in 70% ethanol for a short period of time, the cells that attached to the outside of the bone were killed to prevent the contamination of cells other than the bone marrow. After ethanol treatment, the bone was immediately transferred to Iscove's Modified Dulbecco's Medium (IMDM) (SIGMA) to prevent the effect of the cells inside of the bone marrow. The outside of each bone was wiped with Kimwipe to remove the connective tissue. All of the treated bone was transferred to a mortar containing IMDM, and was smashed with a pestle. After washing several times with IMDM, the bone was cut into pieces with scissors. After further washing with IMDM several times, bone fragments were transferred to centrifuge tubes.

[0378] After removing IMDM, 10 ml of IMDM containing 0.2% collagenase I (manufactured by SIGMA) per bone fragments of five mice was added, and shaken at 37° C. for 1 hour. After shaking, the suspension was stirred several times using a Pipetman, and then the supernatant was transferred to another tube, to which an equal amount of cold 10% FBS-containing IMDM was added to stop the enzyme reaction. The bone fragments after enzyme treatment were transferred to a mortar containing cold 10% FBS-containing IMDM, and smashed again with a pestle, and after stirring several times, the supernatant was collected. The cell suspension thus collected was filtered by sequentially passing through a Nylon mesh of 70 μm and 40 μm in diameter. The cell suspension was centrifuged at 4° C. and 600 g for 7 minutes, and cells derived from the mouse deep bone marrow were collected.

[0379] The cells derived from mouse deep bone marrow were suspended in the MAPC medium, and plated at a density of 10^5 cells/cm^2. For plating of cells, a dish previously coated with a phosphate buffer containing 10 ng/ml fibronectin (Becton Dickinson) was used. To the medium, growth factors [10 ng/ml PDGF-BB (manufactured by Peprotech), 10 ng/ml EGF (manufactured by Peprotech), 1000 units/ml LIF (manufactured by Chemicon)] were added at the time of use. Three days after plating, growth factors were only added without changing the medium. Six days later, non-adherent cells were washed off with the phosphate buffer, and adherent cells were collected by detaching with a 0.05% trypsin-EDTA solution (manufactured by Invitrogen), and using a cell banker (manufactured by Juji Field), the cells were stored frozen as the primary culture.

[0380] The primary culture cells that had been stored frozen were thawed in a 37° C. water bath, and suspended in 10 ml of the MAPC medium that is a medium containing 2% FBS. In order to remove DMSO in the frozen solution, it was centrifuged at 4° C. and 300 g for 7 minutes, and the supernatant was removed. The cell mass obtained was resuspended, and plated at a density of 2.5×10^3 cells/cm^2 on a 12-well plastic plate having the bottom which had been gelatin-coated with 0.1% gelatin/phosphate buffer, and 2 ml each of the MAPC medium was added (the second subculture).

[0381] Eight to 14 hours later, the medium was removed, and 2 ml each of the four gene retrovirus vector solution prepared as in Example 1 was added thereto and cultured at 37° C. for 4 to 14 hours. Then the virus solution was removed, and replaced with the mouse ES medium [the ES medium to which a final concentration of 0.3% FBS (manufactured by Invitrogen), 1000 units/ml LIF (manufactured by Chemicon), and 0.1 mM 2-mercaptoethanol were added]. Then medium change with the mouse ES medium was continued every three days, and 5 to 7 days after the introduction of the four genes, said pluripotent stem cells formed colonies comprising mouse ES cell-like small cells. The colonies of the induced pluripotent stem cells were stained blue violet by alkaline phosphatase activity.

[0382] From the remaining wells of the 12-well plate, the mouse pluripotent stem cells were subcultured, and subculture was continued to a gelatin-coated 100 mm plate. From the seventh subculture cells, RNA was extracted using the RNeasy mini kit (manufactured by QIAGEN) and cDNA was synthesized. Using the cDNA, quantitative PCR was conducted to confirm the expression of Nanog.

[0383] The mouse pluripotent stem cells of the seventh subculture were subcutaneously transplanted to the back of three syngeneic C57BL/6N mice at 3×10^5 cells/mouse, and 38 days later the teratoma that formed was extracted. Teratoma was formed in all three mice. From the extracted teratoma, slices were prepared, and differentiation potential into three germ layers was analyzed by immunological staining and histological staining (HE stain, alcian blue stain). As a result, MAP2-positive cells (the nervous system) and GFAP-positive cells (the nervous system) as the ectodermic system, skeletal muscle cells (myocytes) and cartilage tissues as the mesodermic system, and intestinal tract tissues as the endodermic system were observed.

[0384] In order to maintain and grow the mouse pluripotent stem cells, they were subcultured every 3 to 4 days. The medium was removed from the plastic culture dish in which subculture is carried out, washed with phosphate buffer, a 0.05% trypsin-EDTA solution was added, and cultured at 37° C. for 5 minutes. When the cells detached, the ES medium was added to stop the reaction, and the cell suspension was transferred to a centrifuge tube. By centrifuging at 200 g for 5 minutes, the supernatant was removed, and after suspending the precipitate in the mouse ES medium, the cells were plated in a gelatin-coated plate at a density of 10^4 cells/cm^2. The pluripotent stem cells induced from the cells derived from the mouse bone marrow cultured in low serum in the same subculture method could be cultured for a long time.

[0385] As described above, pluripotent stem cells were induced from the postnatal mouse bone marrow-derived cells established under the low serum condition.

Example 12

Induction of Mouse Pluripotent Stem Cells by the Introduction of Three Genes and Histone Deacetylase Inhibitor Treatment

[0386] Using cells derived from mouse bone marrow that is a mouse postnatal tissue, the induction of pluripotent stem

cells was carried out with the introduction of three genes and histone deacetylase inhibitor treatment.

[0387] The primary culture cells derived from mouse bone marrow containing undifferentiated stem cells that had been stored frozen after preparing in a manner similar to Example 11 were plated at a density of 5×10^3 cells/cm^2 on a 24-well plastic plate (manufactured by Becton Dickinson) having the bottom which had been gelatin-coated with a 0.1% gelatin/phosphate buffer, and 2 ml each of the MAPC medium was added.

[0388] Eight hours later, the medium was removed, 2 ml each of the three gene (human Oct3/4, Sox2 and Klf4) retrovirus vector solution prepared as in Example 1 were added, and after further adding MS-275, a histone deacetylase inhibitor, at a final concentration of 1 or 0.1 μM, they were cultured at 37° C. for 14 hours. Then after removing the virus solution, 2 ml each of the MAPC medium containing MS-275, a histone deacetylase inhibitor, at a final concentration of 1 or 0.1 μM was added. Three days later, the medium was replaced with the mouse ES medium [a final concentration of 0.3% FBS (manufactured by Invitrogen), 1000 units/ml LIF (manufactured by Chemicon) and 0.1 mM 2-mercaptoethanol were added to the ES medium at the time of use].

[0389] Medium change with the mouse ES medium was continued every 2 to 3 days. Twelve days after the introduction of three genes (human Oct3/4, Sox2 and Klf4) retrovirus vector, the cells were subcultured from each well of the 24-well plastic plate to each well of a 6-well plastic plate. A portion of it was also cultured in a 24-well plastic plate. Fifteen days after said three gene introduction and MS-275 treatment, the pluripotent stem cells formed colonies composed of mouse ES cell-like small cells. The colonies of said pluripotent stem cells were stained blue violet by alkaline phosphatase activity.

[0390] Then, the amount expressed of the Nanog gene was confirmed by quantitative PCR, and the expression of mouse Nanog of colonies of pluripotent stem cells having alkaline phosphatase activity was confirmed (FIG. **4**). FIG. **4** shows the relative expression of Nanog and Tert genes in mouse adult bone-marrow-derived cells following introduction of three genes and treatment with histone deacetylase (HDAC) inhibitor. Three genes (Oct3/4, Sox2, and Klf4) were introduced into mouse bone marrow-derived cells established under low serum conditions. The cells were also treated with MS-275 (0.1 or 1.0 μM), an HDAC inhibitor. RNA was extracted from the colonies obtained, and the amount of Nanog expression was determined by quantitative PCR. From the cells in which three genes were introduced and which were treated with a histone deacetylase inhibitor, ALP-positive cell group (colonies) were formed, and it was confirmed that the expression of Nanog in these colonies was significantly higher than the ALP-negative colonies. In the figure, W1, W2, W3, W4, W5 and W6 represent the designation of each well of the 6-well plate used in Example 12.

[0391] Eighteen days after said three gene introduction and MS-275 treatment, the pluripotent stem cells were subcultured from each well of the 6-well plate to a gelatin-coated 100 mm plate. Subculture was continued similarly.

[0392] Twenty nine days after said three gene introduction and MS-275 treatment, the mouse pluripotent stem cells were subcutaneously transplanted to the back of syngeneic C57BL/6N mice at 2×10^7 cells/mouse, and 34 days later the teratoma that formed was extracted. From the extracted teratoma, slices were prepared, and differentiation potential into three germ layers was analyzed by immunological and histological staining (HE stain, alcian blue stain). As a result, GFAP-positive cells (the nervous system) and keratin producing cells (skin cells) as the ectodermic system, smooth muscle actin-positive cells (smooth muscle cells), bone tissues and cartilage tissues as the mesodermic system, and intestinal tract tissues (endodermal epithelium positive for MUC-1) as the endodermic system were observed.

Example 13

Induction of Mouse Pluripotent Stem Cells by the Introduction of Three Genes

[0393] Then, using cells derived from mouse bone marrow that is a mouse postnatal tissue, the induction of mouse pluripotent stem cells was carried out with the introduction of three genes.

[0394] The primary culture cells derived from mouse bone marrow containing undifferentiated stem cells that had been stored frozen after preparing in Example 11 were plated at a density of 1×10^4 cells/cm^2 on a 24-well plastic plate (manufactured by Becton Dickinson) having the bottom which had been gelatin-coated with a 0.1% gelatin/phosphate buffer solution, and 2 ml each of the MAPC medium was added.

[0395] Two days later, the medium was removed, 2 ml each of the three gene (human Oct3/4, Sox2 and Klf4) retrovirus vector solution prepared as in Example 1 were added, and after culturing at 37° C. for 1 day, the virus solution was removed, and 2 ml each of the MAPC medium was added. Three days later, the medium was replaced with the mouse ES medium [a final concentration of 0.3% FBS (manufactured by Invitrogen), 1000 units/ml LIF (manufactured by Chemicon) and 0.1 mM 2-mercaptoethanol were added to the ES medium at the time of use]. Then medium change with the mouse ES medium was continued every 2 to 3 days. Eleven days after the introduction of three gene (human Oct3/4, Sox2 and Klf4) retrovirus vector, the cells were subcultured from each well of the 24-well plastic plate to each well of a 6-well plastic plate.

[0396] Then medium change with the mouse ES medium was continued every 2 to 3 days. Nineteen days after said three gene introduction, the pluripotent stem cells formed colonies composed of mouse ES cell-like small cells. In order to confirm the alkaline phosphatase activity, the medium was removed and then a 10% formalin neutral buffer solution was added to wells, and fixed at room temperature for 5 minutes. After washing with a phosphate buffer etc., the I step NBT/BCIP solution (manufactured by Pierce) comprising a chromogenic substrate of alkaline phosphatase was added and reacted at room temperature for 20 to 30 minutes. The colonies of said pluripotent stem cells were stained blue violet by alkaline phosphatase activity.

[0397] Then, the amount expressed of the Nanog gene was confirmed by quantitative PCR, and the expression of mouse Nanog of colonies of pluripotent stem cells having alkaline phosphatase activity was confirmed.

[0398] Using cells derived from mouse bone marrow that is a mouse postnatal tissue, the induction of pluripotent stem cells was carried out with the introduction of three genes.

[0399] The primary culture cells derived from mouse bone marrow containing undifferentiated stem cells that had been stored frozen after preparing in Example 11 were plated at a density of 1×10^4 cells/cm^2 on a 6-well plastic plate (manufactured by Becton Dickinson) the bottom of which had been

gelatin-coated with a 0.1% gelatin/phosphate buffer solution, and the MAPC medium was added in 2 ml portions.

[0400] Two days later, the medium was removed, the three gene (human Oct3/4, Sox2 and Klf4) retrovirus vector solution prepared as in Example 1 were added in 2 ml portions, and after culturing at 37° C. for 1 day, the virus solution was removed, and the MAPC medium was added in 2 ml portions. Three days later, the medium was replaced with the mouse ES medium [a final concentration of 0.3% FBS (manufactured by Invitrogen), 1000 units/ml LIF (manufactured by Chemicon) and 0.1 mM 2-mercaptoethanol were added to the ES medium at the time of use]. Medium change with the mouse ES medium was continued every 2 to 3 days. Nine days after the introduction of three gene (human Oct3/4, Sox2 and Klf4) retrovirus vector, the cells were subcultured from each well of the 6-well plastic plate to each well of a 10 cm plastic dish.

[0401] Medium change with the mouse ES medium was continued every 2 to 3 days. Seven days after said three gene introduction, the pluripotent stem cells formed colonies composed of mouse ES cell-like small cells. In order to confirm the alkaline phosphatase activity, the medium was removed and then a 10% formalin neutral buffer solution was added to wells, and fixed at room temperature for 5 minutes. After washing with a phosphate buffer etc., the 1 step NBT/BCIP (manufactured by Pierce), a chromogenic substrate of alkaline phosphatase, was added and reacted at room temperature for 20 to 30 minutes. The colonies of said pluripotent stem cells were stained blue violet by alkaline phosphatase activity.

[0402] Then, the amount expressed of the Nanog gene was confirmed by quantitative PCR, and the expression of mouse Nanog of colonies of pluripotent stem cells having alkaline phosphatase activity was confirmed.

[0403] Forty nine days after said three gene introduction, the mouse pluripotent stem cells were subcutaneously transplanted on the back of syngeneic C57BL/6N mice at 2×10^7 cells/mouse, and 13 and 17 days later the teratoma that formed was extracted. Slices were prepared from the extracted teratoma, and differentiation potential into three germ layers was analyzed by immunological and histological staining (HE stain, alcian blue stain). As a result, GFAP-positive cells (the nervous system) and keratin producing cells as the ectodermic system, smooth muscle actin-positive cells (smooth muscle cells), bone tissues and cartilage tissues as the mesodermic system, and intestinal tract tissues (endodermal epithelium positive for MUC-1) as the endodermic system were observed.

[0404] Likewise, after said three gene introduction, the mouse pluripotent stem cells which were single-sorted based on GFP and SSEA-1 positive with FACSAria, were subcutaneously transplanted on the back of syngeneic C57BL/6N mice at 2×10^7 cells/mouse, and 13 and 14 days later the teratoma that formed was extracted. Slices were prepared from the extracted teratoma, and differentiation potential into three germ layers was analyzed by immunological and histological staining (HE stain, alcian blue stain). As a result, neural tube derived cells positive for GFAP, Nestin or Neurofilament as ectodermic system and cartilage tissues as the mesodermic system, and intestinal tract tissues (endodermal epithelium positive for MUC-1 and alpha-fetoprotein) as the endodermic system were observed.

[0405] From the above results, pluripotent stem cell were obtained by the forced expression of each of three genes of Oct3/4, Sox2, and Klf4 in undifferentiated stem cell present in a postnatal tissue. The pluripotent stem cells showed an in vitro long-term self-renewal ability, and were expressed ES cell marker, Nanog expression and alkaline phosphatase activity, and the ability of differentiation of tissues derivative from all three germ layers (ectoderm; mesoderm and endoderm).

Example 14

Long Term Expansion and Characterization of Human Induced Pluripotent Stem Cells

[0406] Human induced pluripotent stem (iPS) cell line generated from neonatal human skin fibroblasts (lot # 5F0438) in Example 6 which was termed iPS-1-8 was further sub-cloned with cloning cylinder and 0.25% trypsin-EDTA as described in Example 6. Nine sub-clones which were termed human iPS-1-1, 1-2, 1-3, 1-4, 1-5, 1-6, 1-7, 1-8 and 1-9 were obtained. One of nine sub clones, termed human iPS-1-8 clone, was successfully expanded on MEF feeder cells in human ES medium supplemented with 0.1 mM 2-mercaptoethanol and 10 ng/ml bFGF or in mTeSR1 defined medium (Stem cell Technologies) on matrigel (BD Biosciences)-coated culture dishes. Medium was changed for human iPS-1-8 clone culture everyday and usually treated with 5 to 20 μM of Y-27632 (Calbiochem) to avoid cell apoptosis triggered by the passaging procedures. For the passage to continue the culture, human induced pluripotent stem cells were washed with Hanks's balanced solution, incubated in 0.25% trypsin-EDTA (Gibco) at 37° C. for 3 minutes, and then added the culture medium to terminate the trypsin activity. Human induced pluripotent stem cells were centrifuged at 300×g at room temperature or 4° C. for 5 minutes and the supernatant was removed. Precipitated human induced pluripotent stem cells were re-suspended into culture medium. The pluripotent stem cells were usually split into new culture dishes using 1:4 to 1:6 splits. Human iPS-1-8 clone was frozen using Cell freezing solution for ES cells (Reprocell) according to the manufacture's manual.

[0407] Human iPS-1-8 clone was morphologically indistinguishable from typical human ES cell colonies with defined edges that consist of small, round, and compact cells when cultured on mitomycin-C treated mouse embryonic fibroblasts (MEFs) (FIG. **5**). FIG. **5** shows the characterization of human iPS clone 1-8. The morphology of its parental fibroblast (lot. 5F0438) is shown in Panel a; the morphology human iPS clone 1-8 cells cultured on murine embryonic fibroblast (MEF) feeder cells is shown in Panel b; the morphology of human iPS clone 1-8 cells in mTeSR1 medium is shown in Panel c; clone 24 cells in mTeSR1 medium are shown in Panel d; and clone 3-2 cells in mTeSR1 medium are shown in Panel e.

[0408] The growth curve of clone 1-8 is shown in Panels f and g. Arrows indicate the dates of examinations. The square indicates the period for counting cell numbers to estimate cell proliferation rate. Panel h is a multicolor karyogram image indicating a normal karyotype of iPS clone 1-8 derived cell at day 101.

[0409] Human iPS-1-8 clone actively proliferated in mTeSR1 medium. Human iPS-1-8 clone derived cells cultured in mTeSR1 medium was termed human iPS-1-8 mTeSR cells. Human iPS-1-8 clone was able to be passaged more than 30 times, and cultured for more than half year after four factor infections (FIG. **5***f, g*). Human iPS-1-8 mTeSR cells were able to be stored in liquid nitrogen and re-cultured in

mTeSR medium in the presence of 5 to 20 μM of Y-27632. Population doubling time of human iPS-1-8 mTeSR cells was approximately 48.5 hours when analyzed between passages 19 to 26 which correspond to days 123 to 148 after four factor infection.

[0410] Karyotype analysis of long-term cultured human iPS-1-8 clone (1-8 mTeSR) was performed using giemsa stain and multicolor-FISH analysis. Human iPS cells were pretreated with 0.02 μg/ml colecemid for 2 hours, followed by incubation with 0.075 M KCl for 20 minutes, and then fixed with Camoy's fixative. For multicolor-FISH analysis, cells were hybridized with the multicolor FISH probe (Cambio) and analyzed under DMRA2 fluorescent microscope (Leica). Human iPS-1-8 mTeSR cells mainly maintained a normal karyotype (46XY) after long-term culture in mTeSR (68%) without any chromosomal translocation or deletion (FIG. **5***h*, Table 3).

[0411] For alkaline phosphatase staining, cells were fixed with 10% formalin neutral buffer solution (Wako) at room temperature for 5 minutes, washed with PBS, and incubated with alkaline phosphatase substrate I step NBT/BCIP (Pierce) at room temperature for 20-30 minutes. Cells having alkaline phosphatase activity were stained in blue violet. For immunocytochemistry, cultured cells were fixed with 10% formaldehyde for 10 minutes and blocked with 0.1% gelatin/PBS at room temperature for 1 hour. The cells were incubated overnight at 4° C. with primary antibodies against SSEA-3 (MC-631; Chemicon), SSEA4 (MC813-70; Chemicon) TRA-1-60 (abcam), TRA-1-81 (abcam), CD9 (M-L13; R&D systems), CD24 (ALB9; abcam), CD90 (5E10; BD bioscience), or Nanog (R&D systems). For Nanog staining, cells were permeabilized with 0.1% Triton X-100/PBS before blocking. The cells were washed with PBS for three times, and then incubated with AlexaFluor 488-conjugated secondary antibodies. (Molecular Probes) and Hoechst 33258 at room temperature for 1 hour. After further washing, fluorescence was detected with an Axiovert 200M microscope (Carl Zeiss).

[0412] Human iPS-1-8 mTeSR cells were positive for alkaline phosphatase (hereinafter referred to as "ALP") activity and the carbohydrate antigens SSEA-3 and SSEA4, the keratin sulfate antigens TRA-1-60 and TRA-1-81, and the protein antigens CD9, CD24, Thy-1 (CD90) staining (FIG. **6**). FIG. **6** shows the characterization of transcription factors, cell surface antigens and ALP activity in human iPS clone 1-8. Human iPS cells (clone 1-8) were stained for Nanog (Panel a), SSEA-3 (Panel b), SSEA4 (Panel c), TRA-1-60 (Panel d), TRA-1-81 (Panel e), CD9 (Panel f), CD24 (Panel g), Thy-1 (also called CD90) (Panel h). Green fluorescent staining indicates that human iPS clone 1-8 expresses all of these surface antigens. ALP staining indicates that iPS clone 1-8 is ALP positive. Arrows illustrate regions of green fluorescent staining.

[0413] Total RNA was isolated from human iPS-1-8 clone, its parental fibroblasts, and crude fibroblasts obtained on 17 days after gene transduction by using RNeasy (Qiagen). cDNA was synthesized by SuperScript III (Invitrogen). Gene expressions were detected by PCR using Extaq (Takara). Sequences of the primers were described in Table 4. "Exo" primer sets selectively detected exogenous expression and "total" primer sets i endogenous expression

[0414] Human iPS-1-8 clone expressed human ES marker genes Nanog, TERT, Sal14, Zfp42, GDF3, Dnmt3b, TDGF1, GABRB3, and CYP26A1 though the parental fibroblasts expressed none of those marker genes (FIG. **7***a*). In contrast to crude fibroblasts, the human iPS-1-8 clone down-regulated forced expression of four genes, Oct4, Sox2, Klf4, and c-Myc (FIG. **7***b*). FIG. **7** shows the RT-PCR analysis of gene expression of human iPS clone 1-8 cells. Panel a depicts a RT-PCR analysis of hES marker gene expression in clone 1-8 and its parental fibroblast (NeoFB). Genes were detected at 30 cycles except for CYP26 μl (35 cycles). Panel b depicts the silencing of four transgenes in clone 1-8. Crude fibroblasts obtained 17 days after gene transduction were used as control. "Exo" primer sets selectively detected the expression of the exogenous genes; and "total" primer sets detected both endogenous and exogenous gene expression.

[0415] Human iPS cells cultured in both mTeSR1 on matrigel (1-8 mTeSR) and MEF-conditioned medium on matrigel (1-8CM) and its parental fibroblasts (5F0438) were analyzed for global gene expression. The microarray study was carried out using the Affymetrix Human Genome U133 Plus 2.0 gene expression arrays (Affymetrix, Santa Clara, Calif.). The GeneChip® Human Genome U133 Plus 2.0 Array provides comprehensive coverage of the transcribed human genome on a single array and analyzes the expression level of over 47,000 transcripts and variants, including 38,500 well-characterized human genes. Briefly, total RNA was extracted from cells with RNAeasy (Qiagen). Biotin-labelled cRNA was reverse transcribed from 1 μg of total RNA according to Affymetrix technical protocols. Fifteen micrograms of cRNA was fragmented and hybridized to a Affymetrix U133 plus 2 GeneChip arrays at 45° C. for 16 hours and then washed and stained using the Affimetrix Fluidics (Affymetrix). The assays were scanned in the Affimetrix GCS3000 scanner, and the images obtained were analyzed using the GCOS software. Data from this experiment and GEO were investigated with the GeneSpring 7.3.1. software.

[0416] For scatter plot analyses, human induced pluripotent stem cell clone-1-8, cultured in mTeSR1 on matrigel (1-8 mTeSR) and its parental fibroblasts (5F0438) were analyzed based on a set of 21,080 genes with present flag call ($P<0.04$) or marginal flag call ($0.04 \leqq P<0.06$) for both clone 1-8 and H14 hES line which is data from GEO (GSM151741), were used as a representative of human ES cells for comparison purposes. FIG. **8** shows a scatter plot analysis of the global gene expression of human iPS clone 1-8 cells. Scatter plots show a comparison of global gene expression between human iPS clone-1-8 cells cultured in mTeSR1 and H14 hES cells with MEFs (GSM151741 from public database GEO) (Panel a), or between clone 1-8 and its parental fibroblasts (Panel b). Symbols of ES cell specific genes were pointed with lines in both scatter plots. Expression intensity was shown in colorimetric order from red (high) to green (low). Arrows indicate representative regions of color.

[0417] For cluster analysis, DNA microarray data for clone-1-8 cultured in mTeSR1 (1-8 mTeSR), clone 1-8 cultured in MEF-conditioned medium (1-8CM) and its parental fibroblasts (5F0438) were compared with DNA microarray data for Sheff 4 line cultured on MEF (hES1:GSM194307, hES2: GSM194308, hES3: GSM194309), Sheff4 line cultured on matrigel (hES4: GSM194313, hES5: GSM194314), H14 line cultured on MEF (hES6: GSM151739, hES7: GSM151741), and three fibroblasts (GSM96262 for Fibroblasts1, GSM96263 for Fibroblasts2 and GSM96264 for Fibroblasts3).

[0418] The global gene expression profiles of the human iPS lines (1-8, 2-4, and 3-2) and their parental fibroblasts were

analyzed using microarray technology. Hierarchical cluster analysis using the gene set defined by the International Stem Cell Initiative (see Table 21) revealed that the human iPS lines (1-8, 24, and 3-2) clustered with human ES cell lines but separated from their parental skin-derived cells (FIG. **9**). FIG. **9** shows global gene expression of different cell lines and gene trees based on global gene expression analysis. Cells were clustered in the gene tree based on a set of genes identified by the International Stem Cell Initiative (see Table 21). Samples were designated "1-8 mTeSR" for clone-1-8 cultured in mTeSR; "1-8CM" for clone 1-8 cultured in MEF-conditioned medium; "1-8 mTeSR(f&t)" for clone 1-8 cultured in mTeSR after freeze-thaw treatment; "1-8MEF" for clone 1-8 cultured on MEF; "2-4 mTeSr" for clone 24 cultured in mTeSR medium; "24MEF" for clone 24 cultured on MEF; "3-2 mTeSR" for clone 3-2 cultured in mTeSR medium; "5F0438" or "5F0416" for the parental fibroblasts; "hES1," "hES2," "hES3" (GSM194307, GSM194308, GSM194309, respectively) for Sheff4 line cultured on MEF; "hES4," or "hES5" (GSM194313, GSM194314, respectively) for Sheff4 line cultured on matrigel; "hES6," or "hES7" (GSM151739, GSM151741) for H14 line cultured on MEF; "Fibroblasts1" for GSM96262; "Fibroblasts2" for GSM96263, and "Fibroblasts3" for GSM96264, respectively. Expression intensity was shown in colorimetric order from red (high) to green (low).

[0419] The Pearson correlation coefficient was 0.675 between human ES cell lines sheff4 and H14, and 0.835 between human iPS cell line 1-8 and human ES cell line H14 (FIG. **9**). Similar Pearson correlation efficients were observed between the global gene expression profiles of iPS lines 1-8, 2-4, and 3-2 and the hES cell lines This analysis indicates that human iPS cell line 1-8 had a similar gene expression pattern to the human ES cell lines H14.

[0420] Scatter plot analysis between human iPS cell line (clone 1-8) and human ES cell line H14 indicates that the human ES cell marker genes, Nanog, Oct3/4, TDGF1, Dnmt3b, GABRB3, GDF3, Zfp42, ALP, CD9, and Thy-1 showed high correlation between human iPS cell line and human ES cell line H14 (FIG. **8***a*). In contrast, clone 1-8 was different from the parental neonatal fibroblasts (FIG. **8***b*). This was confirmed by the cluster analysis using the Nanog-related genes. Pearson correlation coefficient was 0.908 between human iPS cell line 1-8 and human ES cell line H14 and 0.100 between human iPS cell line 1-8 and its parental fibroblasts (FIG. **10**). FIG. **10** shows global gene expression of different cell lines and gene trees based on the global gene expression analysis. Cells were clustered in the gene tree based on a set of genes correlated with Nanog gene expression in human ES cells (seven GEO data) between the ratio of 0.99 and I when compared with fibroblasts (three GEO data). Samples were designated "1-8 mTeSR" for clone-1-8 cultured in mTeSR; "1-8CM" for clone 1-8 cultured in MEF-conditioned medium, "5F0438" for the parental fibroblasts, "hES1," "hES2," "hES3" (GSM194307, GSM194308, GSM194309, respectively) for Sheff 4 line cultured on MEF; "hES4," "hES5" (GSM194313, GSM194314, respectively) for Sheff4 line cultured on matrigel" "hES6," "hES7" (GSM151739, GSM151741, respectively) for H14 line cultured on MEF; "Fibroblasts1" for GSM96262, "Fibroblasts2" for GSM96263, and "Fibroblasts3" for GSM96264, respectively. Expression intensity was shown in colorimetric order from red (high) to green (low). Global gene expression data for the 1-8, 2-4, and 3-2 cell lines and their parental fibroblasts were deposited in the Gene Expression Omnibus (GEO) database under accession number GSE9709. These analyses reveal that human iPS cell line is very similar to human ES cell lines in terms of gene expression.

[0421] The promoter regions of Nanog and Oct3/4 in clones 1-8 and 24 were analyzed for methylation of individual CpG sites. Ten nanograms of bisulfite-treated genomic DNA was PCR-amplified with primers containing a T7-promoter and transcripts treated with RNase A. As fragments originating from a methylated CpG sequence contained a G instead of an A-base, they had a 16 Da higher molecular weight than those resulting from the corresponding non-methylated CpG. This mass difference was detected using a MALDI-TOF mass spectrometer (Autoflex, Bruker Daltonics). The spectra produced by the mass spectrometer were analyzed using the EpiTYPER (Sequenom). The percentage methylation of individual CpG sites was calculated using the area under the peak of the signal from the unmethylated and methylated fragments. The percentage methylation of individual CpG sites was calculated using the area under the peak of the signal from the unmethylated and methylated fragments. Table 9 lists up locations and sizes in genome corresponding to the amplicons used for the methylation analyses. Table 10 lists up the primer sets using for methylation analyses.

[0422] The Oct3/4 proximal promoter including conserved region 1 (CR1), the Oct3/4 promoter distal enhancer including CR4 and the Nanog proximal promoter including Oct3/4 and Sox2 binding sites were examined (FIG. **11***a*). As shown in FIG. **11***b*, cytosine-phosphate-guanosine (CpG) dinucleotides in these regions were demethylated in clones 1-8 and 24 derived cells compared to the parental fibroblasts.

[0423] Human iPS-1-8 mTeSR cell-suspension (0.5 to 2×10^6 cells/mouse) was injected into the medulla of left testis of 7 to 8 week old SCID mice (CB17, Oriental Yeast) using a Hamilton syringe. After 6 to 8 weeks, the teratomas were excised under perfusion with PBS followed with 10% buffered formalin, and subjected to the histological analysis. Human iPS-1-8 mTeSR cells gave rise to teratomas 4 to 8 weeks after transplantation into testes of SCID mice.

[0424] Teratomas were embedded in the mounting medium, and sectioned at 10 μm on a cryostat. Serial sections were stained with hematoxylin-eosin (HE) to visualize the general morphology. For the detection of cartilage, alcian blue staining was employed or combined with HE.

[0425] For immunostaining, sections were treated with Immunoblock (Dainippon-Sumitomo) for 30 minutes to block non-specific binding. Slides were incubated with the following primary antibodies: anti Nestin polyclonal antibody (PRB-570C, COVANCE, 1:300), anti Type II collagen polyclonal antibody (LB-1297, LSL, 1:200), anti Smooth muscle actin polyclonal antibody (RB-9010-R7, LAB VISION, 1:1), anti α-Fetoprotein polyclonal antibody (A0008, DAKO, 1:500), anti MUC-1 polyclonal antibody (RB-9222-P0, LAB VISION, 1:100), and anti Human nuclei monoclonal antibody (HuNu) (MAB1281, CHEMICON, 1:300). For Type II collagen, before the treatment with primary antibody a section was incubated with Hyaluronidase (25 mg/l nL) for 30 minutes. Localization of antigens was visualized by using appropriate secondary antibodies (Alexa fluor 594 and 688, Molecular Probes, 1:600). Nuclei were stained with DAPI. Immunostained teratoma sections were analyzed under a fluorescence microscope (Axio Imager Z1, Zeiss).

[0426] Teratomas of human iPS-1-8 mTeSR cells contained tissues representative of three germ layers, neuroectoderm, mesoderm, and endoderm. FIG. **12** shows teratoma that was derived from human iPS-1-8 mTeSR cells cultured for 94 days (T1). Human iPS-1-8 mTeSR cells were injected into SCID mouse testes and analyzed 56 days after injection. HE and alcian blue staining of teratoma tissues reveled that teratomas contained neural epitherium (positive for nestin) cartilage (positive for collagen II), endodermal tract(alpha-fetoprotein). Human iPS-1-8 mTeSR cell derived tissues were distinguished from host tissues by HuNu staining. In T1 teratoma, smooth muscle cells (positive for alpha-SMA) and secretary epithelium (positive for MUC-1) were also observed (FIG. **13**). Human iPS-1-8 mTeSR cells which were cultured for 102 days and 114 days, were injected into SCID mouse testes and analyzed 48 days and 42 days(T3) after injection, respectively (T2, FIG. **13**, T3, FIG. **14**). Tissues representative of three germ layers, neuroectoderm, mesoderm and endoderm, were observed. To confirm whether human iPS can be cryopreserved, human iPS-1-8 mTeSR cells were frozen down, stored in liquid nitrogen and recultured. These cells were injected into SCID mouse testes and analyzed 46 days(T-F1) and 48 days (T-F2) after injection. Tissues representative of three germ layers, neuroectoderm, mesoderm and endoderm, were observed. Melanocytes were also observed in the T-F2 teratoma (FIG. **14**). Thus, pluripotency was maintained via freezing and thawing.

[0427] Both southern blot analysis and genomic PCR analysis indicated human iPS-1-8 clone carried four transgenes. In southern blot analysis cDNA fragments were prepared by restriction enzyme digestion (XhoI for POU5F1, NotI for Sox2, PstI for KIF4) from the corresponding pMX vector plasmids. These fragments were purified as [32P]-labeled probes with agarose gel electrophoresis and a QIAquick gel extraction kit (QIAGEN). Genomic DNA was prepared from the human iPS clone 1-8 and its parental fibroblasts. Five μg of each genomic DNA was digested with KpnI (POU5F1, Sox2, and Klf4). Fragments were separated on a 0.8% agarose gel, blotted onto HybondXL membrane (GE Healthcare), and hybridized with [32P]-labeled probes. Human iPS clone-1-8 was shown to carry approximately ten copies of both Oct3/4 transgenes and Sox2 transgenes, and a single copy of Klf4 transgene (FIG. **15**). In genomic PCR analysis, primer set indicated as c-Myc-total in Table 4 was designed so that the amplicon included whole second intron of c-Myc. Thus, amplicon size of the transgene (338 bp) was smaller than amplicon of endogene (1814 bp). Vector plasmid and the parental fibroblast genome, crude cultured fibroblast genome obtained from 17 days culture post infection were used as a control template. The genomic PCR confirmed clone-1-8 cells carries c-Myc transgene (FIG. **15**).

[0428] SNP genotyping was performed with the use of the GeneChip Human Mapping 500K Array Set (Affymetrix) according to the manufacture's protocol. Human iPS-1-8 mTeSR cells cultured in mTeSR1 on matrigel, its parental fibroblasts (5F0438), and fibroblast (5F0416) derived from a different donor were analyzed for this assay. The array set includes a StyI and a NspI chip. Two aliquots of 250 ng of DNA each were digested with NspI and StyI, respectively. Each enzyme preparation was hybridized to the corresponding SNP array (262,000 and 238,000 on the NspI and StyI array respectively). The 93% call rate threshold at P=0.33 (dynamic Model algorithm confidence threshold) with the Dynamic Model algorithm 138 was used in individual assays.

[0429] To confirm whether human iPS-1-8 mTeSR cells were generated from fibroblasts (5F0438), we compared SNP genotyping between human iPS-1-8 mTeSR cells and the employed fibroblasts (Table 5). SNPs of human iPS-1-8 mTeSR cells were consistent to that of parental cells in 464,069 (99.17%) of 467,946 of called SNPs and different from that of parental cells in 3,877 (0.83%) of them. In contrast, SNPs of human iPS-1-8 mTeSR cells were consistent to that of unrelated donor cells (5F0416) only in 284,950 (60.50%) of 470,960 of called SNPs and different from that of the unrelated cells in 186,010 (39.50%) of them. Thus, human iPS-1-8 clone (1-8 mTeSR) and parental cells had almost the same SNP genotype to each other, strongly suggesting that both cells originated from a single donor.

[0430] HLA DNA typing was performed by utilizing hybridization of PCR-amplified DNA with sequence specific oligonucleotide probes (SSOP) (Luminex). To investigate the DNA mutation ratio associated with the process of pluripotent stem cell induction, genome-wide single-nucleotide polymorphism array analysis was performed for human iPS clone 1-8 (n=2), its parental skin-derived cells (n=2), and skin cells derived from another donor (n=1). No marked differences were observed between human iPS clone 1-8 and the parental cells (Table 5). Consistent with these observations, HLA genotypes of human iPS cell lines 1-8, 2-4, and 3-2 were identical to those of their respective parental cells. Assays were performed to determine the HLA-A, HLA-B, HLA-Cw, HLA-DR, HLA-DQ, HLA-DP and Bw loci according to manufacturer's instructions. Human iPS cells are promising materials in cell transplantation therapies, they would overcome immune rejection, because human iPS cells can be directly generated from subjects' cells and must be the identical HLA type. We carried out HLA typing of human iPS-1-8 clone (1-8 mTeSR), parental cells (5F0438), and unrelated fibroblasts (5F0416). As expected, HLA type of iPS-1-8 clone was completely identical to that of 5F0438 but not 5F0416 (Table 6).

[0431] From the foregoing, human pluripotent stem cell were obtained by the forced expression of each of four genes of Oct3/4, Sox2, Klf4, and c-Myc in undifferentiated stem cell present in a human postnatal tissue. The human pluripotent stem cells showed an in vitro long-term self-renewal ability and the pluripotency of differentiation into ectoderm, mesoderm and endoderm. The human pluripotent stem cells were expressed cell surface antigens SSEA-3, SSEA4, TRA-1-60, TRA-1-81, CD9, CD24, and CD90, and ES cell marker genes Nanog, Oct3/4, TDGF1, Dnmt3b, GABRB3, GDF3, Zfp42, ALP, CD9, and Thy-1. The promoter regions of Nanog and Oct3/4 in the human pluripotent stem cells were demethylated compared to the parental fibroblasts. The human pluripotent stem cells carries at least a single copy of Oct3/4, Sox2, Klf4, and c-Myc transgene. The induced human pluripotent stem cells and the parental cells (undifferentiated stem cell present in a human postnatal tissue) had almost the same SNP genotype each other, and HLA type of the induced human pluripotent stem cell was completely identical to that of the parental cell (undifferentiated stem cell present in a human postnatal tissue).

Example 15

Gene Expression Profile of Primary Culture of 4 Genes Introduced Neonatal Fibroblast

[0432] Two lots of neonatal fibroblasts (5F0416 and 5F0474) were seeded at 10^3 cells/cm^2 or 10^4 cells/cm^2 into 35 mm diameter wells of 6 well plates and cultured in FBM supplemented with FGM-2 SingleQuots (manufactured by Lonza) before the four genes transduction. Cells were infected with mCAT1-adenovirus vectors at 2×10^5 ifu/well and then infected with the retroviral vectors carrying four genes as described in Example 6. Eight wells were prepared for this study (2 different lot and 2 different densities in duplicate).

[0433] Seventeen days post 4-gene infection, cells were fixed and stained for alkaline phosphatase (ALP) as described in Example 3. In total, 163 ALP positive(+) colonies were observed in four independent experiments. All 163 ALP(+) colonies and 18 ALP-negative (ALP(−)) colonies were dissected, and total RNA from these colonies were extracted using a Recover All Total Nucleic Acid Isolation kit (manufactured by Ambion). After the cDNA preparation, genes of interest were amplified using Taqman preamp (manufactured by Applied Biosystems). Real-time quantitative PCR was performed with ABI PRISM 7900HT (manufactured by Applied Biosystems) using PCR primer sets (manufactured by Applied Biosystems, Nanog, Hs02387400_g1, Dnmt3b, Hs00171876 ml, FoxD3, Hs00255287_s1, Zfp42, Hs01938187_s1, TDGF1, Hs02339499_g1, TERT, Hs00162669_m1, GDF3, Hs00220998_m1, CYP26A1, Hs00175627_m1, GAPDH, Hs99999905_m1) to determine gene expression of human ES cell markers in colonies. Eight genes (Nanog, TDGF1, Dnmt3b Zfp42 FoxD3, GDF3, CYP26A1 and TERT genes) which were reported to express in human ES cells were selected as a pluripotent stem cell marker genes. A standard curves was generated for each primer pair. All expression values were normalized against GAPDH.

[0434] It is known that mouse ES cells and mouse iPS cells form multilayered/aggregated colonies. Thus we first analyzed the mouse ES cell like aggregated colonies which were induced by ectopic expression of four gene in human fibroblasts (e.g., colony #1-2-F and #1-2-B in FIG. **23**). However, these colonies are all ALP(−). Next we analyzed the Nanog gene expression in colonies. Nanog gene expression was observed in 161 out of 163 ALP positive colonies and 16 out of 18 ALP negative colonies. On the other hand expression of TERT and CYP26A1 genes were observed only in 26 and 24 colonies out of 163 ALP positive colonies respectively (FIG. **16***a*). Genes such as Nanog, TDGF, and Dnmt3b which are well know to be close association with the pluripotent state in human ES cells, and to be strongly downregulated upon their differentiation had higher tendency to be induced by the four gene transduction.

[0435] ALP positive colonies can be categorized into 40 groups based on the gene expression pattern of the eight human marker genes (Table 7). When colonies are categorized by the total number of eight marker genes expression, the distribution of colony number followed a normal distribution suggesting the presence of a stochastic process in the colony induction (FIG. **16***c,d*). In addition the efficiency of human ES cell marker gene expression in human fibroblasts was affected by the donor difference. Quantitative gene expression analysis of colonies formed 17 days after infection indicated that the transgenes c-Myc and Oct4 showed high expression in all the analyzed colonies (Table 11). In addition endogenous Nanog expression was very high in most of the ALP positive colonies, including cells lacking expression of one or more of the eight human ES cell marker genes (Table 11). These results indicate that the process of pluripotent stem cell induction from human skin fibroblasts is slower than that described for mouse iPS cell generation. Only 4 out of 163 ALP positive colonies were positive for Nanog, TDGF1, Dnmt3b, Zfp42, FoxD3, GDF3, Cyp26a1 and TERT (octa-positive colony). Cells in these octa-positive colonies showed common features: 1) small size with the high nucleus to cytoplasm ratio and 2) formation of small monolayer colonies within the space between fibroblasts (FIG. **16***c*). These features are consistent to the feature of human ES cells. However, these three features were also observed in some of ALP(+) colonies which lacked one or more ES cell marker expression. In addition, the large colony with these three features lack ALP expression (FIG. **23** colony #7-1-1). ALP (+) colonies with fibroblastic feature (colony #5-1-7, #3-1-214, #3-2-233, #3-1-212, #3-1-215, #5-1-4 in FIG. **17-23** and Table 7, 11) usually lacked one or more ES cell marker gene expressions.

[0436] These results indicate that induced pluripotent stem cells can be isolated from small monolayer colonies comprising small cells with high nucleus to cytoplasm ratio not from fibroblastic colonies, defused colonies or multilayered colonies. Table 8 summarizes all of experiments and results on the ALP positive colony number using human neonatal fibroblasts.

Example 16

Generation of Human iPS-2-4 Clone from Human Neonatal Skin Fibroblasts

[0437] Adenovirus vector plasmids for mCAT1 were transfected into 293 cells. The mCAT1-adenoviruses were isolated from these cells by three freeze-thaw cycles, purified using Adenovirus purification kit (Clontech) and stored at −80° C. The titer of the vector stocks was determined by Adeno-X rapid titer kit (Clontech).

[0438] The replication deficient MMLV derived retrovirus vector pMx was used for the ectopic expression of human Oct3/4, Sox-2, c-Myc and Klf4. Recombinant retroviruses were generated by transfecting vectors to the Plat-E packaging system (Morita et al., (2000), *Gene Therapy,* 7:1063-1066) followed by incubation in FBM (Lonza) supplemented with FGM-2 SingleQuots (Lonza). Between 24 and 48 hours after the transfection, supernatant from the Plat-E culture was collected several times at intervals of at least 4 hours and passed through a 0.45 μm filter.

[0439] For MEF-conditioned medium (MEF-CM) preparation, human ES medium (DMEM/F12 (Gibco) supplemented with 20% Knockout Serum Replacement (KSR, Invitrogen), 2 mM L-glutamine (Sigma), 1× nonessential amino acids (Sigma), 10 μg/ml gentamycin), 10 ng/ml bFGF was conditioned on mitomycin-C treated MEF (Reprocell) for 20-24 hours, harvested, filtered through a 0.45 μm filter and supplemented with 0.1 mM 2-mercaptoethanol (Sigma) and 10 ng/ml bFGF before use.

[0440] Using cells (trade name: Neonatal Normal Human Skin Fibroblasts, primary culture) derived from a human neonatal tissue, a human tissue immediately after birth, the induction of human pluripotent stem cells from undifferentiated stem cells present in the skin of a human neonate was attempted.

[0441] Human neonatal dermal fibroblasts (Lonza; lot SF0416) were cultured in FBM supplemented with FGM-2 SingleQuots. Three days before the 4 gene introduction, fibroblasts were seeded at 10^3 cells/cm^2 into 6 well plates. Eighteen hours later, the cells were mixed with the mCAT1 adenovirus vector solution in 500 μl Hanks' balanced salt solution, and incubated at room temperature for 30 min. The cells were then added to 2 ml of medium and cultured for 48 hrs. Subsequently, the cells were incubated in 2 ml of the retrovirus/polybrene solution (mixture of equal volumes of the retrovirus vector suspension for each of the four genes (Oct3/4, Sox2, Klf4 and c-Myc) prepared in Example 1, supplemented with 5 μg/ml of polybrene) at 37° C. for 4 hrs to overnight. The virus supernatant was replaced with MEF-conditioned ES medium. Then medium was changed every days.

[0442] On day 33 after gene introduction, a colony with a characteristic shape was picked with forceps from a well. The picked colony was transferred into a matrigel-coated well in a 24-well plate and maintained in mTeSR1 defined medium supplemented with 10 μM Y-27632. Fourteen hours later the

medium was changed. Medium change was continued every days. At day 54 after the infection a second culture was carried out. At day 67, human iPS-24 clone was sub-cloned and designated as human iPS-2-4 sub-clone.

[0443] For passaging, medium was removed, and the cells were washed with the Hank's balanced salt solution followed by the treatment with 0.25% trysin-EDTA at 37° C. for 3 minutes. Fresh medium was added to stop the reaction. The cell suspension was centrifuged at 4° C. and 200×g for 5 minutes, and the supernatant was removed. The cells were resuspended in mTeSR1 defined medium supplemented with 10 μM Y-27632 and plated.

[0444] Human iPS-24 sub-clone was successfully expanded in mTeSR1 defined medium (Stem cell Technologies) on matrigel (BD Biosciences)-coated culture dishes. We termed cells derived from the sub-clone iPS-2-4 and cultured in mTeSR1 medium as human iPS-2-4 mTeSR cells. Medium was changed for human iPS-2-4 mTeSR cell culture everyday and usually treated with Y-27632 (Calbiochem) to avoid cell apoptosis after passaging. For passaging, cells were washed with Hanks's balanced solution, incubated in 0.25% trypsin-EDTA (Gibco) at 37° C. for 3 minutes, and then added the culture medium. Cells were centrifuged at 300×g at room temperature or 4° C. for 5 minutes and the supernatant was removed. The cells were re-suspended into culture medium. Human iPS-2-4 mTeSR cells were morphologically indistinguishable from typical human ES cells and human iPS-1-8 mTeSR cells, which grown in colonies with defined edges consisting of small, round cells with a high nucleus to cytoplasm ratio.

[0445] Fifty nine days post 4-gene infection, a part of cells were fixed and stained for alkaline phosphatase (ALP) as described in Example 3. Colonies consisting of cells were positive for ALP and Total RNA from colonies was extracted using a Recover All Total Nucleic Acid Isolation kit (manufactured by Ambion). After the cDNA preparation, genes of interest were amplified using Taqman preamp (manufactured by Applied Biosystems). Real-time quantitative PCR was performed with ABI PRISM 7900HT (manufactured by Applied Biosystems) using PCR primer sets (manufactured by Applied Biosystems, Nanog, Hs02387400_g1, Dnmt3b, Hs00171876_m1, FoxD3, Hs00255287_s1, Zfp42, Hs01938187_s1, TDGF1, Hs02339499_g1, TERT, Hs00162669_m1, GDF3, Hs00220998_m1, CYP26A1, Hs00175627_m1, GAPDH, Hs99999905_m1) to determine gene expression of human ES cell markers in colonies. Clone-2-4 showed expression of ES cell marker genes (Table 12). As observed for the iPS 1-8 line, both southern blot analysis and genomic PCR analysis indicated the 24 line contained integrated Oct 3/4, Sox2, Klf4, and c-Myc transgenes. Likewise, the 24 iPS line expressed the cell surface markers CD24, CD90, TRA 1-60, TRA-1-81, SSEA3, and SSEA4; had a normal karyotype; HLA genotypes identical to its parental cells, a global gene expression pattern similar to that of the 1-8 line; and an Oct 3/4 and Nanog promoter hypomethylation as observed in the 1-8 line.

[0446] From the above results, human pluripotent stem cell were obtained by the forced expression of each of four genes of Oct3/4, Sox2, Klf4, and c-Myc in undifferentiated stem cell present in a human postnatal tissue. The human pluripotent stem cells showed an in vitro long-term self-renewal ability, and expressed the ES cell marker genes Nanog, Oct3/4, TDGF1, Dnmt3b, GABRB3, GDF3, Zfp42, ALP, CD9, and Thy-1.

Example 17

Generation of Human iPS-3-2 Clone from Human Neonatal Skin Fibroblasts

[0447] According to Example 16, human neonatal dermal fibroblasts (Lonza; lot SF0438) were cultured in FBM supplemented with FGM-2 SingleQuots. Three days before the 4 gene introduction, fibroblasts were seeded at 10^3 cells/cm^2 into 6 well plates. Eighteen hours later, the cells were mixed with the mCAT1 adenovirus vector solution in 500 μl Hanks' balanced salt solution, and incubated at room temperature for 30 min. The cells were then added to 2 ml of medium and cultured for 48 hrs. Subsequently, the cells were incubated in 2 ml of the retrovirus/polybrene solution (mixture of equal volumes of the retrovirus vector suspension for each of the four genes (Oct3/4, Sox2, Klf4 and c-Myc) prepared in Example 1, supplemented with 5 μg/ml of polybrene) at 37° C. for 4 hrs to overnight. The virus supernatant was replaced with MEF-conditioned ES medium. Then medium was changed every days.

[0448] On day 21 after gene introduction, a colony with a characteristic shape was directly picked with forceps from one of dishes. The picked colony was transferred into a matrigel-coated well in a 24-well plate and maintained in mTeSR1 defined medium supplemented with 10 μM Y-27632.

[0449] Fourteen hours later the medium was changed. Medium change was continued every days. 40 days after the infection, a second subcloning was carried out, and cells were successfully expanded in mTeSR1 defined medium (Stem cell Technologies) on matrigel-coated culture dishes. Medium was changed everyday and usually treated with Y-27632 (Calbiochem) to avoid cell apoptosis after passaging. For passaging, cells were washed with Hanks's balanced solution, incubated in 0.25% trypsin-EDTA (Gibco) at 37° C. for 5 minutes, and then added the culture medium. Cells were centrifuged at 300×g at room temperature for 5 minutes and the supernatant was removed. The cells were re-suspended into culture medium.

[0450] Cells were morphologically indistinguishable from typical human ES cells, human iPS-1-8 mTeSR cells, and human iPS-2-4 mTeSR cells, which grow in colonies with well defined edges and consist of small, round cells with a high nucleus to cytoplasm ratio. Thus we termed this clone as human iPS-3-2 clone. Human iPS-3-2 clone actively proliferated in mTeSR1 medium. We termed these cells derived from human iPS-3-2 clone which culture in mTeSR1 medium as human iPS-3-2 mTeSR cells.

[0451] Forty eight days post 4-gene infection, cells were fixed and stained for alkaline phosphatase (ALP) as described in Example 3. Total RNA from colonies were extracted using a RecoverAll Total Nucleic Acid Isolation kit (manufactured by Ambion). After the cDNA preparation, genes of interest were amplified using Taqman preamp (manufactured by Applied Biosystems). Real-time quantitative PCR was performed with ABI PRISM 7900HT (manufactured by Applied Biosystems) using PCR primer sets (manufactured by Applied Biosystems, Nanog, Hs02387400_g1, Dnmt3b, Hs00171876_m1, FoxD3, Hs00255287_s1, Zfp42, Hs01938187_s1, TDGF1, Hs02339499_g1, TERT, Hs00162669_m1, GDF3, Hs00220998_m1, CYP26A1, Hs00175627_m1, GAPDH, Hs99999905_m1) to determine gene expression of human ES cell markers in colonies. Clone 3-2 showed expression of ES cell marker genes (Table 12). Genomic PCR analysis indicated the 3-2 line contained integrated Oct 3/4, Sox2, Klf4, and c-Myc transgenes. Likewise, the 3-2 iPS line had HLA genotypes identical to its parental cells and a global gene expression pattern similar to that of the 1-8 line.

[0452] From the above results, human pluripotent stem cell were obtained by the forced expression of each of four genes of Oct3/4, Sox2, Klf4, and c-Myc in undifferentiated stem cell present in a human postnatal tissue. The human pluripotent stem cells showed an in vitro long-term self-renewal

ability, and were expressed ES cell marker genes Nanog, Oct3/4, TDGF1, Dnmt3b, GABRB3, GDF3, Zfp42, ALP, CD9, and Thy-1.

Example 18

Induction of Human Pluripotent Stem Cells by Forced Expression of Oct3/4, Sox2, and Klf4 by Retroviral Transduction Plus HDAC Inhibitor Treatment (Prophetic Example)

[0453] Human postnatal dermal fibroblasts are cultured in FBM supplemented with FGM-2 SingleQuots. Three days before retroviral transduction and histone deacetylase inhibitor treatment, the fibroblasts are seeded at 10^3 cells/cm^2 into 6 well cell culture plates. Eighteen hours later, the cells are incubated for 30 minutes at room temperature, with occasional shaking, in 500 μl Hanks' balanced salt solution containing the mCAT1 adenovirus vector (described in Example 2) at an MOI of 5. Afterwards, 2 ml of FBM medium are added to each well and the cells are cultured for 48 hrs. Subsequently, the cells are incubated in 2 ml of the retrovirus/polybrene solution (a mixture of equal volumes of the retrovirus vectors encoding Oct3/4, Sox2, and Klf4 as described in Examples 1 and 5) at an m.o.i. of approximately 10 for each virus prepared, supplemented with 5 μg/ml of polybrene) at 37° C. for 4 hrs to overnight. The virus supernatant is then replaced with MC-ES medium supplemented with the histone deacetylase inhibitor MS-275 at a final concentration of 1 μM. On the following day, the medium is replaced with MC-ES medium, and is replaced daily afterwards.

[0454] Between days 17-33 after viral transduction plus MS-275 treatment, a colony with a characteristic shape (e.g., small, round, and having a high nucleus to cytoplasm ratio) is picked from a well with forceps. The picked colony is then transferred into a matrigel-coated well in a 24-well plate and maintained in mTeSR1 defined medium supplemented with 10 μM Y-27632. Fourteen hours later the medium is replaced. Afterwards, the medium is changed daily. At days 38-54 after viral transduction plus MS-275 treatment, a second subculture is carried out. For passaging, the medium is removed, and the cells are washed with the Hank's balanced salt solution followed by the treatment with 0.25% trysin-EDTA at 37° C. for 3-5 minutes. Fresh medium is added to stop the reaction. The cell suspension is centrifuged at 4° C. and 200×g for 5 minutes, and the supernatant is then removed. The cells are resuspended in mTeSR1 defined medium supplemented with 10 μM Y-27632 and plated in a matrigel-coated well of a 6-well culture dish.

[0455] The resulting human iPS clones are expanded in mTeSR1 defined medium on matrigel (BD Bioscience)-coated culture dishes. The culture medium is changed daily for human iPS cell culture. For passaging human iPS cell lines, cells are washed with Hanks's balanced solution, incubated in 0.25% trypsin-EDTA (Gibco) at 37° C. for 3-5 minutes, and then added the culture medium. The resulting cell suspension is then centrifuged at 300×g at room temperature or 4° C. for 5 minutes and the supernatant is removed. The cells are re-suspended into culture medium and plated as described above. After passaging, the medium is supplemented with 10 μM Y-27632 (Calbiochem) to avoid cell apoptosis. The resulting human iPS cells are morphologically indistinguishable from typical human ES cells and human iPS-1-8 mTeSRcells grow in colonies with defined edges and consisting of small, round cells with a high nucleus to cytoplasm ratio. According to all analyses described as in Examples 14-15, the resulting human iPS cells show an in vitro long-term self-renewal ability and are very similar to typical human ES cells in many characteristics.

Example 19

Induction of Human Pluripotent Stem Cells by Forced Expression of Oct3/4, Sox2, and Klf4 by Retroviral Transduction (Prophetic Example)

[0456] Human postnatal dermal fibroblasts are cultured in FBM supplemented with FGM-2 SingleQuots. Three days before retroviral transduction, the fibroblasts are seeded at 10^3 cells/cm^2 into 6 well cell culture plates. Eighteen hours later, the cells are incubated for 30 minutes at room temperature, with occasional shaking, in 500 μl Hanks' balanced salt solution containing the mCAT1 adenovirus vector (described in Example 2) at an MOI of 5. Afterwards, 2 ml of FBM medium are added to each well and the cells are cultured for 48 hrs. Subsequently, the cells are incubated in 2 ml of the retrovirus/polybrene solution (a mixture of equal volumes of the retrovirus vectors encoding Oct3/4, Sox2, and Klf4 as described in Examples 1 and 5) at an m.o.i. of approximately 10 for each virus prepared, supplemented with 5 μg/ml of polybrene) at 37° C. for 4 hrs to overnight. The virus supernatant is then replaced with MC-ES medium. On the following day, the medium is replaced with MC-ES medium, and is replaced daily afterwards.

[0457] Between days 17-33 after viral transduction, a colony with a characteristic shape (e.g., small, round, and having a high nucleus to cytoplasm ratio) is picked from a well with forceps. The picked colony is then transferred into a matrigel-coated well in a 24-well plate and maintained in mTeSR1 defined medium supplemented with 10 μM Y-27632. Fourteen hours later the medium is replaced. Afterwards, the medium is replaced daily. At days 38-54 after viral transduction, a second subculture is carried out. For passaging, the medium is removed, and the cells are washed with the Hank's balanced salt solution followed by the treatment with 0.25% trysin-EDTA at 37° C. for 3-5 minutes. Fresh medium is added to stop the reaction. The cell suspension is centrifuged at 4° C. and 200×g for 5 minutes, and the supernatant is then removed. The cells are resuspended in mTeSR1 defined medium supplemented with 10 μM Y-27632 and plated in four matrigel-coated wells of a 6-well culture dish.

[0458] The resulting human iPS clones is expanded in mTeSR1 defined medium on matrigel (BD Bioscience)-coated culture dishes. The culture medium is changed daily for human iPS cell culture. For passaging human iPS cell lines, cells are washed with Hanks's balanced solution, incubated in 0.25% trypsin-EDTA (Gibco) at 37° C. for 3-5 minutes, and then added the culture medium. The resulting cell suspension is then centrifuged at 300×g at room temperature or 4° C. for 5 minutes and the supernatant is removed. The cells are re-suspended in culture medium and plated as described above. After passaging, the medium is supplemented with 10 μM Y-27632 (Calbiochem) to avoid cell apoptosis. The resulting human iPS cells are morphologically indistinguishable from typical human ES cells and human iPS-1-8 mTeSRcells, which grow in colonies with defined edges and consisting of small, round cells with a high nucleus to cytoplasm ratio. According to all analyses described as in Examples 14-15, the resulting human iPS cells show an in vitro long-term self-renewal ability and are very similar to typical human ES cells in many characteristics.

Example 20

Assay for Identifying siRNAs that Induce Pluripotency ("inducing siRNAs") in Combination with a Subset of Induction Factors Using a Tert Reporter Construct (Prophetic Example)

[0459] A whole human genome siRNA library is used in a primary screen to identify siRNAs having the ability to

induce pluripotency or increase the induction of pluripotency in a human adult fibroblast population when used in combination with a subset of three induction factors selected from Oct 3/4, Sox2, Klf4, and c-Myc. The screen utilizes a reporter assay for activation of the iPS-marker gene Tert to identify candidate siRNAs capable of complementing the inducing activity of a subset of three induction factors selected from Oct 3/4, Sox2, Klf4, and c-Myc. For example, a test siRNA may be used in combination with Oct 3/4, Klf4, and c-Myc to identify siRNAs that complement the missing Sox2 activity. In a secondary screen, the candidate inducing siRNAs are tested again in the same assay, and the expression of another, iPS-marker gene Cyp26A1, is also assayed in the tested cells.

Generation of a Tert Promoter Reporter Retrovirus:

[0460] A 0.5 kb fragment of the human tert promoter is PCR amplified from human genomic DNA with using an upstream primer hTERT-475F:

5'-GCAGCCCTGGGTCTCCAGATCTGGCCAGC-3' (SEQ ID NO:14)

and a downstream primer hTERT+49R:

5'GGTGGCCGGGGCCAGGGCTAGCCACGTGC-3' (SEQ ID NO:15)

[0461] Primers are numbered by the number of bases upstream (+) or downstream (−) of the start of hTERT exon 1 (chromosome 5, base 1306027 on human July 2003 genome assembly on the world wide web at genome.ucsc.edu). See, e.g., Padmanabhan et al., (2006), *Journal of Nuclear Medicine,* 47(2) 270-277.

[0462] The amplified fragment is then subcloned 5' to the luc2P ORF in the promoterless pGL4.11[luc2P] vector (Promega, Madison, Wis.). The entire tert-luc2 reporter cassette is then PCR amplified, subcloned into the pMX retroviral vector, validated by sequencing, and packaged in Plat-A cells (see Morita et al., (2000), *Gene Therapy,* 7(12): 1063-1066) to generate a Tert-luc reporter ("TLR") ecotropic retrovirus, as described in Example 1.

Cell Culture, Viral Infection, and siRNA Transfection

[0463] Adult or neonatal normal Human Skin Fibroblasts (Lonza) of 6×10^5 cells in 10 ml of medium are plated with FBM medium in a dish with 10 cm diameter cell culture plates at a density of 10^4 cells/cm^2. Adult or neonatal normal Human Skin Fibroblasts (Lonza) are plated with FBM medium in a dish with 10 cm diameter cell culture plates at a density of 10^4 cells/cm^2 in 10 ml of medium per a dish. Human postnatal dermal fibroblasts are cultured in FBM supplemented with FGM-2 SingleQuots. Eighteen hours later, the cells are incubated at room temperature, with occasional shaking, for 30 minutes with 3 ml of FBM medium or Hanks' balanced salt solution containing the mCAT1 adenovirus vector (described in Example 2) at an MOI of 1 to 5. Afterwards, 12 ml of complete FBM medium are added to each dish and the cells are cultured for 48 hrs. Forty eight hours later, the medium is removed, and a mixture of the TLR retrovirus, and retroviruses encoding any three of Oct 3/4, Sox2, Klf4, and c-Myc prepared as described above is added, each virus at an m.o.i. of about 10-50 in 3 ml of the medium per a dish is added, and the infection is continued at room temperature for 30 minutes. Afterwards 12 ml of the FBM medium was added, and the plates are incubated at 37 C. Twenty four hours after the addition of the TLR retrovirus and retroviruses encoding any three of Oct 3/4, Sox2, Klf4, and c-Myc, cells are plated with FBM medium in 384 or 96-well cell culture plates coated with matrigel (20 g/cm^2) at a density of 10^4 cells/cm^2 in 25 or 100 μl of medium per well. The resulting cells are cultured in FBM supplemented with FGM-2 SingleQuots. Twenty four hours later, the medium of each well is replaced with 50 or 200 μl (for 384 or 96-well, respectively) of a mixture containing antibiotic-free Opti-MEM® I Reduced Serum medium (Invitrogen), Lipofectamine™-RNAiMax transfection reagent (Invitrogen), mixed according to the manufacturer's protocol with 4 siRNAs to a human gene target, with a final concentration of 50 nM for each siRNA ("test siRNA wells"). Thus, siRNAs against a total of approximately 25,000 target human genes (i.e. most, if not all, expressed sequences) are tested in the assay. As a "negative control" in the assay, 20 wells ("negative control wells") of cells transduced as described above are transfected with 20 sets of scrambled siRNAs (checked for lack of homology to vector or mammalian sequences).

Luciferase Assay of TLR Plus siRNA-Treated Human Fibroblasts

[0464] After 48 hours, cell lysates are prepared from each well, and luciferase activity is measured in the presence of luciferin and ATP (Sigma, St. Louis, Mo.), as a measure of nanog promoter activity in Ad-nanog-luc-infected cells, using a Berthold-Lumat B9501 luminometer (Berthold-Lumat, St Albans, Herts, UK). Luciferase activity from each of the test siRNA wells is compared to the mean luciferase activity determined for the negative control wells. Where siRNA wells are determined to have significantly higher luciferase activity than the mean negative control well value, the corresponding siRNA sequences ("candidate inducing siRNAs") are tested in a secondary screen.

Secondary Screens

[0465] In one secondary screen, cells are plated in a 48 well format using the same cell culture conditions as described above. After 24 hours, wells are transfected with the candidate inducing siRNAs (n=10 per target gene) identified in the primary screen, but adjusting the volumes for a 48 well culture format. Cells are then cultured for a further 72 hours. Afterwards, medium is removed, cells are washed with Hanks Buffered Saline solution and the level of Cyp26a1 mRNA is determined by qRT-PCR.

Example 21

Assay for Identifying siRNAs that Induce Pluripotency ("Inducing siRNAs") in Combination with a Subset of Induction Factors Using qRT-PCR (Prophetic Example)

[0466] A whole human genome siRNA library is used in a primary screen to identify siRNAs having the ability to induce pluripotency or increase the induction of pluripotency in a human adult fibroblast population when used in combination with a subset of three induction factors selected from Oct 3/4, Sox2, Klf4, and c-Myc. The screen utilizes a qRT-PCR assay for detecting expression of the iPS marker gene Tert to identify candidate siRNAs capable of complementing the inducing activity of a subset of three induction factors selected from Oct 3/4, Sox2, Klf4, and c-Myc. For example, a test siRNA may be used in combination with Oct 3/4, Klf4, and c-Myc to identify siRNAs that complement the missing Sox2 activity. In a secondary screen, the candidate inducing siRNAs are tested again in the same assay, and the expression of another, iPS-marker gene Cyp26A1, is also assayed in the tested cells.

Cell Culture, Viral Infection, and siRNA Transfection

[0467] Adult or neonatal normal Human Skin Fibroblasts (Lonza) are plated with FBM medium in a dish with 10 cm diameter cell culture plates at a density of 10^4 cells/cm^2 in 10 ml of medium per a dish. Human postnatal dermal fibroblasts are cultured in FBM supplemented with FGM-2 SingleQuots. Eighteen hours later, the cells are incubated, with occasional shaking, for 30 minutes at room temperature with 3 ml of FBM medium or Hanks' balanced salt-solution containing the mCAT1 adenovirus vector (described in Example 2) at an MOI of 1 to 5. Afterwards, 12 ml of complete FBM medium are added to each dish and the cells are cultured for 48 hrs. Forty eight hours later, the medium is removed, and a mixture of the TLR retrovirus, and retroviruses encoding any three of Oct 3/4, Sox2, Klf4, and c-Myc prepared as described above is added, each virus at an m.o.i. of about 10-50 in 3 ml of the medium per a dish is added, and the infection is continued at room temperature for 30 minutes. Afterwards 12 ml of the FBM medium was added, and the plates are incubated at 37 C. Twenty four hours after the addition of the TLR retrovirus and retroviruses encoding any three of Oct 3/4, Sox2, Klf4, and c-Myc, cells are plated with FBM medium in 384 or 96-well cell culture plates coated with matrigel (20 g/cm^2) at a density of 10^4 cells/cm^2 in 25 or 100 μl of medium per well. The resulting cells are cultured in FBM supplemented with FGM-2 SingleQuots. Twenty four hours later, the medium of each well is replaced with 50 or 200 μl (for 384 or 96-well, respectively) of a mixture containing antibiotic-free Opti-MEM® I Reduced Serum medium (Invitrogen), Lipofectamine™-RNAiMax transfection reagent (Invitrogen), mixed according to the manufacturer's protocol with 4 siRNAs to a human gene target, with a final concentration of 50 nM for each siRNA ("test siRNA wells"). Thus, siRNAs against a total of approximately 25,000 target human genes (i.e. most, if not all, expressed sequences) are tested in the assay. As a "negative control" in the assay, 20 wells ("negative control wells") of cells transduced as described above are transfected with 20 sets of scrambled siRNAs (checked for lack of homology to vector or mammalian sequences).

[0468] Total RNA from colonies is extracted using the RecoverAll Total Nucleic Acid Isolation kit (manufactured by Ambion). After reverse transcription, Tert or CYP26A1 are amplified using the Taqman preamp (manufactured by Applied Biosystems). Real-time quantitative PCR is then performed with an ABI PRISM 7900HT device (manufactured by Applied Biosystems) using PCR primer sets TERT, Hs00162669_m1 and CYP26A1, Hs00175627_m1 (available from Applied Biosystems).

[0469] Where siRNA wells are determined to induce a higher level of Tert mRNA expression relative to the negative control level, the corresponding siRNA sequences ("candidate inducing siRNAs") are tested in a secondary screen.

Secondary Screens

[0470] In one secondary screen, cells are plated in a 48 well format using the same cell culture conditions as described above. After 24 hours, wells are transfected with the candidate inducing siRNAs (n=10 per target gene) identified in the primary screen, but adjusting the volumes for a 48 well culture format. Cells are then cultured for a further 72 hours. Afterwards, medium is removed, cells are washed with Hanks Buffered Saline solution and the level of Cyp26A1 mRNA is determined by qRT-PCR as described above. Candidate inducing siRNAs identified as inducing expression of both Tert and Cyp26A1 when used in combination with other induction factors are then further tested to determine if they are indeed capable of inducing pluripotency when used in combination with the corresponding subset of induction factors used in the primary screen.

Example 22

Induction of Human Pluripotent Stem Cells from Fibroblasts Including at Least One Chimeric IF-VP16 Polypeptide (Prophetic Example)

[0471] The induction protocol and assays are carried out as described in Example 7, but a retrovirus expressing a chimeric human Sox2-VP16 fusion polypeptide is used, instead of full length human Sox2 retrovirus, as one of the four IFs. The Sox2-VP16 fusion polypeptide comprises amino acids 1-183 of human Sox2, which includes the Sox2 DNA binding domain, and amino acids 411-490 of the herpes VP16 protein (GenBank Accession No. AAA45864), a strong transactivator domain (see, e.g., Sadowski et al (1988), *Nature,* 6; 335 (6190):563-564) fused to the C-terminal of the human Sox2 fragment. The sequence of the Sox2-VP16 fusion protein is:

(SEQ ID NO:16)

MYNMMETELKPPGPQQTSGGGGGNSTAAAAGGNQKNSPDRVKRPMNAFMV

WSRGQRRKMAQENPKMHNSEISKRLGAEWKLLSETEKRPFIDEAKRLRAL

HMKEHPDYKYRPRRKTKTLMKKDKYTLPGGLLAPGGNSMASGVGVGAGLG

AGVNQRMDSYAHMNGWSNGSYSMMQDQLGYPQHSTTAPITDVSLGDELRL

DGEEVDMTPADALDDFDLEMLGDVESPSPGMTHDPVSYGALDVDDFEFEQ

MFTDALGIDDFGG

Example 23

Induction of Human Pluripotent Stem Cells from Fibroblasts Using a Combination of Viral Expression of Oct 3/4, Sox2, and Klf4, and Protein Transduction of c-Myc (Prophetic Example)

[0472] Cell culture and infection with Oct 3/4, Sox2, and Klf4 retroviruses are performed as described in Example 7, but after the four hour viral infection incubation, the three virus-containing polybrene solution is replaced with MC-medium containing a purified human c-Myc-PTD fusion polypeptide comprising the amino acid sequence of human c-Myc:

SEQ ID NO:12 (Human c-Myc):

MDFFRVVENQQPPATMPLNVSFTNRNYDLDYDSVQPYFYCDEEENFYQQQ

QQSELQPPAPSEDIWKKFELLPTPPLSPSRRSGLCSPSYVAVTPFSLRGD

NDGGGGSFSTADQLEMVTELLGGDMVNQSFICDPDDETFIKNIIIQDCMW

SGFSAAAKLVSEKLASYQAARKDSGSPNPARGHSVCSTSSLYLQDLSAAA

SECIDPSVVFPYPLNDSSSPKSCASQDSSAFSPSSDSLLSSTESSPQGSP

EPLVLHEETPPTTSSDSEEEQEDEEEIDVVSVEKRQAPGKRSESGSPSAG

GHSKPPHSPLVLKRCHVSTHQHNYAAPPSTRKDYPAAKRVKLDSVRVLRQ

-continued

ISNNRKCTSPRSSDTEENVKRRTHNVLERQRRNELKRSFFALRDQIPELE

NNEKAPKVVILKKATAYILSVQAEEQKLISEEDLLRKRREQLKHKLEQLR

NSCA

fused at its N-terminus with a protein transduction domain having the amino acid sequence:

YGRKKRRQRRR; (SEQ ID NO:1)

RKKRRQRR; (SEQ ID NO:2)

YARAAARQARA; (SEQ ID NO:3)

THRLPRRRRRR; (SEQ ID NO:4)

GGRRARRRRRR; (SEQ ID NO:5)
or

KKKKKKKK (SEQ ID NO:17)

[0473] Subcloning and purification of the c-Myc-PTD fusion protein are performed essentially as described in Becker-Hapak et al., (2003), *Curr. Protocols Cell Biol., Unit* 20.2, John Wiley & Sons. After the retroviral infection period (with Oct 3/4, Sox2, and Klf4 retroviruses), the polybrene-viral solution is removed and replaced with 2 ml of MC-ES medium containing purified c-Myc-PTD fusion polypeptide at a concentration of 100 nM, and the cultured is incubated for about three hours at 37° C. Afterwards, the medium is replaced with MC-ES medium, and the induction protocol and assays are continued as described in Example 7. Forced expression of c-Myc by protein transduction, avoids potential long term undesirable effects (e.g., cell transformation or risk of inducing cancer) of introducing an exogenous c-Myc gene, especially where the exogenous gene is integrated into the genome, e.g., following retroviral transduction.

Example 24

Induction of Human Pluripotent Stem Cells from Fibroblasts Using Protein Transduction of Oct 3/4, Sox2, Klf4, and c-Myc (Prophetic Example)

[0474] Human postnatal dermal fibroblasts are cultured in FBM supplemented with FGM-2 SingleQuots. Three days before protein transduction, the fibroblasts are seeded at 10^3 cells/cm^2 into 6 well cell culture plates.

[0475] Subcloning and purification of the Oct 3/4, Sox2, Klf4, and c-Myc fusion proteins are performed essentially as described in Becker-Hapak et al., (2003), *Curr. Protocols Cell Biol.*, Unit 20.2, John Wiley & Sons. Induction is initiated by replacing the culture medium with 2 ml of MC-ES medium containing purified fusion proteins (100 nM each) of Oct 3/4 (SEQ ID NO:6), Sox2 (SEQ ID NO:8), Klf4 (SEQ ID NO: 10), and c-Myc (SEQ ID NO: 12) fused at their N-termini with a protein transduction domain having the amino acid sequence:

[0476] YGRKKRRQRRR (SEQ ID NO: 1); RKKRRQRR (SEQ ID NO:2); YARAAARQARA (SEQ ID NO:3); THRLPRRRRRR (SEQ ID NO:4); GGRRARRRRR (SEQ ID NO:5); or KKKKKKKK (SEQ ID NO:17). The cells are then incubated with the fusion proteins for about three hours at 37° C. Afterwards, the medium is replaced with MC-ES medium supplemented with 10 μM Y-27632. During the induction period the medium is replaced daily with MC-ES medium containing 100 nM of each of the fusion proteins for one hour, and the medium is then replaced with MC-ES medium free of fusion proteins until the following day. After the induction period, assays are performed as described in Example 7 to identify induced pluripotent stem cell candidates.

Example 25

Induction of Human Pluripotent Stem Cells from Fibroblasts Using Protein Transduction of Oct 3/4, Sox2, and Klf4 Plus HDAC Inhibitor Treatment (Prophetic Example)

[0477] Human postnatal dermal fibroblasts are cultured in FBM supplemented with FGM-2 SingleQuots. Three days before protein transduction, the fibroblasts are seeded at 10^3 cells/cm^2 into 6 well cell culture plates.

[0478] Subcloning and purification of the Oct 3/4, Sox2, Klf4, and c-Myc fusion proteins are performed essentially as described in Becker-Hapak et al., (2003), *Curr. Protocols Cell Biol., Unit* 20.2, John Wiley & Sons. Induction is initiated by replacing the culture medium with 2 ml of MC-ES medium containing purified fusion proteins (100 nM each) of Oct 3/4 (SEQ ID NO:6), Sox2 (SEQ ID NO:8), and Klf4 (SEQ ID NO:10 fused at their N-termini with a protein transduction domain having the amino acid sequence:

YGRKKRRQRRR; (SEQ ID NO:1)

RKKRRQRR; (SEQ ID NO:2)

YARAAARQARA; (SEQ ID NO:3)

THRLPRRRRRR; (SEQ ID NO:4)

GGRRARRRRRR; (SEQ ID NO:5)
or

KKKKKKKK. (SEQ ID NO:17)

[0479] The cells are then incubated with the fusion proteins for about three hours at 37° C. Afterwards, the medium is replaced with MC-ES medium supplemented with the is then replaced with MC-ES medium supplemented with the histone deacetylase inhibitor MS-275 at a final concentration of 1 μM, and the Rho kinase inhibitor 10 μM Y-27632. During the subsequent induction period the medium is replaced daily with MC-ES medium containing 100 nM of each of the fusion proteins for one hour, and the medium is then replaced with fusion protein-free MC-ES medium containing 10 μM Y-27632 on subsequent days until the end of the induction period (about 14 days after the beginning of induction). After the induction period, assays are performed as described in Example 7 to identify induced pluripotent stem cell candidates.

Example 26

Induction of Mouse Pluripotent Stem Cells by Forced Expression of Three or Four Exogenous Genes by Retroviral Transduction

[0480] Murine embryonic Fibroblasts (MEFs) were plated into 12-well plates, seeded at a density of 5000 cells/cm^2 in MEF medium (DMEM supplemented with 10% FBS and gentamycin) and cultured overnight (approximately 16 hours). The cells were then incubated in a 1 ml retrovirus/polybrene solution. The retrovirus/polybrene solution included a mixture of 0.25 ml of each retrovirus vectors encoding either four factors (Oct3/4, Sox2, Klf4 and c-Myc);

three factors (the four factors minus either Oct3/4, Sox2, Klf4 or c-Myc); or two factors (Oct3/4 and Sox2) supplemented with 5 μg/ml of polybrene. For two or three genes transduction, culture media was added to virus carrying solution up to 1 ml. Cells were infected with each virus prepared, at 37° C. The "Oct4a" is equivalent to "Oct3/4." The virus supernatant was then replaced with mouse ES_medium on the following day. Media was changed every 2-3 days.

[0481] Approximately 12 days after viral transduction, colonies were subjected to alkaline phosphatase (ALP) staining, and the cloned colony-derived cells were stained blue violet. The number ALP positive colonies were recorded, as indicated by FIG. **28**. ALP-positive colonies were observed in the samples that had received the four factors (Oct3/4, Sox2, Klf4 and c-Myc); any combination of three factors; and two factors (Oct3/4 and Sox2).

Example 27

Induction of Mouse Pluripotent Stem Cells by Forced Expression of Two Three, or Four Exogenous Genes by Retroviral Transduction into Mouse-Derived Neural Stem Cells

[0482] Adult mouse-derived neural stem cells (NSC) were isolated from the subventricular zones of 9-week-old C57BL/6 mice (Oriental Yeast, Tokyo, Japan) as previously described (Reynolds et al., 1992). In brief, adult mouse brains were dissociated into single cells by trypsin digestion, and the cells were suspended in Dulbecco's modified Eagle's medium/Ham's F-12 medium (DMEM/F12; Invitrogen) containing 100 lg/mL human transferrin (Sigma), 20 nM progesterone (Sigma), 100 lM putrescine (Sigma), 30 nM sodium selenite (Sigma), and 5 lg/mL insulin (Sigma). The suspended cells were plated in tissue culture dishes. The cells were maintained in an undifferentiated proliferative state by culturing them as free-floating neurospheres in NSC medium (DMEM/F12 containing 100 lg/mL human transferrin, 20 nM progesterone, 100 lM putrescine, 30 nM sodium selenite, 5 lg/mL insulin, 20 ng/mL human basic fibroblast growth factor (bFGF; Sigma), and 20 ng/mL epidermal growth factor (EGF; Sigma)). The NSCs were seeded at 10^4 cells/cm2 as a monolayer on Ornitin/Lamin coated 12-well cell culture plates one day before infection, and cultured in 1 ml of NSC medium. After over night, the cells were incubated in 1 ml of the retrovirus/polybrene solution. The retrovirus/polybrene solution included a mixture of 0.25 ml of each retrovirus vectors encoding either four factors (Oct3/4, Sox2, Klf4 and c-Myc); three factors (the four factors minus either Sox2 or c-Myc); or two factors (Oct3/4 and Klf4) supplemented with 5 μg/ml of polybrene). For two or three genes transduction, culture media was added to virus carrying solution up to 1 ml. Cells were infected at 37° C. The virus supernatant was then replaced with mouse ES_medium on the following day. Media was changed every 2-3 days.

[0483] Approximately 12 days after viral transduction, colonies were subjected to alkaline phosphatase (ALP) staining, and the cloned colony-derived cells were stained blue violet. The number ALP positive colonies were recorded, as indicated by FIG. **28**. ALP-positive colonies were observed in the samples that had received the four factors (Oct3/4, Sox2, Klf4 and c-Myc); both combinations of three factors; and two factors (Oct3/4 and Klf4) (as shown in FIG. **29**).

Example 28

Induction of Mouse Pluripotent Stem Cells by Forced Expression of Three or Four Exogenous Genes by Retroviral Transduction

[0484] Adult mouse-derived bone marrow cells (Losac) were obtained using the same procedure described in Example 5 relating to FIG. **4**. One day before retroviral transduction, the cells were seeded at 10^4 cells/cm^2 into 6-well cell culture plates and cultured in 2 ml of low serum medium. Over night later, the cells were incubated in 2 ml of the retrovirus/polybrene solution (a mixture of 0.5 ml of each retrovirus vectors encoding either four factors (Oct3/4, Sox2, Klf4 and c-Myc); three factors (the four factors minus either Sox2, Oct3/4, Klf4 or c-Myc) supplemented with 5 μg/ml of polybrene). The virus supernatant was replaced the next day with mouse ES_medium. At this time, some samples also were treated with either 10 ng/ml FGF or 0.1 μM MS-275 for three days. On the following day, the medium was replaced with mouse ES_medium and was replaced every 2-3 days afterwards.

[0485] Approximately 9 or 15 days after viral transduction, colonies were subjected to alkaline phosphatase (ALP) staining, and the cloned colony-derived cells were stained blue violet. The number of ALP-positive colonies was recorded, as indicated in FIG. **30**. Of the samples analyzed on Day 15, ALP-positive colonies were observed in the samples that had received the four factors (Oct3/4, Sox2, Klf4 and c-Myc) and samples that received four factors minus either c-Myc, Oct3/4, or Klf4 (FIG. **28**).

[0486] ALP-positive colonies were also observed in the four-gene transduction samples analyzed on Day 9 after the viral transduction, but this number was less than the number of colonies observed in the four-gene transduction samples from Day 15. On Day 9, in the four-gene transduction samples, more colonies were observed in samples that were exposed to MS-275 compared to samples that were not exposed to MS-275.

Example 29

Induction of Mouse Pluripotent Stem Cells by Forced Expression of Two or Four Exogenous Genes by Retroviral Transduction

[0487] Adult mouse-derived bone marrow cells (Losac) were obtained using the same procedure described in Example 5 relating to FIG. **4**. Retroviral transduction was performed following the methods described in Example 30. However, in this experiment, retrovirus/polybrene solution included a mixture of equal volumes of the retrovirus vectors encoding either four factors (Oct3/4, Sox2, Klf4 and c-Myc); or different combinations of two factors (as show in FIG. **31**).

[0488] Approximately 15 days after viral transduction, colonies were subjected to alkaline phosphatase (ALP) staining, and the cloned colony-derived cells were stained blue violet. The number of ALP-positive colonies was recorded, as indicated in FIG. **31**. ALP-positive colonies were observed in the samples that had received the four factors (Oct3/4, Sox2, Klf4 and c-Myc) and samples that received the combination of Sox2 and c-Myc (FIG. **31**)

Example 30

Analysis of Global Gene Expression Differences in iPS cells versus human ES cell lines and Parental Fibroblasts

[0489] The global gene expression data obtained for iPS cell lines, 1-8, 2-4, and 3-2, as described in Examples 14, 16, and 17, respectively (GEO accession number GSE9709) were compared to global gene expression data for human ES cell (hES cell) lines: Sheff4 cultured on MEF; Sheff4 cultured on matrigel, and the H14 line cultured on MEF; and the iPS line parental fibroblasts. The gene expression data were compared to identify genes that were: (1) expressed at a significantly higher level in the iPS cell lines than in the hES cell lines; (2) expressed at a significantly higher level in the hES cell lines than in the iPS cell lines; (3) expressed at a significantly higher level in the iPS cell lines than in the hES cell lines and the parental fibroblasts; and (4) expressed at a significantly higher level in the iPS cell lines than in the hES cell lines, but not expressed at a significantly higher level than in the parental fibroblasts. Data were compared by Student's t-test with a cut-off of $p \leqq 0.01$. The results are shown in Tables 13-16.

[0490] Table 13 shows a list of genes expressed at a five fold or higher level in the iPS cell lines than in the hES cell lines ($p \leqq 0.01$). Table 14 shows a list of genes expressed at a two fold or higher level in the hES cell lines than in the iPS cell lines ($p \leqq 0.01$). Table 15 shows a list of genes expressed at a five fold or higher level in the iPS cell lines than in both the hES cell lines and in the parental fibroblasts ($p \leqq 0.01$). Table 16 shows a list of genes expressed at a five fold or higher level in the iPS cell lines than in the hES cell lines, but not expressed at a significantly higher level than in the parental fibroblasts ($p \geqq 0.05$).

[0491] These results indicated that notwithstanding the overall similarity in global gene expression between the iPS cell lines and the hES cell lines as described in Example 14, iPS lines do exhibit significant gene expression differences with respect to hES cell lines.

Example 31

Oct3/4 polypeptide amino acid sequence variants (prophetic example)

[0492] Based on Table 17 (PMUT analysis of Human Oct3/4), any of the following Oct3/4 amino acid sequence variants are generated by site-directed mutagenesis and used in conjunction with a Sox2 polypeptide and a Klf4 polypeptide; or with Sox2, Klf4, and c-Myc polypeptides to induce multipotent or pluripotent stem cells as described in previous examples.

[0493] The amino acid sequence of SEQ ID NO:6 with any of the following pairs of amino acid substitutions: Oct3/4 variant$^{2AA\text{-}1}$ (H4→N and F9→I); Oct3/4 variant$^{2AA\text{-}2}$ (P15→M and G18→L); and Oct3/4 variant$^{2AA\text{-}3}$ (I60→F and L84→V).

[0494] The amino acid sequence of SEQ ID NO:6 with the following set of 10 amino acid substitutions (Oct3/4 variant^{20AA}): H4→N, F9→I, P15→M, G18→L, I60→F, L84→V, P62→S, V101→I, G109→I, and P112→I.

[0495] The amino acid sequence of SEQ ID NO:6 with the following set of 20 amino acid substitutions (Oct3/4 variant^{20AA}): H4→N, F9→I, P15→M, G18→L, I60→F, P62→S, Q79→D, L84→V, V101→I, G109→I, P112→I, G161→L, D166→E, L169→I, V173→F, F175→A, E 215→D, E219→D, A223→M, V227→F.

[0496] The amino acid sequence of SEQ ID NO:6 with the following set of 25 amino acid substitutions (Oct3/4 variant^{25AA}): H4→N, F9→I, P15→M, G18→L, V51→I, I6→F, P62→S, C63→S, Y67→F, Q79→D, L84→V, L900M, Q94→D, V101→I, G109→I, P112→I, G161→L, D166→E, L169→I, V173→F, F175→A, E215→D, E219→D, A223→M, V227→F.

[0497] Table I shows the name of gene, the NCBI number, the virus vector in which said gene was inserted, insert size, the restriction site at the 5'-end, the restriction site at the 3'-end, the length of the translated region, the length of the 3'-untranslated region, clone ID, and the supplier of the four genes or the three genes and the receptor of mouse ecotropic retrovirus vector (mCAT: mouse-derived cationic amino acid transporter) used in Examples.

TABLE 1

			Construction data						
Name of gene	NCBI No.	Gene-inserted virus vector	Insert size	5'-end restriction site	3'-end restriction site	Length of translated region	3'-untranslated region	Clone ID	Supplier
human Oct3/4	NM_002701	pMXs-puro	1411	EcoRI	Xho1	1083	274	6578897	Open Biosystems
human Sox2	BC013923	pMXs-neo	1172	EcoRI	Xho1	954	143	2823424	Open Biosystems
human c-Myc	BC058901	pMXs-IB	1876	EcoRI	Xho1	1365	473	6012670	Open Biosystems
human Klf4	BC029923	pMXs-IB	1591	EcoRI	EcoRI	1413	38	5111134	Open Biosystems
mCAT1	NM_007513	Adeno-X	2032	BssS1	BssS1	1869	132	A830015N05	RIKEN FANTOM clone

[0498] Table 2 summarizes the number of alkaline phosphatase-positive colonies of Examples 4 to 7. For cell type, the number of subculture is attached. The day of four gene introduction is a day when a retrovirus vector was infected. Lot No. is that of Lonza products. Age of donors is based on the donor information of Lonza products. The number of colonies is the number of colonies composed of alkaline phosphatase-positive small cells per 10 cm^2.

TABLE 2

Examples 5 to 8 and 10, Number of alkaline phosphatase (ALP)-positive colonies formed by gene introduction

Example	Cell type	Donor age	Lot No.	Serum concentration (%)	No. of passages at the time of gene introduction	Colony count*
8	Neonatal skin fibroblast	Neonate	5F0439	2	3	0.8
6	Neonatal skin fibroblast	Neonate	5F0438	2	2	6.0
6	Neonatal skin fibroblast	Neonate	5F0438	2	2	6.0
6	Neonatal skin fibroblast	Neonate	5F0474	2	2	4.0
6	Neonatal skin fibroblast	Neonate	5F0438	2	2	7.0
6	Neonatal skin fibroblast	Neonate	5F0474	2	2	9.5
7	Adult skin fibroblast	28	6F3535	2	2	2.0
7	Adult skin fibroblast	39	6F4026	2	2	0.0
5	Adult BM-derived cell (low serum)	20	060470B	2	2	0.0
5	Adult BM-derived cell (low serum)	20	060809B	2	2	0.0
5	Adult BM-derived cell (low serum)	20	060809B	2	2	0.2
5	Adult BM-derived cell (low serum)	20	060809B	2	2	0.0
5	Adult BM-derived mesenchymal stem cell (high serum)	20	060809B	10	2	0.0
5	Adult BM-derived mesenchymal stem cell (high serum)	20	060470B	10	2	0.0
10	Neonatal umbilical cord artery smooth muscle cell	Neonate	5F0442	5	4	0.0

*The number of colonies composed of alkaline phosphatase-positive small cells per 10 cm^2.
"BM" in Table 2 means "Bone Marrow".

[0499] Table 3 summarizes the distribution of the karyotype of clone 1-8 at day 101. After the Giemsa stain, chromosome numbers were counted. 67 of 100 cells showed normal karyotype.

TABLE 3

Karyotype Analysis

Chromosome no.	Cell no
44	1
45	22
46	67

TABLE 3-continued

Karyotype Analysis

Chromosome no.	Cell no
47	7
48	1
89	1
136	1

One hundred cells were analyzed in human iPS cells (clone 1-8mTeSR)

[0500] Table 4 shows primer sequences used in FIG. **7** and FIG. **15**.

TABLE 4

Primer Sequences for RT-PCR

	Forward primer sequence	Reverse primer sequence
HPRT	AGTCTGGCTTATATCCAACACTTCG	GACTTTGCTTTCCTTGGTCAGG
Nanog	TACCTCAGCCTCCAGCAGAT	TGCGTCACACCATTGCTATT
TERT	AGCCAGTCTCACCTTCAACCGC	GGAGTAGCAGAGGGAGGCCG
Sall4	AAACCCCAGCACATCAACTC	GTCATTCCCTGGGTGGTTC
Zfp42	TTGGAGTGCAATGGTGTGAT	TCTGTTCACACAGGCTCCAG
GDF3	GGCGTCCGCGGGAATGTACTTC	TGGCTTAGGGGTGGTCTGGCC
Dnmt3b	GCAGCGACCAGTCCTCCGACT	AACGTGGGGAAGGCCTGTGC
TDGF1	ACAGAACCTGCTGCCTGAAT	AGAAATGCCTGAGGAAAGCA
GABRB3	CTTGACAATCGAGTGGCTGA	TCATCCGTGGTGTAGCCATA
CYP26A1	AACCTGCACGACTCCTCGCACA	AGGATGCGCATGGCGATTCG

TABLE 4-continued

Primer Sequences for RT-PCR

	Forward primer sequence	Reverse primer sequence
Oct4-total	GAGAAGGAGAAGCTGGAGCA	AATAGAACCCCCAGGGTGAG
Oct4-exo	AGTAGACGGCATCGCAGCTTGG	GGAAGCTTAGCCAGGTCCGAGG
Sox2-total	CAGGAGAACCCCAAGATGC	GCAGCCGCTTAGCCTCG
Sox2-exo	ACACTGCCCCTCTCACACAT	CGGGACTATGGTTGCTGAGT
Klf4-total	ACCCTGGGTCTTGAGGAAGT	ACGATCGTCTTCCCCTCTTT
Klf4-exo	CTCACCCTTACCGAGTCGGCG	GCAGCTGGGGCACCTGAACC
c-Myc-total	TCCAGCTTGTACCTGCAGGATCTGA	CCTCCAGCAGAAGGTGATCCAGACT
c-Myc-exo	AGTAGACGGCATCGCAGCTTGG	CCTCCAGCAGAAGGTGATCCAGACT

[0501] Table 5 summarizes SNP genotyping of human iPS clone 1-8 and fibroblasts (5F0438 and 5F04156) which were analyzed using the GeneChip Human Mapping 500K Array Set. SNPs of clone 1-8 were consistent to that of parental cells in 464,069 (99.17%) of 467,946 of called SNPs and different from that of parental cells in 3,877 (0.83%) of them. In contrast, SNPs of clone 1-8 mTeSR were consistent to that of unrelated donor cells (5F0416) only in 284,950 (60.50%) of 470,960 of called SNPs and different from that of the unrelated cells in 186,010 (39.50%) of them.

TABLE 5

SNP genotyping
Consistent SNP (%) between human iPS clone 1-8, its parental skin-derived cells (5F0438), and skin cells derived from a different donor (5F0416)

	iPS 1-8_01	iPS 1-8_02	5F0438_01	5F0438_02
iPS 1-8_02	99.41			
5F0438_01	99.17	99.26		
5F0438_02	99.44	99.44	99.32	
5F0416	60.50	60.75	60.72	60.47

[0502] Table 6 The HLA-A, HLA-B, HLA-Cw and HLA-DR types of human iPS1-8 (1-8 mTeSR), iPS 24 (mTeSR), and iPS 3-2 9 mTeSR); and fibroblasts (5F0438 and 5F0416) were classified using hybridization of PCR-amplified DNA with sequence specific oligonucleotide probes (SSOP) (Luminex).

TABLE 6

HLA genotyping

ID	A allele		B allele		Cw allele		DRB1 allele		DQB1 allele		DPB1 allele	
5F0438	*0101/	*0206/	*3801/09	*3905	*0602/	*0702/	*0802	*1104/43/	*0301/	*0402	*0402/	*0501
5F0416	*0201/	—	*1501/	*5101/	*0303/	*0401/	*0401/33/38	*0801/26	*0302/	*0402	*0201	*0301/
iPS 1-8	*0101/	*0206/	*3801/09	*3905	*0602/	*0702/	*0802	*1104/43/	*0301/	*0402	*0402/	*0501/
iPS 2-4	*0201/	—	*1501/	*5101/	*0303/	*0401/	*0401/33/38	*0801/26	*0302/	*0402	*0201	*0301/
iPS 3-2	*0101/	*0206/	*3801/09	*3905	*0802/	*0702/	*0802	*1104/43/	*0301/	*0402	*0402/	*0501

TABLE 6-continued

HLA genotyping													
ID	HLA-A		HLA-B		HLA-Cw		HLA-DR		HLA-DQ		HLA-DP		Bw
5F0438	A1	A2	B38	B39	Cw6	Cw7	DR8.2	DR11	DQ7	DQ4	DP4	DP5	4/6
5F0416	A2	—	B62	B51	Cw9	Cw4	DR4.1	DR8.1	DQ8	DQ4	DP2	DP3	4/6
iPS 1-8	A1	A2	B38	B39	Cw6	Cw7	DR8.2	DR11	DQ7	DQ4	DP4	DP5	4/6
iPS 2-4	A2	—	B62	B51	Cw9	Cw4	DR4.1	DR8.1	DQ8	DQ4	DP2	DP2	4/6
iPS 3-2	A1	A2	B38	B39	Cw6	Cw7	DR8.2	DR11	DQ7	DQ4	DP4	DP5	4/6

[0503] Table 7 summarized hES cell marker gene expression patterns in colonies. Colonies were stained for alkaline phosphatase at 17 days post 4 genes transduction. All ALP(+) colonies and 18 ALP(−) colonies were dissected and determined their hES marker gene expression by RT-PCR. Each colony was categorized and counted the number. "+" represents gene expression, and "−" represents no detection by a 40 cycle RT-PCR using amplified cDNA samples.

TABLE 7

Gene expression patterns in ALP(+) and ALP(−) colonies										
		Gene expression patterns in ALP(+) colonies								
Group No.	No. of gene expressed	Nanog	TDGF1	Dnmt3b	Zfp42	FoxD3	GDF3	CYP26A1	TERT	No. of colony
1	8	+	+	+	+	+	+	+	+	4
2	7	+	+	+	+	+	+	+	−	7
3	7	+	+	+	+	+	+	−	+	11
4	7	+	+	+	+	+	−	+	+	1
5	6	+	+	+	+	+	+	−	−	25
6	6	+	+	+	+	+	−	+	−	4
7	6	+	+	+	+	+	−	−	+	3
8	6	+	+	+	+	−	+	−	+	2
9	6	+	+	+	+	−	+	+	−	3
10	6	+	+	+	−	+	+	+	−	1
11	6	+	+	+	−	−	+	+	+	1
12	5	+	+	+	+	+	−	−	−	22
13	5	+	+	+	+	−	+	−	−	9
14	5	+	+	+	+	−	−	+	−	2
15	5	+	+	+	−	+	+	−	−	4
16	5	+	+	+	−	+	−	+	−	2
17	5	+	+	+	−	−	+	+	−	1
18	5	+	+	−	+	+	+	−	−	2
19	5	+	+	−	+	+	−	−	+	1
20	4	+	+	+	+	−	−	−	−	9
21	4	+	+	+	−	+	−	−	−	3
22	4	+	+	+	−	−	+	−	−	5
23	4	+	+	−	+	+	−	−	−	7
24	4	+	−	+	+	+	−	−	−	1
25	4	+	−	+	−	+	+	−	−	2
26	4	+	−	−	+	+	+	−	−	1
27	3	+	+	+	−	−	−	−	−	1
28	3	+	+	−	+	−	−	−	−	3
29	3	+	+	−	−	+	−	−	−	4
30	3	+	+	−	−	−	−	−	+	1
31	3	+	−	+	+	−	−	−	−	1
32	3	+	−	+	−	+	−	−	−	2
33	3	+	−	+	−	−	+	−	−	1
34	3	+	−	−	+	+	−	−	−	1
35	3	+	−	−	−	+	+	−	−	1
36	2	+	+	−	−	−	−	−	−	4
37	2	+	−	+	−	−	−	−	−	5
38	2	+	−	−	+	−	−	−	−	2
39	1	+	−	−	−	−	−	−	−	2
40	0	−	−	−	−	−	−	−	−	2
41	6	+	+	+	+	+	−	+	−	1
42	6	+	+	−	+	+	+	−	+	1
43	5	+	+	+	+	+	−	−	−	3
44	5	+	+	−	+	+	−	−	+	6
45	4	+	+	+	−	+	−	−	−	1

TABLE 7-continued

Gene expression patterns in ALP(+) and ALP(−) colonies Gene expression patterns in ALP(+) colonies										
Group No.	No. of gene expressed	Nanog	TDGF1	Dnmt3b	Zfp42	FoxD3	GDF3	CYP26A1	TERT	No. of colony
46	4	+	+	−	+	+	−	−	−	1
47	4	+	+	+	−	−	−	−	+	1
48	2	+	−	−	−	−	−	−	+	1
49	1	+	−	−	−	−	−	−	−	1
50	1	−	+	−	−	−	−	−	−	1
51	0	−	−	−	−	−	−	−	−	1

[0504] Table 8 summarizes the number of alkaline phosphatase-positive colonies of the experiments using neonatal fibroblasts. The date of four gene introduction is a day when a retrovirus vector was infected. The donor indicates lot number of Lonza products. The number of colonies is the number of colonies composed of alkaline phosphatase-positive small cells per 10 cm^2. ND: not determined.

TABLE 8

List of experiments

experimental conditions			
donor	cell density (cells/cm^2)	ALP staining number of colony (/10 cm^2)	notes
5F0439	1×10^4	0.8	
5F0438	1×10^4	6.0	iPS clone#1-8
5F0438	1×10^4	6.0	
5F0474	1×10^4	4.0	
5F0438	1×10^4	7.0	
5F0474	1×10^4	9.5	
5F0474	1×10^4	13.3	
5F0416	1×10^3	19.0	
5F0416	1×10^4	17.5	
5F0474	1×10^4	14.0	
5F0416	1×10^3	3.0	
5F0416	1×10^4	9.0	
5F0416	1×10^3	21.0	ALP(+)
5F0416	1×10^4	21.5	colony
5F0474	1×10^3	17.0	classification
5F0474	1×10^4	19.5	
5F0416	1×10^3	ND	iPS clone #2-4
5F0416	1×10^4	ND	
5F0474	1×10^3	ND	
5F0474	1×10^4	ND	
5F1195	1×10^3	ND	
5F0438	1×10^3	ND	iPS clone #3-2

[0505] Table 9 lists up locations and sizes in genome corresponding to amplicons using for methylation analyses of the promoter regions of Nanog and Oct3/4. Columns A, B and C indicate amplicon name, locations and sizes in genome corresponding to amplicons, respectively.

TABLE 9

Promoter regions in methylation analysis

amplicon name	location in genome corresponding to amplicon	size of amplicon
Nanog-z1	chr12: 7832645-7832959	315
Nanog-z2	chr12: 7832877-7833269	393

TABLE 9-continued

Promoter regions in methylation analysis

amplicon name	location in genome corresponding to amplicon	size of amplicon
Oct3/4-z1	chr6: 31248581-31249029	449
Oct3/4-z2	chr6_qbl_hap2: 2388299-2388525	227

[0506] Table 10 lists up the primer sets using for methylation analyses of the promoter regions of Nanog and Oct3/4. Columns A and B indicate names of primers and sequences of primers (capital for gene-specific sequences, lower case for tag sequences), respectively.

TABLE 10

Primer sequences for methylation analyses

names of primers	sequences of primers (capital for gene-specific sequences, lower case for tag sequences)
Nanog-z1-L	aggaagagagGGAATTTAAGGTGTATGTATTTTTTATTTT
Nanog-z1-R	cagtaatacgactcactatagggagaaggctATAACCCACCCCTATAATCCCAATA
Nanog-z2-L	aggaagagagGTTAGGTTGGTTTTAAATTTTTGAT
Nanog-z2-R	cagtaatacgactcactatagggagaaggctTTTATAATAAAAACTCTATCACCTTAAACC
Oct3/4-z1-L	aggaagagagTAGTAGGGATTTTTTGGATTGGTTT
Oct3/4-z1-R	cagtaatacgactcactatagggagaaggctAAAACTTTTCCCCCACTCTTATATTAC
Oct3/4-z2-L	aggaagagagGGTAATAAAGTGAGATTTTGTTTTAAAAA
Oct3/4-z2-R	cagtaatacgactcactatagggagaaggctCCACCCACTAACCTTAACCTCTAA

[0507] Table 11 summarizes relative mRNA expression in ALP positive colonies of Examples 15. Numbers of colonies are corresponding to FIG. **16-23**. Colony #5-2-32, #5-249, #5-2-51, #7-2-37 expressed all analyzed human ES cell markers. In contrast, fibroblastic colonies #3-1-212, #3-1-215, #5-1-4 expressed only Nanog though it highly expressed transgenes.

TABLE 11

Relative mRNA expression of ES cell markers in ALP positive colonies

no. of genes	ALP	Nanog mean SD	GDF3 mean SD	CYP26A1 mean SD	TERT mean SD	c-Myc mean SD	Oct3/4 mean SD
8	ALP(+)	9.3 ± 1.5	4.8 ± 0.3	27.2 ± 12.5	0.2 ± 0.0	1121.1 ± 25.3	39.3 ± 1.5
8	ALP(+)	15.9 ± 5.7	242.9 ± 78.8	3.0 ± 0.3	3.7 ± 0.5	1106.3 ± 51.8	770.6 ± 9.3
8	ALP(+)	27.1 ± 2.2	419.2 ± 24.7	73.5 ± 8.2	2.5 ± 0.1	1329.4 ± 272.1	101.6 ± 5.1
8	ALP(+)	36.9 ± 7.8	171.3 ± 20.0	110.1 ± 15.4	6.2 ± 1.1	566.9 ± 22.1	30.9 ± 2.4
7	ALP(+)	21.0 ± 2.4	59.2 ± 10.2	0.0 ± 0.0	0.12 ± 0.09	436 ± 12	25.0 ± 1.2
7	ALP(+)	127.6 ± 6.0	259.7 ± 3.9	0.0 ± 0.0	0.6 ± 0.3	59.2 ± 1.2	9.1 ± 0.1
7	ALP(+)	32.6 ± 8.4	34.0 ± 5.0	0.0 ± 0.0	1.1	446.9 ± 15.8	14.9 ± 0.1
7	ALP(+)	9.5 ± 1.0	3.4 ± 0.9	0.0 ± 0.0	1.6 ± 0.1	1052.8 ± 129.5	17.1 ± 0.3
7	ALP(+)	141.5 ± 64.3	328.8 ± 54.1	0.0 ± 0.0	7.0 ± 0.7	9796.2 ± 275.5	324.2 ± 29.8
7	ALP(+)	78.0 ± 16.6	188.2 ± 3.8	0.0 ± 0.0	67.6 ± 7.1	9714.4 ± 15.7	258.7 ± 13.3
7	ALP(+)	55.5 ± 12.2	151.3 ± 21.2	0.0 ± 0.0	5.2 ± 0.1	285.3 ± 49.6	24.8 ± 3.2
7	ALP(+)	0.1 ± 0.1	0.1 ± 0.1	0.0 ± 0.0	1.1 ± 0.0	13065.1 ± 769.8	241.8 ± 0.7
7	ALP(+)	10.9 ± 2.6	67.9 ± 12.3	0.0 ± 0.0	4.4 ± 0.8	171.5 ± 2.3	578.7 ± 13.4
7	ALP(+)	0.1 ± 0.0	0.4 ± 0.1	0.0 ± 0.0	0.7 ± 0.5	3176.2 ± 751.2	233.4 ± 17.7
7	ALP(+)	51.5 ± 14.4	126.4 ± 1.1	0.0 ± 0.0	2.5 ± 0.3	1446.0 ± 421.7	33.8 ± 2.6
7	ALP(+)	0.7 ± 0.1	0.0 ± 0.0	5.0	0.5 ± 0.2	6049.2 ± 396.9	3.8 ± 0.3
6	ALP(+)	14.6 ± 1.1	0.0 ± 0.0	0.0 ± 0.0	40.0 ± 5.7	27086.4 ± 3870.8	530.6 ± 84.1
6	ALP(+)	20.1 ± 5.9	0.0 ± 0.0	0.0 ± 0.0	1.9 ± 1.0	9125.8 ± 883.7	7.5 ± 0.7
6	ALP(+)	1.1 ± 0.4	0.0 ± 0.0	0.0 ± 0.0	20.6 ± 0.6	8344.9 ± 2054.5	6.7 ± 0.5
6	ALP(+)	103.4 ± 11.7	195.3 ± 17.7	0.0 ± 0.0	18.1 ± 1.8	95692.9 ± 5109.8	2843.9 ± 113.9
6	ALP(+)	50.8 ± 3.6	291.3 ± 43.9	0.0 ± 0.0	20.2 ± 2.9	29701.1 ± 4821.3	483.1 ± 13.9
6	ALP(+)	50.3 ± 14.5	34.3 ± 3.6	10.4 ± 2.0	1.3 ± 0.1	533.8 ± 24.8	30.2 ± 1.2
5	ALP(+)	9.3 ± 0.5	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0	16848.2 ± 1742.0	4.7 ± 0.2
5	ALP(+)	126.4 ± 65.3	0.0 ± 0.0	0.0 ± 0.0	28.7 ± 4.9	23614.4 ± 388.9	310.9 ± 19.2
4	ALP(+)	3.7 ± 1.3	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0	2927.9 ± 412.5	130.3 ± 10.1
4	ALP(+)	1.9 ± 0.3	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0	19433.2 ± 297.0	4.2 ± 0.5
4	ALP(+)	17.4 ± 5.1	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0	1959.8 ± 379.9	8.5 ± 0.7
3	ALP(+)	2.2 ± 0.3	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0	6065.6 ± 704.9	3.4 ± 0.3
3	ALP(+)	1.9 ± 0.3	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0	4572.6 ± 303.7	7.4 ± 0.1
3	ALP(+)	1.4 ± 0.2	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0	53755.3 ± 10897.7	22.9 ± 3.0
3	ALP(+)	5.6 ± 2.9	0.0 ± 0.0	0.0 ± 0.0	807.1 ± 13.4	25595.8 ± 2002.8	414.9 ± 22.6
6	ALP(−)	0.5 ± 0.1	0.07	0.0 ± 0.0	0.01 ± 0.01	5873.2 ± 156.2	226.3 ± 12.9
5	ALP(−)	0.8 ± 0.2	0.0 ± 0.0	0.0 ± 0.0	0.5 ± 0.2	8698.4 ± 492.3	58.7 ± 2.6
5	ALP(−)	6.9 ± 1.1	0.0 ± 0.0	0.0 ± 0.0	0.7 ± 0.1	9350.1 ± 201.0	2.1 ± 0.1
5	ALP(−)	7.2 ± 2.0	0.0 ± 0.0	0.0 ± 0.0	7.3 ± 1.8	26133.6 ± 3528.5	8.0 ± 0.1
5	ALP(−)	0.2 ± 0.1	0.0 ± 0.0	0.0 ± 0.0	0.5 ± 0.1	5211.8 ± 618.7	370.7 ± 7.8
5	ALP(−)	2.5 ± 0.5	0.0 ± 0.0	0.0 ± 0.0	0.5 ± 0.1	8971.8 ± 110.3	266.6 ± 21.4
5	ALP(−)	3.4 ± 0.9	0.0 ± 0.0	0.0 ± 0.0	11.8 ± 3.4	9748.3 ± 530.0	7.3 ± 0.1
4	ALP(−)	0.2 ± 0.1	0.0 ± 0.0	0.0 ± 0.0	14.6 ± 1.9	7681.0 ± 286.9	261.0 ± 26.0
2	ALP(−)	0.6 ± 0.3	0.0 ± 0.0	0.0 ± 0.0	8.2 ± 0.6	53887.9 ± 1343.2	13.3 ± 1.2
1	ALP(−)	3.4 ± 0.5	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0	7721.3 ± 437.0	52.1 ± 2.3
1	ALP(−)	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0	96049.6 ± 2394.1	23.7 ± 2.1
0	ALP(−)	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0	1454.7 ± 371.7	11.6 ± 0.3
clone1-8 (Std)		1.0	1.0	1.0	1.0	1.0	1.0

[0508] Table 12 summarizes relative mRNA expression in clone-24 and 3-2. Total RNA was extracted from clones 24 and 3-2. Expression of ES cell marker genes were determined by qRT-PCR as described in Example 16 and 17. Both clone-24 and -3-2 showed ES cell marker gene expression. All expression values were normalized against human iPS clone-1-8 (day 94).

TABLE 12

relative mRNA expression in clone-2-4 and 3-2.

	#3-2_day48	#2-4_day59	#1-8_day82	#1-8_day94
Nanog	4.21 ± 1.11	2.88 ± 0.43	2.41	1.00 ± 0.24
TERT	1.52 ± 0.50	1.94 ± 0.14	0.69	1.00 ± 0.70
GDF3	6.42 ± 0.16	6.65 ± 0.05	0.92	1.00 ± 0.49

TABLE 12-continued

relative mRNA expression in clone-2-4 and 3-2.

	#3-2_day48	#2-4_day59	#1-8_day82	#1-8_day94
CYP26A1	72.45 ± 14.92	49.12 ± 0.06	62.50	1.00 ± 0.01
TDGF1	2.55 ± 0.10	3.53 ± 0.05	3.53	1.00 ± 0.01
Dnmt3b	2.66 ± 0.04	0.96 ± 0.02	0.91	1.00 ± 0.01
Foxd3	1.16 ± 0.08	0.59 ± 0.17	1.14	1.00 ± 0.18
Zfp42	0.98 ± 0.15	0.76 ± 0.01	2.44	1.00 ± 0.02
Myc	6.14 ± 0.58	4.58 ± 0.16	3.82	1.00 ± 0.05
Oct3/4	2.00 ± 0.07	1.08 ± 0.01	1.33	1.00 ± 0.00

TABLE 13

Table 13: Genes Expressed at a 5 fold or Greater Level in iPS Cell Lines versus hES Cell Lines ($p \leqq 0.01$)

Systematic Name	Genbank	Description
235940_at	AW983691	chromosome 9 open reading frame 64
239206_at	BE552138	complement component (3b/4b) receptor 1-like
239205_s_at	BE552138	complement component (3b/4b) receptor 1 (Knops blood group) /// complement component (3b/4b) receptor 1-like /// similar to complement component (3b/4b) receptor 1 isoform F precursor
215101_s_at	BG166705	chemokine (C—X—C motif) ligand 5
AFFX-r2-Ec-bioD-3_at	AFFX-ThrX-M	—
AFFX-M27830_5_at	AFFX-M27830_3	—
210697_at	AF070651	zinc finger protein 257
213122_at	AI096375	TSPY-like 5
223551_at	AF225513	protein kinase (cAMP-dependent, catalytic) inhibitor beta
214974_x_at	AK026546	chemokine (C—X—C motif) ligand 5
237552_at	BF056473	CDNA clone IMAGE: 4667929
212575_at	BF966155	chromosome 19 open reading frame 6
229328_at	T90358	Zinc finger protein 540
231120_x_at	AL569326	protein kinase (cAMP-dependent, catalytic) inhibitor beta
235075_at	AI813438	desmoglein 3 (pemphigus vulgaris antigen)
211906_s_at	AB046400	serpin peptidase inhibitor, clade B (ovalbumin), member 4
225061_at	N45231	DnaJ (Hsp40) homolog, subfamily A, member 4
217230_at	AF199015	villin 2 (ezrin)
225908_at	AI829927	isoamyl acetate-hydrolyzing esterase 1 homolog (*S. cerevisiae*)
232881_at	AI500353	GNAS1 antisense
239951_at	AI734093	Transcribed locus
1554333_at	BC031044	DnaJ (Hsp40) homolog, subfamily A, member 4
1553276_at	NM_152476	zinc finger protein 560
1553970_s_at	BC042510	carboxyl ester lipase (bile salt-stimulated lipase)
219837_s_at	NM_018659	cytokine-like 1
228063_s_at	AW025330	nucleosome assembly protein 1-like 5
208542_x_at	NM_007153	zinc finger protein 208
243110_x_at	AI868441	neuropeptide W
239319_at	BE542563	Hypothetical protein LOC728342
215826_x_at	AK023017	hypothetical BC37295_3
1555229_a_at	BC007010	complement component 1, s subcomponent
235779_at	AW467077	Hypothetical protein LOC284408
220638_s_at	NM_012116	Cas-Br-M (murine) ecotropic retroviral transforming sequence c
232315_at	AU149712	Zinc finger-like
222546_s_at	AW204755	EPS8-like 2
235913_at	AI285722	zinc finger-like
215019_x_at	AW474158	zinc finger protein 528
210362_x_at	AF230409	promyelocytic leukemia
231299_at	AI494590	centaurin, gamma 3
214336_s_at	AI621079	coatomer protein complex, subunit alpha
210171_s_at	S68134	cAMP responsive element modulator
219807_x_at	NM_016154	RAB4B, member RAS oncogene family
205827_at	NM_000729	cholecystokinin
1559503_a_at	AA350425	Similar to zinc finger protein 91
228062_at	AW025330	nucleosome assembly protein 1-like 5
223789_s_at	AF116627	GTP binding protein 2
215634_at	AF007137	Clone 23618 mRNA sequence
201679_at	BE646076	ARS2 protein
213695_at	L48516	paraoxonase 3
1553219_a_at	NM_015365	Alport syndrome, mental retardation, midface hypoplasia and elliptocytosis chromosomal region, gene 1
1552470_a_at	NM_148914	abhydrolase domain containing 11
216884_at	S69182	protein tyrosine phosphatase, non-receptor type 12
237215_s_at	N76327	transferrin receptor (p90, CD71)
209040_s_at	U17496	proteasome (prosome, macropain) subunit, beta type, 8 (large multifunctional peptidase 7)
214090_at	BF732462	PRKC, apoptosis, WT1, regulator
223629_at	BC001186	protocadherin beta 5
216971_s_at	Z54367	plectin 1, intermediate filament binding protein 500 kDa
201008_s_at	AA812232	thioredoxin interacting protein
233754_x_at	AC007228	zinc finger protein 71
200621_at	NM_004078	cysteine and glycine-rich protein 1
208978_at	U36190	cysteine-rich protein 2
1552914_a_at	NM_025240	CD276 molecule
1559051_s_at	AK097148	chromosome 6 open reading frame 150
212105_s_at	BF313832	DEAH (Asp-Glu-Ala-His) box polypeptide 9
222814_s_at	AI916361	zinc finger, HIT type 2
236562_at	N29327	zinc finger protein 439
1562245_a_at	AL833487	MRNA; cDNA DKFZp686H1629 (from clone DKFZp686H1629)
203872_at	NM_001100	actin, alpha 1, skeletal muscle
222935_x_at	AW139759	solute carrier family 39 (zinc transporter), member 8

TABLE 13-continued

Table 13: Genes Expressed at a 5 fold or Greater Level in iPS Cell Lines versus hES Cell Lines ($p \leqq 0.01$)

Systematic Name	Genbank	Description
1555695_a_at	AF388368	clarin 1
207080_s_at	NM_004160	peptide YY
243195_s_at	BF438407	zinc finger protein 551
220179_at	NM_022357	dipeptidase 3
207099_s_at	NM_000390	choroideremia (Rab escort protein 1)
222898_s_at	BE350882	delta-like 3 (*Drosophila*)
226539_s_at	BF436337	—
229332_at	AI653050	4-hydroxyphenylpyruvate dioxygenase-like
207852_at	NM_002994	chemokine (C—X—C motif) ligand 5
1554334_a_at	BC031044	DnaJ (Hsp40) homolog, subfamily A, member 4
1555731_a_at	AF393369	adaptor-related protein complex 1, sigma 3 subunit
AFFX-r2-Ec-bioC-5_at	AFFX-ThrX-5	—
215337_at	AK022508	mediator complex subunit 24
211124_s_at	AF119835	KIT ligand
1553873_at	NM_153270	kelch-like 34 (*Drosophila*)
201796_s_at	BE790854	valyl-tRNA synthetase
235942_at	AI272059	LOC401629 /// LOC401630
202873_at	BF034973	ATPase, H+ transporting, lysosomal 42 kDa, V1 subunit C1
244178_at	AW451792	COMM domain containing 7
215172_at	AL050040	protein tyrosine phosphatase, non-receptor type 20B /// protein tyrosine phosphatase, non-receptor type 20A
228251_at	BE467577	UBX domain containing 1
224463_s_at	BC006128	chromosome 11 open reading frame 70
206797_at	NM_000015	N-acetyltransferase 2 (arylamine N-acetyltransferase)
212278_x_at	BF588511	ubiquitin protein ligase E3A (human papilloma virus E6-associated protein, Angelman syndrome)
1555766_a_at	AF493870	guanine nucleotide binding protein (G protein), gamma 2
211107_s_at	AB017332	aurora kinase C
214519_s_at	NM_005059	relaxin 2
226504_at	AA522720	family with sequence similarity 109, member B
216469_at	AL163202	similar to zinc finger protein 43 (HTF6)
221123_x_at	NM_018660	zinc finger protein 395
1568574_x_at	AB019562	Secreted phosphoprotein 1 (osteopontin, bone sialoprotein I, early T-lymphocyte activation 1)
215989_at	BE258133	chromobox homolog 2 (Pc class homolog, *Drosophila*)
205195_at	NM_001283	adaptor-related protein complex 1, sigma 1 subunit
223994_s_at	BC000154	solute carrier family 12 (potassium/chloride transporters), member 9
205095_s_at	NM_005177	ATPase, H+ transporting, lysosomal V0 subunit a1
1554777_at	BI092935	zinc finger protein 42 homolog (mouse)
217494_s_at	AF023139	phosphatase and tensin homolog (mutated in multiple advanced cancers 1), pseudogene 1
201169_s_at	BG326045	basic helix-loop-helix domain containing, class B, 2
214123_s_at	AI126492	chromosome 4 open reading frame 10
229896_at	H41907	CDNA clone IMAGE: 6106200
211214_s_at	BC003614	death-associated protein kinase 1
203402_at	AL520102	potassium voltage-gated channel, shaker-related subfamily, beta member 2
205920_at	NM_003043	solute carrier family 6 (neurotransmitter transporter, taurine), member 6
212937_s_at	M20776	collagen, type VI, alpha 1
200796_s_at	BF594446	myeloid cell leukemia sequence 1 (BCL2-related)
1558697_a_at	BI600341	KIAA0430
232771_at	Z83850	Nik related kinase
1559501_at	BC037580	CDNA clone IMAGE: 5262521
238750_at	AW083576	chemokine (C-C motif) ligand 28
239818_x_at	AA576947	tribbles homolog 1 (*Drosophila*)
1555765_a_at	AF493872	guanine nucleotide binding protein (G protein), gamma 4
233573_s_at	AK001080	WD repeat domain 6
206220_s_at	NM_007368	RAS p21 protein activator 3
212113_at	AI927479	hypothetical LOC552889
205577_at	NM_005609	phosphorylase, glycogen; muscle (McArdle syndrome, glycogen storage disease type V)
201130_s_at	L08599	cadherin 1, type 1, E-cadherin (epithelial)
219911_s_at	NM_016354	solute carrier organic anion transporter family, member 4A1
227598_at	AI762857	chromosome 7 open reading frame 29
226654_at	AF147790	mucin 12, cell surface associated
205461_at	NM_006861	RAB35, member RAS oncogene family
221285_at	NM_006011	ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2
203027_s_at	AI189359	mevalonate (diphospho) decarboxylase
243639_at	R51605	Transcribed locus
211162_x_at	AF116616	stearoyl-CoA desaturase (delta-9-desaturase)
213667_at	AB002307	Snf2-related CBP activator protein
1559361_at	AF086401	Full length insert cDNA clone ZD75H06
218000_s_at	NM_007350	pleckstrin homology-like domain, family A, member 1
209260_at	BC000329	stratifin

TABLE 13-continued

Table 13: Genes Expressed at a 5 fold or Greater Level in iPS Cell Lines versus hES Cell Lines ($p \leqq 0.01$)

Systematic Name	Genbank	Description
211530_x_at	M90686	HLA-G histocompatibility antigen, class I, G
AFFX-r2-Bs-dap-M_at	AFFX-r2-Bs-phe-M	—
239947_at	AI969304	Transcribed locus
215955_x_at	Y10388	Rho GTPase activating protein 26
227806_at	BG285710	chromosome 16 open reading frame 74
220259_at	NM_024927	pleckstrin homology domain containing, family H (with MyTH4 domain) member 3
1560154_a_at	AK026500	CDNA: FLJ22847 fis, clone KAIA686
AFFX-r2-Bs-dap-5_at	AFFX-r2-Bs-phe-5	—
223708_at	AF329838	C1q and tumor necrosis factor related protein 4
215581_s_at	AK022303	minichromosome maintenance complex component 3 associated protein
1552399_a_at	NM_145696	BRF1 homolog, subunit of RNA polymerase III transcription initiation factor IIIB (*S. cerevisiae*)
221310_at	NM_004115	fibroblast growth factor 14
234939_s_at	AL161953	PHD finger protein 12
218944_at	NM_023078	pyrroline-5-carboxylate reductase-like
206673_at	NM_007223	G protein-coupled receptor 176
205910_s_at	NM_001807	carboxyl ester lipase (bile salt-stimulated lipase)
206232_s_at	NM_004775	UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase, polypeptide 6
212009_s_at	AL553320	stress-induced-phosphoprotein 1 (Hsp70/Hsp90-organizing protein)
204815_s_at	AI924903	DEAH (Asp-Glu-Ala-His) box polypeptide 34
234237_s_at	AL137611	hypothetical protein FLJ20294
229502_at	AW242403	choline dehydrogenase
1554776_at	AF450454	zinc finger protein 42 homolog (mouse)
242070_at	AI014470	hypothetical protein LOC728485
1554508_at	BC029917	phosphoinositide-3-kinase adaptor protein 1
210935_s_at	AF274954	WD repeat domain 1
236741_at	AW299463	WD repeat domain 72
205081_at	NM_001311	cysteine-rich protein 1 (intestinal)
1555240_s_at	AF493879	guanine nucleotide binding protein (G protein), gamma 12
205824_at	NM_001541	heat shock 27 kDa protein 2
230033_at	BF436398	chromosome 19 open reading frame 51
206832_s_at	NM_004186	sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3F
223083_s_at	AW057545	egl nine homolog 2 (*C. elegans*)
235234_at	AA359612	FLJ36874 protein
206604_at	NM_004561	ovo-like 1(*Drosophila*)
1555829_at	BC001224	family with sequence similarity 62 (C2 domain containing) member B
1555434_a_at	BC015770	solute carrier family 39 (zinc transporter), member 14
205196_s_at	NM_001283	adaptor-related protein complex 1, sigma 1 subunit
1564706_s_at	AF110329	glutaminase 2 (liver, mitochondrial)
242519_at	BF432331	Selenoprotein P, plasma, 1
205344_at	NM_006574	chondroitin sulfate proteoglycan 5 (neuroglycan C)
201123_s_at	NM_001970	eukaryotic translation initiation factor 5A
220825_s_at	NM_018240	kin of IRRE like (*Drosophila*)
224805_s_at	BF508824	chromosome 15 open reading frame 17
224033_at	AF130083	—
1564339_a_at	AF279779	cholinergic receptor, muscarinic 3 /// similar to cholinergic receptor, muscarinic 3
216031_x_at	T53900	hematological and neurological expressed 1-like
202627_s_at	AL574210	serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1
221628_s_at	AF326966	cytokine-like nuclear factor n-pac
201432_at	NM_001752	catalase
223285_s_at	AW044319	ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide alpha-2,6-sialyltransferase 4
1555800_at	BC038422	zinc finger protein 533
209261_s_at	BF000629	nuclear receptor subfamily 2, group F, member 6
1553055_a_at	NM_144975	schlafen family member 5
233492_s_at	AC005587	olfactory receptor, family 2, subfamily A, member 4 /// olfactory receptor, family 2, subfamily A, member 7 /// similar to rho guanine nucleotide exchange factor 5
205867_at	NM_002834	protein tyrosine phosphatase, non-receptor type 11 (Noonan syndrome 1)
1554417_s_at	AY113699	anterior pharynx defective 1 homolog A (*C. elegans*)
223799_at	AF253976	KIAA1826
214040_s_at	BE675337	gelsolin (amyloidosis, Finnish type)
201045_s_at	BF513857	RAB6A, member RAS oncogene family /// RAB6C-like
1557910_at	BG612458	heat shock protein 90 kDa alpha (cytosolic), class B member 1
204823_at	NM_014903	neuron navigator 3
1553852_at	NM_152564	vacuolar protein sorting 13 homolog B (yeast)
1557924_s_at	S76738	alkaline phosphatase, liver/bone/kidney
221807_s_at	BG399562	TraB domain containing
1552995_at	NM_145659	interleukin 27
1567013_at	AF323119	nuclear factor (erythroid-derived 2)-like 2
216360_x_at	AK000238	ribosomal RNA processing 12 homolog (*S. cerevisiae*)

TABLE 13-continued

Table 13: Genes Expressed at a 5 fold or Greater Level in iPS Cell Lines versus hES Cell Lines ($p \leqq 0.01$)

Systematic Name	Genbank	Description
242676_at	AA401733	Transcribed locus
205925_s_at	NM_002867	RAB3B, member RAS oncogene family
232751_at	AL121893	retinoblastoma binding protein 9
1555680_a_at	AY033891	spermine oxidase
231452_at	AW510925	HRAS-like suppressor family, member 5
210068_s_at	U63622	aquaporin 4
205384_at	NM_005031	FXYD domain containing ion transport regulator 1 (phospholemman)
213171_s_at	AL121753	matrix metallopeptidase 24 (membrane-inserted)
210732_s_at	AF342816	lectin, galactoside-binding, soluble, 8 (galectin 8)
203890_s_at	BF686824	death-associated protein kinase 3
209756_s_at	AI871354	v-myc myelocytomatosis viral related oncogene, neuroblastoma derived (avian)
232506_s_at	AK026504	chromosome 15 open reading frame 41
211708_s_at	BC005807	stearoyl-CoA desaturase (delta-9-desaturase)
1556670_at	AK098715	CDNA FLJ25849 fis, clone TST08968
1558214_s_at	BG330076	catenin (cadherin-associated protein), alpha 1, 102 kDa
1555559_s_at	AF419247	ubiquitin specific peptidase 25
209458_x_at	AF105974	hemoglobin, alpha 1 /// hemoglobin, alpha 2
222385_x_at	AF346602	Sec61 alpha 1 subunit (*S. cerevisiae*)
228102_at	AA127691	Neuropilin 2
229284_at	R60683	Methionine adenosyltransferase II, beta
227759_at	W92036	proprotein convertase subtilisin/kexin type 9
208621_s_at	BF663141	villin 2 (ezrin)
211538_s_at	U56725	heat shock 70 kDa protein 2
218832_x_at	NM_004041	arrestin, beta 1
229289_at	AL517395	hypothetical protein BC004941
1553698_a_at	NM_145257	chromosome 1 open reading frame 96
209427_at	AF064238	smoothelin
214971_s_at	AV695711	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1
235854_x_at	AA167669	Rho-associated, coiled-coil containing protein kinase 1
217601_at	AL523184	nucleoporin 188 kDa
205715_at	NM_004334	bone marrow stromal cell antigen 1
207532_at	NM_006891	crystallin, gamma D
239852_at	AL532029	methylmalonic aciduria (cobalamin deficiency) cb1A type
206997_s_at	NM_004807	heparan sulfate 6-O-sulfotransferase 1 /// similar to Heparan-sulfate 6-O-sulfotransferase 1 (HS6ST-1)
219424_at	NM_005755	Epstein-Barr virus induced gene 3
225322_s_at	AL514147	chromosome 17 open reading frame 70
221414_s_at	NM_030931	defensin, beta 126
214154_s_at	AA888057	plakophilin 2
1562527_at	AF519622	hypothetical protein LOC283027
221213_s_at	NM_017661	suppressor of hairy wing homolog 4 (*Drosophila*)
214007_s_at	AW665024	twinfilin, actin-binding protein, homolog 1 (*Drosophila*)
1556834_at	BC042986	CDNA clone IMAGE: 5296106
227757_at	AL563297	cullin 4A
236340_at	AI769947	Transcribed locus, strongly similar to XP_001146557.1 hypothetical protein [Pantroglodytes]
204698_at	NM_002201	interferon stimulated exonuclease gene 20 kDa
1554383_a_at	BC028121	translocation associated membrane protein 2
210978_s_at	BC002616	transgelin 2
234773_x_at	AL442080	MRNA; cDNA DKFZp434A0226 (from clone DKFZp434A0226)
208504_x_at	NM_018931	protocadherin beta 11
214008_at	N25562	Twinfilin, actin-binding protein, homolog 1 (*Drosophila*)
209875_s_at	M83248	secreted phosphoprotein 1 (osteopontin, bone sialoprotein I, early T-lymphocyte activation 1)
1555821_a_at	BC016043	AKT1 substrate 1 (proline-rich)
216915_s_at	S69182	protein tyrosine phosphatase, non-receptor type 12
1568905_at	BC030750	CDNA clone IMAGE: 4795773
233421_s_at	AU146738	nucleoporin 133 kDa
232490_s_at	U67085	prune homolog (*Drosophila*)
227419_x_at	AW964972	placenta-specific 9
242948_x_at	T97602	Transcribed locus
227175_at	AI806486	Myeloid cell leukemia sequence 1 (BCL2-related)
209213_at	BC002511	carbonyl reductase 1
208262_x_at	NM_000243	Mediterranean fever
227486_at	AI086864	5'-nucleotidase, ecto (CD73)
239239_at	W58601	Transcribed locus
236574_at	AI304870	Hypothetical protein LOC284373
219360_s_at	NM_017636	transient receptor potential cation channel, subfamily M, member 4
1558423_at	BE715671	hypothetical LOC349114
221408_x_at	NM_018932	protocadherin beta 12
1562234_a_at	AF397731	neuron navigator 3 /// similar to neuron navigator 3
226632_at	AL513673	cytoglobin
216831_s_at	AF018283	runt-related transcription factor 1; translocated to, 1 (cyclin D-related)

TABLE 13-continued

Table 13: Genes Expressed at a 5 fold or Greater Level in iPS Cell Lines versus hES Cell Lines ($p \leqq 0.01$)

Systematic Name	Genbank	Description
206932_at	NM_003956	cholesterol 25-hydroxylase
213210_at	AI005317	TAF6-like RNA polymerase II, p300/CBP-associated factor (PCAF)-associated factor, 65 kDa
201167_x_at	D13989	Rho GDP dissociation inhibitor (GDI) alpha
212016_s_at	AA679988	polypyrimidine tract binding protein 1
203324_s_at	NM_001233	caveolin 2
214828_s_at	AL157851	CGI-96 protein /// similar to CGI-96
219298_at	NM_024693	enoyl Coenzyme A hydratase domain containing 3
233305_at	AF193756	EF-hand calcium binding protein 1
216985_s_at	AJ002077	syntaxin 3
214738_s_at	BE792298	NIMA (never in mitosis gene a)-related kinase 9
231789_at	AV722990	protocadherin beta 15
200841_s_at	AI142677	glutamyl-prolyl-tRNA synthetase
204570_at	NM_001864	cytochrome c oxidase subunit VIIa polypeptide 1 (muscle)
226983_at	AA626717	zinc finger protein 777
212938_at	M20776	collagen, type VI, alpha 1
230255_at	AI936907	gamma-aminobutyric acid (GABA) A receptor, delta
211363_s_at	AF109294	methylthioadenosine phosphorylase
219430_at	NM_020155	G protein-coupled receptor 137
210990_s_at	U77706	laminin, alpha 4
205259_at	NM_000901	nuclear receptor subfamily 3, group C, member 2
217294_s_at	U88968	enolase 1, (alpha)
211922_s_at	AY028632	catalase
204018_x_at	NM_000558	hemoglobin, alpha 1 /// hemoglobin, alpha 2
211823_s_at	D86862	paxillin
219593_at	NM_016582	solute carrier family 15, member 3
223143_s_at	AI742378	chromosome 6 open reading frame 166
243347_at	AW003107	—
222896_at	AA196034	transmembrane protein 38A
213767_at	U43586	kinase suppressor of ras 1
206595_at	NM_001323	cystatin E/M
203508_at	NM_001066	tumor necrosis factor receptor superfamily, member 1B
238125_at	AI740544	ADAM metallopeptidase with thrombospondin type 1 motif, 16
209958_s_at	AF095771	Bardet-Biedl syndrome 9
225800_at	AI990891	JAZF zinc finger 1
233900_at	U46120	Expressed unknown mRNA
238692_at	AL040935	BTB (POZ) domain containing 11
201048_x_at	NM_002869	RAB6A, member RAS oncogene family
206390_x_at	NM_002619	platelet factor 4 (chemokine (C—X—C motif) ligand 4)
210572_at	BC003126	protocadherin alpha 2
231881_at	AU145225	caldesmon 1
1567274_at	Z36814	—
1555034_at	AF482697	clarin 1
210587_at	BC005161	inhibin, beta E
210298_x_at	AF098518	four and a half LIM domains 1
209727_at	M76477	GM2 ganglioside activator
213550_s_at	AA993683	transmembrane and coiled-coil domains 6
231013_at	W80446	—
213807_x_at	BE870509	met proto-oncogene (hepatocyte growth factor receptor)
206665_s_at	NM_001191	BCL2-like 1
206882_at	NM_005071	solute carrier family 1 (high affinity aspartate/glutamate transporter), member 6
1555716_a_at	AY072911	coxsackie virus and adenovirus receptor
244852_at	AU119545	dermatan sulfate epimerase-like
211082_x_at	Z25427	MAP/microtubule affinity-regulating kinase 2
203726_s_at	NM_000227	laminin, alpha 3
213928_s_at	AI742626	HIV-1 Rev binding protein
217051_s_at	AF257501	synovial sarcoma translocation, chromosome 18
206488_s_at	NM_000072	CD36 molecule (thrombospondin receptor)
222508_s_at	AU135021	hypothetical protein FLJ10154
211529_x_at	M90684	HLA-G histocompatibility antigen, class I, G
220108_at	NM_004297	guanine nucleotide binding protein (G protein), alpha 14
203676_at	NM_002076	glucosamine (N-acetyl)-6-sulfatase (Sanfilippo disease IIID)
1558775_s_at	AU142380	neutral sphingomyelinase (N-SMase) activation associated factor
209555_s_at	M98399	CD36 molecule (thrombospondin receptor)
1561367_a_at	BC035104	CDNA clone IMAGE: 5262438
211272_s_at	AF064771	diacylglycerol kinase, alpha 80 kDa
217248_s_at	AL365343	solute carrier family 7 (cationic amino acid transporter, y+ system), member 8
201156_s_at	AF141304	RAB5C, member RAS oncogene family
211022_s_at	BC002521	alpha thalassemia/mental retardation syndrome X-linked (RAD54 homolog, *S. cerevisiae*)
AFFX-HSAC07/X00351_5_at	AFFX-HSAC07/X00351_5	actin, beta
218931_at	NM_022449	RAB17, member RAS oncogene family

TABLE 13-continued

Table 13: Genes Expressed at a 5 fold or Greater Level in iPS Cell Lines versus hES Cell Lines ($p \leqq 0.01$)

Systematic Name	Genbank	Description
240407_at	AW450035	*Homo sapiens*, clone IMAGE: 5171705, mRNA
214505_s_at	AF220153	four and a half LIM domains 1
213363_at	AW170549	*Homo sapiens*, clone IMAGE: 5244869, mRNA
1555724_s_at	BC010946	transgelin
230112_at	AB037820	membrane-associated ring finger (C3HC4) 4
209136_s_at	BG390445	ubiquitin specific peptidase 10
203047_at	NM_005990	serine/threonine kinase 10
227137_at	N25937	Chromosome 10 open reading frame 46
212125_at	NM_002883	Ran GTPase activating protein 1
243409_at	AI005407	forkhead box L1
1568646_x_at	BC038199	zinc finger protein 208
217370_x_at	S75762	fusion (involved in t(12; 16) in malignant liposarcoma)
87100_at	AI832249	abhydrolase domain containing 2
211016_x_at	BC002526	heat shock 70 kDa protein 4
241661_at	AA001021	jumonji domain containing 1C
222611_s_at	AA969958	paraspeckle component 1
210930_s_at	AF177761	v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian)
213722_at	AW007161	SRY (sex determining region Y)-box 2
228901_at	AI040910	Cyclin-dependent kinase 9 (CDC2-related kinase)
208850_s_at	AL558479	Thy-1 cell surface antigen
212574_x_at	AC004528	chromosome 19 open reading frame 6
204952_at	NM_014400	LY6/PLAUR domain containing 3
204876_at	NM_014699	zinc finger protein 646
213014_at	BG222394	mitogen-activated protein kinase 8 interacting protein 1
219928_s_at	NM_012189	calcium binding tyrosine-(Y)-phosphorylation regulated (fibrousheathin 2)
204895_x_at	NM_004532	mucin 4, cell surface associated
208275_x_at	NM_003577	undifferentiated embryonic cell transcription factor 1
200917_s_at	BG474541	signal recognition particle receptor ('docking protein')
213643_s_at	AK022846	inositol polyphosphate-5-phosphatase, 75 kDa
232001_at	AW193600	hypothetical gene supported by AY007155
223828_s_at	AF222694	lectin, galactoside-binding, soluble, 12 (galectin 12)
210654_at	AF021233	tumor necrosis factor receptor superfamily, member 10d, decoy with truncated death domain
208721_s_at	BF967271	anaphase promoting complex subunit 5
206208_at	NM_000717	carbonic anhydrase IV
1553535_a_at	NM_002883	Ran GTPase activating protein 1
206531_at	NM_004647	D4, zinc and double PHD fingers family 1
1563719_a_at	AK024924	CDNA: FLJ21271 fis, clone COL01751
236731_at	BF223086	leucine zipper protein pseudogene 1
1555337_a_at	AF307097	zinc finger protein 317
222936_s_at	AF151904	chromosome 1 open reading frame 121
209999_x_at	AI056051	suppressor of cytokine signaling 1
1555730_a_at	D00682	cofilin 1 (non-muscle)
1566764_at	AL359055	MRNA full length insert cDNA clone EUROIMAGE 2344436
215315_at	AC003682	zinc finger protein 549
211019_s_at	D63807	lanosterol synthase (2,3-oxidosqualene-lanosterol cyclase)
226913_s_at	BF527050	SRY (sex determining region Y)-box 8
217569_x_at	AA017093	—
231146_at	AI300541	family with sequence similarity 24, member B
208478_s_at	NM_004324	BCL2-associated X protein
210892_s_at	BC004472	general transcription factor II, i
206100_at	NM_001874	carboxypeptidase M
216926_s_at	AC003030	KIAA0892
222511_x_at	AW140098	Fas (TNFRSF6) associated factor 1
202662_s_at	NM_002223	inositol 1,4,5-triphosphate receptor, type 2
1552667_a_at	NM_005489	SH2 domain containing 3C
228851_s_at	AV726322	endosulfine alpha
AFFX-r2-Bs-dap-3_at	AFFX-r2-Bs-phe-3	—
206552_s_at	NM_003182	tachykinin, precursor 1 (substance K, substance P, neurokinin 1, neurokinin 2, neuromedin L, neurokinin alpha, neuropeptide K, neuropeptide gamma)
233757_x_at	AK026906	CDNA: FLJ23253 fis, clone COL04706
213943_at	X99268	twist homolog 1 (acrocephalosyndactyly 3; Saethre-Chotzen syndrome) (*Drosophila*)
209198_s_at	BC004291	synaptotagmin XI
1553138_a_at	NM_152363	ankyrin repeat domain 41
232915_at	AW571715	DEAD (Asp-Glu-Ala-Asp) box polypeptide 49
1560224_at	BF327463	AT hook containing transcription factor 1
239959_x_at	AI147520	—
211699_x_at	AF349571	hemoglobin, alpha 1 /// hemoglobin, alpha 2
228261_at	BE045549	mindbomb homolog 2 (*Drosophila*)
206617_s_at	NM_002910	renin binding protein
207402_at	NM_003433	zinc finger protein 132

TABLE 13-continued

Table 13: Genes Expressed at a 5 fold or Greater Level in iPS Cell Lines versus hES Cell Lines ($p \leqq 0.01$)

Systematic Name	Genbank	Description
224539_s_at	AF152474	protocadherin alpha subfamily C, 2
240397_x_at	AI801626	Transcribed locus
208894_at	M60334	major histocompatibility complex, class II, DR alpha
229566_at	AA149250	similar to WDNM1-like protein
238742_x_at	AW302207	Transcribed locus
215236_s_at	AV721177	phosphatidylinositol binding clathrin assembly protein
210256_s_at	U78576	phosphatidylinositol-4-phosphate 5-kinase, type I, alpha
1555639_a_at	AF315633	RNA binding motif protein 14
1566666_at	AK074225	CDNA FLJ23645 fis, clone COL02691
211899_s_at	AF082185	TNF receptor-associated factor 4
222387_s_at	BG476669	vacuolar protein sorting 35 homolog (*S. cerevisiae*)
1553694_a_at	NM_002645	phosphoinositide-3-kinase, class 2, alpha polypeptide
203348_s_at	BF060791	ets variant gene 5 (ets-related molecule)
213548_s_at	BG257762	CDV3 homolog (mouse)
219656_at	NM_016580	protocadherin 12
241198_s_at	BE645435	chromosome 11 open reading frame 70
219878_s_at	NM_015995	Kruppel-like factor 13
1556748_x_at	AI476341	CDNA FLJ39784 fis, clone SPLEN2002314
1554988_at	BC042592	solute carrier family 9, member 11
227071_at	AI762558	zinc finger protein 414
213926_s_at	AI742626	HIV-1 Rev binding protein
234971_x_at	AI521584	phospholipase C, delta 3
219899_x_at	NM_014434	NADPH dependent diflavin oxidoreductase 1
215774_s_at	AV650470	—
229339_at	AI093327	Transcribed locus
238013_at	BF347859	pleckstrin homology domain containing, family A (phosphoinositide binding specific) member 2
214000_s_at	AI744627	Regulator of G-protein signalling 10
203729_at	NM_001425	epithelial membrane protein 3
203085_s_at	BC000125	transforming growth factor, beta 1
1558689_a_at	BG701300	hypothetical gene supported by BC030123
211668_s_at	K03226	plasminogen activator, urokinase
205457_at	NM_024294	chromosome 6 open reading frame 106
202639_s_at	AI689052	RAN binding protein 3
211527_x_at	M27281	vascular endothelial growth factor A
207118_s_at	NM_004659	matrix metallopeptidase 23B /// matrix metallopeptidase 23A (pseudogene)
204560_at	NM_004117	FK506 binding protein 5
232591_s_at	AK022883	transmembrane protein 30A
236158_at	R42281	Similar to KIAA1875 protein
230257_s_at	AI264325	chromosome 1 open reading frame 19
230629_s_at	AI809582	E1A binding protein p400
238969_at	BF512162	chromosome 3 open reading frame 55
1569895_at	BC016994	*Homo sapiens*, clone IMAGE: 4401848, mRNA
1554544_a_at	L18865	myelin basic protein
229901_at	AI056483	zinc finger protein 488
211051_s_at	BC006363	exostoses (multiple)-like 3
236657_at	AW014647	Full length insert cDNA YI37C01
202017_at	NM_000120	epoxide hydrolase 1, microsomal (xenobiotic)
229746_x_at	BF439451	*Homo sapiens*, clone IMAGE: 3885733, mRNA
205382_s_at	NM_001928	complement factor D (adipsin)
222458_s_at	AI205764	chromosome 1 open reading frame 108
1553565_s_at	NM_012137	dimethylarginine dimethylaminohydrolase 1
230809_at	R45446	Transcribed locus
222363_at	AW979018	Transcribed locus
217767_at	NM_000064	similar to Complement C3 precursor
221279_at	NM_018972	ganglioside-induced differentiation-associated protein 1
211087_x_at	Z25432	mitogen-activated protein kinase 14
204994_at	NM_002463	myxovirus (influenza virus) resistance 2 (mouse)
225245_x_at	BG386566	H2A histone family, member J
243319_at	AI274981	Transcribed locus
216252_x_at	Z70519	Fas (TNF receptor superfamily, member 6)
215891_s_at	X61094	GM2 ganglioside activator
238493_at	AI559570	zinc finger protein 506
224169_at	AF257210	neuropeptide FF receptor 2
232343_at	AK022200	CDNA FLJ12138 fis, clone MAMMA1000331
1569039_s_at	BC029855	zinc finger protein 677
201971_s_at	NM_001690	ATPase, H+ transporting, lysosomal 70 kDa, V1 subunit A
211564_s_at	BC003096	PDZ and LIM domain 4
200869_at	NM_000980	ribosomal protein L18a /// similar to ribosomal protein L18a; 60S ribosomal protein L18a
233297_s_at	AL139377	hypothetical protein LOC728591
219058_x_at	NM_022164	tubulointerstitial nephritis antigen-like 1

TABLE 13-continued

Table 13: Genes Expressed at a 5 fold or Greater Level in iPS Cell Lines versus hES Cell Lines ($p \leqq 0.01$)

Systematic Name	Genbank	Description
242762_s_at	AA372349	KIAA1946
1552611_a_at	AL555086	Janus kinase 1 (a protein tyrosine kinase)
1554660_a_at	BC036200	chromosome 1 open reading frame 71
236771_at	AW511485	chromosome 6 open reading frame 159
221943_x_at	AW303136	Ribosomal protein L38
221665_s_at	BC004907	EPS8-like 1
205391_x_at	M28880	ankyrin 1, erythrocytic
207678_s_at	NM_007017	SRY (sex determining region Y)-box 30
215728_s_at	AL031848	acyl-CoA thioesterase 7
224346_at	AF116671	—
205822_s_at	NM_002130	3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 (soluble)
241084_x_at	BF062339	dynein, cytoplasmic 1, heavy chain 1
1554757_a_at	AF273055	inositol polyphosphate-5-phosphatase, 40 kDa
222542_x_at	BF724826	chaperone, ABC1 activity of bc1 complex homolog (*S. pombe*)
206749_at	NM_001764	CD1b molecule
219558_at	NM_024524	ATPase type 13A3
240703_s_at	AW591969	hect (homologous to the E6-AP (UBE3A) carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1
231805_at	AL563031	prolactin releasing hormone receptor
232566_at	AK026258	nucleolar protein family 6 (RNA-associated)
228683_s_at	AI925361	potassium channel tetramerisation domain containing 15
235271_s_at	BG027325	zinc finger protein 397
214300_s_at	AI676092	topoisomerase (DNA) III alpha
220472_at	NM_014150	zinc finger, CCHC domain containing 4
214992_s_at	AD000092	deoxyribonuclease II, lysosomal
236491_at	AI813346	BCL2-like 10 (apoptosis facilitator)
208474_at	NM_021195	claudin 6
76897_s_at	AA628140	FK506 binding protein 15, 133 kDa
238461_at	AA228031	eukaryotic translation initiation factor 4E family member 3
223567_at	AB022433	sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6B
214975_s_at	AK001816	myotubularin related protein 1
217399_s_at	AF032887	forkhead box O3
208879_x_at	BG469030	PRP6 pre-mRNA processing factor 6 homolog (*S. cerevisiae*)
1558662_s_at	BG200452	B-cell scaffold protein with ankyrin repeats 1
1552367_a_at	AF276507	scinderin
201367_s_at	AI356398	zinc finger protein 36, C3H type-like 2
215719_x_at	X83493	Fas (TNF receptor superfamily, member 6)
200601_at	U48734	actinin, alpha 4
210620_s_at	BC000212	general transcription factor IIIC, polypeptide 2, beta 110 kDa
1554321_a_at	BC018471	NFS1 nitrogen fixation 1 homolog (*S. cerevisiae*)
210932_s_at	AF293342	ring finger protein (C3H2C3 type) 6
211020_at	L19659	glucosaminyl (N-acetyl) transferase 2, I-branching enzyme (I blood group)
231698_at	AV661152	hypothetical LOC647115
216205_s_at	AK021947	mitofusin 2
227316_at	AI761798	CSRP2 binding protein
1555814_a_at	AF498970	ras homolog gene family, member A
235728_at	AA845646	zinc finger protein 3 homolog (mouse)
238542_at	AA831769	UL16 binding protein 2
238795_at	AA424537	chromosome 10 open reading frame 18
213713_s_at	R48779	hypothetical protein BC008326
219703_at	NM_018365	meiosis-specific nuclear structural 1
205186_at	NM_003462	dynein, axonemal, light intermediate chain 1
225294_s_at	BG340967	trafficking protein particle complex 1
224505_s_at	BC006355	phospholipase C, delta 4
203626_s_at	NM_005983	S-phase kinase-associated protein 2 (p45)
217448_s_at	AL117508	TOX high mobility group box family member 4 /// similar to Epidermal Langerhans cell protein LCP1
237206_at	AI452798	myocardin
210413_x_at	U19557	serpin peptidase inhibitor, clade B (ovalbumin), member 4
214190_x_at	AI799984	golgi associated, gamma adaptin ear containing, ARF binding protein 2
205924_at	BC005035	RAB3B, member RAS oncogene family
242660_at	AA846789	chromosome 10 open reading frame 112
1555197_a_at	AY039243	chromosome 21 open reading frame 58
225369_at	AL573851	endothelial cell adhesion molecule
238025_at	AA706818	mixed lineage kinase domain-like
235358_at	AW961205	hypothetical protein LOC728485
1554628_at	BC028974	zinc finger protein 57
1565347_s_at	AY034078	transcription factor binding to IGHM enhancer 3
219168_s_at	NM_017701	proline rich 5 (renal)
212154_at	AI380298	syndecan 2
1569486_at	BC035176	CDNA clone IMAGE: 5266012
206847_s_at	AF026397	homeobox A7

TABLE 13-continued

Table 13: Genes Expressed at a 5 fold or Greater Level in iPS Cell Lines versus hES Cell Lines ($p \leqq 0.01$)

Systematic Name	Genbank	Description
218260_at	NM_024050	chromosome 19 open reading frame 58
1554466_a_at	BC007207	chromosome 16 open reading frame 13
241611_s_at	BE675600	fibronectin type III domain containing 3A
215876_at	AK022254	CDNA FLJ12192 fis, clone MAMMA1000851
200756_x_at	U67280	calumenin
237211_x_at	AA860341	MORN repeat containing 3
216501_at	U25801	Vac14 homolog (*S. cerevisiae*)
207664_at	NM_001464	ADAM metallopeptidase domain 2 (fertilin beta)
217465_at	AK001291	NCK-associated protein 1
235136_at	BF337528	ORM1-like 3 (*S. cerevisiae*)
201171_at	NM_003945	ATPase, H+ transporting, lysosomal 9 kDa, V0 subunit e1
203892_at	NM_006103	WAP four-disulfide core domain 2
218810_at	NM_025079	zinc finger CCCH-type containing 12A
241574_s_at	H93038	Insulin-like growth factor 2 mRNA binding protein 1
211811_s_at	AF152484	protocadherin alpha 6
210457_x_at	AF176039	high mobility group AT-hook 1
208430_s_at	NM_001390	dystrobrevin, alpha
AFFX-HUMISGF3A/M97935_5_at	AFFX-HUMISGF3A/M97935_5	signal transducer and activator of transcription 1, 91 kDa
223631_s_at	AF213678	chromosome 19 open reading frame 33
1555733_s_at	AF393369	adaptor-related protein complex 1, sigma 3 subunit
209208_at	AF059752	mannose-P-dolichol utilization defect 1
206917_at	NM_006572	guanine nucleotide binding protein (G protein), alpha 13
213160_at	D86964	dedicator of cytokinesis 2
236058_at	AA573775	chromosome 1 open reading frame 172
217270_s_at	AC005393	dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1B
1558015_s_at	BU175810	ARP2 actin-related protein 2 homolog (yeast)
227971_at	AI653107	Nik related kinase
204284_at	N26005	protein phosphatase 1, regulatory (inhibitor) subunit 3C
210421_s_at	AB014602	solute carrier family 24 (sodium/potassium/calcium exchanger), member 1
220892_s_at	NM_021154	phosphoserine aminotransferase 1
221762_s_at	AL162458	chromosome 20 open reading frame 67
230926_s_at	AW452022	outer dense fiber of sperm tails 2-like
210079_x_at	U16953	potassium voltage-gated channel, shaker-related subfamily, beta member 1
202859_x_at	NM_000584	interleukin 8
37549_g_at	U87408	Bardet-Biedl syndrome 9
224321_at	AB004064	transmembrane protein with EGF-like and two follistatin-like domains 2
210828_s_at	AF001307	aryl hydrocarbon receptor nuclear translocator
222406_s_at	AV738970	proline-rich nuclear receptor coactivator 2
222419_x_at	AW205983	ubiquitin-conjugating enzyme E2H (UBC8 homolog, yeast)
207686_s_at	NM_001228	caspase 8, apoptosis-related cysteine peptidase
213597_s_at	BF002474	CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) small phosphatase-like
202226_s_at	NM_016823	v-crk sarcoma virus CT10 oncogene homolog (avian)
221048_x_at	NM_017941	chromosome 17 open reading frame 80
1553191_at	NM_020388	dystonin
213087_s_at	BF690020	CDNA clone IMAGE: 4838699
1554327_a_at	AF328554	calcium activated nucleotidase 1
233298_at	AL139377	spermatogenesis and oogenesis specific basic helix-loop-helix 2 /// hypothetical protein LOC728591
223393_s_at	AL136805	teashirt zinc finger homeobox 3
240983_s_at	AW292273	cysteinyl-tRNA synthetase
226905_at	BG036514	family with sequence similarity 101, member B
212797_at	BE742268	sortilin 1
209719_x_at	U19556	serpin peptidase inhibitor, clade B (ovalbumin), member 3
221364_at	NM_001510	glutamate receptor, ionotropic, delta 2
1552641_s_at	NM_031921	ATPase family, AAA domain containing 3A /// ATPase family, AAA domain containing 3B /// similar to ATPase family, AAA domain containing 3A /// similar to AAA-ATPase TOB3
222501_s_at	BE674760	replication initiator 1
1552477_a_at	BC014852	interferon regulatory factor 6
222711_s_at	AI761828	rhomboid 5 homolog 1 (*Drosophila*)
1552528_at	NM_058189	chromosome 21 open reading frame 69
232498_at	AK023386	hypothetical protein KIAA1833
226876_at	AI961778	family with sequence similarity 101, member B
230747_s_at	AA406435	Chromosome 18 open reading frame 17
201979_s_at	NM_006247	protein phosphatase 5, catalytic subunit
210869_s_at	M29277	melanoma cell adhesion molecule
237911_at	BF057809	Transcribed locus
215037_s_at	U72398	BCL2-like 1
AFFX-DapX-5_at	AFFX-DapX-5	—

TABLE 13-continued

Table 13: Genes Expressed at a 5 fold or Greater Level in iPS Cell Lines versus hES Cell Lines ($p \leqq 0.01$)

Systematic Name	Genbank	Description
217211_at	D50604	similar to cytoplasmic beta-actin
214014_at	W81196	CDC42 effector protein (Rho GTPase binding) 2
230517_at	AI416964	similar to GLI-Kruppel family member HKR1
1563312_at	BI603681	CDNA clone IMAGE: 5302682
206024_at	NM_002150	4-hydroxyphenylpyruvate dioxygenase
1552610_a_at	NM_002227	Janus kinase 1 (a protein tyrosine kinase)
224279_s_at	AF295039	calcium binding tyrosine-(Y)-phosphorylation regulated (fibrousheathin 2)
220426_at	NM_024059	chromosome 20 open reading frame 195
1553105_s_at	NM_001943	desmoglein 2
234688_x_at	AF141344	centrobin, centrosomal BRCA2 interacting protein
210022_at	BC004952	polycomb group ring finger 1
226306_at	BF984592	chromosome 6 open reading frame 1
203771_s_at	AA740186	biliverdin reductase A
201465_s_at	BC002646	jun oncogene
216549_s_at	AL096712	TBC1 domain family, member 22B
1553229_at	NM_152412	zinc finger protein 572
205065_at	AU130282	—
224301_x_at	BC003602	H2A histone family, member J
223616_at	BC005368	zinc finger protein 649
209629_s_at	AF201942	nuclear transport factor 2-like export factor 2
224037_at	AF132198	—
91826_at	AI219073	EPS8-like 1
227841_at	BG260181	Cementum protein 1
216641_s_at	U58994	ladinin 1
217300_at	U80771	—
1552649_a_at	NM_057178	ring finger and FYVE-like domain containing 1
221220_s_at	NM_017988	SCY1-like 2 (*S. cerevisiae*)
229296_at	AI659477	CDNA FLJ34873 fis, clone NT2NE2014950
212003_at	BG171020	chromosome 1 open reading frame 144
218922_s_at	NM_024552	LAG1 homolog, ceramide synthase 4
237872_at	AI026919	Transcribed locus
209373_at	BC003179	mal, T-cell differentiation protein-like
224795_x_at	AW575927	immunoglobulin kappa constant /// immunoglobulin kappa variable 1-5 /// immunoglobulin kappa variable 2-24
203065_s_at	NM_001753	caveolin 1, caveolae protein, 22 kDa
239623_at	N93197	hypothetical gene supported by AK126569
231243_s_at	R93946	basic helix-loop-helix domain containing, class B, 3
234730_s_at	AP001743	receptor-interacting serine-threonine kinase 4
228881_at	N30347	presenilin associated, rhomboid-like
231723_at	NM_013346	sorting nexin 12
205462_s_at	NM_002149	hippocalcin-like 1
200628_s_at	M61715	tryptophanyl-tRNA synthetase
230404_at	AI418538	—
1563809_a_at	AK094768	MCF.2 cell line derived transforming sequence-like
204470_at	NM_001511	chemokine (C—X—C motif) ligand 1 (melanoma growth stimulating activity, alpha)
205210_at	NM_004257	transforming growth factor, beta receptor associated protein 1
228634_s_at	BF195718	Cold shock domain protein A
210971_s_at	AB000815	aryl hydrocarbon receptor nuclear translocator-like
243358_at	BF347362	insulin-like growth factor 1 receptor
1561039_a_at	BC039609	zinc finger protein 81
222509_s_at	BG490634	zinc finger protein 672
1552717_s_at	NM_153243	centrosomal protein 170 kDa /// centrosomal protein 170 kDa-like
221754_s_at	AI341234	coronin, actin binding protein, 1B
234920_at	AK022466	Zinc finger protein 7
242571_at	AW962020	RALBP1 associated Eps domain containing 2
222085_at	AW452357	Hypothetical gene supported by AK075564; BC060873
1553697_at	NM_145257	chromosome 1 open reading frame 96
1555830_s_at	BC001224	family with sequence similarity 62 (C2 domain containing) member B
217010_s_at	AF277724	cell division cycle 25 homolog C (*S. pombe*)
214845_s_at	AF257659	calumenin
218537_at	NM_017885	host cell factor C1 regulator 1 (XPO1 dependent)
202790_at	NM_001307	claudin 7
1559528_at	BC040652	Polycomb group ring finger 3
1567105_at	AF362887	—
211772_x_at	BC006114	cholinergic receptor, nicotinic, alpha 3
219270_at	NM_024111	ChaC, cation transport regulator homolog 1 (*E. coli*)
207087_x_at	NM_020478	ankyrin 1, erythrocytic
213714_at	AI040163	calcium channel, voltage-dependent, beta 2 subunit
215649_s_at	AF217536	mevalonate kinase (mevalonic aciduria)
204638_at	NM_001611	acid phosphatase 5, tartrate resistant
228208_x_at	AL134573	Hypothetical LOC645944
239664_at	H18857	Transcribed locus

TABLE 13-continued

Table 13: Genes Expressed at a 5 fold or Greater Level in iPS Cell Lines versus hES Cell Lines ($p \leqq 0.01$)

Systematic Name	Genbank	Description
215585_at	AK024081	KIAA0174
211613_s_at	U79250	glycerol-3-phosphate dehydrogenase 2 (mitochondrial)
214903_at	AF070580	synaptotagmin II
1566472_s_at	AK098125	retinol saturase (all-trans-retinol 13,14-reductase)
234155_at	AK024928	CDNA: FLJ21275 fis, clone COL01827
243952_at	BF000009	TPTE pseudogene
210994_x_at	AF230398	tripartite motif-containing 23
205810_s_at	NM_003941	Wiskott-Aldrich syndrome-like
210455_at	AF050198	chromosome 10 open reading frame 28
211672_s_at	AF019888	actin related protein 2/3 complex, subunit 4, 20 kDa
233827_s_at	AK024072	suppressor of Ty 16 homolog (*S. cerevisiae*)
201621_at	NM_005380	neuroblastoma, suppression of tumorigenicity 1
1560020_at	BC043583	DnaJ (Hsp40) homolog, subfamily C, member 13
202290_at	NM_014891	PDGFA associated protein 1
216271_x_at	AC004794	synapse defective 1, Rho GTPase, homolog 1 (*C. elegans*)
210933_s_at	BC004908	fascin homolog 1, actin-bundling protein (Strongylocentrotus purpuratus)
1555569_a_at	BC042482	potassium channel tetramerisation domain containing 7
221889_at	AW026481	potassium channel tetramerisation domain containing 13
37547_at	U85995	Bardet-Biedl syndrome 9
205117_at	X59065	fibroblast growth factor 1 (acidic)
201122_x_at	BC000751	eukaryotic translation initiation factor 5A
233638_s_at	AK026430	protein O-linked mannose beta1,2-N-acetylglucosaminyltransferase
221035_s_at	NM_031272	testis expressed 14
223318_s_at	BC004393	alkB, alkylation repair homolog 7 (*E. coli*)
1555609_a_at	AF355465	zinc finger, matrin type 3
232675_s_at	BG149850	uridine-cytidine kinase 1-like 1
1555220_a_at	AB040820	aldo-keto reductase family 1, member C-like 2
220246_at	NM_020397	calcium/calmodulin-dependent protein kinase ID
206943_at	NM_004612	transforming growth factor, beta receptor I (activin A receptor type II-like kinase, 53 kDa)
202779_s_at	NM_014501	ubiquitin-conjugating enzyme E2S /// similar to Ubiquitin-conjugating enzyme E2S (Ubiquitin-conjugating enzyme E2-24 kDa) (Ubiquitin-protein ligase) (Ubiquitin carrier protein) (E2-EPF5)
206336_at	NM_002993	chemokine (C—X—C motif) ligand 6 (granulocyte chemotactic protein 2)
210405_x_at	AF153687	tumor necrosis factor receptor superfamily, member 10b
1554339_a_at	BC038953	component of oligomeric golgi complex 3
209062_x_at	AF010227	nuclear receptor coactivator 3
234992_x_at	BG170335	epithelial cell transforming sequence 2 oncogene
1557637_at	BC038734	CDNA clone IMAGE: 5267718
217711_at	BF594294	TEK tyrosine kinase, endothelial (venous malformations, multiple cutaneous and mucosal)
1553351_at	NM_130901	OTU domain containing 7A
61734_at	AI797684	reticulocalbin 3, EF-hand calcium binding domain
203994_s_at	U84569	chromosome 21 open reading frame 2
1565162_s_at	D16947	microsomal glutathione S-transferase 1
231011_at	AI339785	La ribonucleoprotein domain family, member 2
206209_s_at	NM_000717	carbonic anhydrase IV
209722_s_at	L40378	serpin peptidase inhibitor, clade B (ovalbumin), member 9
214369_s_at	AI688812	RAS guanyl releasing protein 2 (calcium and DAG-regulated)
205390_s_at	NM_000037	ankyrin 1, erythrocytic
204188_s_at	M57707	retinoic acid receptor, gamma
232132_at	AB043635	par-6 partitioning defective 6 homolog gamma (*C. elegans*)
1552389_at	NM_173549	chromosome 8 open reading frame 47
211911_x_at	L07950	major histocompatibility complex, class I, B
231402_at	AI830201	Transcribed locus, strongly similar to XP_531081.2 hypothetical protein [Pantroglodytes]
215913_s_at	AK023668	GULP, engulfment adaptor PTB domain containing 1
213426_s_at	AA150110	Caveolin 2
233543_s_at	AK021582	coiled-coil domain containing 98
201559_s_at	AF109196	chloride intracellular channel 4
241168_at	AV651242	Transcribed locus
216710_x_at	AL359578	zinc finger protein 287
1555006_at	BC036233	WD repeat domain 66
207453_s_at	NM_012266	DnaJ (Hsp40) homolog, subfamily B, member 5
217234_s_at	AF199015	villin 2 (ezrin)
214446_at	NM_012081	elongation factor, RNA polymerase II, 2
209372_x_at	BF971587	tubulin, beta 2A /// tubulin, beta 2B
218261_at	NM_005498	adaptor-related protein complex 1, mu 2 subunit
217445_s_at	AF008655	phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase
205595_at	NM_001944	desmoglein 3 (pemphigus vulgaris antigen)
233669_s_at	AA868267	tripartite motif-containing 54
1559028_at	BC037172	chromosome 21 open reading frame 15

TABLE 13-continued

Table 13: Genes Expressed at a 5 fold or Greater Level in iPS Cell Lines versus hES Cell Lines ($p \leqq 0.01$)

Systematic Name	Genbank	Description
1561330_at	BC039098	desmoglein 4
1562080_at	AK057351	CDNA FLJ32789 fis, clone TESTI2002326
234976_x_at	BG324504	Solute carrier family 4, sodium bicarbonate cotransporter, member 5
234085_at	AL139377	spermatogenesis and oogenesis specific basic helix-loop-helix 2 /// hypothetical protein LOC728591
208067_x_at	NM_007125	ubiquitously transcribed tetratricopeptide repeat gene, Y-linked
231957_s_at	AC005594	dipeptidyl-peptidase 9
1562244_at	AL833487	MRNA; cDNA DKFZp686H1629 (from clone DKFZp686H1629)
227488_at	AV728999	hypothetical protein MGC16121
239407_at	AI793248	CDNA clone IMAGE: 4837199
207540_s_at	NM_003177	spleen tyrosine kinase
1557984_s_at	BI464019	RNA polymerase II associated protein 3
208608_s_at	NM_021021	syntrophin, beta 1 (dystrophin-associated protein A1, 59 kDa, basic component 1)
1554795_a_at	BC019895	filamin binding LIM protein 1
209950_s_at	BC004300	villin-like
1558809_s_at	AK094324	hypothetical protein LOC284408
225333_at	AI218383	zinc finger protein 496
204522_at	NM_005510	dom-3 homolog Z (*C. elegans*)
218154_at	NM_024736	gasdermin domain containing 1
201060_x_at	AI537887	stomatin
201012_at	NM_000700	annexin A1
220889_s_at	NM_020178	carbonic anhydrase X
217729_s_at	NM_001130	amino-terminal enhancer of split
211187_at	AF118079	—
231396_s_at	AA776721	family with sequence similarity 126, member A
AFFX-LysX-M_at	AFFX-LysX-5	—
222678_s_at	BF057821	DCN1, defective in cullin neddylation 1, domain containing 1 (*S. cerevisiae*)
220234_at	NM_004056	carbonic anhydrase VIII
1553962_s_at	BI668074	ras homolog gene family, member B
207950_s_at	NM_001149	ankyrin 3, node of Ranvier (ankyrin G)
221981_s_at	AA702154	WD repeat domain 59
1568593_a_at	CA431328	nudix (nucleoside diphosphate linked moiety X)-type motif 16 pseudogene
223321_s_at	AF312678	fibroblast growth factor receptor-like 1
206042_x_at	NM_022804	small nuclear ribonucleoprotein polypeptide N /// SNRPN upstream reading frame
210334_x_at	AB028869	baculoviral IAP repeat-containing 5 (survivin)
216591_s_at	AF080579	succinate dehydrogenase complex, subunit C, integral membrane protein, 15 kDa /// hCG1776980
210206_s_at	U33833	DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 11 (CHL1-like helicase homolog, *S. cerevisiae*)
226786_at	BF507952	regulatory factor X, 1 (influences HLA class II expression)
211561_x_at	L35253	mitogen-activated protein kinase 14
211796_s_at	AF043179	T cell receptor beta variable 19 /// T cell receptor beta variable 7-2 /// T cell receptor beta variable 5-4 /// T cell receptor beta variable 3-1 /// T cell receptor beta constant 1
216493_s_at	AL023775	insulin-like growth factor 2 mRNA binding protein 3 /// similar to insulin-like growth factor 2 mRNA binding protein 3 /// similar to IGF-II mRNA-binding protein 3
230309_at	BE876610	Transcribed locus
204806_x_at	NM_018950	major histocompatibility complex, class I, F
205369_x_at	J03208	dihydrolipoamide branched chain transacylase E2
1556165_at	AK057525	CDNA FLJ32963 fis, clone TESTI2008405
215047_at	AL080170	tripartite motif-containing 58
225454_at	AW248770	coiled-coil domain containing 124
1552480_s_at	NM_080923	protein tyrosine phosphatase, receptor type, C
205388_at	NM_003279	troponin C type 2 (fast)
218510_x_at	AI816291	family with sequence similarity 134, member B
1553685_s_at	NM_138473	Sp1 transcription factor
228672_at	AI971618	inhibitor of growth family, member 5
205377_s_at	AI190022	acetylcholinesterase (Yt blood group)
230633_at	AI285730	transmembrane protein 102
207704_s_at	NM_003644	growth arrest-specific 7
215668_s_at	AJ011414	plexin B1
212107_s_at	BE561014	DEAH (Asp-Glu-Ala-His) box polypeptide 9
237282_s_at	AW137676	A kinase (PRKA) anchor protein 14
220285_at	NM_016014	family with sequence similarity 108, member B1
207979_s_at	NM_004931	CD8b molecule
226937_at	BF110844	Cardiolipin synthase 1
226051_at	BF973568	selenoprotein M
212272_at	AA813260	lipin 1
229881_at	R41200	Kruppel-like factor 12
217524_x_at	AA018923	Transcribed locus
1559409_a_at	BE893129	KIAA1345 protein
238480_at	AI871745	Chromosome 18 open reading frame 50
1553042_a_at	NM_032721	T-cell activation NFKB-like protein
221418_s_at	NM_005481	mediator complex subunit 16

TABLE 13-continued

Table 13: Genes Expressed at a 5 fold or Greater Level in iPS Cell Lines versus hES Cell Lines ($p \leqq 0.01$)

Systematic Name	Genbank	Description
202465_at	NM_002593	procollagen C-endopeptidase enhancer
231004_s_at	BE219961	H1 histone family, member X
242552_x_at	AW274047	zinc finger, BED-type containing 5
238699_s_at	AI659225	calcium/calmodulin-dependent serine protein kinase (MAGUK family)
242162_at	AA904430	WD repeat domain 69
207379_at	NM_005711	EGF-like repeats and discoidin I-like domains 3
211513_s_at	AF172449	opioid growth factor receptor
216981_x_at	X60502	sialophorin (leukosialin, CD43)
243938_x_at	AI872645	dynein, axonemal, heavy chain 5
211027_s_at	BC006231	inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta
231354_at	AW510748	hypothetical LOC780529
232984_at	AL137259	hydrocephalus inducing homolog (mouse)
1554464_a_at	BC008745	cartilage associated protein
223661_at	AF130080	—
224282_s_at	AB040138	1-acylglycerol-3-phosphate O-acyltransferase 3
214520_at	NM_005251	forkhead box C2 (MFH-1, mesenchyme forkhead 1)
1569076_a_at	BE791720	FLJ16287 protein
210585_s_at	AF007748	transportin 2 (importin 3, karyopherin beta 2b)
211599_x_at	U19348	met proto-oncogene (hepatocyte growth factor receptor)
221051_s_at	NM_014446	integrin beta 1 binding protein 3
217246_s_at	L22650	diaphanous homolog 2 (*Drosophila*)
221623_at	AF229053	brevican
238420_at	AV721958	CDNA clone IMAGE: 5263531
1558643_s_at	AA297258	EGF-like repeats and discoidin I-like domains 3
211266_s_at	U35399	G protein-coupled receptor 4
208851_s_at	AL161958	Thy-1 cell surface antigen
220102_at	NM_023067	forkhead box L2
214878_at	AU118165	zinc finger protein 37A /// zinc finger protein 37B
204480_s_at	NM_024112	chromosome 9 open reading frame 16
1558247_s_at	BC021210	hypothetical protein BC018697
206696_at	NM_000273	G protein-coupled receptor 143
1560316_s_at	N32168	glucocorticoid induced transcript 1
203990_s_at	AI140752	ubiquitously transcribed tetratricopeptide repeat, X chromosome
221638_s_at	AF008937	syntaxin 16
230146_s_at	BF111850	frequenin homolog (*Drosophila*)
231151_at	AL122010	discs, large (*Drosophila*) homolog-associated protein 3
233767_at	AU148706	CDNA FLJ12557 fis, clone NT2RM4000783
211681_s_at	AF116705	PDZ and LIM domain 5
225088_at	BG546917	chromosome 16 open reading frame 63
203234_at	NM_003364	uridine phosphorylase 1
202028_s_at	BC000603	ribosomal protein L38
200954_at	NM_001694	ATPase, H+ transporting, lysosomal 16 kDa, V0 subunit c
211317_s_at	AF041461	CASP8 and FADD-like apoptosis regulator
208729_x_at	D83043	major histocompatibility complex, class I, B
206486_at	NM_002286	lymphocyte-activation gene 3
1558093_s_at	BI832461	matrin 3 /// similar to Matrin-3 (Nuclear scaffold protein P130/MAT3)
204149_s_at	NM_000850	glutathione S-transferase M4
1555942_a_at	AK091113	NPC-A-5
1555202_a_at	BC010136	hypothetical protein FLJ10656
231721_at	AF356518	junctional adhesion molecule 3
224127_at	AF116660	—
224241_s_at	BC002350	—
216788_at	AK025564	CDNA: FLJ21911 fis, clone HEP03855
228371_s_at	BF196007	—
221440_s_at	NM_006606	retinoblastoma binding protein 9
220585_at	NM_025130	hexokinase domain containing 1
229439_s_at	AI830823	RNA-binding protein
206026_s_at	NM_007115	tumor necrosis factor, alpha-induced protein 6
209086_x_at	BE964361	melanoma cell adhesion molecule
229440_at	AI830823	RNA-binding protein
221875_x_at	AW514210	major histocompatibility complex, class I, F
1557918_s_at	AU131482	solute carrier family 16, member 1 (monocarboxylic acid transporter 1)
244735_at	AI377758	coiled-coil domain containing 54
227358_at	Z39566	zinc finger and BTB domain containing 46
224252_s_at	AF177940	FXYD domain containing ion transport regulator 5
206025_s_at	AW188198	tumor necrosis factor, alpha-induced protein 6
203953_s_at	BE791251	claudin 3
231341_at	BE670584	solute carrier family 35, member D3
213211_s_at	AI005317	TAF6-like RNA polymerase II, p300/CBP-associated factor (PCAF)-associated factor, 65 kDa
226988_s_at	AI709055	myosin, heavy chain 14
208677_s_at	AL550657	basigin (Ok blood group)

TABLE 13-continued

Table 13: Genes Expressed at a 5 fold or Greater Level in iPS Cell Lines versus hES Cell Lines ($p \leqq 0.01$)

Systematic Name	Genbank	Description
234625_at	AK025055	CDNA: FLJ21402 fis, clone COL03734
206769_at	NM_004202	thymosin, beta 4, Y-linked
229432_at	AV696264	N-acetylglutamate synthase
242338_at	BG535396	transmembrane protein 64
1554029_a_at	BC030966	KIAA0372
202793_at	NM_005768	membrane bound O-acyltransferase domain containing 5
210449_x_at	AF100544	mitogen-activated protein kinase 14
244171_at	AW505004	muskelin 1, intracellular mediator containing kelch motifs
238848_at	BF750565	OTU domain containing 4
221354_s_at	NM_005297	melanin-concentrating hormone receptor 1
204431_at	NM_003260	transducin-like enhancer of split 2 (E(sp1) homolog, *Drosophila*)
206491_s_at	NM_003827	N-ethylmaleimide-sensitive factor attachment protein, alpha
217371_s_at	Y09908	interleukin 15
204891_s_at	NM_005356	lymphocyte-specific protein tyrosine kinase
200948_at	NM_005439	myeloid leukemia factor 2
237806_s_at	AI684717	Hypothetical protein LOC729296
203849_s_at	BG473130	kinesin family member 1A
211514_at	AF068286	receptor interacting protein kinase 5
234724_x_at	AF152528	protocadherin beta 18 pseudogene
213665_at	AI989477	SRY (sex determining region Y)-box 4
1552736_a_at	NM_138966	neuropilin (NRP) and tolloid (TLL)-like 1
211088_s_at	Z25433	polo-like kinase 4 (*Drosophila*)
1554576_a_at	BC007242	ets variant gene 4 (E1A enhancer binding protein, E1AF)
243323_s_at	AI872979	AT-binding transcription factor 1
220354_at	NM_025266	hypothetical protein MGC2780
223821_s_at	BC004888	sushi domain containing 4
200824_at	NM_000852	glutathione S-transferase pi
227619_at	BF195628	Werner helicase interacting protein 1
201428_at	NM_001305	claudin 4
215984_s_at	AL121845	ADP-ribosylation factor related protein 1
206396_at	NM_004170	solute carrier family 1 (neuronal/epithelial high affinity glutamate transporter, system Xag), member 1
229406_at	AI674243	hypothetical protein LOC146713
243936_x_at	T85061	—
215495_s_at	AL117523	sterile alpha motif domain containing 4A
224003_at	AF332243	testis-specific transcript, Y-linked 14
230102_at	AW206458	Ets variant gene 5 (ets-related molecule)
203267_s_at	BF223206	developmentally regulated GTP binding protein 2
236940_at	W60647	Transcribed locus, weakly similar to NP_066953.1 isomerase A isoform 1 [*Homo sapiens*]
202002_at	AW072302	acetyl-Coenzyme A acyltransferase 2 (mitochondrial 3-oxoacyl-Coenzyme A thiolase)
1560228_at	BC041461	snail homolog 3 (*Drosophila*)
221317_x_at	NM_018939	protocadherin beta 6
217552_x_at	AI432713	complement component (3b/4b) receptor 1 (Knops blood group)
214279_s_at	W74452	NDRG family member 2
208629_s_at	BG472176	hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-Coenzyme A thiolase/enoyl-Coenzyme A hydratase (trifunctional protein), alpha subunit

TABLE 14

Table 14: Genes Expressed at a 2 fold or Greater Level in hES Cell Lines versus iPS Cell Lines ($p \leqq 0.01$)

Systematic Name	Genbank	Description
234626_at	AF137396	olfactory receptor, family 51, subfamily I, member 1
211006_s_at	L02840	potassium voltage-gated channel, Shab-related subfamily, member 1
228239_at	AA148789	chromosome 21 open reading frame 51
233583_at	AA608889	Transcribed locus
205911_at	NM_000316	parathyroid hormone receptor 1
217715_x_at	BE045142	—
1566477_at	AL832530	MRNA; cDNA DKFZp547F1316 (from clone DKFZp547F1316)
205693_at	NM_006757	troponin T type 3 (skeletal, fast)
215406_at	AK024860	CDNA: FLJ21207 fis, clone COL00362
1564121_at	AK026788	CDNA: FLJ23135 fis, clone LNG08666
220002_at	NM_018012	kinesin family member 26B
233939_at	AL117522	REX1, RNA exonuclease 1 homolog (*S. cerevisiae*)
210382_at	U13989	secretin receptor
220596_at	NM_015590	G patch domain containing 4
208448_x_at	NM_002173	interferon, alpha 16

TABLE 14-continued

Table 14: Genes Expressed at a 2 fold or Greater Level in hES Cell Lines versus iPS Cell Lines ($p \leqq 0.01$)

Systematic Name	Genbank	Description
231670_at	AA057519	—
223472_at	AF071594	Wolf-Hirschhorn syndrome candidate 1
1554542_at	BC025747	similar to CG4995 gene product
1559623_at	CA446227	Chromosome 11 open reading frame 54
1562036_at	BC043279	CDNA clone IMAGE: 5297259
229817_at	AI452715	zinc finger protein 608
234674_at	AK027027	CDNA: FLJ23374 fis, clone HEP16126
242628_at	AA194956	Transcribed locus
243081_at	AA824282	CDNA clone IMAGE: 5296106
1553721_at	NM_173557	ring finger protein 152
239200_at	BE503484	Transcribed locus
226286_at	AI686411	RNA binding motif and ELMO/CED-12 domain 1
1558570_at	AK096657	hypothetical protein LOC145783
1566204_at	AL589610	CDNA FLJ35929 fis, clone TESTI2010833
233608_at	AU146417	CDNA FLJ11929 fis, clone HEMBB1000434
217070_at	AJ249275	5,10-methylenetetrahydrofolate reductase (NADPH)
220577_at	NM_025006	GTPase, very large interferon inducible 1
220491_at	NM_021175	hepcidin antimicrobial peptide
242398_x_at	AA605121	Transcribed locus
237168_at	AA708016	Transcribed locus
1556638_at	AI250939	hypothetical protein LOC284530
216928_at	X51990	T-cell acute lymphocytic leukemia 1
209639_s_at	AF030111	regulator of G-protein signaling 12
1561255_at	BC040329	CDNA clone IMAGE: 4827712
233164_x_at	AK026955	rhomboid domain containing 1
236038_at	N50714	Transcribed locus
238126_at	AA886236	CDNA clone IMAGE: 4791585
243942_at	AI400012	Transcribed locus
1568978_s_at	BM547346	chromosome 11 open reading frame 21
1566672_at	AK093656	CDNA FLJ36337 fis, clone THYMU2006324
237663_at	AI681941	Transcribed locus
237151_s_at	BF433885	similar to hypothetical protein
212616_at	BF668950	chromodomain helicase DNA binding protein 9
231792_at	AF325549	myosin light chain kinase 2, skeletal muscle
1555554_at	AY180924	breast cancer and salivary gland expression gene
1553512_at	NM_173860	homeobox C12
211483_x_at	AF081924	calcium/calmodulin-dependent protein kinase (CaM kinase) II beta
1565588_at	BG708117	SP140 nuclear body protein
1559240_at	AA811339	—
230802_at	AI761947	Rho GTPase activating protein 24
213369_at	AI825832	protocadherin 21
235724_at	AW513684	Acyl-CoA synthetase short-chain family member 1
238279_x_at	BF062155	—
1569167_at	BC013250	*Homo sapiens*, clone IMAGE: 3867502, mRNA
208559_at	NM_013311	pancreatic and duodenal homeobox 1
217122_s_at	AL031282	solute carrier family 35, member E2 /// similar to solute carrier family 35, member E2
234108_at	AF264628	taste receptor, type 2, member 45
229480_at	AI341053	MRNA; cDNA DKFZp686I18116 (from clone DKFZp686I18116)
240623_at	BF589421	Transcribed locus
224519_at	BC006438	CDNA clone MGC: 13162 IMAGE: 3010103
221456_at	NM_016943	taste receptor, type 2, member 3
236728_at	AW070437	leucyl/cystinyl aminopeptidase
219839_x_at	NM_012468	T-cell leukemia/lymphoma 6
238894_at	AW665144	Transcribed locus
231276_at	BF591245	Phosphodiesterase 3B, cGMP-inhibited
1552732_at	AL832152	actin-binding Rho activating protein
210292_s_at	AF332218	protocadherin 11 X-linked /// protocadherin 11 Y-linked
230354_at	BG236273	Transcribed locus
1557208_at	AA609739	hypothetical protein LOC219731
240305_at	AI291536	CDNA clone IMAGE: 5285563
233075_at	AF071178	hect domain and RLD 2 pseudogene 7
226134_s_at	AI978754	Transcribed locus
235796_at	AI927957	Transcribed locus
1567375_at	AJ011596	Trapped 3' terminal exon, clone B2E8
232140_at	BF056548	CDNA FLJ13474 fis, clone PLACE1003593
216707_at	AL162044	MRNA; cDNA DKFZp761L0812 (from clone DKFZp761L0812); partial cds
1557395_at	AW243434	hypothetical LOC255130
1554629_at	BC027940	EPH receptor A7
215488_at	AF052095	Clone 23911 mRNA sequence
211004_s_at	BC002553	aldehyde dehydrogenase 3 family, member B1
244847_at	AA988223	Transcribed locus

TABLE 14-continued

Table 14: Genes Expressed at a 2 fold or Greater Level in hES Cell Lines versus iPS Cell Lines ($p \leqq 0.01$)

Systematic Name	Genbank	Description
222079_at	BF739971	—
237996_at	AV650867	—
216644_at	AK000185	CDNA FLJ20178 fis, clone COL09990
238588_at	AI623295	CDNA clone IMAGE: 5265193
222061_at	AA700015	CD58 molecule
211315_s_at	AB012043	calcium channel, voltage-dependent, T type, alpha 1G subunit
210037_s_at	L24553	nitric oxide synthase 2A (inducible, hepatocytes)
209957_s_at	M30262	natriuretic peptide precursor A
206449_s_at	NM_001879	mannan-binding lectin serine peptidase 1 (C4/C2 activating component of Ra-reactive factor)
1569064_at	BC027487	hypothetical LOC643338
209747_at	J03241	transforming growth factor, beta 3
224220_x_at	AF063824	transient receptor potential cation channel, subfamily C, member 4
244711_at	BF512863	Transcribed locus
239452_at	AI088640	Transcribed locus
243281_at	AW188311	Transcribed locus
1560346_at	AL080057	MRNA; cDNA DKFZp564D032 (from clone DKFZp564D032)
1566623_at	AL050263	DKFZP547J0410 protein
222381_at	AI907083	Programmed cell death 6 /// CDNA FLJ37304 fis, clone BRAMY2016070
227504_s_at	N64630	MRNA; cDNA DKFZp686F09227 (from clone DKFZp686F09227)
235164_at	BG433539	zinc finger protein 25
1559159_at	AK094069	centrosomal protein 68 kDa
1570128_at	BC025771	DEAD (Asp-Glu-Ala-As) box polypeptide 19A
231055_at	BF432941	Transcribed locus
1557453_at	BM662646	Full length insert cDNA clone ZD77B03
1564996_at	AK000024	CDNA FLJ20017 fis, clone ADSE00552
243107_at	AI910590	—
204914_s_at	AW157202	SRY (sex determining region Y)-box 11
1564855_at	AK058056	hypothetical protein LOC727924
1564559_at	AL833395	hypothetical protein LOC728073
204556_s_at	AL568422	DAZ interacting protein 1
1562372_at	AK094917	synaptic vesicle glycoprotein 2C
205777_at	NM_001395	dual specificity phosphatase 9
231475_at	BE671790	TBC1 domain family, member 21
224239_at	AF301470	defensin, beta 103B
238228_at	AI732206	—
230763_at	AA905508	spermatogenesis associated 17
229508_at	BF434828	U2 small nuclear RNA auxiliary factor 2
236479_at	BF513986	—
205183_at	NM_002138	heterogeneous nuclear ribonucleoprotein D (AU-rich element RNA binding protein 1, 37 kDa)
216135_at	AK000122	IQ motif containing K
1553207_at	NM_173664	ADP-ribosylation factor-like 10
217162_at	M94893	testis specific protein, Y-linked 1
244328_x_at	T86832	—
1566003_x_at	AK096064	CDNA FLJ38745 fis, clone KIDNE2012291
236736_at	AW274301	Transcribed locus
238532_at	AI125562	D4, zinc and double PHD fingers, family 3
223781_x_at	M15943	alcohol dehydrogenase 4 (class II), pi polypeptide
222940_at	U55764	sulfotransferase family 1E, estrogen-preferring, member 1
213953_at	AI732381	keratin 20
241033_at	AI821633	Transcribed locus
1569332_at	BC022563	chromosome 3 open reading frame 66
214049_x_at	AI829961	CD7 molecule
233165_at	AJ242655	NCK interacting protein with SH3 domain
241555_at	AI032090	Transcribed locus
1553405_a_at	NM_033225	CUB and Sushi multiple domains 1
238406_x_at	AI734001	seizure related 6 homolog (mouse)-like 2
203084_at	NM_000660	transforming growth factor, beta 1
232182_at	AI142853	hypothetical protein LOC286272
1559821_at	BC025328	*Homo sapiens*, clone IMAGE: 3944699, mRNA
206660_at	NM_020070	immunoglobulin lambda-like polypeptide 1
1564658_at	BC037583	Chromosome 7 open reading frame 52
220095_at	NM_017738	chromosome 9 open reading frame 39
230694_at	AI340341	—
202341_s_at	AA149745	tripartite motif-containing 2
1566577_at	AL831879	MRNA; cDNA DKFZp547I1410 (from clone DKFZp547I1410)
237587_at	AI733359	Transcribed locus, weakly similar to NP_001041360.1 protein LOC317588 [*Rattus norvegicus*]
1553868_a_at	NM_173665	chromosome 5 open reading frame 36
238731_at	AW977837	SET domain, bifurcated 2
235055_x_at	BF913667	Mucin 4, cell surface associated

TABLE 14-continued

Table 14: Genes Expressed at a 2 fold or Greater Level in hES Cell Lines versus iPS Cell Lines ($p \leqq 0.01$)

Systematic Name	Genbank	Description
230189_x_at	BF434897	Transcribed locus
1562656_at	BC043591	CDNA clone IMAGE: 5248626
219898_at	NM_018970	G protein-coupled receptor 85
217585_at	BE502910	nebulette
1554147_s_at	AB063297	chromosome 3 open reading frame 15
231047_at	R56808	Transcribed locus
213525_at	AC002310	CDNA clone IMAGE: 4906981
1553872_at	NM_152914	transcript expressed during hematopoiesis 2
1557452_at	AF088024	Full length insert cDNA clone ZC19A03
211618_s_at	M31008	alkaline phosphatase, intestinal
227121_at	BF476076	MRNA; cDNA DKFZp586K1922 (from clone DKFZp586K1922)
244364_at	AA443280	myosin IIIA
243797_at	AW070323	serine/threonine kinase 17b
1561396_at	AK092565	EPH receptor A6
241071_at	BF432757	—
1554739_at	BC032544	intracisternal A particle-promoted polypeptide
237015_at	AI097501	CDNA FLJ37017 fis, clone BRACE2010642
243825_at	T79768	B-cell CLL/lymphoma 6, member B (zinc finger protein)
232934_at	AA526468	CDNA FLJ13422 fis, clone PLACE1002213
1561669_at	BC018424	*Homo sapiens*, clone IMAGE: 4508536, mRNA
244545_at	AI769647	CDNA clone IMAGE: 5296106
1561200_at	BM981856	von Willebrand factor A domain containing 3B
244291_x_at	BE348646	Transcribed locus
1564854_at	AK058061	CDNA FLJ25332 fis, clone TST00642
229962_at	W68731	leucine rich repeat containing 37, member A3
225491_at	AL157452	solute carrier family 1 (glial high affinity glutamate transporter), member 2
205713_s_at	NM_000095	cartilage oligomeric matrix protein
240692_at	AI809153	SPR pseudogene
1553894_at	NM_144974	coiled-coil domain containing 122
217530_at	AW295295	solute carrier family 34 (sodium phosphate), member 1
228376_at	AI972498	glycoprotein, alpha-galactosyltransferase 1 /// similar to glycoprotein galactosyltransferase alpha 1, 3
244204_at	W87300	—
206128_at	AI264306	adrenergic, alpha-2C-, receptor
221275_s_at	NM_030896	—
233701_at	AK024580	CDNA: FLJ20927 fis, clone ADSE01007
240588_at	AI821798	—
217233_at	Z97206	—
236719_at	AI042187	Transcribed locus, moderately similar to XP_001086437.1 hypothetical protein [*Macaca mulatta*]
1561205_at	BC036409	CDNA clone IMAGE: 5266702
216129_at	AL117659	ATPase, Class II, type 9A
214428_x_at	K02403	complement component 4A (Rodgers blood group) /// complement component 4B (Childo blood group)
211579_at	U95204	integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61)
209354_at	BC002794	tumor necrosis factor receptor superfamily, member 14 (herpesvirus entry mediator)
207896_s_at	NM_007337	deleted in lung and esophageal cancer 1
1561319_at	BC041486	CDNA clone IMAGE: 5492202
1569454_a_at	BG475827	hypothetical protein LOC283352
240568_at	AW206555	—
1552872_at	NM_025091	chromosome X and Y open reading frame 2
233734_s_at	AW271225	oxysterol binding protein-like 5
214347_s_at	AW772056	dopa decarboxylase (aromatic L-amino acid decarboxylase)
1556803_at	BC033542	polymerase (RNA) III (DNA directed) polypeptide B
236154_at	R41907	Quaking homolog, KH domain RNA binding (mouse)
205623_at	NM_000691	aldehyde dehydrogenase 3 family, member A1
220818_s_at	NM_016179	transient receptor potential cation channel, subfamily C, member 4
1555043_at	BC028630	lipoma HMGIC fusion partner-like 5
1568977_at	BC019871	ribonuclease T2
235600_at	N63890	Transcribed locus
220150_s_at	NM_024581	chromosome 6 open reading frame 60
210381_s_at	BC000740	cholecystokinin B receptor
1558397_at	BF976693	CDNA FLJ34100 fis, clone FCBBF3007597
216214_at	AF070602	Clone 24504 mRNA sequence
221990_at	AI948472	paired box 8
243817_at	AI874267	—
241380_at	BF508325	FLJ41603 protein
237604_at	AA906413	BC038740
243708_at	AI678145	transmembrane protein 132E
233876_at	AK000677	—
240858_at	AA680403	Transcribed locus
1560806_at	BC037249	hypothetical protein LOC150527

TABLE 14-continued

Table 14: Genes Expressed at a 2 fold or Greater Level in hES Cell Lines versus iPS Cell Lines ($p \leqq 0.01$)

Systematic Name	Genbank	Description
239480_at	AA608964	Transcribed locus
1559580_at	AL832694	leucine rich repeat containing 39
230610_at	AW008915	Transcribed locus, moderately similar to XP_001087523.1 similar to Mid-1-related chloride channel 1 isoform 4 [*Macaca mulatta*]
221022_s_at	NM_031293	polyamine modulated factor 1 binding protein 1
239178_at	AL583692	fibroblast growth factor 9 (glia-activating factor)
237365_at	AI798981	CDNA clone IMAGE: 5269899
1568870_at	BC034805	CDNA clone IMAGE: 4818211
214411_x_at	AW584011	chymotrypsinogen B2
244035_at	BF003032	Full length insert cDNA clone YZ11B11
237094_at	AI953086	family with sequence similarity 19 (chemokine (C-C motif)-like), member A5
239312_at	AW419032	—
207640_x_at	NM_006181	netrin 2-like (chicken)
242171_at	AA693730	—
1553248_at	NM_152675	coiled-coil domain containing 57
234480_at	AL137340	Hypothetical protein DKFZp761C1711
1555474_at	BC009479	tubulin tyrosine ligase-like family, member 3
234261_at	AL137313	MRNA; cDNA DKFZp761M10121 (from clone DKFZp761M10121)
243459_x_at	AW300077	—
237676_at	AW274369	Transcribed locus
206819_at	NM_014549	POM121-like protein
1556125_at	BM668595	G patch domain containing 2
1556065_at	BG828817	Hypothetical protein LOC284926
232120_at	AA678124	CDNA FLJ14259 fis, clone PLACE1001076
1553562_at	NM_172100	CD8b molecule
217016_x_at	AK026825	hypothetical LOC389177
232807_at	AU158601	family with sequence similarity 131, member A
227389_x_at	AA058858	—
237528_at	D80212	Transcribed locus
242714_at	AW500340	—
205050_s_at	NM_012324	mitogen-activated protein kinase 8 interacting protein 2
240159_at	AA836116	solute carrier family 15 (H+/peptide transporter), member 2
240887_at	AI017957	Transcribed locus
1562577_at	BC025331	*Homo sapiens*, clone IMAGE: 4546564, mRNA
244715_at	R39803	Transcribed locus
1561500_at	AW575915	Hypothetical protein LOC348180
239627_at	BG034114	Transmembrane emp24 protein transport domain containing 9
222901_s_at	AF153815	potassium inwardly-rectifying channel, subfamily J, member 16
233351_at	AF339776	Clone IMAGE: 1542282, mRNA sequence
1566898_at	X53943	succinate dehydrogenase flavoprotein subunit
228136_s_at	AI280446	Chromosome 17 open reading frame 70
233387_s_at	AK024009	pericentrin (kendrin)
231911_at	AA736604	KIAA1189
240402_at	H05918	kin of IRRE like 3 (*Drosophila*)
244840_x_at	AW452588	dedicator of cytokinesis 4
1556172_at	AL832916	MRNA; cDNA DKFZp762I0915 (from clone DKFZp762I0915)
232833_at	AF070565	Clone 24425 mRNA sequence
1558797_at	BC017743	*Homo sapiens*, clone IMAGE: 4391558, mRNA
243542_at	BF445273	prolyl endopeptidase-like
223717_s_at	AB051833	acrosin binding protein
231324_at	AW452134	Transcribed locus
1556713_at	AK022031	CDNA FLJ11969 fis, clone HEMBB1001142
232186_at	AK027041	chromosome 20 open reading frame 142
231158_x_at	AI380289	Polypyrimidine tract binding protein 1
228816_at	AK022625	hypothetical protein LOC92270
1567390_at	AJ011600	Trapped 3' terminal exon, clone C2B5
1565732_at	BI254450	MRNA; cDNA DKFZp761B0218 (from clone DKFZp761B0218)
230228_at	W94546	hypothetical LOC284297
217462_at	AC004770	chromosome 11 open reading frame 9
1561759_at	AF085995	Similar to septin 7
211225_at	U27329	fucosyltransferase 5 (alpha (1,3) fucosyltransferase)
210565_at	U03469	glucagon receptor
237523_at	AI939584	Transcribed locus
221921_s_at	AI951798	cell adhesion molecule 3
234764_x_at	U96394	Immunoglobulin lambda variable 1-44 /// Immunoglobulin anti-HBsAg lambda light chain (LM25) /// Immunoglobulin lambda locus

TABLE 15

Table 15: Genes Expressed at a 5 fold or Greater Level in iPS Cell Lines versus both hES Cell Lines and Parental Fibroblasts ($p \leqq 0.01$)

Systematic Name	Genbank	Description
AFFX-r2-Ec-bioD-5_at	BF057809	Transcribed locus
239206_at	AF268617	POU class 5 homeobox 1 pseudogene 3
239205_s_at	AW003929	claudin 6
215101_s_at	NM_004360	cadherin 1, type 1, E-cadherin (epithelial)
210697_at	NM_017697	RNA binding motif protein 35A
223551_at	NM_003212	teratocarcinoma-derived growth factor 1 /// teratocarcinoma-derived growth factor 3, pseudogene
214974_x_at	AK022821	developmental pluripotency associated 4
237552_at	AF268615	POU class 5 homeobox 1 /// POU class 5 homeobox 1 pseudogene 1 /// POU class 5 homeobox 1 pseudogene 3 /// POU class 5 homeobox 1 pseudogene 4
231120_x_at	AI554075	Transcribed locus
235075_at	NM_024674	lin-28 homolog (*C. elegans*)
211906_s_at	AY072911	coxsackie virus and adenovirus receptor
217230_at	NM_005356	lymphocyte-specific protein tyrosine kinase
225908_at	BF001941	RNA binding motif protein 35A
232881_at	BC028721	solute carrier family 1 (high affinity aspartate/glutamate transporter), member 6
239951_at	L08599	cadherin 1, type 1, E-cadherin (epithelial)
1553276_at	BG166705	chemokine (C—X—C motif) ligand 5
219837_s_at	NM_001100	actin, alpha 1, skeletal muscle
208542_x_at	NM_014474	sphingomyelin phosphodiesterase, acid-like 3B
239319_at	BI092935	zinc finger protein 42 homolog (mouse)
235779_at	AL117612	mal, T-cell differentiation protein 2
220638_s_at	M83248	secreted phosphoprotein 1 (osteopontin, bone sialoprotein I, early T-lymphocyte activation 1)
214336_s_at	AU148706	CDNA FLJ12557 fis, clone NT2RM4000783
219807_x_at	NM_003413	Zic family member 3 heterotaxy 1 (odd-paired homolog, *Drosophila*)
1559503_a_at	AL515381	coronin, actin binding protein, 2A
209040_s_at	AF450454	zinc finger protein 42 homolog (mouse)
214090_at	BG327863	CD24 molecule
223629_at	NM_020436	sal-like 4 (*Drosophila*)
1559051_s_at	NM_014446	integrin beta 1 binding protein 3
212105_s_at	AI674565	family with sequence similarity 110, member C
203872_at	BE974098	tumor protein D52
222935_x_at	AL136825	ubiquitin specific peptidase 44
243195_s_at	W92748	sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6A
220179_at	AL556409	galanin
222898_s_at	AL533416	kinesin family member 1A
229332_at	AU143918	hypothetical gene supported by AJ002784
1555731_a_at	X69397	CD24 molecule
1553873_at	NM_024939	RNA binding motif protein 35B
235942_at	NM_005755	Epstein-Barr virus induced gene 3
244178_at	NM_173553	hypothetical protein FLJ25801
224463_s_at	AF493872	guanine nucleotide binding protein (G protein), gamma 4
206797_at	NM_002196	insulinoma-associated 1
212278_x_at	NM_021195	claudin 6
211107_s_at	AA594937	cordon-bleu homolog (mouse)
214519_s_at	AK000168	CD24 molecule
216469_at	BE552138	complement component (3b/4b) receptor 1-like
221123_x_at	AI963203	solute carrier family 7 (cationic amino acid transporter, y+ system), member 3
1568574_x_at	NM_006892	DNA (cytosine-5-)-methyltransferase 3 beta
1554777_at	AB020630	protein phosphatase 1, regulatory (inhibitor) subunit 16B
211214_s_at	AF154005	F11 receptor
205920_at	BE542563	Hypothetical protein LOC728342
232771_at	NM_001943	desmoglein 2
1555765_a_at	AB019562	Secreted phosphoprotein 1 (osteopontin, bone sialoprotein I, early T-lymphocyte activation 1)
206220_s_at	AF027205	serine peptidase inhibitor, Kunitz type, 2
201130_s_at	AF225513	protein kinase (cAMP-dependent, catalytic) inhibitor beta
219911_s_at	NM_024749	vasohibin 2
226654_at	NM_003991	endothelin receptor type B
1559361_at	NM_000273	G protein-coupled receptor 143
209260_at	AL359055	MRNA full length insert cDNA clone EUROIMAGE 2344436
1552399_a_at	NM_001038	sodium channel, nonvoltage-gated 1 alpha
205910_s_at	BE552138	complement component (3b/4b) receptor 1 (Knops blood group) /// complement component (3b/4b) receptor 1-like /// similar to complement component (3b/4b) receptor 1 isoform F precursor
206232_s_at	AK057525	CDNA FLJ32963 fis, clone TESTI2008405
212009_s_at	AB020630	protein phosphatase 1, regulatory (inhibitor) subunit 16B
204815_s_at	AI935915	SH3-binding domain kinase 1

TABLE 15-continued

Table 15: Genes Expressed at a 5 fold or Greater Level in iPS Cell Lines versus both hES Cell Lines and Parental Fibroblasts ($p \leqq 0.01$)

Systematic Name	Genbank	Description
1554776_at	BG389015	tumor protein D52
242070_at	NM_005397	podocalyxin-like
1554508_at	AK026546	chemokine (C—X—C motif) ligand 5
236741_at	AA761181	CD24 molecule
206604_at	NM_003182	tachykinin, precursor 1 (substance K, substance P, neurokinin 1, neurokinin 2, neuromedin L, neurokinin alpha, neuropeptide K, neuropeptide gamma)
1555829_at	NM_014392	DNA segment on chromosome 4 (unique) 234 expressed sequence
1555434_a_at	AF070651	zinc finger protein 257
1564706_s_at	BF056473	CDNA clone IMAGE: 4667929
242519_at	AF225425	sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6A
205344_at	AI653107	Nik related kinase
201123_s_at	AA074145	proline dehydrogenase (oxidase) 1
1564339_a_at	AL569326	protein kinase (cAMP-dependent, catalytic) inhibitor beta
216031_x_at	NM_004929	calbindin 1, 28 kDa
223285_s_at	AI824954	SRY (sex determining region Y)-box 3
1555800_at	AF110329	glutaminase 2 (liver, mitochondrial)
1557910_at	AW014927	calbindin 1, 28 kDa
204823_at	BC038422	zinc finger protein 533
1553852_at	BC028721	solute carrier family 1 (high affinity aspartate/glutamate transporter), member 6
1557924_s_at	NM_006984	claudin 10
1552995_at	AI492376	killer cell lectin-like receptor subfamily G, member 2
216360_x_at	AI830823	RNA-binding protein
232751_at	L19659	glucosaminyl (N-acetyl) transferase 2, I-branching enzyme (I blood group)
231452_at	NM_031272	testis expressed 14
213171_s_at	N23258	Transcribed locus
209756_s_at	NM_013267	glutaminase 2 (liver, mitochondrial)
1556670_at	AI014470	hypothetical protein LOC728485
227759_at	NM_003007	semenogelin I
208621_s_at	NM_012116	Cas-Br-M (murine) ecotropic retroviral transforming sequence c
229289_at	NM_004775	UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase, polypeptide 6
1553698_a_at	R61322	coiled-coil domain containing 64
207532_at	NM_004485	guanine nucleotide binding protein (G protein), gamma 4
219424_at	AW193600	hypothetical gene supported by AY007155
214154_s_at	AW007161	SRY (sex determining region Y)-box 2
221213_s_at	AI056483	zinc finger protein 488
1556834_at	M74921	endothelin receptor type B
227757_at	NM_005498	adaptor-related protein complex 1, mu 2 subunit
208504_x_at	Z83838	Rho GTPase activating protein 8 /// PRR5-ARHGAP8 fusion
214008_at	AB037776	immunoglobulin superfamily, member 9
209875_s_at	AI989477	SRY (sex determining region Y)-box 4
1555821_a_at	NM_000224	keratin 18
216915_s_at	W58601	Transcribed locus
239239_at	NM_152332	tandem C2 domains, nuclear
221408_x_at	U07236	lymphocyte-specific protein tyrosine kinase
212016_s_at	NM_153270	kelch-like 34 (*Drosophila*)
214828_s_at	AI193252	leucine rich repeat and Ig domain containing 1
233305_at	AF335278	cytochrome P450, family 2, subfamily S, polypeptide 1
216985_s_at	BF527050	SRY (sex determining region Y)-box 8
231789_at	AA205873	chromosome 9 open reading frame 58
211363_s_at	H93038	Insulin-like growth factor 2 mRNA binding protein 1
217294_s_at	AA573775	chromosome 1 open reading frame 172
211922_s_at	AL566906	Transcribed locus
204018_x_at	AI669212	protein phosphatase 2 (formerly 2A), regulatory subunit B, gamma isoform
243347_at	AIF191495	F11 receptor
206595_at	BF791631	kelch domain containing 8A
238125_at	NM_003822	nuclear receptor subfamily 5, group A, member 2
209958_s_at	NM_007267	transmembrane channel-like 6
238692_at	BC007230	coagulation factor C homolog, cochlin (*Limulus polyphemus*)
206390_x_at	NM_024794	abhydrolase domain containing 9
210572_at	BG479856	family with sequence similarity 60, member A /// similar to teratocarcinoma expressed, serine rich /// similar to Protein FAM60A (Tera protein)
1555034_at	NM_003385	visinin-like 1
210587_at	AL137763	grainyhead-like 3 (*Drosophila*)
231013_at	AI420156	MARVEL domain containing 3
206665_s_at	AW139759	solute carrier family 39 (zinc transporter), member 8
206882_at	BC041633	chromosome 1 open reading frame 210
1555716_a_at	AB046400	serpin peptidase inhibitor, clade B (ovalbumin), member 4
217051_s_at	NM_022449	RAB17, member RAS oncogene family
222508_s_at	AF193756	EF-hand calcium binding protein 1
211529_x_at	BC039098	desmoglein 4

TABLE 15-continued

Table 15: Genes Expressed at a 5 fold or Greater Level in iPS Cell Lines versus both hES Cell Lines and Parental Fibroblasts ($p \leqq 0.01$)

Systematic Name	Genbank	Description
220108_at	BC015108	*Homo sapiens*, Similar to otoconin 90, clone IMAGE: 4044247, mRNA
1561367_a_at	AW299463	WD repeat domain 72
211022_s_at	AL537457	neurofilament, light polypeptide 68 kDa
218931_at	BE791251	claudin 3
213363_at	AF039555	visinin-like 1
230112_at	AV706971	polycystic kidney and hepatic disease 1 (autosomal recessive)-like 1
209136_s_at	AA888057	plakophilin 2
212125_at	AI268404	protocadherin alpha 9 /// protocadherin alpha subfamily C, 2 /// protocadherin alpha subfamily C, 1 /// protocadherin alpha 13 /// protocadherin alpha 12 /// protocadherin alpha 11 /// protocadherin alpha 10 /// protocadherin alpha 8 /// protocadherin alpha 7 /// protocadherin alpha 6 /// protocadherin alpha 5 /// protocadherin alpha 4 /// protocadherin alpha 3 /// protocadherin alpha 2 /// protocadherin alpha 1
217370_x_at	BG473130	kinesin family member 1A
211016_x_at	BC001745	DNA segment on chromosome 4 (unique) 234 expressed sequence
241661_at	NM_000814	gamma-aminobutyric acid (GABA) A receptor, beta 3
222611_s_at	AI792670	Full-length cDNA clone CS0DC002YA18 of Neuroblastoma Cot 25-normalized of *Homo sapiens* (human)
213722_at	U46745	dystrobrevin, alpha
212574_x_at	NM_014289	calpain 6
219928_s_at	AF152474	protocadherin alpha subfamily C, 2
204895_x_at	BC029917	phosphoinositide-3-kinase adaptor protein 1
208275_x_at	NM_001877	complement component (3d/Epstein Barr virus) receptor 2
232001_at	BC000181	G protein-coupled receptor 160
223828_s_at	AI871354	v-myc myelocytomatosis viral related oncogene, neuroblastoma derived (avian)
210654_at	NM_006465	AT rich interactive domain 3B (BRIGHT-like)
206208_at	BF905445	Proline rich Gla (G-carboxyglutamic acid) 4 (transmembrane)
1553535_a_at	BC000329	stratifin
222936_s_at	BC014155	Ras homolog enriched in brain like 1
1566764_at	NM_016354	solute carrier organic anion transporter family, member 4A1
226913_s_at	NM_001307	claudin 7
208478_s_at	AB032179	erythrocyte membrane protein band 4.1 like 4B
202662_s_at	AF152528	protocadherin beta 18 pseudogene
228851_s_at	U53823	occludin /// occludin pseudogene
206552_s_at	NM_003389	coronin, actin binding protein, 2A
213943_at	AA565499	NLR family, pyrin domain containing 7
209198_s_at	AF232238	hairy/enhancer-of-split related with YRPW motif 2
211699_x_at	AF213678	chromosome 19 open reading frame 33
207402_at	NM_004297	guanine nucleotide binding protein (G protein), alpha 14
224539_s_at	BF732462	PRKC, apoptosis, WT1, regulator
229566_at	AV681807	v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian)
238742_x_at	BC007242	ets variant gene 4 (E1A enhancer binding protein, E1AF)
1555639_a_at	AI768894	cingulin
211899_s_at	NM_004968	islet cell autoantigen 1, 69 kDa
1553694_a_at	AA565509	Transcribed locus, strongly similar to XP_531332.1 hypothetical protein XP_531332 [Pantroglodytes]
213926_s_at	AW961205	hypothetical protein LOC728485
214000_s_at	NM_005562	laminin, gamma 2
203729_at	BC001186	protocadherin beta 5
203085_s_at	BE350882	delta-like 3 (*Drosophila*)
207118_s_at	NM_000015	N-acetyltransferase 2 (arylamine N-acetyltransferase)
232591_s_at	BE080109	similar to embigin homolog
236158_at	AL359055	MRNA full length insert cDNA clone EUROIMAGE 2344436
229901_at	BF057784	G protein-coupled receptor 114
211051_s_at	U58994	ladinin 1
222458_s_at	NM_024306	fatty acid 2-hydroxylase
230809_at	NM_007153	zinc finger protein 208
221279_at	BC000568	transmembrane protein 108
224169_at	AB018009	solute carrier family 7 (cationic amino acid transporter, y+ system), member 5
233297_s_at	U53470	inositol polyphosphate-5-phosphatase, 145 kDa
221665_s_at	NM_002773	protease, serine, 8
205391_x_at	AA702685	organic solute transporter alpha
215728_s_at	BC004907	EPS8-like 1
208474_at	NM_021209	NLR family, CARD domain containing 4
223567_at	AA910946	adaptor-related protein complex 1, mu 2 subunit
1558662_s_at	BC011672	G protein regulated inducer of neurite outgrowth 2
210620_s_at	U73844	E74-like factor 3 (ets domain transcription factor, epithelial-specific)
211020_at	AI740544	ADAM metallopeptidase with thrombospondin type 1 motif, 16
231698_at	AI434443	Zinc finger protein 81
227316_at	R99562	forkhead box A3
1555814_a_at	AI694320	zinc finger protein 533

TABLE 15-continued

Table 15: Genes Expressed at a 5 fold or Greater Level in iPS Cell Lines versus both hES Cell Lines and Parental Fibroblasts ($p \leqq 0.01$)

Systematic Name	Genbank	Description
235728_at	NM_003121	Spi-B transcription factor (Spi-1/PU.1 related)
213713_s_at	NM_025266	hypothetical protein MGC2780
237206_at	BC035960	protein tyrosine phosphatase, receptor type, O
210413_x_at	NM_006467	polymerase (RNA) III (DNA directed) polypeptide G (32 kD)
242660_at	NM_003577	undifferentiated embryonic cell transcription factor 1
225369_at	AV709406	transmembrane protein 125
235358_at	AI653169	adenylate kinase 3-like 2
1554628_at	BC035104	CDNA clone IMAGE: 5262438
212154_at	NM_004659	matrix metallopeptidase 23B /// matrix metallopeptidase 23A (pseudogene)
218260_at	AI928513	—
207664_at	NM_005477	hyperpolarization activated cyclic nucleotide-gated potassium channel 4
201171_at	NM_004973	jumonji, AT rich interactive domain 2
203892_at	BF739767	homolog of rat pragma of Rnd2
241574_s_at	AF059274	chondroitin sulfate proteoglycan 5 (neuroglycan C)
210457_x_at	NM_018593	solute carrier family 16, member 10 (aromatic amino acid transporter)
223631_s_at	AA531023	family with sequence similarity 46, member B
1555733_s_at	AI566130	adenylate kinase 3-like 2
206917_at	NM_002045	growth associated protein 43
236058_at	AW173071	UDP glycosyltransferase 3 family, polypeptide A1
1558015_s_at	AI885670	selenophosphate synthetase 1
227971_at	AF257210	neuropeptide FF receptor 2
220892_s_at	AI653050	4-hydroxyphenylpyruvate dioxygenase-like
230926_s_at	AK026966	adenylate kinase 3-like 2
37549_g_at	NM_003364	uridine phosphorylase 1
210828_s_at	H23979	CD200 molecule
222406_s_at	R45446	Transcribed locus
1553191_at	NM_022357	dipeptidase 3
1554327_a_at	AF147790	mucin 12, cell surface associated
240983_s_at	NM_024645	zinc finger, matrin type 4
212797_at	L40378	serpin peptidase inhibitor, clade B (ovalbumin), member 9
209719_x_at	AL139377	hypothetical protein LOC728591
1552641_s_at	NM_001464	ADAM metallopeptidase domain 2 (fertilin beta)
222501_s_at	NM_002119	major histocompatibility complex, class II, DO alpha
1552477_a_at	AB055704	LIM homeobox 4
226876_at	AI936724	Transcribed locus, weakly similar to XP_001114804.1 spectrin, beta, non-erythrocytic 1 isoform 4 [*Macaca mulatta*]
210869_s_at	NM_002286	lymphocyte-activation gene 3
237911_at	U19557	serpin peptidase inhibitor, clade B (ovalbumin), member 4
215037_s_at	BC000740	cholecystokinin B receptor
206024_at	AL137145	protein kinase C, theta
224279_s_at	AL080170	tripartite motif-containing 58
1553105_s_at	NM_003177	spleen tyrosine kinase
210022_at	BC005368	zinc finger protein 649
223616_at	AC006539	zinc finger protein 682
209629_s_at	NM_005712	HERV-H LTR-associating 1
224037_at	NM_001944	desmoglein 3 (pemphigus vulgaris antigen)
91826_at	AL832535	hypothetical protein LOC157627
216641_s_at	AI807681	SH3 domain containing ring finger 2
218922_s_at	NM_006574	chondroitin sulfate proteoglycan 5 (neuroglycan C)
237872_at	R38389	olfactomedin 1
203065_s_at	AF279779	cholinergic receptor, muscarinic 3 /// similar to cholinergic receptor, muscarinic 3
228634_s_at	AW242668	hypothetical LOC645321
234920_at	AK057525	CDNA FLJ32963 fis, clone TESTI2008405
1553697_at	NM_022307	islet cell autoantigen 1, 69 kDa
217010_s_at	AV682679	selenophosphate synthetase 1
202790_at	AB045118	frequently rearranged in advanced T-cell lymphomas 2
211772_x_at	AW302207	Transcribed locus
219270_at	AW510925	HRAS-like suppressor family, member 5
207087_x_at	BC013944	spermatogenesis and oogenesis specific basic helix-loop-helix 2
213714_at	NM_005242	coagulation factor II (thrombin) receptor-like 1
215649_s_at	NM_004615	tetraspanin 7
214903_at	AF052167	MRS2-like, magnesium homeostasis factor (*S. cerevisiae*)
210455_at	NM_152476	zinc finger protein 560
233827_s_at	AW268880	Solute carrier family 25, member 13 (citrin)
37547_at	NM_018931	protocadherin beta 11
233638_s_at	AW166283	protein phosphatase 2 (formerly 2A), regulatory subunit B, gamma isoform
221035_s_at	Z39566	zinc finger and BTB domain containing 46
1555609_a_at	R83905	IBR domain containing 2
202779_s_at	NM_004532	mucin 4, cell surface associated
206336_at	AW139719	Transcribed locus
1554339_a_at	BF059512	delta/notch-like EGF repeat containing

TABLE 15-continued

Table 15: Genes Expressed at a 5 fold or Greater Level in iPS Cell Lines versus both hES Cell Lines and Parental Fibroblasts ($p \leqq 0.01$)

Systematic Name	Genbank	Description
217711_at	AK023446	aminoadipate-semialdehyde synthase
231011_at	NM_003027	SH3-domain GRB2-like 3
206209_s_at	NM_013410	adenylate kinase 3-like 1 /// adenylate kinase 3-like 2 /// similar to Adenylate kinase isoenzyme 4, mitochondrial (ATP-AMP transphosphorylase)
209722_s_at	AK093656	CDNA FLJ36337 fis, clone THYMU2006324
214369_s_at	NM_020662	MRS2-like, magnesium homeostasis factor (*S. cerevisiae*)
1552389_at	AF086401	Full length insert cDNA clone ZD75H06
215913_s_at	L01087	protein kinase C, theta
201559_s_at	AA868267	tripartite motif-containing 54
217234_s_at	W25881	CDNA: FLJ21041 fis, clone CAE10652
209372_x_at	AI807356	—
218261_at	BF063271	UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 3 (GalNAc-T3)
217445_s_at	AW006735	CD8a molecule
205595_at	NM_023940	RAS-like, family 11, member B
233669_s_at	AF222694	lectin, galactoside-binding, soluble, 12 (galectin 12)
1561330_at	U92817	—
234976_x_at	AW440392	Hypothetical protein LOC342892
234085_at	AA824282	CDNA clone IMAGE: 5296106
207540_s_at	NM_014901	ring finger protein 44
208608_s_at	AF061785	gamma-aminobutyric acid (GABA) A receptor, alpha 5 /// similar to gamma-aminobutyric acid (GABA) A receptor, alpha 5
207950_s_at	AF229180	aminoadipate-semialdehyde synthase
221981_s_at	AV723167	synaptotagmin I
206042_x_at	NM_000366	tropomyosin 1 (alpha)
210334_x_at	BI825302	transmembrane protein 37
210206_s_at	AI554106	polyhomeotic homolog 1 (*Drosophila*)
226786_at	M61870	zinc finger protein 90
211796_s_at	BC027940	EPH receptor A7
216493_s_at	AY026481	galactose-3-O-sulfotransferase 3
204806_x_at	BF438028	Transcribed locus
1556165_at	AI830823	RNA-binding protein
215047_at	AF115765	artemin
1552480_s_at	NM_000363	troponin I type 3 (cardiac)
205388_at	AB019490	RAB GTPase activating protein 1-like
228672_at	BF195936	hypothetical LOC342979
205377_s_at	BC005161	inhibin, beta E
230633_at	BC014852	interferon regulatory factor 6
207704_s_at	BF060667	gap junction protein, beta 3, 31 kDa
215668_s_at	U26744	dystrobrevin, alpha
212107_s_at	NM_021978	suppression of tumorigenicity 14 (colon carcinoma)
237282_s_at	NM_006103	WAP four-disulfide core domain 2
220285_at	NM_002993	chemokine (C—X—C motif) ligand 6 (granulocyte chemotactic protein 2)
207979_s_at	AI208292	chromosome 5 open reading frame 35
229881_at	BC003574	T-cell leukemia/lymphoma 1A
242162_at	NM_005490	SH2 domain containing 3A
207379_at	NM_004202	thymosin, beta 4, Y-linked
216981_x_at	AI452798	myocardin
224282_s_at	AY116207	NLR family, pyrin domain containing 12
221051_s_at	NM_003260	transducin-like enhancer of split 2 (E(sp1) homolog, *Drosophila*)
221623_at	NM_000810	gamma-aminobutyric acid (GABA) A receptor, alpha 5
206696_at	T15991	—
203990_s_at	AV731490	synaptotagmin I
233767_at	NM_001902	cystathionase (cystathionine gamma-lyase)
211681_s_at	Z83850	Nik related kinase
203234_at	AF243527	kallikrein-related peptidase 5
208729_x_at	U63824	TEA domain family member 4
206486_at	AF070580	synaptotagmin II
1558093_s_at	BC001606	neutrophil cytosolic factor 2 (65 kDa, chronic granulomatous disease, autosomal 2)
1555942_a_at	AI857639	phorbol-12-myristate-13-acetate-induced protein 1
1555202_a_at	AB022433	sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6B
229439_s_at	AI862542	CDNA clone IMAGE: 4837650
209086_x_at	AL517395	hypothetical protein BC004941
229440_at	BC002693	spermatid perinuclear RNA binding protein
1557918_s_at	U19556	serpin peptidase inhibitor, clade B (ovalbumin), member 3
227358_at	NM_052836	cadherin-like 23
203953_s_at	NM_003054	solute carrier family 18 (vesicular monoamine), member 2
206769_at	H58488	Transcribed locus
242338_at	AA174083	Clone IMAGE: 609847, mRNA sequence
1554029_a_at	NM_003963	transmembrane 4 L six family member 5

TABLE 15-continued

Table 15: Genes Expressed at a 5 fold or Greater Level in iPS Cell Lines versus both hES Cell Lines and Parental Fibroblasts ($p \leqq 0.01$)

Systematic Name	Genbank	Description
244171_at	AK000794	—
204431_at	AK025747	fidgetin
204891_s_at	NM_057162	kelch-like 4 (*Drosophila*)
203849_s_at	BG289314	cadherin-like 26
234724_x_at	AF060924	mitochondrial protein 18 kDa
213665_at	AA608964	Transcribed locus
1552736_a_at	AI733281	Transcribed locus
211088_s_at	AK022644	dysbindin (dystrobrevin binding protein 1) domain containing 1
1554576_a_at	BC001387	HRAS-like suppressor 3
220354_at	NM_004426	polyhomeotic homolog 1 (*Drosophila*) /// similar to polyhomeotic 1-like
223821_s_at	NM_016323	hect domain and RLD 5
227619_at	AL121753	matrix metallopeptidase 24 (membrane-inserted)
215984_s_at	AA401492	GNAS complex locus
1560228_at	NM_004432	ELAV (embryonic lethal, abnormal vision, *Drosophila*)-like 2 (Hu antigen B)
217552_x_at	NM_005071	solute carrier family 1 (high affinity aspartate/glutamate transporter), member 6
214279_s_at	NM_018283	nudix (nucleoside diphosphate linked moiety X)-type motif 15
1554952_s_at	NM_002235	potassium voltage-gated channel, shaker-related subfamily, member 6
215313_x_at	NM_002090	chemokine (C—X—C motif) ligand 3
237145_at	AF043179	T cell receptor beta variable 19 /// T cell receptor beta variable 7-2 /// T cell receptor beta variable 5-4 /// T cell receptor beta variable 3-1 /// T cell receptor beta constant 1
1556348_at	AI613010	F-box and leucine-rich repeat protein 16
201140_s_at	AA350425	Similar to zinc finger protein 91
1556128_a_at	W48843	sprouty homolog 4 (*Drosophila*)
213810_s_at	NM_001149	ankyrin 3, node of Ranvier (ankyrin G)
226857_at	NM_002583	PRKC, apoptosis, WT1, regulator
1553257_at	BC009701	peptidyl arginine deiminase, type II
1559880_at	NM_001275	chromogranin A (parathyroid secretory protein 1)
1552849_at	NM_014289	calpain 6
1552804_a_at	AF279774	growth associated protein 43
1554689_a_at	NM_016510	selenocysteine lyase
1552580_at	AF482697	clarin 1
237461_at	NM_002744	protein kinase C, zeta
1559954_s_at	NM_173549	chromosome 8 open reading frame 47
219367_s_at	AW003107	—
207419_s_at	AK023059	CDNA FLJ12997 fis, clone NT2RP3000247
201750_s_at	AU132789	zinc finger protein 273
206907_at	AL139377	spermatogenesis and oogenesis specific basic helix-loop-helix 2 /// hypothetical protein LOC728591
220756_s_at	AF097159	UDP-Gal: betaGlcNAc beta 1,4-galactosyltransferase, polypeptide 6
223510_at	NM_022552	DNA (cytosine-5-)-methyltransferase 3 alpha
214671_s_at	AU131482	solute carrier family 16, member 1 (monocarboxylic acid transporter 1)
208750_s_at	AI738919	ligand of numb-protein X 1
1554052_at	NM_012282	KCNE1-like
222234_s_at	NM_024037	chromosome 1 open reading frame 135
221423_s_at	AF277724	cell division cycle 25 homolog C (*S. pombe*)
205528_s_at	NM_002450	metallothionein 1X
205531_s_at	BC037211	hypothetical protein LOC283432
221162_at	NM_022154	solute carrier family 39 (zinc transporter), member 8
203381_s_at	AF307451	cat eye syndrome chromosome region, candidate 6
210001_s_at	AJ011414	plexin B1
215509_s_at	AA522514	KIAA0746 protein
205174_s_at	NM_003740	potassium channel, subfamily K, member 5
41037_at	NM_015894	stathmin-like 3
206701_x_at	AA527080	KIAA1727 protein
205121_at	U87408	Bardet-Biedl syndrome 9
1555106_a_at	AV722990	protocadherin beta 15
214414_x_at	AK091113	NPC-A-5
214390_s_at	AA894574	FK506 binding protein 4, 59 kDa
237810_at	NM_016365	nebulette
217441_at	BF971587	tubulin, beta 2A /// tubulin, beta 2B
1562022_s_at	NM_000573	complement component (3b/4b) receptor 1 (Knops blood group)
207279_s_at	AF096296	chemokine (C-C motif) ligand 26
202400_s_at	AA825563	Transcribed locus
203798_s_at	BC006117	L-2-hydroxyglutarate dehydrogenase
230641_at	AI979334	chromosome 12 open reading frame 35
221539_at	NM_017894	zinc finger and SCAN domain containing 2
238716_at	NM_005059	relaxin 2
223402_at	BC023610	CDNA clone IMAGE: 4638753
209619_at	NM_003914	cyclin A1
209949_at	AA329676	CDNA FLJ45742 fis, clone KIDNE2016327
243354_at	NM_004720	endothelial differentiation, lysophosphatidic acid G-protein-coupled receptor, 4

TABLE 15-continued

Table 15: Genes Expressed at a 5 fold or Greater Level in iPS Cell Lines versus both hES Cell Lines and Parental Fibroblasts ($p \leqq 0.01$)

Systematic Name	Genbank	Description
212953_x_at	AW450586	family with sequence similarity 124A
208949_s_at	NM_005110	glutamine-fructose-6-phosphate transaminase 2
212647_at	AF136972	protein phosphatase 1B (formerly 2C), magnesium-dependent, beta isoform
231195_at	NM_006334	olfactomedin 1
209995_s_at	AF393369	adaptor-related protein complex 1, sigma 3 subunit
242422_at	AI758697	zinc finger protein 493
209569_x_at	AA524029	chromosome 9 open reading frame 61
235235_s_at	NM_012099	CD3e molecule, epsilon associated protein
207043_s_at	AL043927	tubulin tyrosine ligase-like family, member 4
228530_at	AI272059	LOC401629 /// LOC401630
205184_at	NM_005314	gastrin-releasing peptide receptor
222871_at	NM_016089	zinc finger protein 589
209772_s_at	R48779	hypothetical protein BC008326
228570_at	AF007143	Clone 23738 mRNA sequence
1554751_at	AK098715	CDNA FLJ25849 fis, clone TST08968
211392_s_at	D53659	myotubularin related protein 7
213869_x_at	NM_000717	carbonic anhydrase IV
1555659_a_at	N33009	apolipoprotein E
1553156_at	AW451792	COMM domain containing 7
227429_at	BC010432	CDNA clone IMAGE: 3528357
212720_at	NM_001392	dystrobrevin, alpha
206442_at	BG328998	glutamic pyruvate transaminase (alanine aminotransferase) 2
238959_at	AL040935	BTB (POZ) domain containing 11
226281_at	AW292273	cysteinyl-tRNA synthetase
223385_at	AF393369	adaptor-related protein complex 1, sigma 3 subunit
217996_at	NM_018932	protocadherin beta 12
220010_at	AI683694	EF-hand calcium binding domain 4A
237217_at	NM_002915	replication factor C (activator 1) 3, 38 kDa
1556854_at	AW139618	synapsin II
239012_at	NM_003213	TEA domain family member 4
1555618_s_at	NM_145019	family with sequence similarity 124A
218707_at	AI971618	inhibitor of growth family, member 5
1564494_s_at	NM_005958	melatonin receptor 1A
205262_at	AF095784	gamma-aminobutyric acid (GABA) B receptor, 2
208352_x_at	AW268880	solute carrier family 25, member 13 (citrin)
204326_x_at	AB040903	regulator of chromosome condensation 2
201201_at	H90656	nicotinamide nucleotide adenylyltransferase 2
219885_at	NM_004561	ovo-like 1 (*Drosophila*)
236070_at	BF663141	villin 2 (ezrin)
212142_at	AW966474	sushi domain containing 3
204452_s_at	NM_024595	chromosome 1 open reading frame 108
1553328_a_at	NM_022804	small nuclear ribonucleoprotein polypeptide N /// SNRPN upstream reading frame
205899_at	NM_004346	caspase 3, apoptosis-related cysteine peptidase
234842_at	NM_003236	transforming growth factor, alpha
1570253_a_at	NM_012168	F-box protein 2
1559057_at	NM_016941	delta-like 3 (*Drosophila*)
207850_at	AI219073	EPS8-like 1
205204_at	NM_001254	cell division cycle 6 homolog (*S. cerevisiae*)
218075_at	BE896137	DCP2 decapping enzyme homolog (*S. cerevisiae*)
213022_s_at	AA928939	transmembrane protein 63C
210039_s_at	NM_004931	CD8b molecule
215758_x_at	AL136179	SRY (sex determining region Y)-box 4
1554397_s_at	NM_000148	fucosyltransferase 1 (galactoside 2-alpha-L-fucosyltransferase, H blood group)
219165_at	AB012043	calcium channel, voltage-dependent, T type, alpha 1G subunit
217110_s_at	AA588400	ovo-like 1 (*Drosophila*)
203879_at	BF438407	zinc finger protein 551
221098_x_at	AL163202	similar to zinc finger protein 43 (HTF6)
218533_s_at	M98528	DNA segment on chromosome 4 (unique) 234 expressed sequence
218178_s_at	NM_012261	chromosome 20 open reading frame 103
208980_s_at	M28880	ankyrin 1, erythrocytic
206961_s_at	AF199015	villin 2 (ezrin)
202307_s_at	NM_032785	ATP/GTP binding protein-like 4
219735_s_at	NM_022006	FXYD domain containing ion transport regulator 7
228800_x_at	U77949	cell division cycle 6 homolog (*S. cerevisiae*)
225103_at	NM_173549	chromosome 8 open reading frame 47
223074_s_at	AF277724	cell division cycle 25 homolog C (*S. pombe*)
233348_at	AC003682	zinc finger protein interacting with K protein 1 homolog (mouse)
220158_at	AF498927	Rho GDP dissociation inhibitor (GDI) beta
1559701_s_at	BF594294	TEK tyrosine kinase, endothelial (venous malformations, multiple cutaneous and mucosal)
223392_s_at	NM_013447	egf-like module containing, mucin-like, hormone receptor-like 2

TABLE 15-continued

Table 15: Genes Expressed at a 5 fold or Greater Level in iPS Cell Lines versus both hES Cell Lines and Parental Fibroblasts ($p \leqq 0.01$)

Systematic Name	Genbank	Description
203331_s_at	AE000659	T-cell receptor alpha-chain pseudogene mRNA, clone HAP60 (V-alpha-1.1 family)
1569022_a_at	NM_018093	WD repeat domain 74
1555467_a_at	AF255647	transmembrane protein 163
225868_at	AA906413	BC038740
240982_at	NM_003097	small nuclear ribonucleoprotein polypeptide N /// SNRPN upstream reading frame
238315_s_at	NM_005738	ADP-ribosylation factor-like 4A
215708_s_at	AF231021	NLR family, pyrin domain containing 12
205007_s_at	BF446578	RasGEF domain family, member 1A
201742_x_at	NM_017965	solute carrier family 7, (neutral amino acid transporter, y+ system) member 10
1554374_at	BC004940	naked cuticle homolog 2 (*Drosophila*)
1560303_at	AI813438	desmoglein 3 (pemphigus vulgaris antigen)
219468_s_at	AA496034	BAI1-associated protein 2-like 1
219875_s_at	NM_000558	hemoglobin, alpha 1 /// hemoglobin, alpha 2
225608_at	NM_006426	dihydropyrimidinase-like 4
200806_s_at	AB017332	aurora kinase C
201309_x_at	AK094809	Ras protein-specific guanine nucleotide-releasing factor 2
241013_at	BG291649	OCIA domain containing 2
1554586_a_at	AF332218	protocadherin 11 X-linked /// protocadherin 11 Y-linked
1553430_a_at	AF279900	minichromosome maintenance complex component 7
205019_s_at	NM_025243	solute carrier family 19, member 3
226955_at	AB011446	aurora kinase B
216458_at	AF136381	sorbin and SH3 domain containing 1
204347_at	AF229053	brevican
214240_at	AF336127	solute carrier family 4, sodium borate transporter, member 11
211656_x_at	BC006114	cholinergic receptor, nicotinic, alpha 3
204395_s_at	AI205764	chromosome 1 open reading frame 108
1554593_s_at	W92036	proprotein convertase subtilisin/kexin type 9
224097_s_at	AF199015	villin 2 (ezrin)
204890_s_at	NM_006891	crystallin, gamma D
219121_s_at	S76738	alkaline phosphatase, liver/bone/kidney
225063_at	BC038538	*Homo sapiens*, clone IMAGE: 5172739, mRNA
202874_s_at	NM_004994	matrix metallopeptidase 9 (gelatinase B, 92 kDa gelatinase, 92 kDa type IV collagenase)
1554199_at	AC007204	zinc finger protein 93
208206_s_at	BF509686	chromosome 8 open reading frame 42
1554261_at	AI939470	glutamate receptor, ionotropic, AMPA 2
1554752_a_at	BE671925	Transcribed locus
208868_s_at	NM_004252	solute carrier family 9 (sodium/hydrogen exchanger), member 3 regulator 1
234238_at	D88357	cell division cycle 2, G1 to S and G2 to M
235149_at	AC005587	similar to CTAGE family, member 5
215362_at	NM_018944	chromosome 21 open reading frame 45
212529_at	AI333651	frizzled homolog 7 (*Drosophila*)
1570266_x_at	AI830073	chromosome 1 open reading frame 88
202660_at	AI692696	Transcribed locus
202284_s_at	AL080057	MRNA; cDNA DKFZp564D032 (from clone DKFZp564D032)
209197_at	M29277	melanoma cell adhesion molecule
219463_at	NM_018891	laminin, gamma 2
219513_s_at	AF114817	zinc finger protein 589
202129_s_at	AL573851	endothelial cell adhesion molecule
223038_s_at	NM_002150	4-hydroxyphenylpyruvate dioxygenase
229230_at	N64686	chromosome 1 open reading frame 96
204281_at	NM_080923	protein tyrosine phosphatase, receptor type, C
219869_s_at	AW138134	PHD finger protein 17
210357_s_at	BG255416	KIAA0114
206119_at	AA921835	hypothetical protein LOC283501
206445_s_at	NM_004595	spermine synthase
201812_s_at	NM_000041	apolipoprotein E
206946_at	BC042986	CDNA clone IMAGE: 5296106
209774_x_at	NM_018139	chromosome 14 open reading frame 104
1554384_at	NM_000238	potassium voltage-gated channel, subfamily H (eag-related), member 2
209346_s_at	NM_024081	proline rich Gla (G-carboxyglutamic acid) 4 (transmembrane)
227641_at	NM_016629	tumor necrosis factor receptor superfamily, member 21
205748_s_at	AB020676	WW and C2 domain containing 1
208646_at	BF510581	BTB (POZ) domain containing 11
205861_at	BG164358	DEAD (Asp-Glu-Ala-Asp) box polypeptide 21
1557067_s_at	BC000729	A kinase (PRKA) anchor protein 1
227171_at	NM_018087	transmembrane protein 48
1558212_at	NM_018182	chromosome 17 open reading frame 63
227733_at	AV753544	phosphoglucomutase 2-like 1
231420_at	U85995	Bardet-Biedl syndrome 9
201538_s_at	NM_001444	fatty acid binding protein 5 (psoriasis-associated) /// similar to Fatty acid-binding

TABLE 15-continued

Table 15: Genes Expressed at a 5 fold or Greater Level in iPS Cell Lines versus both hES Cell Lines and Parental Fibroblasts ($p \leqq 0.01$)

Systematic Name	Genbank	Description
		protein, epidermal (E-FABP) (Psoriasis-associated fatty acid-binding protein homolog) (PA-FABP)
212457_at	AF095771	Bardet-Biedl syndrome 9
203163_at	NM_001786	cell division cycle 2, G1 to S and G2 to M
224334_s_at	AB055703	LIM homeobox 4
201946_s_at	AI829603	chromosome 13 open reading frame 3
205845_at	NM_018351	FYVE, RhoGEF and PH domain containing 6
210038_at	NM_025151	RAB11 family interacting protein 1 (class I)
213932_x_at	NM_025047	ADP-ribosylation factor-like 14
1562378_s_at	AI140752	ubiquitously transcribed tetratricopeptide repeat, X chromosome
214532_x_at	NM_017791	feline leukemia virus subgroup C cellular receptor family, member 2
1555788_a_at	NM_007196	kallikrein-related peptidase 8
242329_at	BE542381	methionyl-tRNA synthetase 2, mitochondrial
242387_at	NM_024785	family with sequence similarity 124B
222283_at	NM_021154	phosphoserine aminotransferase 1
226094_at	BE645821	cell adhesion molecule 4
239303_at	AI026919	Transcribed locus
227248_at	AI343600	Transcribed locus
206116_s_at	AK024583	keratin, hair, basic, 5
209464_at	AF289220	BCL2-like 12 (proline rich)
222701_s_at	BF513674	MRNA; cDNA DKFZp779C0742 (from clone DKFZp779C0742)
210091_s_at	BC002652	crumbs homolog 3 (*Drosophila*)
231715_s_at	NM_004741	nucleolar and coiled-body phosphoprotein 1
241172_at	NM_006086	tubulin, beta 3
210008_s_at	NM_002394	solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2
217644_s_at	AF426267	chromosome 21 open reading frame 88
230675_at	U49396	purinergic receptor P2X, ligand-gated ion channel, 5
65517_at	NM_005504	branched chain aminotransferase 1, cytosolic
222841_s_at	BC000258	tubulin, delta 1
210291_s_at	NM_014285	exosome component 2
239492_at	AI476267	zinc finger protein 195
200894_s_at	AI761824	zinc finger protein 398

TABLE 16

Table 16: Genes Expressed at a 5 fold or Greater Level in iPS Cell Lines versus hES Cell Lines ($p \leqq 0.01$), but not Significantly Different from Parental Fibroblasts ($p \geqq 0.05$)

Systematic Name	Genbank	Description
217211_at	D50604	similar to cytoplasmic beta-actin
231723_at	NM_013346	sorting nexin 12
228371_s_at	BF196007	—
215172_at	AL050040	protein tyrosine phosphatase, non-receptor type 20B /// protein tyrosine phosphatase, non-receptor type 20A
225088_at	BG546917	chromosome 16 open reading frame 63
223994_s_at	BC000154	solute carrier family 12 (potassium/chloride transporters), member 9
1554660_a_at	BC036200	chromosome 1 open reading frame 71
1554334_a_at	BC031044	DnaJ (Hsp40) homolog, subfamily A, member 4
1555197_a_at	AY039243	chromosome 21 open reading frame 58
220472_at	NM_014150	zinc finger, CCHC domain containing 4
213014_at	BG222394	mitogen-activated protein kinase 8 interacting protein 1
1554795_a_at	BC019895	filamin binding LIM protein 1
232132_at	AB043635	par-6 partitioning defective 6 homolog gamma (*C. elegans*)
206749_at	NM_001764	CD1b molecule
213426_s_at	AA150110	Caveolin 2
223318_s_at	BC004393	alkB, alkylation repair homolog 7 (*E. coli*)
221310_at	NM_004115	fibroblast growth factor 14
211513_s_at	AF172449	opioid growth factor receptor
211527_x_at	M27281	vascular endothelial growth factor A
1560154_a_at	AK026500	CDNA: FLJ22847 fis, clone KAIA686
205196_s_at	NM_001283	adaptor-related protein complex 1, sigma 1 subunit
200954_at	NM_001694	ATPase, H+ transporting, lysosomal 16 kDa, V0 subunit c
208067_x_at	NM_007125	ubiquitously transcribed tetratricopeptide repeat gene, Y-linked
224241_s_at	BC002350	—
200621_at	NM_004078	cysteine and glycine-rich protein 1
205095_s_at	NM_005177	ATPase, H+ transporting, lysosomal V0 subunit a1

TABLE 16-continued

Table 16: Genes Expressed at a 5 fold or Greater Level in iPS Cell Lines versus hES Cell Lines ($p \leqq 0.01$), but not Significantly Different from Parental Fibroblasts ($p \geqq 0.05$)

Systematic Name	Genbank	Description
222546_s_at	AW204755	EPS8-like 2
206832_s_at	NM_004186	sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3F
1552470_a_at	NM_148914	abhydrolase domain containing 11
220259_at	NM_024927	pleckstrin homology domain containing, family H (with MyTH4 domain) member 3
220426_at	NM_024059	chromosome 20 open reading frame 195
213597_s_at	BF002474	CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) small phosphatase-like
1555220_a_at	AB040820	aldo-keto reductase family 1, member C-like 2
219430_at	NM_020155	G protein-coupled receptor 137
233492_s_at	AC005587	olfactory receptor, family 2, subfamily A, member 4 /// olfactory receptor, family 2, subfamily A, member 7 /// similar to rho guanine nucleotide exchange factor 5
231146_at	AI300541	family with sequence similarity 24, member B
243936_x_at	T85061	—
232498_at	AK023386	hypothetical protein KIAA1833
211823_s_at	D86862	paxillin
231243_s_at	R93946	basic helix-loop-helix domain containing, class B, 3
235854_x_at	AA167669	Rho-associated, coiled-coil containing protein kinase 1
215634_at	AF007137	Clone 23618 mRNA sequence
226983_at	AA626717	zinc finger protein 777
1569076_a_at	BE791720	FLJ16287 protein
208894_at	M60334	major histocompatibility complex, class II, DR alpha
208430_s_at	NM_001390	dystrobrevin, alpha
210171_s_at	S68134	cAMP responsive element modulator
1552528_at	NM_058189	chromosome 21 open reading frame 69
1568905_at	BC030750	CDNA clone IMAGE: 4795773
214520_at	NM_005251	forkhead box C2 (MFH-1, mesenchyme forkhead 1)
217248_s_at	AL365343	solute carrier family 7 (cationic amino acid transporter, y+ system), member 8
1558214_s_at	BG330076	catenin (cadherin-associated protein), alpha 1, 102 kDa
213160_at	D86964	dedicator of cytokinesis 2
210978_s_at	BC002616	transgelin 2
214878_at	AU118165	zinc finger protein 37A /// zinc finger protein 37B
240703_s_at	AW591969	hect (homologous to the E6-AP (UBE3A) carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1
204698_at	NM_002201	interferon stimulated exonuclease gene 20 kDa
205822_s_at	NM_002130	3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 (soluble)
1558809_s_at	AK094324	hypothetical protein LOC284408
1569486_at	BC035176	CDNA clone IMAGE: 5266012
241168_at	AV651242	Transcribed locus
216205_s_at	AK021947	mitofusin 2
205810_s_at	NM_003941	Wiskott-Aldrich syndrome-like
206396_at	NM_004170	solute carrier family 1 (neuronal/epithelial high affinity glutamate transporter, system Xag), member 1
216710_x_at	AL359578	zinc finger protein 287
243323_s_at	AI872979	AT-binding transcription factor 1
229284_at	R60683	Methionine adenosyltransferase II, beta
238699_s_at	AI659225	calcium/calmodulin-dependent serine protein kinase (MAGUK family)
217767_at	NM_000064	similar to Complement C3 precursor
205924_at	BC005035	RAB3B, member RAS oncogene family
224301_x_at	BC003602	H2A histone family, member J
206932_at	NM_003956	cholesterol 25-hydroxylase
222419_x_at	AW205983	ubiquitin-conjugating enzyme E2H (UBC8 homolog, yeast)
216501_at	U25801	Vac14 homolog (*S. cerevisiae*)
233421_s_at	AU146738	nucleoporin 133 kDa
202627_s_at	AL574210	serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1
205867_at	NM_002834	protein tyrosine phosphatase, non-receptor type 11 (Noonan syndrome 1)
204480_s_at	NM_024112	chromosome 9 open reading frame 16
206026_s_at	NM_007115	tumor necrosis factor, alpha-induced protein 6
222678_s_at	BF057821	DCN1, defective in cullin neddylation 1, domain containing 1 (*S. cerevisiae*)
220246_at	NM_020397	calcium/calmodulin-dependent protein kinase ID
208677_s_at	AL550657	basigin (Ok blood group)
206997_s_at	NM_004807	heparan sulfate 6-O-sulfotransferase 1 /// similar to Heparan-sulfate 6-O-sulfotransferase 1 (HS6ST-1)
213807_x_at	BE870509	met proto-oncogene (hepatocyte growth factor receptor)
211187_at	AF118079	—
236940_at	W60647	Transcribed locus, weakly similar to NP_066953.1 isomerase A isoform 1 [*Homo sapiens*]
224505_s_at	BC006355	phospholipase C, delta 4
205210_at	NM_004257	transforming growth factor, beta receptor associated protein 1
206025_s_at	AW188198	tumor necrosis factor, alpha-induced protein 6

TABLE 16-continued

Table 16: Genes Expressed at a 5 fold or Greater Level in iPS Cell Lines versus hES Cell Lines ($p \leq 0.01$), but not Significantly Different from Parental Fibroblasts ($p \geq 0.05$)

Systematic Name	Genbank	Description
238461_at	AA228031	eukaryotic translation initiation factor 4E family member 3
224003_at	AF332243	testis-specific transcript, Y-linked 14
1553685_s_at	NM_138473	Sp1 transcription factor
1561039_a_at	BC039609	zinc finger protein 81
235136_at	BF337528	ORM1-like 3 (*S. cerevisiae*)
205117_at	X59065	fibroblast growth factor 1 (acidic)
213643_s_at	AK022846	inositol polyphosphate-5-phosphatase, 75 kDa
225322_s_at	AL514147	chromosome 17 open reading frame 70
232506_s_at	AK026504	chromosome 15 open reading frame 41
AFFX-r2-P1-cre-3_at	AFFX-TrpnX-5	—
221220_s_at	NM_017988	SCY1-like 2 (*S. cerevisiae*)
224127_at	AF116660	—
215876_at	AK022254	CDNA FLJ12192 fis, clone MAMMA1000851
205195_at	NM_001283	adaptor-related protein complex 1, sigma 1 subunit
1563809_a_at	AK094768	MCF.2 cell line derived transforming sequence-like
238480_at	AI871745	Chromosome 18 open reading frame 50
206673_at	NM_007223	G protein-coupled receptor 176
206100_at	NM_001874	carboxypeptidase M
231299_at	AI494590	centaurin, gamma 3
202793_at	NM_005768	membrane bound O-acyltransferase domain containing 5
205925_s_at	NM_002867	RAB3B, member RAS oncogene family
204522_at	NM_005510	dom-3 homolog Z (*C. elegans*)
233543_s_at	AK021582	coiled-coil domain containing 98
233573_s_at	AK001080	WD repeat domain 6
242552_x_at	AW274047	zinc finger, BED-type containing 5
232566_at	AK026258	nucleolar protein family 6 (RNA-associated)
202859_x_at	NM_000584	interleukin 8
231396_s_at	AA776721	family with sequence similarity 126, member A
1557637_at	BC038734	CDNA clone IMAGE: 5267718
232343_at	AK022200	CDNA FLJ12138 fis, clone MAMMA1000331
238025_at	AA706818	mixed lineage kinase domain-like
210256_s_at	U78576	phosphatidylinositol-4-phosphate 5-kinase, type I, alpha
239959_x_at	AI147520	—
227175_at	AI806486	Myeloid cell leukemia sequence 1 (BCL2-related)
223708_at	AF329838	C1q and tumor necrosis factor related protein 4
1554417_s_at	AY113699	anterior pharynx defective 1 homolog A (*C. elegans*)
217300_at	U80771	—
234688_x_at	AF141344	centrobin, centrosomal BRCA2 interacting protein
210935_s_at	AF274954	WD repeat domain 1
201048_x_at	NM_002869	RAB6A, member RAS oncogene family
209208_at	AF059752	mannose-P-dolichol utilization defect 1
219168_s_at	NM_017701	proline rich 5 (renal)
201045_s_at	BF513857	RAB6A, member RAS oncogene family /// RAB6C-like
219878_s_at	NM_015995	Kruppel-like factor 13
223143_s_at	AI742378	chromosome 6 open reading frame 166
212575_at	BF966155	chromosome 19 open reading frame 6
210930_s_at	AF177761	v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian)
217270_s_at	AC005393	dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1B
AFFX-r2-Ec-bioD-3_at	AFFX-ThrX-M	—
210994_x_at	AF230398	tripartite motif-containing 23
222511_x_at	AW140098	Fas (TNFRSF6) associated factor 1
208262_x_at	NM_000243	Mediterranean fever
AFFX-HSAC07/X00351_5_at	AFFX-HSAC07/X00351_5	actin, beta
AFFX-hum_alu_at	AFFX-r2-Bs-lys-M	—
237806_s_at	AI684717	Hypothetical protein LOC729296
211599_x_at	U19348	met proto-oncogene (hepatocyte growth factor receptor)
1554544_a_at	L18865	myelin basic protein
235913_at	AI285722	zinc finger-like
231957_s_at	AC005594	dipeptidyl-peptidase 9
210421_s_at	AB014602	solute carrier family 24 (sodium/potassium/calcium exchanger), member 1
243319_at	AI274981	Transcribed locus
220825_s_at	NM_018240	kin of IRRE like (*Drosophila*)
1563719_a_at	AK024924	CDNA: FLJ21271 fis, clone COL01751
234155_at	AK024928	CDNA: FLJ21275 fis, clone COL01827
213210_at	AI005317	TAF6-like RNA polymerase II, p300/CBP-associated factor (PCAF)-associated factor, 65 kDa
230257_s_at	AI264325	chromosome 1 open reading frame 19
236657_at	AW014647	Full length insert cDNA YI37C01

TABLE 16-continued

Table 16: Genes Expressed at a 5 fold or Greater Level in iPS Cell Lines versus hES Cell Lines ($p \leqq 0.01$), but not Significantly Different from Parental Fibroblasts ($p \geqq 0.05$)

Systematic Name	Genbank	Description
236771_at	AW511485	chromosome 6 open reading frame 159
1552649_a_at	NM_057178	ring finger and FYVE-like domain containing 1
225245_x_at	BG386566	H2A histone family, member J
228261_at	BE045549	mindbomb homolog 2 (*Drosophila*)
1566666_at	AK074225	CDNA FLJ23645 fis, clone COL02691
207686_s_at	NM_001228	caspase 8, apoptosis-related cysteine peptidase
224321_at	AB004064	transmembrane protein with EGF-like and two follistatin-like domains 2
201169_s_at	BG326045	basic helix-loop-helix domain containing, class B, 2
207678_s_at	NM_007017	SRY (sex determining region Y)-box 30
1555724_s_at	BC010946	transgelin
228901_at	AI040910	Cyclin-dependent kinase 9 (CDC2-related kinase)
223083_s_at	AW057545	egl nine homolog 2 (*C. elegans*)
1562080_at	AK057351	CDNA FLJ32789 fis, clone TESTI2002326
AFFX-r2-P1-cre-5_at	AFFX-TrpnX-M	—
210971_s_at	AB000815	aryl hydrocarbon receptor nuclear translocator-like
219298_at	NM_024693	enoyl Coenzyme A hydratase domain containing 3
222814_s_at	AI916361	zinc finger, HIT type 2
217246_s_at	L22650	diaphanous homolog 2 (*Drosophila*)
1560224_at	BF327463	AT hook containing transcription factor 1
217448_s_at	AL117508	TOX high mobility group box family member 4 /// similar to Epidermal Langerhans cell protein LCP1
200841_s_at	AI142677	glutamyl-prolyl-tRNA synthetase
211087_x_at	Z25432	mitogen-activated protein kinase 14
1552717_s_at	NM_153243	centrosomal protein 170 kDa /// centrosomal protein 170 kDa-like
241084_x_at	BF062339	dynein, cytoplasmic 1, heavy chain 1
1555559_s_at	AF419247	ubiquitin specific peptidase 25
203890_s_at	BF686824	death-associated protein kinase 3
223393_s_at	AL136805	teashirt zinc finger homeobox 3
224805_s_at	BF508824	chromosome 15 open reading frame 17
AFFX-LysX-M_at	AFFX-LysX-5	—
227071_at	AI762558	zinc finger protein 414
216788_at	AK025564	CDNA: FLJ21911 fis, clone HEP03855
205081_at	NM_001311	cysteine-rich protein 1 (intestinal)
203626_s_at	NM_005983	S-phase kinase-associated protein 2 (p45)
211613_s_at	U79250	glycerol-3-phosphate dehydrogenase 2 (mitochondrial)
219703_at	NM_018365	meiosis-specific nuclear structural 1
238420_at	AV721958	CDNA clone IMAGE: 5263531
205186_at	NM_003462	dynein, axonemal, light intermediate chain 1
214975_s_at	AK001816	myotubularin related protein 1
215585_at	AK024081	KIAA0174
204994_at	NM_002463	myxovirus (influenza virus) resistance 2 (mouse)
202017_at	NM_000120	epoxide hydrolase 1, microsomal (xenobiotic)
222509_s_at	BG490634	zinc finger protein 672
228683_s_at	AI925361	potassium channel tetramerisation domain containing 15
208978_at	U36190	cysteine-rich protein 2
243952_at	BF000009	TPTE pseudogene
235940_at	AW983691	chromosome 9 open reading frame 64
222085_at	AW452357	Hypothetical gene supported by AK075564; BC060873
229746_x_at	BF439451	*Homo sapiens*, clone IMAGE: 3885733, mRNA
1553219_a_at	NM_015365	Alport syndrome, mental retardation, midface hypoplasia and elliptocytosis chromosomal region, gene 1
1559028_at	BC037172	chromosome 21 open reading frame 15
205390_s_at	NM_000037	ankyrin 1, erythrocytic
1554988_at	BC042592	solute carrier family 9, member 11
205065_at	AU130282	—
1555569_a_at	BC042482	potassium channel tetramerisation domain containing 7
226632_at	AL513673	cytoglobin
210732_s_at	AF342816	lectin, galactoside-binding, soluble, 8 (galectin 8)
AFFX-r2-Bs-dap-3_at	AFFX-r2-Bs-phe-3	—
213087_s_at	BF690020	CDNA clone IMAGE: 4838699
221638_s_at	AF008937	syntaxin 16
213211_s_at	AI005317	TAF6-like RNA polymerase II, p300/CBP-associated factor (PCAF)-associated factor, 65 kDa
238848_at	BF750565	OTU domain containing 4
229328_at	T90358	Zinc finger protein 540
1553962_s_at	BI668074	ras homolog gene family, member B
238013_at	BF347859	pleckstrin homology domain containing, family A (phosphoinositide binding specific) member 2
205382_s_at	NM_001928	complement factor D (adipsin)
222711_s_at	AI761828	rhomboid 5 homolog 1 (*Drosophila*)
1567274_at	Z36814	—

TABLE 16-continued

Table 16: Genes Expressed at a 5 fold or Greater Level in iPS Cell Lines versus hES Cell Lines ($p \leqq 0.01$), but not Significantly Different from Parental Fibroblasts ($p \geqq 0.05$)

Systematic Name	Genbank	Description
224346_at	AF116671	—
219058_x_at	NM_022164	tubulointerstitial nephritis antigen-like 1
234939_s_at	AL161953	PHD finger protein 12
217524_x_at	AA018923	Transcribed locus
214190_x_at	AI799984	golgi associated, gamma adaptin ear containing, ARF binding protein 2
228208_x_at	AL134573	Hypothetical LOC645944
239664_at	H18857	Transcribed locus
237211_x_at	AA860341	MORN repeat containing 3
203402_at	AL520102	potassium voltage-gated channel, shaker-related subfamily, beta member 2
1555766_a_at	AF493870	guanine nucleotide binding protein (G protein), gamma 2
202873_at	BF034973	ATPase, H+ transporting, lysosomal 42 kDa, V1 subunit C1
205577_at	NM_005609	phosphorylase, glycogen; muscle (McArdle syndrome, glycogen storage disease type V)
213928_s_at	AI742626	HIV-1 Rev binding protein
200601_at	U48734	actinin, alpha 4
216549_s_at	AL096712	TBC1 domain family, member 22B
211564_s_at	BC003096	PDZ and LIM domain 4
221418_s_at	NM_005481	mediator complex subunit 16
210933_s_at	BC004908	fascin homolog 1, actin-bundling protein (*Strongylocentrotus purpuratus*)
210585_s_at	AF007748	transportin 2 (importin 3, karyopherin beta 2b)
203726_s_at	NM_000227	laminin, alpha 3
224795_x_at	AW575927	immunoglobulin kappa constant /// immunoglobulin kappa variable 1-5 /// immunoglobulin kappa variable 2-24
231354_at	AW510748	hypothetical LOC780529
AFFX-r2-Ec-bioC-5_at	AFFX-ThrX-5	—
1552367_a_at	AF276507	scinderin
201796_s_at	BE790854	valyl-tRNA synthetase
206847_s_at	AF026397	homeobox A7
225333_at	AI218383	zinc finger protein 496
211514_at	AF068286	receptor interacting protein kinase 5
1560316_s_at	N32168	glucocorticoid induced transcript 1
232315_at	AU149712	Zinc finger-like
221628_s_at	AF326966	cytokine-like nuclear factor n-pac
239623_at	N93197	hypothetical gene supported by AK126569
AFFX-DapX-5_at	AFFX-DapX-5	—
238542_at	AA831769	UL16 binding protein 2
200628_s_at	M61715	tryptophanyl-tRNA synthetase
231881_at	AU145225	caldesmon 1
233754_x_at	AC007228	zinc finger protein 71
61734_at	AI797684	reticulocalbin 3, EF-hand calcium binding domain
215955_x_at	Y10388	Rho GTPase activating protein 26
201979_s_at	NM_006247	protein phosphatase 5, catalytic subunit
213767_at	U43586	kinase suppressor of ras 1
87100_at	AI832249	abhydrolase domain containing 2
1562234_a_at	AF397731	neuron navigator 3 /// similar to neuron navigator 3
230309_at	BE876610	Transcribed locus
1558247_s_at	BC021210	hypothetical protein BC018697
205462_s_at	NM_002149	hippocalcin-like 1
221440_s_at	NM_006606	retinoblastoma binding protein 9
206488_s_at	NM_000072	CD36 molecule (thrombospondin receptor)
223661_at	AF130080	—
211019_s_at	D63807	lanosterol synthase (2,3-oxidosqualene-lanosterol cyclase)
211811_s_at	AF152484	protocadherin alpha 6
1562527_at	AF519622	hypothetical protein LOC283027
1569895_at	BC016994	Homo sapiens, clone IMAGE: 4401848, mRNA
231402_at	AI830201	Transcribed locus, strongly similar to XP_531081.2 hypothetical protein [*Pan troglodytes*]
1567105_at	AF362887	—
209555_s_at	M98399	CD36 molecule (thrombospondin receptor)
227137_at	N25937	Chromosome 10 open reading frame 46
212937_s_at	M20776	collagen, type VI, alpha 1
1560020_at	BC043583	DnaJ (Hsp40) homolog, subfamily C, member 13
214040_s_at	BE675337	gelsolin (amyloidosis, Finnish type)
201465_s_at	BC002646	jun oncogene
234625_at	AK025055	CDNA: FLJ21402 fis, clone COL03734
1554466_a_at	BC007207	chromosome 16 open reading frame 13
208721_s_at	BF967271	anaphase promoting complex subunit 5
213667_at	AB002307	Snf2-related CBP activator protein
231151_at	AL122010	discs, large (*Drosophila*) homolog-associated protein 3
1552610_a_at	NM_002227	Janus kinase 1 (a protein tyrosine kinase)
1565347_s_at	AY034078	transcription factor binding to IGHM enhancer 3

TABLE 16-continued

Table 16: Genes Expressed at a 5 fold or Greater Level in iPS Cell Lines versus hES Cell Lines ($p \leqq 0.01$), but not Significantly Different from Parental Fibroblasts ($p \geqq 0.05$)

Systematic Name	Genbank	Description
209261_s_at	BF000629	nuclear receptor subfamily 2, group F, member 6
AFFX-r2-Bs-dap-M_at	AFFX-r2-Bs-phe-M	—
242948_x_at	T97602	Transcribed locus
214300_s_at	AI676092	topoisomerase (DNA) III alpha
1556748_x_at	AI476341	CDNA FLJ39784 fis, clone SPLEN2002314
1562244_at	AL833487	MRNA; cDNA DKFZp686H1629 (from clone DKFZp686H1629)
244735_at	AI377758	coiled-coil domain containing 54
215581_s_at	AK022303	minichromosome maintenance complex component 3 associated protein
1555240_s_at	AF493879	guanine nucleotide binding protein (G protein), gamma 12
216971_s_at	Z54367	plectin 1, intermediate filament binding protein 500 kDa
234971_x_at	AI521584	phospholipase C, delta 3
212938_at	M20776	collagen, type VI, alpha 1
230404_at	AI418538	—
210298_x_at	AF098518	four and a half LIM domains 1
204952_at	NM_014400	LY6/PLAUR domain containing 3
232915_at	AW571715	DEAD (Asp-Glu-Ala-Asp) box polypeptide 49
243358_at	BF347362	insulin-like growth factor 1 receptor
225061_at	N45231	DnaJ (Hsp40) homolog, subfamily A, member 4
218154_at	NM_024736	gasdermin domain containing 1
203324_s_at	NM_001233	caveolin 2
1554757_a_at	AF273055	inositol polyphosphate-5-phosphatase, 40 kDa
242676_at	AA401733	Transcribed locus
1569039_s_at	BC029855	zinc finger protein 677
221048_x_at	NM_017941	chromosome 17 open reading frame 80
1553042_a_at	NM_032721	T-cell activation NFKB-like protein
218944_at	NM_023078	pyrroline-5-carboxylate reductase-like
204638_at	NM_001611	acid phosphatase 5, tartrate resistant
241611_s_at	BE675600	fibronectin type III domain containing 3A
222363_at	AW979018	Transcribed locus
201008_s_at	AA812232	thioredoxin interacting protein
224252_s_at	AF177940	FXYD domain containing ion transport regulator 5
225800_at	AI990891	JAZF zinc finger 1
240407_at	AW450035	*Homo sapiens*, clone IMAGE: 5171705, mRNA
200796_s_at	BF594446	myeloid cell leukemia sequence 1 (BCL2-related)
214992_s_at	AD000092	deoxyribonuclease II, lysosomal
209373_at	BC003179	mal, T-cell differentiation protein-like
212272_at	AA813260	lipin 1
242571_at	AW962020	RALBP1 associated Eps domain containing 2
215019_x_at	AW474158	zinc finger protein 528
211668_s_at	K03226	plasminogen activator, urokinase
204876_at	NM_014699	zinc finger protein 646
201167_x_at	D13989	Rho GDP dissociation inhibitor (GDI) alpha
211672_s_at	AF019888	actin related protein 2/3 complex, subunit 4, 20 kDa
212003_at	BG171020	chromosome 1 open reading frame 144
217465_at	AK001291	NCK-associated protein 1
236340_at	AI769947	Transcribed locus, strongly similar to XP_001146557.1 hypothetical protein [*Pan troglodytes*]
226504_at	AA522720	family with sequence similarity 109, member B
219899_x_at	NM_014434	NADPH dependent diflavin oxidoreductase 1
1567013_at	AF323119	nuclear factor (erythroid-derived 2)-like 2
203348_s_at	BF060791	ets variant gene 5 (ets-related molecule)
215315_at	AC003682	zinc finger protein 549
209062_x_at	AF010227	nuclear receptor coactivator 3
1555229_a_at	BC007010	complement component 1, s subcomponent
203508_at	NM_001066	tumor necrosis factor receptor superfamily, member 1B
217494_s_at	AF023139	phosphatase and tensin homolog (mutated in multiple advanced cancers 1), pseudogene 1
210362_x_at	AF230409	promyelocytic leukemia
201060_x_at	AI537887	stomatin
204560_at	NM_004117	FK506 binding protein 5
236574_at	AI304870	Hypothetical protein LOC284373
222542_x_at	BF724826	chaperone, ABC1 activity of bc1 complex homolog (*S. pombe*)
211162_x_at	AF116616	stearoyl-CoA desaturase (delta-9-desaturase)
203771_s_at	AA740186	biliverdin reductase A
217569_x_at	AA017093	—
240397_x_at	AI801626	Transcribed locus
207080_s_at	NM_004160	peptide YY
213695_at	L48516	paraoxonase 3
216591_s_at	AF080579	succinate dehydrogenase complex, subunit C, integral membrane protein, 15 kDa /// hCG1776980

TABLE 16-continued

Table 16: Genes Expressed at a 5 fold or Greater Level in iPS Cell Lines versus hES Cell Lines ($p \leq 0.01$), but not Significantly Different from Parental Fibroblasts ($p \geq 0.05$)

Systematic Name	Genbank	Description
1554464_a_at	BC008745	cartilage associated protein
201971_s_at	NM_001690	ATPase, H+ transporting, lysosomal 70 kDa, V1 subunit A
AFFX-r2-Bs-dap-5_at	AFFX-r2-Bs-phe-5	—
215337_at	AK022508	mediator complex subunit 24
227806_at	BG285710	chromosome 16 open reading frame 74
216271_x_at	AC004794	synapse defective 1, Rho GTPase, homolog 1 (*C. elegans*)
212113_at	AI927479	hypothetical LOC552889
230517_at	AI416964	similar to GLI-Kruppel family member HKR1
214123_s_at	AI126492	chromosome 4 open reading frame 10
219360_s_at	NM_017636	transient receptor potential cation channel, subfamily M, member 4
205715_at	NM_004334	bone marrow stromal cell antigen 1
1558775_s_at	AU142380	neutral sphingomyelinase (N-SMase) activation associated factor
1558423_at	BE715671	hypothetical LOC349114
218510_x_at	AI816291	family with sequence similarity 134, member B
205457_at	NM_024294	chromosome 6 open reading frame 106
214446_at	NM_012081	elongation factor, RNA polymerase II, 2
210449_x_at	AF100544	mitogen-activated protein kinase 14
1552667_a_at	NM_005489	SH2 domain containing 3C
205827_at	NM_000729	cholecystokinin
231004_s_at	BE219961	H1 histone family, member X
220102_at	NM_023067	forkhead box L2
222387_s_at	BG476669	vacuolar protein sorting 35 homolog (*S. cerevisiae*)
211708_s_at	BC005807	stearoyl-CoA desaturase (delta-9-desaturase)
207453_s_at	NM_012266	DnaJ (Hsp40) homolog, subfamily B, member 5
1568646_x_at	BC038199	zinc finger protein 208
210932_s_at	AF293342	ring finger protein (C3H2C3 type) 6
1559528_at	BC040652	Polycomb group ring finger 3
225454_at	AW248770	coiled-coil domain containing 124
230747_s_at	AA406435	Chromosome 18 open reading frame 17
202226_s_at	NM_016823	v-crk sarcoma virus CT10 oncogene homolog (avian)
228881_at	N30347	presenilin associated, rhomboid-like
238969_at	BF512162	chromosome 3 open reading frame 55
235234_at	AA359612	FLJ36874 protein
243409_at	AI005407	forkhead box L1
202465_at	NM_002593	procollagen C-endopeptidase enhancer
211124_s_at	AF119835	KIT ligand
200948_at	NM_005439	myeloid leukemia factor 2
204149_s_at	NM_000850	glutathione S-transferase M4
217371_s_at	Y09908	interleukin 15
218000_s_at	NM_007350	pleckstrin homology-like domain, family A, member 1
211272_s_at	AF064771	diacylglycerol kinase, alpha 80 kDa
211266_s_at	U35399	G protein-coupled receptor 4
205384_at	NM_005031	FXYD domain containing ion transport regulator 1 (phospholemman)
1553970_s_at	BC042510	carboxyl ester lipase (bile salt-stimulated lipase)
230146_s_at	BF111850	frequenin homolog (*Drosophila*)
1559409_a_at	BE893129	KIAA1345 protein
211561_x_at	L35253	mitogen-activated protein kinase 14
220585_at	NM_025130	hexokinase domain containing 1
234237_s_at	AL137611	hypothetical protein FLJ20294
243110_x_at	AI868441	neuropeptide W
214014_at	W81196	CDC42 effector protein (Rho GTPase binding) 2
215774_s_at	AV650470	—
203994_s_at	U84569	chromosome 21 open reading frame 2
227419_x_at	AW964972	placenta-specific 9
206531_at	NM_004647	D4, zinc and double PHD fingers family 1
208851_s_at	AL161958	Thy-1 cell surface antigen
201621_at	NM_005380	neuroblastoma, suppression of tumorigenicity 1
231341_at	BE670584	solute carrier family 35, member D3
214505_s_at	AF220153	four and a half LIM domains 1
211027_s_at	BC006231	inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta
201428_at	NM_001305	claudin 4
211317_s_at	AF041461	CASP8 and FADD-like apoptosis regulator
216926_s_at	AC003030	KIAA0892
221875_x_at	AW514210	major histocompatibility complex, class I, F
209213_at	BC002511	carbonyl reductase 1
1552914_a_at	NM_025240	CD276 molecule
211530_x_at	M90686	HLA-G histocompatibility antigen, class I, G
1558697_a_at	BI600341	KIAA0430
244852_at	AU119545	dermatan sulfate epimerase-like
226306_at	BF984592	chromosome 6 open reading frame 1
221943_x_at	AW303136	Ribosomal protein L38

TABLE 16-continued

Table 16: Genes Expressed at a 5 fold or Greater Level in iPS Cell Lines versus hES Cell Lines ($p \leqq 0.01$), but not Significantly Different from Parental Fibroblasts ($p \geqq 0.05$)

Systematic Name	Genbank	Description
204470_at	NM_001511	chemokine (C—X—C motif) ligand 1 (melanoma growth stimulating activity, alpha)
1552611_a_at	AL555086	Janus kinase 1 (a protein tyrosine kinase)
208879_x_at	BG469030	PRP6 pre-mRNA processing factor 6 homolog (*S. cerevisiae*)
209427_at	AF064238	smoothelin
1565162_s_at	D16947	microsomal glutathione S-transferase 1
227841_at	BG260181	Cementum protein 1
234773_x_at	AL442080	MRNA; cDNA DKFZp434A0226 (from clone DKFZp434A0226)
238750_at	AW083576	chemokine (C-C motif) ligand 28
228251_at	BE467577	UBX domain containing 1
206943_at	NM_004612	transforming growth factor, beta receptor I (activin A receptor type II-like kinase, 53 kDa)
226051_at	BF973568	selenoprotein M
202639_s_at	AI689052	RAN binding protein 3
200756_x_at	U67280	calumenin
217399_s_at	AF032887	forkhead box O3
1555730_a_at	D00682	cofilin 1 (non-muscle)
216831_s_at	AF018283	runt-related transcription factor 1; translocated to, 1 (cyclin D-related)
215719_x_at	X83493	Fas (TNF receptor superfamily, member 6)
233298_at	AL139377	spermatogenesis and oogenesis specific basic helix-loop-helix 2 /// hypothetical protein LOC728591
215495_s_at	AL117523	sterile alpha motif domain containing 4A
218537_at	NM_017885	host cell factor C1 regulator 1 (XPO1 dependent)
201367_s_at	AI356398	zinc finger protein 36, C3H type-like 2
223321_s_at	AF312678	fibroblast growth factor receptor-like 1
203676_at	NM_002076	glucosamine (N-acetyl)-6-sulfatase (Sanfilippo disease IIID)
AFFX-HUMISGF3A/M97935_5_at	AFFX-HUMISGF3A/M97935_5	signal transducer and activator of transcription 1, 91 kDa
232984_at	AL137259	hydrocephalus inducing homolog (mouse)
217601_at	AL523184	nucleoporin 188 kDa
238795_at	AA424537	chromosome 10 open reading frame 18
222385_x_at	AF346602	Sec61 alpha 1 subunit (*S. cerevisiae*)
214971_s_at	AV695711	ST6 beta-galactosamide alpha-2,6-sialyltranferase 1
202002_at	AW072302	acetyl-Coenzyme A acyltransferase 2 (mitochondrial 3-oxoacyl-Coenzyme A thiolase)
236491_at	AI813346	BCL2-like 10 (apoptosis facilitator)
231721_at	AF356518	junctional adhesion molecule 3
220234_at	NM_004056	carbonic anhydrase VIII
213548_s_at	BG257762	CDV3 homolog (mouse)
1554321_a_at	BC018471	NFS1 nitrogen fixation 1 homolog (*S. cerevisiae*)
231805_at	AL563031	prolactin releasing hormone receptor
1555006_at	BC036233	WD repeat domain 66
221889_at	AW026481	potassium channel tetramerisation domain containing 13
201156_s_at	AF141304	RAB5C, member RAS oncogene family
1554383_a_at	BC028121	translocation associated membrane protein 2
210079_x_at	U16953	potassium voltage-gated channel, shaker-related subfamily, beta member 1
219558_at	NM_024524	ATPase type 13A3
220889_s_at	NM_020178	carbonic anhydrase X
227488_at	AV728999	hypothetical protein MGC16121
221762_s_at	AL162458	chromosome 20 open reading frame 67
209727_at	M76477	GM2 ganglioside activator
76897_s_at	AA628140	FK506 binding protein 15, 133 kDa

TABLE 17

Human Oct3/4 Amino Acid Substitution Matrix
(Predictions Based on PMUT Analysis)

WT	Position		Number of Predicted Deleterious Mutations	Number of Predicted Neutral Mutations
M	1	M G A P V I L F S **C** T **N** Q H Y W D E **K** **R**	4	16
A	2	M G A **P** **V** **I** L **F** S C T **N** Q H **Y** **W** D E **K** **R**	9	11
G	3	M G A P **V** I L **F** S **C** T N Q H **Y** **W** D E **K** **R**	7	13

TABLE 17-continued

Human Oct3/4 Amino Acid Substitution Matrix
(Predictions Based on PMUT Analysis)

WT	Position		Number of Predicted Deleterious Mutations	Number of Predicted Neutral Mutations
H	4	M G **A** P V I L **F** S **C** T N Q H Y **W** D E **K** R	5	15
L	5	M G A P V I L F S **C** T **N** **Q** H **Y** **W** D E **K** R	6	14
A	6	**M** G A **P** **V** **I** **L** **F** S **C** T **N** **Q** H **Y** **W** **D** **E** **K** **R**	15	5
S	7	M G A P **V** I L **F** S C T N Q H Y **W** D E K **R**	4	16
D	8	M G A P **V** **I** L **F** S C T N Q H **Y** **W** D E K R	5	15
F	9	**M** G **A** **P** **V** I L F **S** **C** **T** **N** **Q** **H** Y **W** **D** **E** **K** **R**	15	5
A	10	M G A P **V** **I** **L** F S C T **N** **Q** H **Y** **W** **D** **E** **K** **R**	11	9
F	11	M G A **P** **V** I L F S **C** T **N** Q H Y W D E K **R**	5	15
S	12	M G A P **V** **I** L **F** S **C** T N Q H Y **W** D E **K** **R**	7	13
P	13	M G A P **V** **I** L F S **C** T N Q H **Y** W D E **K** R	5	15
P	14	M G A P **V** I L F S **C** T N **Q** H Y **W** D E **K** **R**	6	14
P	15	M G A P V I L F S C T N Q H Y **W** D E K **R**	2	18
G	16	M G A P **V** I L **F** S **C** **T** N Q H **Y** **W** **D** **E** **K** **R**	10	10
G	17	M G A P V I L **F** S C T N Q H **Y** **W** **D** E **K** **R**	6	14
G	18	**M** G A **P** **V** **I** L **F** S **C** **T** **N** Q **H** **Y** **W** **D** **E** **K** **R**	15	5
G	19	M G A P V I L **F** S C T **N** Q H Y **W** D **E** **K** **R**	6	14
D	20	M **G** **A** P V I L **F** S C T N Q H **Y** **W** D E **K** R	6	14
G	21	**M** G A **P** **V** I **L** **F** S **C** T **N** **Q** **H** **Y** **W** **D** **E** **K** **R**	14	6
P	22	M G A P **V** I L F S C T **N** Q H **Y** **W** D E **K** R	5	15
G	23	M G A P V I L F S C T N Q H Y **W** D **E** **K** **R**	4	16
G	24	M G **A** **P** V I L **F** S **C** T **N** **Q** **H** **Y** **W** **D** **E** **K** **R**	13	7
P	25	M G A P V I L F S C **T** N Q **H** Y **W** D E **K** **R**	5	15
E	26	M **G** A **P** V **I** L F **S** C T N Q H **Y** **W** D E **K** **R**	8	12
P	27	M **G** A P V **I** L F S C T **N** Q H Y **W** D E **K** **R**	6	14
G	28	M G A P **V** I L **F** S C T N Q H Y **W** **D** **E** **K** **R**	7	13
W	29	**M** **G** **A** **P** **V** I **L** F **S** **C** T **N** Q H **Y** W **D** **E** **K** **R**	14	6
V	30	M **G** A P V I L F S C T N Q H **Y** **W** **D** E **K** **R**	6	14
D	31	M **G** **A** P **V** **I** **L** **F** **S** C T **N** **Q** **H** Y **W** D E **K** **R**	13	7
P	32	M G A P V I L F S C T N Q H Y W D E **K** **R**	2	18
R	33	**M** **G** **A** **P** **V** **I** **L** F **S** **C** **T** N **Q** **H** Y **W** **D** **E** K R	15	5
T	34	M G A P V **I** **L** **F** S C T N Q H **Y** **W** D E **K** **R**	7	13
W	35	M **G** **A** **P** **V** I **L** F S **C** **T** **N** **Q** **H** **Y** W **D** **E** **K** **R**	15	5
L	36	M G A P V I L F S C **T** **N** Q H Y **W** D E **K** **R**	5	15
S	37	**M** G A **P** **V** **I** L **F** S **C** T N Q H **Y** **W** D **E** **K** **R**	11	9

TABLE 17-continued

Human Oct3/4 Amino Acid Substitution Matrix
(Predictions Based on PMUT Analysis)

WT	Position		Number of Predicted Deleterious Mutations	Number of Predicted Neutral Mutations
F	38	M G A P V I L F S C T **N** Q H Y W **D** E K **R**	3	17
Q	39	M **G** **A** **P** **V** **I** **L** F **S** **C** T **N** Q H Y **W** **D** E K R	11	9
G	40	**M** G A **P** V I L **F** S **C** T **N** **Q** H **Y** **W** **D** **E** **K** **R**	12	8
P	41	**M** G A P **V** I L **F** S C **T** N **Q** **H** **Y** **W** D E **K** **R**	10	10
P	42	M **G** A P **V** **I** **L** F S C T N **Q** **H** Y **W** D **E** **K** **R**	10	10
G	43	M G A P V **I** L **F** S **C** T **N** **Q** H **Y** **W** D **E** **K** **R**	10	10
G	44	M G A P V I L **F** S C T N Q H **Y** **W** D E **K** **R**	5	15
P	45	M **G** A P **V** **I** L **F** S C **T** **N** **Q** **H** Y **W** D E **K** **R**	11	9
G	46	M G A **P** **V** I L **F** S C T N Q H **Y** **W** D **E** **K** **R**	8	12
I	47	M G A P V I L F S C T **N** Q H Y **W** **D** E **K** **R**	5	15
G	48	M G A P V I L **F** S C T N Q H Y **W** D E **K** **R**	4	16
P	49	M **G** A P V I L F S C T N Q H Y **W** D E **K** **R**	4	16
G	50	M G A P V **I** L **F** S C T **N** **Q** H **Y** **W** **D** **E** **K** **R**	10	10
V	51	M G A P V I L F S C T N Q H Y **W** D E K **R**	2	18
G	52	M G A P V I L F S C T N Q H Y **W** D E K **R**	2	18
P	53	M G A P **V** **I** L F S C T N Q H **Y** W D E **K** **R**	5	15
G	54	M G A P V I L **F** S C T **N** Q H **Y** **W** **D** E **K** **R**	7	13
S	55	**M** G A P **V** I L **F** S C T N Q H **Y** **W** **D** E **K** **R**	8	12
E	56	**M** **G** A **P** V **I** L F **S** C T N Q H **Y** **W** D E **K** R	8	12
V	57	M G A P V I L F S **C** T N Q H **Y** **W** D E **K** **R**	5	15
W	58	**M** **G** **A** P **V** **I** **L** F **S** **C** **T** **N** Q H **Y** W D **E** **K** **R**	14	6
G	59	**M** G A P **V** I L **F** **S** **C** **T** **N** **Q** H **Y** **W** **D** **E** **K** **R**	14	6
I	60	M G A P V I L F S C T **N** Q H Y W D E **K** **R**	3	17
P	61	M G A P V I L F S **C** T N Q H **Y** **W** D E **K** **R**	5	15
P	62	M G A P **V** I L F S C T N Q H Y W D E **K** **R**	3	17
C	63	M G A P V I L F S C T N Q **H** **Y** **W** D E **K** **R**	5	15
P	64	M **G** A P **V** I L F S C T N Q **H** **Y** W D E **K** **R**	6	14
P	65	M G A P **V** I L F S C T N **Q** H Y W D E **K** **R**	4	16
P	66	**M** G A P **V** I L F S C T N **Q** H Y **W** D E **K** **R**	6	14
Y	67	M G A P **V** I L F S **C** **T** **N** Q H Y W **D** E **K** R	5	15
E	68	M **G** **A** **P** **V** **I** L F **S** C T N Q H Y **W** D E K R	7	13
F	69	M **G** A P **V** I L F S C T **N** Q H Y W D E K **R**	4	16
C	70	M G A P **V** **I** L **F** S C T N Q H Y **W** D E **K** **R**	6	14
G	71	M G A P V I L F S **C** T N Q H Y **W** D E K R	2	18

TABLE 17-continued

Human Oct3/4 Amino Acid Substitution Matrix
(Predictions Based on PMUT Analysis)

WT	Position		Number of Predicted Deleterious Mutations	Number of Predicted Neutral Mutations
G	72	**M** G A **P** **V** I **L** **F** **S** **C** **T** N **Q** H **Y** **W** **D** **E** **K** **R**	15	5
M	73	M **G** A P V I L F S **C** **T** **N** Q H Y W **D** **E** **K** **R**	8	12
A	74	**M** G A **P** **V** **I** L **F** S C T **N** **Q** H **Y** **W** **D** **E** **K** **R**	13	7
Y	75	M G A P V I L F S C T N Q H Y W D E K R	0	20
C	76	M G A P **V** **I** L F S C T N Q H **Y** **W** D E **K** **R**	6	14
G	77	M G A P **V** I L **F** S **C** T **N** **Q** H Y **W** D E **K** **R**	8	12
P	78	M G A P V I L F S C T N Q H **Y** W D E **K** **R**	3	17
Q	79	M G A P V **I** L F S C T N Q H Y W D E K R	1	19
V	80	M G A P V I L **F** S **C** T **N** Q H **Y** W D E **K** **R**	6	14
G	81	M G A P V I L **F** S C T N Q H **Y** **W** D E **K** **R**	5	15
V	82	M G A P V I L **F** S C T N Q H **Y** W D E **K** **R**	4	16
G	83	**M** G A P **V** **I** L **F** S **C** **T** **N** **Q** **H** **Y** **W** **D** **E** **K** **R**	15	5
L	84	M G A **P** V I L F S C T N Q H Y W D E K R	1	19
V	85	M G A P V I L F S C T N Q H **Y** **W** D E **K** **R**	4	16
P	86	M G A P V I L F S C T **N** **Q** **H** Y **W** D E **K** **R**	6	14
Q	87	M G **A** P V I L F S C T N Q H Y **W** D E K R	2	18
G	88	M G A **P** V I L **F** S **C** T **N** **Q** H **Y** **W** **D** **E** **K** **R**	11	9
G	89	**M** G A P V I L **F** S C T N Q **H** Y **W** D **E** **K** **R**	7	13
L	90	M G A P V I L F S C T N Q H Y W D E K R	0	20
E	91	M G **A** P V **I** L F **S** C T N Q H **Y** **W** D E K R	5	15
T	92	**M** **G** A P V **I** **L** **F** S C T N Q **H** **Y** **W** D E **K** **R**	10	10
S	93	**M** G A **P** **V** I L **F** S **C** T N **Q** **H** **Y** **W** D **E** **K** **R**	12	8
Q	94	M **G** **A** **P** V I **L** F S C T N Q H Y **W** D E K R	5	15
P	95	M G A P V I L F S **C** T N Q H **Y** **W** D E **K** **R**	5	15
E	96	**M** **G** **A** **P** V **I** L F **S** C T N Q H Y **W** D E **K** R	8	12
G	97	**M** G A P V I L **F** S C T **N** Q H **Y** **W** **D** E **K** **R**	8	12
E	98	**M** **G** **A** **P** **V** **I** L F **S** C T N Q H **Y** **W** D E **K** R	10	10
A	99	M G A **P** **V** I **L** **F** S C T **N** Q H **Y** **W** **D** **E** **K** **R**	11	9
G	100	**M** G A **P** V I L **F** S C T N Q H Y **W** **D** **E** **K** R	7	13
V	101	M G A P V I L F S C T N Q H Y W D E K R	0	20
G	102	M G A P **V** I L **F** S **C** T N Q **H** **Y** **W** D E **K** **R**	8	12
V	103	M G A P V I L F S **C** T N Q H **Y** **W** **D** E **K** **R**	6	14
E	104	**M** **G** **A** **P** V **I** L F **S** C T N Q H Y **W** D E **K** R	8	12
S	105	M G A **P** **V** I L **F** S **C** T N Q H **Y** **W** **D** **E** **K** **R**	10	10

TABLE 17-continued

Human Oct3/4 Amino Acid Substitution Matrix
(Predictions Based on PMUT Analysis)

WT	Position		Number of Predicted Deleterious Mutations	Number of Predicted Neutral Mutations
N	106	M **G** **A** P V **I** L **F** S C T N Q H **Y** **W** D E K R	6	14
S	107	**M** G A **P** **V** **I** **L** **F** S **C** T N **Q** **H** **Y** **W** **D** **E** **K** **R**	15	5
D	108	M **G** A P V I L F S C T N Q **H** Y **W** D E K R	4	16
G	109	M G A P V I L F S C T N Q H Y **W** D E K R	1	19
A	110	M G A **P** **V** I L **F** S C T N **Q** **H** **Y** **W** **D** **E** **K** **R**	11	9
S	111	M G A P V I L **F** S C T N **Q** H Y **W** D E **K** **R**	5	15
P	112	M G A P V I L F S C T N Q **H** Y W D E K **R**	2	18
E	113	**M** G A **P** V **I** L F **S** C T N Q H **Y** **W** D E K R	6	14
P	114	M G A P **V** I L F S C T **N** Q **H** **Y** W D E **K** **R**	6	14
C	115	M G A **P** **V** **I** L **F** S C T N Q **H** **Y** **W** D E **K** **R**	9	11
T	116	**M** **G** A P V I L **F** S C T N Q **H** Y **W** D E K **R**	6	14
V	117	M G A P V I L F S C T N Q **H** **Y** **W** D E **K** R	4	16
T	118	**M** G A P V **I** L **F** S C T N Q H **Y** **W** D E **K** **R**	7	13
P	119	M **G** A P V I L F S C T N Q H **Y** W D E **K** **R**	4	16
G	120	M G A P **V** I L **F** S **C** T **N** **Q** **H** **Y** **W** **D** **E** **K** **R**	12	8
A	121	**M** G A **P** V **I** **L** **F** S C T **N** **Q** **H** **Y** **W** **D** **E** **K** **R**	14	6
V	122	M G A P V I L **F** S C T **N** Q H **Y** W D E **K** **R**	5	15
K	123	**M** **G** **A** **P** **V** **I** L **F** **S** **C** **T** N Q H **Y** **W** **D** E K R	13	7
L	124	M G A P V I L F S C **T** **N** Q **H** **Y** **W** D **E** **K** **R**	8	12
E	125	M G A P V I L **F** **S** C T N Q H Y **W** D E **K** R	4	16
K	126	M **G** **A** **P** **V** **I** L F **S** C **T** N Q H **Y** **W** **D** E K R	10	10
E	127	**M** **G** **A** **P** V **I** **L** F **S** C T N Q H Y **W** D E K R	8	12
K	128	**M** **G** **A** **P** **V** I **L** **F** **S** C **T** N Q H **Y** **W** **D** E K R	12	8
L	129	M G A **P** V I L F S C T N Q H Y **W** D E **K** R	3	17
E	130	M **G** **A** **P** V **I** L F **S** C T N Q H **Y** **W** D E **K** R	8	12
Q	131	M **G** **A** **P** V I **L** F **S** **C** **T** **N** Q H Y **W** D E **K** R	10	10
N	132	**M** **G** A P V I L **F** S C T N Q H **Y** **W** D E K R	5	15
P	133	M G A P V I L **F** S **C** **T** **N** **Q** H Y W D **E** **K** **R**	7	13
E	134	**M** **G** **A** **P** V **I** L F **S** C T N Q H **Y** **W** D E **K** R	9	11
E	135	**M** **G** **A** **P** **V** **I** L F **S** C T N Q H **Y** **W** D E **K** R	10	10
S	136	**M** G A **P** **V** I L **F** S C T N **Q** **H** **Y** **W** D **E** **K** **R**	11	9
Q	137	M **G** **A** **P** V **I** **L** F **S** C T N Q H Y **W** D E K R	7	13
D	138	M **G** A P V I L **F** S C T N Q H **Y** **W** D E K R	4	16
I	139	M G A P V I L F S C T **N** Q H Y W **D** E **K** R	4	16

TABLE 17-continued

Human Oct3/4 Amino Acid Substitution Matrix
(Predictions Based on PMUT Analysis)

WT	Position		Number of Predicted Deleterious Mutations	Number of Predicted Neutral Mutations
K	140	M **G** **A** **P** **V** **I** L **F** **S** **C** **T** N Q **H** **Y** **W** **D** E K R	13	7
A	141	**M** G A **P** V **I** **L** **F** S C T **N** **Q** **H** **Y** W D E K R	9	11
L	142	M G A P V I L F S C T N Q H Y W **D** E **K** R	2	18
Q	143	M **G** **A** **P** V I **L** F **S** **C** **T** N Q H Y **W** **D** E K R	9	11
K	144	**M** **G** **A** **P** **V** **I** **L** F **S** C **T** N Q H **Y** **W** **D** E K R	12	8
E	145	**M** **G** **A** **P** V **I** L F **S** C T N Q H **Y** **W** D E **K** R	9	11
L	146	M G A P V I L F **S** C T N Q H Y **W** D E K R	2	18
E	147	M **G** **A** **P** V **I** **L** **F** **S** C T N Q H **Y** **W** D E K R	9	11
Q	148	M **G** **A** **P** **V** **I** **L** F **S** C **T** N Q **H** Y **W** **D** E **K** R	12	8
F	149	M **G** **A** **P** V I L F **S** C T **N** Q **H** Y W **D** E K **R**	8	12
A	150	M G A **P** **V** **I** L **F** S C T **N** **Q** **H** **Y** **W** **D** **E** **K** **R**	13	7
K	151	M **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** N **Q** **H** **Y** **W** **D** **E** K R	16	4
L	152	M G A P V I L F **S** C T **N** **Q** H Y W **D** E **K** R	5	15
L	153	M G A **P** V I L F S C T **N** Q H Y **W** **D** E **K** R	5	15
K	154	**M** **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** N **Q** **H** **Y** **W** **D** **E** K R	17	3
Q	155	M **G** **A** **P** V I **L** F **S** **C** **T** N Q H Y **W** D E **K** R	9	11
K	156	**M** **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** N **Q** H **Y** **W** **D** **E** K R	16	4
R	157	**M** **G** **A** **P** **V** **I** **L** F **S** **C** **T** **N** **Q** **H** Y **W** **D** **E** K R	16	4
I	158	M G A P V I L F S **C** T **N** Q H Y **W** **D** **E** **K** **R**	7	13
T	159	M **G** A P V **I** L **F** S C T N **Q** H **Y** **W** D E **K** **R**	8	12
L	160	M G A P V I L F S C T N Q H Y W **D** E **K** **R**	3	17
G	161	M G A P V I L F S C T N Q H Y **W** **D** E K **R**	3	17
Y	162	M **G** **A** **P** **V** **I** L F S C **T** **N** Q H Y W D **E** **K** R	9	11
T	163	**M** **G** A P V **I** **L** **F** S C T N **Q** **H** **Y** **W** D E **K** **R**	11	9
Q	164	M **G** **A** **P** **V** **I** **L** F **S** **C** **T** **N** Q H Y **W** **D** E K **R**	13	7
A	165	M G A **P** V I **L** F S C T N Q H **Y** **W** **D** E **K** R	6	14
D	166	**M** G A P V I **L** **F** S C T N Q H **Y** **W** D E **K** R	6	14
V	167	M **G** A **P** V I L **F** **S** **C** **T** **N** Q **H** **Y** **W** **D** **E** **K** **R**	13	7
G	168	M G A P **V** **I** **L** **F** **S** **C** **T** **N** **Q** **H** **Y** **W** **D** **E** **K** **R**	17	3
L	169	M G A P V I L F S C T **N** Q H Y W D E K R	1	19
T	170	**M** **G** A P V **I** **L** **F** S C T N **Q** H **Y** **W** D **E** **K** **R**	11	9
L	171	M G A P V I L F S C T N Q H Y W D E **K** R	1	19
G	172	M G A **P** V I L **F** S **C** T **N** **Q** H Y **W** D E **K** **R**	8	12
V	173	M G A P V I L F S C T **N** Q H **Y** W D E **K** **R**	4	16

TABLE 17-continued

Human Oct3/4 Amino Acid Substitution Matrix
(Predictions Based on PMUT Analysis)

WT	Position		Number of Predicted Deleterious Mutations	Number of Predicted Neutral Mutations
L	174	M G A P V I L F S C T N Q H Y **W** D E **K** R	2	18
F	175	M G A P V I L F **S** **C** T **N** Q **H** Y W D E K **R**	5	15
G	176	M G A **P** V I L **F** **S** **C** **T** **N** **Q** H **Y** **W** **D** **E** **K** **R**	13	7
K	177	**M** **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** N Q H **Y** **W** **D** **E** K R	15	5
V	178	M G A P V I L **F** S C T **N** Q H **Y** W **D** **E** **K** **R**	7	13
F	179	M **G** A **P** V **I** L F **S** **C** **T** **N** Q H Y W D E K **R**	8	12
S	180	**M** G A **P** V **I** **L** **F** S **C** T N Q H **Y** **W** **D** **E** **K** **R**	12	8
Q	181	M **G** **A** **P** **V** **I** **L** F **S** **C** **T** **N** Q **H** Y **W** D E **K** R	14	6
T	182	**M** **G** A P V **I** **L** **F** S C T N **Q** H **Y** **W** D **E** **K** **R**	11	9
T	183	M **G** A P V **I** **L** **F** S C T **N** Q H **Y** **W** D E **K** **R**	9	11
I	184	M G A P V I L F **S** **C** **T** **N** Q H **Y** **W** **D** E **K** **R**	9	11
C	185	**M** **G** A **P** **V** **I** **L** **F** **S** C T **N** **Q** **H** **Y** **W** **D** **E** **K** **R**	17	3
R	186	**M** **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** **N** **Q** **H** Y **W** **D** E K **R**	17	3
F	187	M **G** **A** **P** V I **L** F **S** **C** **T** **N** **Q** **H** Y W **D** E **K** **R**	13	7
E	188	**M** **G** **A** **P** V **I** **L** **F** **S** C **T** **N** Q H **Y** **W** D E **K** R	13	7
A	189	M G A **P** V I **L** **F** S C **T** **N** Q **H** **Y** **W** **D** **E** **K** **R**	11	9
L	190	M G A P V I L F S C T **N** Q H Y W D E **K** R	2	18
Q	191	**M** **G** **A** **P** V **I** **L** F **S** C **T** **N** Q H Y **W** **D** E **K** **R**	13	7
L	192	M G A P V I L F S C T **N** **Q** H Y W **D** E K **R**	4	16
S	193	M G A **P** V **I** L **F** S C T N **Q** H **Y** **W** **D** **E** **K** **R**	10	10
F	194	M G **A** P V **I** L F **S** C **T** N Q H Y W **D** **E** K **R**	7	13
K	195	**M** **G** **A** **P** **V** **I** **L** **F** **S** C **T** N **Q** H **Y** **W** **D** **E** K R	15	5
N	196	**M** **G** **A** **P** **V** **I** **L** **F** S **C** T N **Q** **H** **Y** **W** D **E** **K** **R**	16	4
M	197	M **G** **A** **P** V I L F **S** **C** **T** **N** Q H Y **W** **D** **E** **K** **R**	12	8
C	198	**M** **G** A **P** **V** **I** L **F** **S** C T **N** Q **H** **Y** **W** **D** E **K** **R**	14	6
K	199	M **G** **A** **P** **V** I L F **S** **C** **T** N Q H **Y** **W** D E K R	9	11
L	200	M **G** **A** **P** V I L F **S** **C** **T** **N** **Q** H Y **W** **D** **E** **K** **R**	12	8
R	201	**M** **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** **N** **Q** **H** **Y** **W** **D** **E** K R	18	2
P	202	**M** **G** **A** P **V** I **L** **F** **S** C **T** **N** **Q** **H** **Y** **W** D **E** **K** **R**	16	4
L	203	M **G** A P V I L F S C **T** N **Q** H **Y** **W** **D** E **K** **R**	8	12
L	204	M **G** A P V I L **F** S C **T** **N** **Q** H **Y** **W** **D** E **K** R	9	11
Q	205	M **G** **A** P V **I** **L** F **S** C T N Q H Y **W** D E K R	6	14
K	206	M **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** N **Q** H **Y** **W** **D** **E** K R	15	5
W	207	**M** **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** **N** **Q** **H** Y W **D** **E** **K** **R**	18	2

TABLE 17-continued

Human Oct3/4 Amino Acid Substitution Matrix
(Predictions Based on PMUT Analysis)

WT	Position		Number of Predicted Deleterious Mutations	Number of Predicted Neutral Mutations
V	208	M G A **P** V I L **F S C T N** Q **H Y W D E K R**	13	7
E	209	**M** G **A P V I L F S C** T N Q H **Y W** D E **K** R	12	8
E	210	**M G A P V I L F S C T N** Q H **Y W** D E **K R**	16	4
A	211	**M G** A **P V I L F** S C **T N Q H Y W D E K R**	17	3
D	212	**M G A** P **V I L F** S C T N **Q H Y W** D E **K** R	12	8
N	213	**M G A P V I L F** S C T N **Q H Y W** D **E K R**	15	5
N	214	**M G** A P V **I L F** S C T N Q H **Y W** D E **K** R	8	12
E	215	M **G** A P V **I** L F **S** C T N Q H Y **W** D E **K** R	5	15
N	216	**M G A P V I L F** S **C T N Q H** Y **W D E K R**	18	2
L	217	M **G A P** V I L F **S** C T **N Q H** Y **W** D E **K R**	10	10
Q	218	M **G A** P **V I L** F **S C T N** Q H Y **W D** E **K** R	12	8
E	219	M G **A P** V **I** L F S C T N Q H Y **W** D E **K** R	5	15
I	220	M **G A** P V I L **F S C T N** Q H **Y** W **D E K R**	12	8
C	221	**M G** A **P V I L F S** C T **N Q H Y W D E K R**	17	3
K	222	M **G A P V I L F S** C **T** N **Q** H **Y W D** E K R	13	7
A	223	M G A P V I L **F** S C T N Q H **Y W D E** K **R**	6	14
E	224	**M G A P** V **I L F S** C **T** N Q H **Y W** D E **K R**	13	7
T	225	M **G** A P V **I L F** S C T N **Q H Y W** D **E K R**	11	9
L	226	M G **A P** V I L F S C T **N** Q H Y **W D** E **K R**	7	13
V	227	M **G** A P V I L F S C T **N** Q H Y W **D E K R**	6	14
Q	228	**M G A P V I L F S C T N** Q **H Y W** D E **K R**	18	2
A	229	**M** G A **P V I L F** S C T **N Q H Y W D E K R**	15	5
R	230	**M G A P V I L F S C T N Q H Y W D E** K R	18	2
K	231	M **G A P V I L F S** C **T** N **Q** H **Y W D E** K R	14	6
R	232	**M G A P V I L F S C T N Q H Y W D E** K R	18	2
K	233	M **G A P V I** L F **S C** T N Q H Y **W** D E K R	8	12
R	234	**M G A P V I L F S C T N Q H Y W D E** K R	18	2
T	235	**M G** A P V **I L F** S C T **N Q** H **Y W** D E **K R**	11	9
S	236	**M G** A **P V I L F** S **C** T N **Q H Y W** D **E K R**	15	5
I	237	M **G A** P V I L F **S C T N Q** H **Y W D E K R**	13	7
E	238	M **G A** P V **I L F** S **C** T N Q H **Y W** D E **K** R	9	11
N	239	**M G A P V I L F** S C T N **Q** H **Y W** D **E K R**	14	6
R	240	**M G A P V I L F S C T N Q H Y W D E** K R	18	2
V	241	M G A P V I L **F S** C T **N Q H Y W D E K R**	11	9

TABLE 17-continued

Human Oct3/4 Amino Acid Substitution Matrix
(Predictions Based on PMUT Analysis)

WT	Position		Number of Predicted Deleterious Mutations	Number of Predicted Neutral Mutations
R	242	**M G A P V I L F S C T N Q H Y W D E** K R	18	2
G	243	**M** G **A** P **V I L F** S **C T N Q** H **Y W** D **E K R**	15	5
N	244	**M G A P V I L F S C T** N **Q H Y W D E K R**	19	1
L	245	M G A **P** V I L F **S** C **T N** Q H **Y W D E K R**	10	10
E	246	**M G A P** V **I L F S C T** N Q H **Y W** D E K **R**	13	7
N	247	**M G A P V I L F** S **C T** N Q **H Y W** D **E K R**	16	4
L	248	M **G** A **P** V I L F **S** C T **N Q** H Y **W** D E **K R**	9	11
F	249	M **G A P V I L** F **S C T N Q H** Y **W D E** K **R**	16	4
L	250	M **G A P V** I L **F S C T N Q H Y W D E K R**	16	4
Q	251	**M G A P V I L F S C T N** Q **H Y W** D E **K R**	18	2
C	252	**M G** A **P V I L F S** C T **N Q H Y W** D **E K R**	16	4
P	253	**M G A** P **V I L F S C** T **N Q H Y W** D **E K R**	17	3
K	254	M **G A P** V **I L F S** C **T** N Q H Y **W D E** K R	11	9
P	255	M **G** A P **V I L F S C T N Q H Y W** D **E K R**	16	4
T	256	**M G** A **P V I L F** S C T **N Q H Y W** D **E K R**	15	5
L	257	M G **A** P V I L F **S** C T **N Q** H Y **W D E K R**	9	11
Q	258	**M G A P V I L F S C T N** Q **H Y W** D E **K R**	18	2
Q	259	**M G A P V I L F S** C **T N** Q H **Y W** D E **K R**	15	5
I	260	M **G A P** V I L F **S C T N Q** H **Y W D E K R**	14	6
S	261	**M** G A **P V I L F S C** T **N Q H Y W** D E **K R**	15	5
H	262	**M G A P V I L F S C T N Q** H **Y W D E K R**	18	2
I	263	M **G A P** V I L F **S C T N** Q H **Y W D E K R**	13	7
A	264	**M** G A **P V I L F** S C T **N Q H Y W D E K R**	15	5
Q	265	M G **A P** V **I L F S** C **T** N Q H Y **W** D E **K** R	9	11
Q	266	**M G A P V I L F S C T N** Q **H Y W** D E **K R**	18	2
L	267	M **G A P V** I L F **S** C **T N Q H** Y **W D E K R**	14	6
G	268	**M** G A **P V I L F** S **C T N Q H Y W D E K R**	17	3
L	269	M **G** A **P V** I L F **S** C **T N** Q H **Y W D E K R**	11	9
E	270	**M G A P V I L F S C T N** Q H **Y W** D E **K R**	16	4
K	271	M **G A P V I L F S C T** N **Q** H **Y W D** E K R	14	6
D	272	**M G A P V I L F S** C T N **Q H Y W** D E **K R**	15	5
V	273	M **G** A **P** V I **L F S C** T **N Q H Y W D E K R**	15	5
V	274	M **G A P** V I L **F S C T N Q H Y W D E K R**	16	4
R	275	**M G A P V I L F S C T N Q H Y W D E** K R	18	2

TABLE 17-continued

Human Oct3/4 Amino Acid Substitution Matrix
(Predictions Based on PMUT Analysis)

WT	Position		Number of Predicted Deleterious Mutations	Number of Predicted Neutral Mutations
V	276	**M G A P** V I L **F S C T N Q H Y W D E K R**	17	3
W	277	**M G A P V I L F S C T N Q H Y** W **D E K R**	19	1
F	278	**M G A P V I L** F **S C T N Q H** Y **W D E K R**	18	2
C	279	**M G A P V I L F S** C **T N Q H Y W D E K R**	19	1
N	280	**M G A P V I L F S C T** N **Q H Y** W D **E K R**	18	2
R	281	**M G A P V I L F S C T N Q H Y W D E** K R	18	2
R	282	**M G A P V I L F S C T** N Q H Y **W D** E K R	13	7
Q	283	**M G A P V I L F S C T N** Q **H Y W D E K R**	18	2
K	284	M **G A P V I L F S C T** N Q H Y **W** D E K R	11	9
G	285	**M** G **A P V I L F** S **C T N Q H Y W D E K R**	18	2
K	286	M **G A P V I L F S C T** N Q H **Y W** D E K R	12	8
R	287	**M G A P V I L F S C T N Q H Y W D E** K R	18	2
S	288	**M G** A **P V I L F** S **C** T N **Q H Y W** D **E K R**	15	5
S	289	**M** G A **P V I L F** S **C** T N Q **H Y W** D **E K R**	13	7
S	290	**M** G A **P V I L F** S **C** T N **Q H Y W D E K R**	15	5
D	291	**M G A P V I L F** S C T N Q **H Y W** D E **K R**	13	7
Y	292	**M G A P V I L** F **S C T N Q H** Y W **D E K R**	17	3
A	293	**M G** A **P V I L F** S C T **N Q H Y W D E K R**	16	4
Q	294	**M G A P V I L F S C T** N Q **H Y W D** E **K R**	18	2
R	295	**M G A P V I L F S C T N Q H Y W D E** K R	18	2
E	296	**M G A P V I L F S C T N** Q **H Y W** D E **K R**	17	3
D	297	**M G A P V I L F** S C T **N Q H Y W** D E **K R**	15	5
F	298	M **G A P V I** L F **S C T N Q H Y W D E** K **R**	14	6
E	299	**M** G A **P** V **I L F** S C T N Q H **Y W** D E K R	7	13
A	300	**M** G A **P V I L F** S C **T N Q H Y W D E K R**	16	4
A	301	**M** G A **P V I L F** S C T **N Q H Y W D E K R**	15	5
G	302	**M** G **A P V I L F S C T N Q H Y W D E K R**	19	1
S	303	**M G** A **P V I L F** S **C** T N **Q H Y W** D **E K R**	15	5
P	304	**M G** A P **V I L F** S **C** T **N Q H Y W** D E **K R**	14	6
F	305	M **G A P V I L** F **S C T N Q H** Y W **D E K R**	16	4
S	306	M G A P **V I L F** S C T N Q H **Y W** D E K **R**	7	13
G	307	**M** G **A P V I L F S C T** N **Q H Y W D E K R**	18	2
G	308	**M** G **A P V I L F S C T N Q H Y W D E K R**	19	1
P	309	**M G A** P **V I L F S C T N Q H Y W** D **E K R**	17	3

TABLE 17-continued

Human Oct3/4 Amino Acid Substitution Matrix
(Predictions Based on PMUT Analysis)

WT	Position		Number of Predicted Deleterious Mutations	Number of Predicted Neutral Mutations
V	310	M **G** **A** **P** V I L **F** **S** **C** **T** **N** **Q** **H** **Y** **W** **D** **E** **K** **R**	16	4
S	311	**M** G A **P** **V** **I** **L** **F** S **C** T N **Q** **H** **Y** **W** D **E** **K** **R**	14	6
F	312	**M** **G** **A** **P** **V** **I** **L** F **S** **C** **T** **N** **Q** **H** Y **W** **D** **E** **K** **R**	18	2
P	313	**M** **G** **A** P **V** **I** **L** **F** **S** **C** **T** **N** **Q** **H** **Y** **W** D **E** **K** **R**	18	2
L	314	M **G** **A** **P** **V** I L **F** **S** C T **N** **Q** H Y **W** **D** **E** **K** **R**	12	8
A	315	**M** **G** A **P** **V** **I** **L** **F** **S** C T **N** **Q** **H** **Y** **W** **D** **E** **K** **R**	17	3
P	316	**M** **G** **A** P **V** **I** **L** **F** **S** **C** **T** **N** **Q** **H** **Y** **W** D **E** **K** **R**	18	2
G	317	**M** G **A** **P** **V** **I** **L** **F** **S** **C** **T** **N** **Q** **H** **Y** **W** **D** **E** **K** **R**	19	1
P	318	**M** **G** **A** P **V** **I** **L** **F** **S** **C** **T** **N** **Q** **H** **Y** **W** D **E** **K** **R**	18	2.
H	319	**M** **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** N **Q** H **Y** **W** **D** **E** **K** **R**	18	2
F	320	**M** **G** **A** **P** **V** **I** **L** F **S** **C** **T** **N** **Q** **H** Y **W** **D** **E** **K** **R**	18	2
G	321	**M** G **A** **P** **V** **I** **L** **F** S **C** **T** **N** **Q** **H** **Y** **W** **D** **E** **K** **R**	18	2
T	322	**M** **G** **A** **P** V **I** **L** **F** S C T **N** **Q** **H** **Y** **W** D E **K** **R**	14	6
P	323	**M** **G** **A** P **V** **I** **L** **F** **S** **C** **T** **N** **Q** **H** **Y** **W** D **E** **K** **R**	18	2
G	324	**M** G **A** **P** **V** **I** **L** **F** S **C** **T** N **Q** **H** **Y** **W** **D** **E** **K** **R**	17	3
Y	325	**M** **G** **A** **P** **V** **I** **L** F **S** **C** **T** **N** **Q** H Y W **D** **E** **K** **R**	16	4
G	326	**M** G **A** **P** **V** **I** **L** **F** **S** **C** **T** **N** **Q** **H** **Y** **W** **D** **E** **K** **R**	19	1
S	327	**M** **G** A **P** **V** **I** **L** **F** S **C** T N **Q** **H** **Y** **W** D **E** **K** **R**	15	5
P	328	**M** **G** **A** P **V** **I** **L** **F** **S** **C** **T** **N** **Q** **H** **Y** **W** D **E** **K** **R**	18	2
H	329	**M** **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** N **Q** H **Y** **W** **D** **E** **K** **R**	18	2
F	330	M **G** **A** **P** **V** **I** **L** F **S** **C** **T** **N** **Q** **H** Y **W** **D** **E** K **R**	16	4
T	331	**M** **G** **A** **P** **V** **I** **L** **F** S C T **N** **Q** **H** **Y** **W** **D** **E** **K** **R**	17	3
A	332	**M** G A **P** V **I** **L** **F** S C T **N** **Q** **H** **Y** **W** **D** **E** **K** **R**	14	6
L	333	M **G** **A** **P** V I L F **S** C **T** **N** **Q** **H** **Y** **W** **D** **E** **K** **R**	14	6
Y	334	**M** **G** **A** **P** **V** **I** **L** F **S** **C** **T** **N** **Q** H Y W **D** **E** **K** **R**	16	4
S	335	**M** **G** A **P** **V** **I** **L** **F** **S** **C** T N **Q** **H** **Y** **W** **D** **E** **K** **R**	16	4
S	336	**M** **G** A **P** **V** **I** **L** **F** S **C** T N **Q** **H** **Y** **W** **D** **E** **K** **R**	16	4
V	337	M **G** A **P** V I L **F** **S** **C** **T** **N** **Q** **H** **Y** **W** **D** **E** **K** **R**	15	5
P	338	**M** **G** **A** P **V** **I** **L** **F** **S** **C** **T** **N** **Q** **H** **Y** **W** D **E** **K** **R**	18	2
F	339	**M** **G** **A** **P** **V** **I** **L** F **S** **C** **T** **N** **Q** **H** Y **W** **D** **E** **K** **R**	18	2
P	340	**M** **G** **A** P **V** **I** **L** **F** **S** **C** **T** **N** **Q** **H** **Y** **W** D **E** **K** **R**	18	2
E	341	**M** **G** **A** **P** V **I** **L** **F** **S** **C** **T** **N** Q H **Y** **W** D E **K** **R**	15	5
G	342	**M** G **A** **P** **V** **I** **L** **F** **S** **C** **T** **N** **Q** **H** **Y** **W** **D** **E** **K** **R**	19	1
E	343	**M** G A P V **I** **L** **F** S **C** T N Q H **Y** **W** D E K R	7	13

TABLE 17-continued

Human Oct3/4 Amino Acid Substitution Matrix
(Predictions Based on PMUT Analysis)

WT	Position		Number of Predicted Deleterious Mutations	Number of Predicted Neutral Mutations
A	344	**M G A P V I L F** S C **T N Q H Y W D E K R**	17	3
F	345	**M G A P V I L** F **S C T N Q H** Y **W D E** K **R**	17	3
P	346	**M G A** P **V I L F S C T N Q H Y W** D **E K R**	17	3
P	347	M **G** A P **V I L F** S C T N Q **H Y W** D E **K R**	10	10
V	348	M **G A P** V I L **F S C T N Q H Y W D E K R**	15	5
S	349	**M** G A **P V I L F** S **C** T N **Q H Y W** D E **K R**	13	3
V	350	M **G A P** V I L **F S C T N Q H Y W D E K R**	16	4
T	351	**M G A P V I L F** S C T N **Q H Y W** D E **K R**	15	5
T	352	**M G A P V I L F** S C T N **Q H Y W** D **E K R**	15	5
L	353	M **G A P** V I L F **S** C **T N Q H Y W D E K R**	14	6
G	354	**M** G **A P** V **I L F S C T N Q H Y W D E K R**	19	1
S	355	**M** G A **P V I L F** S C T N **Q H Y W** D **E K R**	14	6
P	356	**M G A** P **V I L F S C T N Q H Y W** D **E K R**	18	2
M	357	M **G A P V I** L **F S C T N Q H Y W D E K R**	18	2
H	358	**M G A P V I L F S C T** N **Q** H **Y W D E K R**	18	2
S	359	**M G** A **P V I L F** S **C** T N **Q H Y W** D **E K R**	15	5
N	360	**M G A P V I L F S C** T N Q H **Y W** D E K **R**	13	3

TABLE 18

Human Sox2 Amino Acid Substitution Matrix
(Predictions Based on PMUT Analysis)

WT	Position		Number of Predicted Deleterious Mutations	Number of Predicted Neutral Mutations
M	1	M G **A P** V I L **F S C T N** Q H Y **W D E K R**	12	8
Y	2	M G **A P V I** L F S **C T N** Q H Y W D E **K** R	8	12
N	3	**M G A P V I L F** S **C** T N **Q** H **Y W** D **E K R**	15	5
M	4	M **G A P** V I L **F S C T N Q** H Y **W D E K R**	14	6
M	5	M **G A P** V I L F **S C T N** Q H Y **W D E K R**	8	12
E	6	**M G A P V I L F S** C **T** N Q H **Y W** D E **K** R	13	7
T	7	M **G** A **P** V **I L F** S C T N **Q** H **Y W** D E **K R**	10	10
E	8	**M G A P** V **I L** F S **C** T N Q H Y **W** D E **K R**	10	10
L	9	M G A P V I L F S C T N Q H Y W D E K R	0	20
K	10	**M** G **A P V I L** F **S** C **T** N Q H Y **W** D E K R	9	11
P	11	M G A P V **I L F** S **C T N Q H Y W** D E **K R**	11	9

TABLE 18-continued

Human Sox2 Amino Acid Substitution Matrix
(Predictions Based on PMUT Analysis)

WT	Position		Number of Predicted Deleterious Mutations	Number of Predicted Neutral Mutations
P	12	M G A P V **I L F** S **C** T N **Q H Y W** D **E K R**	11	9
G	13	**M** G **A P V I L F S C T N Q H Y W D E K R**	19	1
P	14	M G A P **V I L** F S C **T** N **Q H Y W** D E **K** R	9	11
Q	15	M **G A P** V **I L** F **S** C T N Q H Y **W** D E K R	7	13
Q	16	M G **A P** V I **L** F S **C** T N Q H Y **W** D E K R	5	15
T	17	M G A P V **I L F** S C T N Q H **Y W** D **E K** R	7	13
S	18	M G A P V I L F S **C** T N Q H Y W D E K R	1	19
G	19	M G A P **V** I **L F** S **C** T **N Q** H **Y W** D **E K R**	11	9
G	20	**M** G **A P V I L F** S **C T N Q H Y W D E K R**	17	3
G	21	M G A P V I L **F S** C T N Q **H Y** W **D** E **K R**	7	13
C	22	M G A **P V I L F** S **C** T N **Q H Y W** D **E K R**	13	7
C	23	M G **A** P **V I L F** S **C T N Q** H **Y W D E K R**	15	5
N	24	M G A P V **I L F** S C T N Q H **Y W** D E K R	5	15
S	25	M G A P V **I L F** S **C** T N Q H Y **W** D **E** K R	6	14
T	26	M G A P V I **L F** S C T N Q H **Y W** D E **K** R	5	15
A	27	**M** G A P **V I L F** S C T **N Q H Y W D E K R**	14	6
A	28	M G A P V I L F S C T N Q H **Y W D** E K R	3	17
A	29	M G A **P** V I **L F** S C T N **Q** H **Y W D E K R**	10	10
A	30	**M** G A **P V I L F** S C T N **Q H Y W D E K R**	14	6
G	31	M G A P V I L F S **C T** N Q H **Y** W D E **K** R	4	16
G	32	M G A P **V** I L **F** S **C T** N Q H Y **W D** E K R	6	14
N	33	**M G A** P V **I L F** S **C** T N **Q** H **Y W** D **E K R**	13	7
Q	34	M G **A** P V **I L** F S C **T** N Q H Y **W** D E K R	5	15
K	35	M G **A P V I L F S C T** N Q H **Y W D** E K R	12	8
N	36	M **G A** P **V I L F** S C T N **Q** H **Y W** D **E K** R	11	9
S	37	M G A **P** V I L **F** S **C** T N Q H **Y W** D E K R	5	15
P	38	M G A P V I L F S C T N Q H Y W D E **K** R	1	19
D	39	**M G** A P **V I L F** S C **T** N **Q H Y W** D E **K** R	12	8
R	40	**M G A P V I L F S C T N Q H Y W D E** K R	18	2
V	41	M **G** A P V I L **F S C** T **N** Q **H Y** W **D** E **K R**	10	10
K	42	**M G A P V I L F S C T N Q H Y W D E** K R	18	2
R	43	**M G A P V I L F S C T N Q H Y W D E** K R	18	2
P	44	**M G A** P **V I L F S C T N Q H Y W** D **E K R**	18	2
M	45	M **G A P V** I L **F S C T N** Q H Y **W D E K R**	15	5

TABLE 18-continued

Human Sox2 Amino Acid Substitution Matrix
(Predictions Based on PMUT Analysis)

WT	Position		Number of Predicted Deleterious Mutations	Number of Predicted Neutral Mutations
N	46	**M G A P V I L F** S **C T N Q H Y W** D **E K R**	17	3
A	47	**M** G A **P V I L F** S **C T N Q H Y W D E K R**	17	3
F	48	**M G A P V I L** F S **C T N** Q **H** Y **W D E** K **R**	16	4
M	49	M **G A P** V I L **F S C T N** Q H Y **W D E K R**	13	7
V	50	**M G A P** V I **L F S C T N Q H Y W D E K R**	18	2
W	51	**M G A P V I L F S C T N Q H Y** W **D E K R**	19	1
S	52	**M G** A **P V I L F** S **C** T N **Q H Y W D E K R**	16	4
R	53	**M G A P V I L F S C T N Q H Y W D E** K R	18	2
G	54	M G **A P V** I L **F** S **C T N Q H Y W** D **E K R**	14	6
Q	55	**M G A P V I L F S C T N** Q **H Y W D E K R**	18	2
R	56	**M G A P V I L F S C T N Q H** Y **W D E** K R	17	3
R	57	**M G A P V I L F S C T N Q H Y W D E** K R	18	2
K	58	**M G A P V I L F S C T N Q H Y W D E** K R	18	2
M	59	M **G A P** V I L **F S C T N Q** H **Y W D E K R**	15	5
A	60	**M** G A **P V I L F** S **C T N Q H Y W D E K R**	17	3
Q	61	**M G A P V I L F S C T N** Q **H Y W D** E **K R**	18	2
E	62	**M G A P V I L F S C T N** Q H **Y W** D E **K R**	16	4
N	63	**M G A P V I L F** S **C T N Q H Y W** D **E K R**	17	3
P	64	M **G** A P **V I L F S C T N Q H Y W** D **E K R**	16	4
K	65	**M G A P V I L F S C T N Q** H **Y W D E K** R	16	4
M	66	M **G A P** V I L **F S C T N** Q H Y **W D E K R**	13	7
H	67	**M G A P V I L F S C T N Q** H **Y W D E K R**	18	2
N	68	**M G A P V I L F** S **C T N Q H Y W D E K R**	18	2
S	69	**M** G A P **V I L F** S **C** T N **Q H Y W** D **E K R**	13	7
E	70	M **G A P V I L** F **S C T** N Q H Y **W** D E **K R**	12	8
4 I	71	M **G A P** V I L F **S C T N Q** H **Y W D E K R**	15	5
S	72	**M** G A **P V I L F** S **C** T **N Q H Y W D E K R**	16	4
K	73	**M G A P V I L** F **S C T** N **Q H Y W D E** K R	16	4
R	74	**M G A P V I L** F **S C T N Q H** Y **W D E** K R	16	4
L	75	M **G A P V** I L **F S C T N** Q H Y **W D** E **K** R	12	8
G	76	**M** G A P **V I L F** S **C T N Q H Y W D E K R**	17	3
A	77	**M G** A **P V I L F** S **C T N Q H Y W D E K R**	18	2
E	78	**M G A** P V **I L** F **S C** T N Q H Y **W** D E **K** R	9	11
W	79	**M G A P V I L F S C T N Q H Y** W **D E K R**	19	1

TABLE 18-continued

Human Sox2 Amino Acid Substitution Matrix
(Predictions Based on PMUT Analysis)

WT	Position		Number of Predicted Deleterious Mutations	Number of Predicted Neutral Mutations
K	80	**M G A P V I L F S C T N Q** H Y **W D E** K R	16	4
L	81	M **G A P** V I L **F S C T N** Q H Y **W D E K** R	12	8
L	82	M **G** A P V I L F **S C T N Q H** Y **W D** E **K** R	10	10
S	83	M G A P V I L **F** S C T N Q H Y **W** D E K R	2	18
E	84	**M G A P** V **I L F S C** T N Q H Y **W** D E K R	10	10
T	85	M G A P V I L F S C T N Q H Y W D E K R	0	20
E	86	**M G** A P **V I L F S C T** N Q H Y **W** D E **K** R	11	9
K	87	**M G A P V I L** F **S C T** N **Q H** Y **W D E** K R	15	5
R	88	**M G A P V I L F S C T N Q H** Y **W D E** K R	17	3
P	89	M **G A** P **V I L F S C T N Q H Y W** D **E K R**	17	3
F	90	**M G A P V I L** F **S C T N Q H** Y **W D E K R**	18	2
I	91	M G A P V I L F **S C T N Q** H Y **W D E K R**	10	10
D	92	M **G A** P **V I L F S** C **T** N Q **H Y W** D E K R	11	9
E	93	**M G A P V I L F S** C **T** N Q H Y **W** D E **K** R	12	8
A	94	**M** G A **P V I L F** S **C T N Q H Y W D E K R**	17	3
K	95	**M G A P V I L F S C T** N **Q** H **Y W D** E K R	15	5
R	96	**M G A P V I L F S C T N Q H Y W D E** K R	18	2
L	97	M **G A P** V I L **F S C T N Q H** Y **W D E K** R	14	6
R	98	**M G A P V I L F S C T N Q H Y W D E** K R	18	2
A	99	**M** G A **P V I L F** S **C** T **N Q H Y W D E K R**	16	4
L	100	M G **A** P V I L F **S** C T **N** Q H Y **W** D **E** K R	5	15
H	101	**M G A P V I L F S C T N Q** H Y **W** D E **K R**	18	2
M	102	M **G A P** V I L **F S C T N** Q H Y **W D E K R**	13	7
K	103	**M G A P V I L F S C T** N Q H **Y W D** E K R	14	6
E	104	**M G A P** V **I L F S C** T N Q H **Y W** D E K R	11	9
H	105	M **G A P V I L F S C T** N Q H Y **W D** E **K R**	14	6
P	106	**M G** A P **V I L F** S C **T N Q H Y W** D E **K R**	15	5
D	107	M **G A** P **V I L F** S C T N **Q H Y W** D E **K R**	12	8
Y	108	**M G A P V I L** F **S C T N Q** H Y **W D E K R**	17	3
K	109	M **G A P V I L F S C T** N **Q** H **Y W D** E K R	14	6
Y	110	M **G A P V I L** F **S C T N** Q **H** Y **W D E K R**	16	4
R	111	**M G A P V I L F S C T N Q H Y W D E** K R	18	2
P	112	**M G** A P **V I L F S C T N Q H Y W** D **E K R**	17	3
R	113	**M G A P V I L F S C T N Q H** Y **W D E** K R	17	3

TABLE 18-continued

Human Sox2 Amino Acid Substitution Matrix
(Predictions Based on PMUT Analysis)

WT	Position		Number of Predicted Deleterious Mutations	Number of Predicted Neutral Mutations
R	114	**M G A P V I L F S C T N Q H Y W D E** K R	18	2
K	115	**M G A P V I L F S C T** N Q H **Y W D** E K R	14	6
T	116	**M G** A P **V I L F** S C T **N Q H Y W D E K R**	15	5
K	117	**M G A P V I L F S C T** N **Q** H **Y W D E** K R	16	4
T	118	M **G** A P V **I L F** S C T N **Q H Y W** D **E K R**	11	9
L	119	M **G** A **P** V I L F S C **T N Q H Y W D E K R**	12	8
M	120	M **G A P** V I L F S C **T N** Q H Y **W D E K R**	10	10
K	121	**M G A P V I L F S** C T N **Q** H **Y W D** E K R	14	6
K	122	**M G A P V I L F S C T N Q H** Y **W D E** K R	17	3
0	123	M **G A** P **V I L F S** C T **N Q** H **Y W** D E **K R**	13	7
K	124	**M G A P V I L F S C T** N **Q** H **Y W D E** K R	16	4
Y	125	M **G A P V I L** F **S C T N** Q H Y W **D E K R**	14	6
T	126	M G A P V **I L F** S C T N Q **H Y W** D **E K R**	9	11
L	127	M G **A P** V I L F S C **T N Q** H Y W **D E K R**	9	11
P	128	**M G** A P **V I L F S** C **T N Q H** Y **W** D **E K R**	15	5
G	129	M G **A P V I L F S C T N Q H Y W D E K R**	18	2
G	130	**M** G **A P V I L F S C T N Q H Y W D E K R**	19	1
L	131	M G A **P** V I L F **S** C T **N Q** H **Y W** D E **K R**	8	12
L	132	M G A P V I L F S C **T N Q** H Y W **D** E **K R**	6	14
A	133	M G A **P V** I **L F** S C T **N Q H Y W D E K R**	13	7
P	134	M G A P **V I L F** S **C T N** Q **H** Y W D E **K R**	10	10
G	135	M G A P **V I L F** S **C T N Q** H **Y W** D **E K R**	12	8
G	136	M G A P V I L **F** S C T **N** Q H Y W **D E K R**	6	14
N	137	**M G A** P **V I L F** S C T N Q H **Y W** D **E K R**	12	8
S	138	M G A P V I **L F** S **C** T N **Q** H Y **W** D E **K R**	7	13
M	139	M **G** A P V I L F S **C T N** Q H Y **W D E K R**	9	11
A	140	M G A **P** V **I** L F S C T N Q **H Y W D E K R**	9	11
S	141	M G A **P** V **I L F** S C T N **Q** H Y **W** D **E K** R	8	12
G	142	M G A P **V I L F** S **C T N Q** H **Y W D E K R**	14	6
V	143	M G A P V I L F **S** C T **N Q** H **Y W** D E **K R**	7	13
G	144	M G A P **V I** L **F** S **C** T **N** Q H **Y W** D **E K R**	10	10
V	145	M G A P V I L **F** S C T **N Q** H Y **W** D E **K R**	6	14
G	146	M G A P V **I** L **F** S C T N **Q** H **Y W** D **E K** R	7	13
A	147	**M** G A **P V I L F** S C T **N** Q **H Y W D E K R**	14	6

TABLE 18-continued

Human Sox2 Amino Acid Substitution Matrix
(Predictions Based on PMUT Analysis)

WT	Position		Number of Predicted Deleterious Mutations	Number of Predicted Neutral Mutations
G	148	M G A **P** **V** **I** L **F** S **C** T N **Q** H Y **W** D **E** **K** **R**	10	10
L	149	M G A P V I L F S C T **N** Q H Y W D E **K** **R**	3	17
G	150	**M** G A **P** **V** **I** **L** **F** S **C** T **N** **Q** H **Y** **W** **D** **E** **K** **R**	15	5
A	151	M G A P V I L F S C T N Q H Y **W** D E K R	1	19
G	152	**M** G A **P** **V** **I** **L** **F** S **C** **T** **N** **Q** **H** **Y** **W** **D** **E** **K** **R**	17	3
V	153	M G A P V I L F **S** C T **N** Q **H** Y **W** D **E** **K** **R**	7	13
N	154	M **G** **A** P V **I** **L** **F** S C T N **Q** H **Y** **W** **D** E **K** **R**	10	10
Q	155	M **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** N Q **H** Y **W** **D** E **K** **R**	15	5
R	156	**M** **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** **N** **Q** **H** **Y** **W** **D** **E** K R	18	2
M	157	M **G** **A** **P** V I L **F** **S** **C** **T** **N** Q H Y **W** **D** **E** **K** **R**	13	7
D	158	**M** **G** **A** **P** **V** **I** **L** **F** **S** C **T** N **Q** **H** **Y** **W** D E **K** **R**	16	4
S	159	**M** G A **P** **V** **I** **L** **F** S **C** T N **Q** H **Y** **W** **D** **E** **K** **R**	14	6
Y	160	M **G** **A** **P** **V** **I** **L** F **S** **C** **T** **N** Q H Y W **D** **E** **K** R	13	7
A	161	**M** G A **P** **V** **I** L **F** S C T N Q **H** **Y** **W** **D** **E** **K** **R**	12	8
H	162	M **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** N Q H Y **W** **D** E **K** **R**	14	6
M	163	M **G** **A** **P** V I L F **S** **C** **T** **N** Q H Y W **D** **E** **K** **R**	11	9
N	164	**M** **G** **A** **P** **V** **I** **L** **F** S C T N **Q** **H** **Y** **W** D E **K** **R**	16	4
G	165	**M** G A **P** **V** I **L** **F** S **C** **T** N Q H **Y** **W** D **E** **K** **R**	12	8
W	166	**M** **G** **A** **P** **V** **I** **L** F **S** **C** **T** **N** **Q** H Y W **D** **E** **K** **R**	16	4
S	167	M G A P V I L **F** S C T N Q H **Y** **W** **D** E **K** **R**	6	14
N	168	**M** **G** **A** P **V** **I** **L** **F** S C T N **Q** H **Y** **W** D E K **R**	11	9
G	169	**M** G A **P** **V** I **L** **F** S **C** **T** **N** **Q** H **Y** **W** **D** **E** **K** **R**	15	5
S	170	M G A P V I L **F** S C T N **Q** H Y **W** **D** **E** **K** **R**	7	13
Y	171	M **G** **A** **P** **V** **I** L F S **C** **T** **N** Q H Y W **D** **E** **K** R	11	9
S	172	M G A **P** **V** **I** **L** **F** S **C** T N **Q** **H** **Y** **W** D **E** **K** **R**	13	7
M	173	M **G** **A** **P** V I L F S **C** **T** **N** Q H Y **W** **D** **E** **K** **R**	11	9
M	174	M **G** **A** **P** V I L **F** **S** **C** **T** **N** Q H Y **W** **D** **E** **K** **R**	13	7
Q	175	M **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** N Q **H** Y **W** **D** E **K** **R**	15	5
D	176	**M** **G** **A** P **V** **I** **L** **F** **S** C T **N** Q H **Y** **W** D E **K** **R**	13	7
Q	177	M **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** **N** Q H Y **W** **D** E **K** R	14	6
L	178	M G A **P** V I L F S C T **N** Q H Y **W** **D** **E** **K** **R**	7	13
G	179	M G A **P** **V** **I** **L** **F** S **C** **T** **N** **Q** **H** **Y** **W** **D** **E** **K** **R**	16	4
Y	180	**M** **G** **A** **P** **V** **I** **L** F **S** **C** **T** **N** **Q** H Y **W** **D** **E** **K** **R**	17	3
P	181	M **G** A P **V** **I** **L** **F** S **C** **T** **N** **Q** H Y **W** D **E** **K** **R**	13	7

TABLE 18-continued

Human Sox2 Amino Acid Substitution Matrix
(Predictions Based on PMUT Analysis)

WT	Position		Number of Predicted Deleterious Mutations	Number of Predicted Neutral Mutations
Q	182	**M G A P V I L F S C T N** Q H Y **W D E K R**	16	4
H	183	M G **A P V I L F S C T** N Q H Y **W D E K R**	14	6
P	184	**M G** A P **V I L F** S C **T N Q H Y W** D **E K R**	15	5
G	185	M G A P **V I** L **F** S **C** T N Q H **Y W D E K R**	10	10
L	186	M G A P V I L F S C T **N** Q H Y **W** D **E K** R	4	16
N	187	**M G A P V I L F** S **C T N Q H Y W** D **E K R**	17	3
A	188	M G A P **V** I L **F** S C T N **Q** H Y **W** D E **K** R	5	15
H	189	M **G** A **P** V **I L F S C T** N Q H Y **W D** E **K** R	11	9
G	190	**M** G A P V **I L F** S **C** T N **Q** H Y **W** D **E K R**	10	10
A	191	M G A P V I L **F** S C T N **Q** H **Y W D E K R**	8	12
A	192	M G A P V I **L F** S C T **N** Q H **Y W D E K R**	9	11
Q	193	M **G A P** V **I L** F **S C** T N Q H Y **W** D E K **R**	9	11
M	194	M **G** A **P** V I L F **S C** T **N** Q H Y **W D E K R**	10	10
Q	195	M **G A P V I L F S C T N** Q H Y **W** D E K R	12	8
P	196	M **G** A P **V I L F** S C **T N** Q H Y W D E **K R**	9	11
M	197	M **G A P** V I L **F S C T N Q** H Y **W D E K R**	14	6
H	198	M **G A P V I L F S C T** N **Q** H **Y W D E K R**	16	4
R	199	**M G A P V I L F S C T N Q H Y W D E** K R	18	2
Y	200	M **G A P V I L** F **S C T N** Q H Y W **D E K R**	14	6
D	201	**M G A** P **V I L F S** C T **N Q H Y W** D E **K R**	15	5
V	202	M G A P V I L F S C T N Q **H** Y W D E **K R**	3	17
S	203	**M** G A P **V I L F** S **C** T N **Q** H **Y W** D E **K R**	11	9
A	204	**M** G A P V **I L F** S C T **N Q H Y W D E K R**	13	7
L	205	M **G** A **P** V I L F S C **T N Q H Y W D E K R**	12	8
Q	206	**M G A P V I L F S C T N** Q **H Y W** D E **K R**	18	2
Y	207	M **G A P V I L** F **S C T N Q H** Y W **D E K R**	16	4
N	208	**M G A** P **V I L F** S C T N Q H **Y W** D E **K** R	10	10
S	209	M **G** A P **V I L F** S **C** T N **Q H Y W** D **E K R**	13	7
M	210	M **G A P** V I L **F S C T N** Q H Y **W D E K R**	13	7
T	211	M **G** A P V **I L F** S C T N Q H **Y W** D E **K R**	8	12
S	212	**M** G A **P V I L F** S **C** T N **Q H Y W** D E **K R**	13	7
S	213	**M** G A **P V I L F** S **C** T N **Q H Y W** D E **K R**	13	7
Q	214	**M G A P V I L F S C T N** Q **H Y W** D E **K** R	16	4
T	215	**M G** A P **V I L F** S C T **N Q H Y W** D **E K R**	14	6

TABLE 18-continued

Human Sox2 Amino Acid Substitution Matrix
(Predictions Based on PMUT Analysis)

WT	Position		Number of Predicted Deleterious Mutations	Number of Predicted Neutral Mutations
Y	216	**M G A P V I L** F **S C T N Q H** Y W **D E K R**	17	3
M	217	M **G A P** V I L **F S C T N Q** H Y **W D E K R**	14	6
N	218	**M G A** P **V I L F** S **C** T N **Q** H **Y W** D **E** K **R**	13	7
G	219	**M** G A P **V I L F S C T N Q H Y W D E K R**	18	2
S	220	**M** G A **P** V **I L F** S **C** T N **Q H Y W** D E **K R**	12	8
P	221	M **G** A P **V I L F** S **C T** N **Q H** Y **W** D **E K R**	13	7
T	222	**M G** A P V **I L F** S C T N **Q** H **Y W** D E **K R**	10	10
Y	223	M **G A P V I L** F **S C T N** Q H Y W **D E K R**	14	6
S	224	**M** G A **P V I L F** S **C** T N **Q H Y W** D E **K R**	13	7
M	225	M **G A P** V I L F **S C T N** Q H Y **W D E K R**	12	8
S	226	M G A **P V I L F** S **C** T N **Q** H **Y W** D E **K R**	11	9
Y	227	M **G A P V I L** F **S C T N** Q **H** Y W **D E K R**	15	5
S	228	**M** G A **P V I L F** S **C** T N **Q H Y W** D E **K R**	13	7
Q	229	M **G A P V I L F S C T N Q** H Y **W** D E K **R**	13	7
Q	230	M **G A P V I L F S C T** N Q H Y **W D** E K R	12	8
G	231	M G A P **V I L F** S **C** T **N Q H Y W D E K R**	14	6
T	232	M G A P V I L **F** S C T N Q H **Y W** D **E K R**	3	17
P	233	**M G** A P **V I L F** S **C** T **N Q H Y W** D **E K R**	15	5
G	234	M G A P **V I L F** S **C T N Q H Y W D E K R**	14	6
M	235	M **G A P** V I L **F S C T N Q** H Y **W D E K R**	14	6
A	236	M G A **P** V I **L F** S C T **N Q H Y W D E K R**	12	8
L	237	M **G** A **P** V I L F **S C** T **N Q H** Y **W D E K R**	12	8
G	238	**M** G A **P V I L F S C T N Q H Y W D E K R**	19	1
S	239	**M** G A **P V I L F** S **C** T N **Q H Y W D E K R**	15	5
M	240	M **G A P** V I L **F S C T N Q** H Y **W D E K R**	14	6
G	241	**M** G **A P V I L F S C T N Q H Y W D E K R**	19	1
S	242	**M** G A **P V I L F** S **C** T N **Q H Y W D E K R**	15	5
V	243	M **G** A P V I L **F S** C **T N Q H Y W D E K R**	13	7
V	244	M **G** A **P** V I **L F S** C T **N Q H Y W D** E **K R**	13	7
K	245	**M G A P V I L F S** C **T** N **Q** H **Y W D** E K R	14	6
S	246	**M G** A **P V I L F** S **C** T N **Q H Y W** D **E K R**	15	5
E	247	**M G A P** V **I L F S C T** N Q H **Y W** D E K R	12	8
A	248	M G A P V I L F S C T N Q H Y **W** D **E** K **R**	3	17
S	249	**M** G A **P** V **I L F** S **C** T N Q H **Y W** D E **K R**	10	10

TABLE 18-continued

Human Sox2 Amino Acid Substitution Matrix
(Predictions Based on PMUT Analysis)

WT	Position		Number of Predicted Deleterious Mutations	Number of Predicted Neutral Mutations
S	250	**M** G A **P** V **I** **L** **F** S **C** T N Q H **Y** **W** D E **K** **R**	10	10
S	251	M **G** A **P** **V** **I** **L** **F** S **C** T N **Q** **H** **Y** **W** D **E** **K** **R**	14	6
P	252	**M** **G** **A** P **V** **I** **L** **F** S **C** **T** **N** **Q** **H** Y **W** D **E** **K** **R**	16	4
P	253	**M** **G** **A** P **V** **I** **L** **F** **S** **C** **T** **N** **Q** **H** **Y** **W** D **E** **K** **R**	18	2
V	254	M **G** A **P** V I L F **S** C **T** **N** Q **H** **Y** **W** **D** **E** **K** **R**	12	8
V	255	M G A P V I L F **S** C T **N** Q H **Y** **W** **D** E **K** **R**	7	13
T	256	**M** **G** A P **V** **I** **L** **F** S C T N **Q** **H** **Y** **W** D **E** **K** **R**	13	7
S	257	M G A **P** **V** **I** **L** **F** S C T N Q H **Y** **W** D **E** **K** **R**	10	10
S	258	**M** G A **P** **V** **I** **L** **F** S **C** T N **Q** **H** **Y** **W** D **E** **K** **R**	14	6
S	259	M G A **P** **V** **I** **L** **F** S **C** T N **Q** H **Y** **W** **D** E **K** **R**	12	8
H	260	**M** **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** N **Q** H **Y** **W** **D** **E** **K** **R**	18	2
S	261	**M** G A **P** **V** **I** **L** **F** S **C** T N **Q** **H** **Y** **W** D **E** **K** **R**	14	6
R	262	**M** **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** **N** **Q** **H** **Y** **W** **D** **E** K R	18	2
A	263	**M** G A **P** V **I** **L** **F** S **C** **T** **N** **Q** **H** **Y** **W** **D** **E** **K** **R**	16	4
P	264	**M** **G** A P **V** **I** **L** **F** **S** **C** **T** **N** **Q** **H** **Y** **W** D **E** **K** **R**	17	3
C	265	**M** **G** **A** **P** **V** **I** **L** **F** **S** C T **N** **Q** **H** **Y** **W** **D** **E** **K** **R**	17	3
Q	266	**M** **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** **N** Q **H** **Y** **W** D E **K** **R**	18	2
A	267	M G A P **V** I L **F** S C T **N** Q **H** **Y** **W** **D** **E** **K** **R**	10	10
G	268	**M** G **A** **P** **V** **I** **L** **F** **S** **C** **T** **N** **Q** **H** **Y** **W** **D** **E** **K** **R**	19	1
D	269	**M** **G** **A** **P** **V** **I** **L** **F** **S** C **T** **N** **Q** **H** **Y** **W** D E **K** **R**	17	3
L	270	M **G** **A** **P** V I L F **S** **C** **T** **N** **Q** **H** Y **W** **D** **E** **K** **R**	14	6
R	271	**M** **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** **N** **Q** **H** **Y** **W** **D** **E** K R	18	2
D	272	**M** **G** **A** **P** **V** **I** **L** **F** **S** C T **N** **Q** **H** **Y** **W** D E **K** **R**	16	4
M	273	M **G** **A** **P** **V** **I** L **F** **S** **C** **T** **N** **Q** H **Y** **W** **D** **E** **K** **R**	17	3
I	274	M **G** **A** **P** V I L **F** **S** **C** **T** **N** **Q** **H** **Y** **W** **D** **E** **K** **R**	16	4
S	275	**M** **G** A **P** **V** **I** **L** **F** S **C** T N **Q** **H** **Y** **W** **D** **E** **K** **R**	16	4
M	276	M **G** **A** **P** **V** I L **F** **S** **C** **T** **N** **Q** H **Y** **W** **D** **E** **K** **R**	16	4
Y	277	**M** **G** **A** **P** **V** **I** **L** F **S** **C** **T** **N** **Q** **H** Y **W** **D** **E** **K** **R**	18	2
L	278	M G **A** **P** V I L F **S** C **T** **N** **Q** H Y **W** **D** **E** **K** **R**	11	9
P	279	**M** **G** **A** P **V** **I** **L** **F** **S** **C** **T** **N** **Q** **H** **Y** **W** D **E** **K** **R**	18	2
G	280	**M** G **A** **P** **V** **I** **L** **F** **S** **C** **T** **N** **Q** **H** **Y** **W** **D** **E** **K** **R**	19	1
A	281	**M** G A **P** V **I** **L** **F** S C **T** **N** **Q** **H** **Y** **W** **D** **E** **K** **R**	15	5
E	282	**M** **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** **N** Q H **Y** **W** D E **K** **R**	16	4
V	283	M G A P V I L **F** S C T **N** **Q** **H** **Y** **W** **D** **E** **K** **R**	10	10

TABLE 18-continued

Human Sox2 Amino Acid Substitution Matrix
(Predictions Based on PMUT Analysis)

WT	Position		Number of Predicted Deleterious Mutations	Number of Predicted Neutral Mutations
P	284	M G A P **V I L F** S C T N **Q H Y W** D E **K R**	10	10
E	285	**M G A** P V **I L F S C** T N Q H **Y W** D E K R	10	10
P	286	**M G** A P **V I L F** S **C** T **N Q** H **Y W** D **E K R**	14	6
A	287	**M** G A **P V I L F** S C T **N Q H Y W D E K R**	15	5
A	288	**M G** A **P V I L F** S C T **N Q H Y W D E K R**	16	4
P	289	M G A P V I L F S C T N Q H Y **W** D E **K R**	3	17
S	290	**M G** A **P V I L F** S **C** T N **Q H Y W** D **E K R**	15	5
R	291	**M G A P V I L F S C T N Q H Y W D E** K R	18	2
L	292	M **G A P** V I L F **S C T N Q** H Y **W D E K R**	13	7
H	293	**M G A P V I L F S C T N Q** H Y **W D E K R**	19	1
M	294	M **G A P** V I L F **S C T N Q** H Y **W D E K R**	13	7
S	295	M G A **P V I L F** S C T N **Q** H Y **W** D **E K R**	12	8
Q	296	**M G A P V I L F S C T N** Q **H Y W D** E **K R**	18	2
H	297	**M G A P V I L F S C T** N **Q** H **Y W D E K R**	18	2
Y	298	**M G A P V I L** F **S C T N Q** H Y **W D E K R**	17	3
Q	299	**M G A P V I L F S C T N** Q H **Y W D** E **K R**	17	3
S	300	**M G** A **P V I L F** S C T **N Q H Y W** D **E K R**	16	4
G	301	**M** G A **P V I L F S C T** N **Q H Y W D E K R**	17	3
P	302	M G A P V **I L** F S C T N **Q** H **Y W** D E **K R**	8	12
V	303	M **G A P** V I L **F S C** T **N Q H Y W D E K R**	16	4
P	304	**M G A** P **V I L F S C T N Q H Y W** D **E K R**	18	2
G	305	**M** G **A P V I L F S C T N Q H Y W D E K R**	19	1
T	306	**M G** A **P V I L F** S C T **N Q H Y W** D **E K R**	15	5
A	307	**M** G A **P** V **I L F** S C **T N Q H Y W D E K R**	15	5
I	308	M **G A P** V I L F **S C T N Q** H **Y W D E K R**	14	6
N	309	**M G A P V I L F S C T** N **Q H Y W** D **E K R**	18	2
G	310	**M** G **A P V I L F S C T N Q H Y W D E K R**	19	1
T	311	**M G A P V I L F** S C T **N Q H Y W** D **E K R**	17	3
L	312	M **G A P** V I L F **S** C T **N Q** H Y **W D E K R**	11	9
P	313	**M G A** P **V I L F S C T N Q H Y W** D **E K R**	18	2
L	314	M **G A P** V I L F **S C T N Q H Y W D E K R**	15	5
S	315	**M** G A **P V I L F S C** T N Q **H Y W** D E **K R**	12	8

TABLE 18-continued

Human Sox2 Amino Acid Substitution Matrix
(Predictions Based on PMUT Analysis)

WT	Position		Number of Predicted Deleterious Mutations	Number of Predicted Neutral Mutations
H	316	**M G A P V I L F S C T** N **Q** H **Y W D E K R**	18	2
M	317	M **G A P V** I L **F S C T N Q** H **Y W D E K R**	16	4

TABLE 19

Human Klf4 Amino Acid Substitution Matrix
(Predictions Based on PMUT Analysis)

WT	Position		Number of Predicted Deleterious Mutations	Number of Predicted Neutral Mutations
M	1	M G A P V I L F S C T **N** Q H Y W **D** E K **R**	3	17
A	2	M G A P **V I** L F S C T N Q H Y **W D** E K R	4	16
V	3	M G A P V I L F S C T N Q H Y W D E K R	0	20
S	4	M G A P V I L **F** S C T N Q H Y **W** D E **K** R	3	17
D	5	M G **A** P V I L **F** S C T N Q H Y **W** D E K R	3	17
A	6	M G A P V I L F S C T N Q H Y W D E **K** R	1	19
L	7	M G A P V I L F S C T N Q H Y W D E K R	0	20
L	8	M G A P V I L F S C T N Q H Y W D E K R	0	20
P	9	M G A P V I L F S C T N Q H Y W D E K R	0	20
S	10	M G A P V I L F S C T N Q H Y **W** D E K R	1	19
F	11	M **G A P V I L** F **S C T N** Q H Y W **D E** K **R**	13	7
S	12	M G A P V I L **F** S C T N Q H Y **W** D E K R	2	18
T	13	**M** G A P V I L F S C T N Q H Y **W** D E **K** R	3	17
F	14	M G A P V I L F S C T N Q H Y W D E K R	0	20
A	15	M G A P V I L F S C T N Q H Y W D E K R	0	20
S	16	M G A P V I L F S C T N Q H Y **W** D E K R	1	19
G	17	M G A P V I L **F** S C T N Q H Y **W** D **E K R**	5	15
P	18	M G A P **V** I L F S C T N Q H Y W D E K R	1	19
A	19	M G A P V I L F S C T N Q H Y **W D E** K R	3	17
G	20	**M** G A P V I **L F** S C T **N Q** H **Y W D E K** R	10	10
R	21	**M** G **A P** V I L F S C T N Q H Y **W** D E K R	4	16
E	22	M G A P V I L F S C T N Q H Y **W** D E K R	1	19
K	23	M G A P V I L F S C T N Q H Y **W** D E K R	1	19
T	24	M G A P V I L F S C T N Q H Y W D E K R	0	20
L	25	M G A P V I L F S C T N Q H Y W D E K R	0	20
R	26	M G **A P** V **I** L F S C T N Q H Y **W D** E K R	5	15

TABLE 19-continued

Human Klf4 Amino Acid Substitution Matrix
(Predictions Based on PMUT Analysis)

WT	Position		Number of Predicted Deleterious Mutations	Number of Predicted Neutral Mutations
Q	27	M**G**A P V I **L** F S C T N Q H Y **W** **D** E K R	5	15
A	28	M G A P V I **L** F S C T N Q H Y **W** **D** **E** **K** R	5	15
G	29	**M** G A P V I L F S C T N Q H Y W D E K R	1	19
A	30	M G A P V I L F S C T **N** Q H Y **W** **D** E K **R**	4	16
P	31	M G A P V I L F S C T N Q H Y W D E K R	0	20
N	32	M G A P V I L **F** S C T N Q H Y **W** D E K R	2	18
N	33	M G A P V I L **F** S C T N Q H Y W D E K R	1	19
R	34	**M** G **A** P V **I** L F S **C** **T** **N** Q H Y **W** D E K R	7	13
W	35	M G A P **V** I **L** F S C T N Q H Y W D E K **R**	3	17
R	36	**M** G A P **V** **I** **L** F S C T **N** Q H Y **W** D E K R	6	14
E	37	**M** G **A** **P** V **I** **L** F **S** C T N Q H Y **W** D E K R	7	13
E	38	M G A P V I L F S C T N Q H Y W D E K R	0	20
L	39	M G A P V I L F S C T N Q H Y W D E K R	0	20
S	40	M G A **P** V I L **F** S C T N Q H Y **W** D E **K** **R**	5	15
H	41	M G **A** **P** **V** I **L** **F** S C **T** N Q H Y **W** **D** E **K** **R**	10	10
M	42	M G A P V I L F S C T N Q H Y W **D** E K R	1	19
K	43	**M** **G** **A** **P** **V** **I** L F **S** **C** **T** N Q H **Y** **W** **D** E K R	12	8
R	44	**M** **G** **A** **P** **V** I **L** F **S** C T **N** **Q** H Y **W** **D** **E** K R	12	8
L	45	M G A **P** V I L F S C T N Q H Y **W** D E **K** R	3	17
P	46	**M** G A P **V** I **L** F S C T N Q H **Y** W D E **K** R	5	15
P	47	M G A P V I L F S C T N Q H Y W D E K R	0	20
V	48	M G A P V I L F S C T N Q H Y W D E K R	0	20
L	49	M G A P V I L F S C T N Q H Y W D E K R	0	20
P	50	M G A P V I L F S C T **N** Q H Y **W** D E **K** **R**	4	16
C	51	M G A P V I L F S C T N Q H Y W D E K R	0	20
R	52	**M** G **A** **P** **V** I **L** F **S** C **T** **N** Q H Y **W** **D** **E** K R	11	9
P	53	M G A P V I L F S C T N **Q** H Y W D E **K** R	2	18
Y	54	M G A P V I L F S C T **N** Q H Y W D E K R	1	19
D	55	M G **A** P V I L **F** S C T N Q H Y **W** D E **K** R	4	16
L	56	M G A P V I L F S C T N Q H Y W D E K R	0	20
A	57	M G A P V I L F S C T N Q H Y **W** D E K R	1	19
A	58	M G A P V I L F S C T **N** Q H Y W D E **K** R	2	18
A	59	M G A P V I L F S C T N Q H Y W D E K R	0	20
T	60	**M** G A P V **I** L **F** S C T N Q H Y **W** D E **K** R	5	15

TABLE 19-continued

Human Klf4 Amino Acid Substitution Matrix
(Predictions Based on PMUT Analysis)

WT	Position		Number of Predicted Deleterious Mutations	Number of Predicted Neutral Mutations
V	61	MGAPVILFSCTNQHYWDEKR	0	20
A	62	MGAPVILFSCTNQHYWDEKR	0	20
T	63	**M**GAPV**I**L**F**SCTNQHY**W**DE**K**R	7	13
D	64	MG**A**PVIL**F**SCTNQHY**W**DEKR	3	17
L	65	MGAPVILFSCTNQHYWDEKR	0	20
E	66	MGAPV**I**LFSCTNQHY**W**DEKR	2	18
S	67	**M**GAP**V**I LFSCTNQHY**W**D**E**KR	6	14
G	68	**M**GAP**V**ILFSCTNQHY**W**D**E**K**R**	6	14
G	69	**M**GA**P**V ILFSCT**N**QHY**W**DEKR	6	14
A	70	**M**GA**P**V ILFSCT**N**QHY**W**DEKR	5	15
G	71	**M**GA**P**V**I**L**F**SCT**N**Q**H**Y**W**D**E**K**R**	14	6
A	72	MGAP**V**ILFSCTNQHYWDEKR	1	19
A	73	MGA**P**V**I**LFSCT**N**QHY**W**D**E**KR	7	13
C	74	MGAP**V**I LFSCTNQH**Y**W DE**K**R	6	14
G	75	MG**A**P VIL**F**SCTNQHY**W**D**E**K R	7	13
G	76	MG**A**PVIL**F**SCT**N**QH**Y**W**D**E**K**R	9	11
S	77	**M**GAPVIL**F**SCTNQHY**W**D EKR	4	16
N	78	**M**G**A**PVI**L**F SCTNQH**Y**W DEKR	7	13
L	79	MGAPVILFSCTNQHYWDEKR	0	20
A	80	**M**GA**P**V ILFSCT**N**Q HY**W**D E**K**R	8	12
P	81	MGAPVILFSCTNQHYWDEKR	0	20
L	82	MGAPVILFSCTNQHYWDEKR	0	20
P	83	MGAPVILFSCTNQHYWDEKR	0	20
R	84	**M**GA**P**V**I**L F**S**CT**N**QHY**W**D**E**KR	11	9
R	85	**M**G**A**P**V**I**L**F**S**C**T**N**Q**H**Y**W**D**E**KR	17	3
E	86	MGA**P**VILF**S**CTNQHY**W**DEKR	3	17
T	87	MGAPVILFSCTNQHYWDEKR	0	20
E	88	M**G**A**P**V**I**L F**S**CTNQHY**W**DE**K**R	9	11
E	89	MGAPVILFSCTNQHY**W**DEKR	1	19
F	90	MGAPVILFSCTNQHYWDEKR	0	20
N	91	MGAPVIL**F**SCTNQHY**W**DEKR	2	18
D	92	MG**A**PVIL**F**SCTNQHY**W**DEKR	3	17
L	93	MGAPVILFSCTNQHYWDEKR	0	20
L	94	MGAPVILFSCTNQHYWDEKR	0	20

TABLE 19-continued

Human Klf4 Amino Acid Substitution Matrix
(Predictions Based on PMUT Analysis)

WT	Position		Number of Predicted Deleterious Mutations	Number of Predicted Neutral Mutations
D	95	M**G**A**P**V**I**L**F**S**C**T**N**Q**H**Y**W**D**E**K**R**	13	7
L	96	M**G**A**P**V**I**L**F**S**C**T**N**Q**H**Y**W**D**E**K**R**	13	7
D	97	M**G**A**P**V**I**L**F**S**C**T**N**Q**H**Y**W**D**E**K**R**	13	7
F	98	M**G**A**P**V**I**L**F**S**C**T**N**Q**H**Y**W**D**E**K**R**	13	7
I	99	M**G**A**P**V**I**L**F**S**C**T**N**Q**H**Y**W**D**E**K**R**	13	7
L	100	M**G**A**P**V**I**L**F**S**C**T**N**Q**H**Y**W**D**E**K**R**	13	7
S	101	M**G**A**P**V**I**L**F**S**C**T**N**Q**H**Y**W**D**E**K**R**	13	7
N	102	M**G**A**P**V**I**L**F**S**C**T**N**Q**H**Y**W**D**E**K**R**	13	7
S	103	M**G**A**P**V**I**L**F**S**C**T**N**Q**H**Y**W**D**E**K**R**	13	7
L	104	M**G**A**P**V**I**L**F**S**C**T**N**Q**H**Y**W**D**E**K**R**	13	7
T	105	M**G**A**P**V**I**L**F**S**C**T**N**Q**H**Y**W**D**E**K**R**	13	7
H	106	M**G**A**P**V**I**L**F**S**C**T**N**Q**H**Y**W**D**E**K**R**	13	7
P	107	M**G**A**P**V**I**L**F**S**C**T**N**Q**H**Y**W**D**E**K**R**	13	7
P	108	M**G**A**P**V**I**L**F**S**C**T**N**Q**H**Y**W**D**E**K**R**	13	7
E	109	M**G**A**P**V**I**L**F**S**C**T**N**Q**H**Y**W**D**E**K**R**	13	7
S	110	M**G**A**P**V**I**L**F**S**C**T**N**Q**H**Y**W**D**E**K**R**	13	7
V	111	M**G**A**P**V**I**L**F**S**C**T**N**Q**H**Y**W**D**E**K**R**	13	7
A	112	M**G**A**P**V**I**L**F**S**C**T**N**Q**H**Y**W**D**E**K**R**	13	7
A	113	M**G**A**P**V**I**L**F**S**C**T**N**Q**H**Y**W**D**E**K**R**	13	7
T	114	M**G**A**P**V**I**L**F**S**C**T**N**Q**H**Y**W**D**E**K**R**	13	7
V	115	M**G**A**P**V**I**L**F**S**C**T**N**Q**H**Y**W**D**E**K**R**	13	7
S	116	M**G**A**P**V**I**L**F**S**C**T**N**Q**H**Y**W**D**E**K**R**	13	7
S	117	M**G**A**P**V**I**L**F**S**C**T**N**Q**H**Y**W**D**E**K**R**	13	7
S	118	M**G**A**P**V**I**L**F**S**C**T**N**Q**H**Y**W**D**E**K**R**	13	7
A	119	M**G**A**P**V**I**L**F**S**C**T**N**Q**H**Y**W**D**E**K**R**	13	7
S	120	M**G**A**P**V**I**L**F**S**C**T**N**Q**H**Y**W**D**E**K**R**	13	7
A	121	M**G**A**P**V**I**L**F**S**C**T**N**Q**H**Y**W**D**E**K**R**	13	7
S	122	M**G**A**P**V**I**L**F**S**C**T**N**Q**H**Y**W**D**E**K**R**	13	7
S	123	M**G**A**P**V**I**L**F**S**C**T**N**Q**H**Y**W**D**E**K**R**	13	7
S	124	M**G**A**P**V**I**L**F**S**C**T**N**Q**H**Y**W**D**E**K**R**	13	7
S	125	M**G**A**P**V**I**L**F**S**C**T**N**Q**H**Y**W**D**E**K**R**	13	7
S	126	M**G**A**P**V**I**L**F**S**C**T**N**Q**H**Y**W**D**E**K**R**	13	7
P	127	M**G**A**P**V**I**L**F**S**C**T**N**Q**H**Y**W**D**E**K**R**	13	7
S	128	M**G**A**P**V**I**L**F**S**C**T**N**Q**H**Y**W**D**E**K**R**	13	7

TABLE 19-continued

Human Klf4 Amino Acid Substitution Matrix
(Predictions Based on PMUT Analysis)

WT	Position		Number of Predicted Deleterious Mutations	Number of Predicted Neutral Mutations
S	129	M G A **P** V I **L** **F** S **C** T N **Q** H **Y** **W** D E **K** **R**	9	11
S	130	M G A **P** **V** **I** **L** **F** S **C** T N **Q** H **Y** **W** D E **K** **R**	11	9
G	131	M G **A** **P** **V** **I** **L** **F** S **C** **T** **N** **Q** H **Y** **W** **D** **E** **K** **R**	16	4
P	132	M **G** **A** P **V** I **L** **F** S C T **N** **Q** H **Y** **W** D E **K** **R**	11	9
A	133	M G A **P** V I L F S C T N Q H Y **W** **D** E K **R**	4	16
S	134	M G A **P** **V** **I** **L** **F** S **C** T N **Q** H **Y** **W** D **E** **K** R	11	9
A	135	M G A **P** V **I** **L** **F** S C T **N** **Q** H **Y** **W** **D** **E** **K** **R**	12	8
P	136	**M** **G** A P **V** **I** **L** **F** **S** C **T** **N** **Q** H Y **W** D **E** **K** **R**	14	6
S	137	M G A **P** **V** **I** **L** **F** S **C** T N **Q** H **Y** **W** D E K R	9	11
T	138	M **G** A P V **I** L **F** S C T N Q H **Y** **W** D E **K** **R**	7	13
A	139	M **G** A **P** **V** **I** L **F** **S** C T **N** Q **H** **Y** **W** **D** **E** **K** **R**	14	6
S	140	M G A **P** V I L **F** S C T N **Q** H **Y** **W** D **E** **K** **R**	8	12
F	141	M **G** **A** **P** **V** I L F **S** C **T** **N** **Q** H Y **W** **D** **E** K R	11	9
T	142	M G A P V I L F S C T N Q H Y **W** D E K R	1	19
Y	143	M **G** **A** **P** **V** **I** **L** F **S** **C** **T** **N** Q H Y W **D** **E** **K** R	13	7
P	144	M G A P V **I** **L** F S C T N **Q** H Y **W** D **E** **K** R	6	14
I	145	M G A P V I L F S C T **N** **Q** H Y **W** **D** **E** **K** **R**	7	13
R	146	M **G** **A** P **V** **I** L F S **C** T N **Q** H Y **W** D E K R	7	13
A	147	M G A P V **I** **L** **F** S C T **N** **Q** H **Y** **W** **D** E **K** **R**	10	10
G	148	M G A P V I **L** **F** S C T N Q H Y **W** D **E** **K** **R**	6	14
N	149	M **G** A P V I L **F** S C T N Q H Y **W** D E K R	3	17
D	150	**M** **G** **A** P **V** **I** **L** **F** **S** C T N Q H **Y** **W** D E **K** **R**	12	8
P	151	**M** **G** A P **V** **I** **L** **F** **S** C **T** **N** **Q** **H** **Y** **W** D **E** **K** **R**	16	4
G	152	M G A P V I L **F** S C T N Q H Y **W** D **E** **K** **R**	5	15
V	153	M G A P V I L F **S** C T **N** Q H Y **W** **D** E **K** **R**	6	14
A	154	M G A P **V** **I** L **F** S C T **N** Q H **Y** **W** **D** **E** **K** **R**	10	10
P	155	M **G** **A** P V **I** **L** **F** S C T N **Q** H **Y** **W** D **E** **K** **R**	11	9
G	156	M G A P V I L **F** S C T N Q H **Y** **W** D E **K** **R**	5	15
G	157	**M** G **A** **P** **V** **I** **L** **F** **S** **C** **T** **N** **Q** H **Y** **W** **D** **E** **K** **R**	18	2
T	158	M G A P V I L **F** S C T N Q H Y **W** D E **K** **R**	4	16
G	159	**M** G A **P** **V** **I** **L** **F** S C T N **Q** H **Y** **W** D **E** **K** **R**	12	8
G	160	**M** G A P **V** **I** **L** **F** S C **T** N **Q** H **Y** **W** D **E** **K** **R**	12	8
G	161	M G A P V **I** **L** **F** S **C** T N Q H **Y** **W** D E **K** **R**	8	12
L	162	M **G** A P V I L F **S** C T N Q H Y **W** **D** E **K** R	5	15

TABLE 19-continued

Human Klf4 Amino Acid Substitution Matrix
(Predictions Based on PMUT Analysis)

WT	Position		Number of Predicted Deleterious Mutations	Number of Predicted Neutral Mutations
L	163	MGAPVILFSCTNQHYWDEKR	2	18
Y	164	MGAPVILFSCTNQHYWDEKR	7	13
G	165	MGAPVILFSCTNQHYWDEKR	17	3
R	166	MGAPVILFSCTNQHYWDEKR	7	13
E	167	MGAPVILFSCTNQHYWDEKR	6	14
S	168	MGAPVILFSCTNQHYWDEKR	8	12
A	169	MGAPVILFSCTNQHYWDEKR	14	6
P	170	MGAPVILFSCTNQHYWDEKR	13	7
P	171	MGAPVILFSCTNQHYWDEKR	5	15
P	172	MGAPVILFSCTNQHYWDEKR	5	15
T	173	MGAPVILFSCTNQHYWDEKR	3	17
A	174	MGAPVILFSCTNQHYWDEKR	14	6
P	175	MGAPVILFSCTNQHYWDEKR	11	9
F	176	MGAPVILFSCTNQHYWDEKR	15	5
N	177	MGAPVILFSCTNQHYWDEKR	11	9
L	178	MGAPVILFSCTNQHYWDEKR	5	15
A	179	MGAPVILFSCTNQHYWDEKR	5	15
D	180	MGAPVILFSCTNQHYWDEKR	13	7
I	181	MGAPVILFSCTNQHYWDEKR	8	12
N	182	MGAPVILFSCTNQHYWDEKR	7	13
D	183	MGAPVILFSCTNQHYWDEKR	8	12
V	184	MGAPVILFSCTNQHYWDEKR	9	11
S	185	MGAPVILFSCTNQHYWDEKR	7	13
P	186	MGAPVILFSCTNQHYWDEKR	8	12
S	187	MGAPVILFSCTNQHYWDEKR	6	14
G	188	MGAPVILFSCTNQHYWDEKR	13	7
G	189	MGAPVILFSCTNQHYWDEKR	14	6
F	190	MGAPVILFSCTNQHYWDEKR	12	8
V	191	MGAPVILFSCTNQHYWDEKR	8	12
A	192	MGAPVILFSCTNQHYWDEKR	13	7
E	193	MGAPVILFSCTNQHYWDEKR	6	14
L	194	MGAPVILFSCTNQHYWDEKR	5	15
L	195	MGAPVILFSCTNQHYWDEKR	6	14
R	196	MGAPVILFSCTNQHYWDEKR	11	9

TABLE 19-continued

Human Klf4 Amino Acid Substitution Matrix
(Predictions Based on PMUT Analysis)

WT	Position		Number of Predicted Deleterious Mutations	Number of Predicted Neutral Mutations
P	197	M G A P V **I L** F **S** C T N Q **H** Y **W** D E **K R**	7	13
E	198	M G **A** P V **I** L F **S** C T N Q H Y **W** D E K R	4	16
L	199	M **G** A **P** V I L F S C T **N Q** H Y **W D E K** R	8	12
D	200	**M** G A P **V I L F S** C T N **Q** H **Y W** D E **K R**	12	8
P	201	M G A P V I L **F** S C T N Q H Y **W** D **E K R**	5	15
V	202	M G A P V I L F S C T N Q H Y **W D** E **K R**	4	16
Y	203	M **G A P V I L** F **S C T N** Q H Y W **D E K** R	13	7
I	204	M **G A P** V I L F **S C** T **N Q** H Y **W D E K R**	12	8
P	205	M **G** A P **V I L F** S C T **N Q H Y** W D **E K R**	13	7
P	206	M G A P V I **L** F S C T N Q H Y **W** D E **K R**	4	16
Q	207	M **G A** P V **I L** F **S** C **T** N Q H Y **W** D E K R	7	13
Q	208	M **G A P** V **I L F** S **C T N** Q H Y **W** D E **K** R	12	8
P	209	M G A P V I L **F** S C T N Q H Y **W** D E **K R**	4	16
Q	210	M G A P V **I L** F S C T N Q H Y **W** D E **K** R	4	16
P	211	M **G** A P V I **L F** S C T N Q H Y **W** D E **K R**	6	14
P	212	M G A P **V I L F** S C T **N** Q **H Y W** D E **K R**	10	10
G	213	**M** G A **P V I L F** S **C T** N **Q H Y W D E K R**	16	4
G	214	M G A P **V I L F S C** T N Q H **Y W** D **E K R**	11	9
G	215	**M** G A P **V I L F S C** T N **Q** H **Y W D E K R**	14	6
L	216	M G A P V I L F S C T **N** Q H Y W **D** E **K** R	3	17
M	217	M **G A P** V I L F **S** C T **N** Q H Y W D **E K R**	8	12
G	218	M G A P **V I L F** S **C** T N **Q** H **Y W** D **E K R**	11	9
K	219	M **G A P V I L F S C T** N **Q** H Y **W D** E K R	13	7
F	220	M **G A P V** I L F **S C T N Q H** Y W **D E** K **R**	13	7
V	221	M **G** A **P** V I L **F S** C T N Q **H Y W D** E **K R**	10	10
L	222	M **G** A **P** V I L F **S** C T **N** Q H Y **W D** E **K R**	8	12
K	223	M **G A P V I L F S C** T N Q H **Y W** D **E** K R	12	8
A	224	M G A **P** V I **L F** S C T **N Q H Y W D E K R**	12	8
S	225	M G A P V I L **F** S C T N Q H **Y W** D E K R	3	17
L	226	M **G** A **P** V I L F S C T **N** Q H Y **W** D **E K** R	6	14
S	227	M G A P V I L **F** S C T N Q H Y **W** D E **K** R	3	17
A	228	M G A **P** V **I** L **F** S C T **N Q** H **Y W D E K R**	11	9
P	229	**M G A** P **V I L F S** C T **N Q** H **Y W** D E **K R**	14	6
G	230	**M** G A **P V I L F** S **C T N Q** H **Y W D E K R**	17	3

TABLE 19-continued

Human Klf4 Amino Acid Substitution Matrix
(Predictions Based on PMUT Analysis)

WT	Position		Number of Predicted Deleterious Mutations	Number of Predicted Neutral Mutations
S	231	**M** G A **P** **V** **I** **L** **F** S **C** T N **Q** H **Y** **W** **D** E **K** **R**	13	7
E	232	M G A P V **I** L F S C T N Q H Y **W** D E **K** R	4	16
Y	233	M **G** **A** **P** **V** **I** L F **S** **C** **T** **N** Q H Y W **D** **E** **K** R	12	8
G	234	**M** G **A** **P** **V** **I** **L** **F** S **C** T N **Q** H **Y** **W** D **E** **K** **R**	14	6
S	235	M G A **P** V I L **F** S C T N Q H **Y** **W** D **E** K **R**	6	14
P	236	M G A P V **I** **L** **F** S C T N Q H Y **W** D E **K** **R**	6	14
S	237	M G A P V I L **F** S C T N Q H **Y** **W** D E **K** R	4	16
V	238	M **G** A P V I L F **S** C T N Q H Y **W** **D** E **K** **R**	6	14
I	239	M **G** **A** **P** V I L F **S** C T **N** **Q** H Y **W** **D** **E** **K** **R**	11	9
S	240	M G A P V I L **F** S C T N Q H **Y** **W** D E **K** R	4	16
V	241	M G A P V I **L** F **S** C **T** **N** Q **H** **Y** **W** **D** E **K** **R**	10	10
S	242	**M** **G** A **P** **V** **I** **L** **F** S **C** T N Q **H** **Y** **W** D E **K** **R**	13	7
K	243	M G **A** P V **I** L F **S** C T N Q H Y **W** D E K R	4	16
G	244	M G A P **V** **I** **L** **F** S **C** **T** N **Q** H **Y** **W** **D** **E** **K** **R**	13	7
S	245	**M** **G** A **P** **V** **I** **L** **F** S **C** T N Q H **Y** **W** D E **K** **R**	12	8
P	246	M G A P V I **L** **F** S C T N Q H Y **W** D **E** **K** **R**	6	14
D	247	**M** G A P **V** **I** **L** **F** **S** C T N **Q** H **Y** **W** D E **K** R	10	10
G	248	**M** G A **P** **V** **I** **L** **F** S **C** T N **Q** H **Y** **W** D **E** **K** **R**	13	7
S	249	M G A P V I L **F** S C T N Q H **Y** **W** D E **K** R	4	16
H	250	**M** **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** N Q H **Y** **W** **D** **E** **K** **R**	17	3
P	251	M **G** A P **V** **I** **L** **F** S C T N Q **H** **Y** **W** D **E** **K** **R**	11	9
V	252	M **G** **A** P V I L F **S** C **T** **N** Q **H** **Y** **W** **D** E **K** **R**	11	9
V	253	M **G** A P V I **L** F S C T N Q **H** Y **W** **D** E **K** **R**	7	13
V	254	M **G** **A** **P** V I L **F** **S** C T **N** **Q** **H** **Y** **W** D E **K** **R**	12	8
A	255	M **G** A **P** V I L **F** S C T **N** **Q** **H** **Y** **W** **D** **E** **K** **R**	12	8
P	256	M **G** A P **V** **I** **L** **F** S C T N **Q** **H** **Y** **W** D E **K** **R**	11	9
Y	257	M **G** **A** **P** **V** I L F **S** **C** **T** **N** Q H Y W **D** **E** **K** R	11	9
N	258	M G A P V I L **F** S C T N Q H Y **W** D E K R	2	18
G	259	M G A **P** **V** **I** **L** **F** S **C** **T** N **Q** H **Y** **W** D **E** **K** **R**	13	7
G	260	**M** G A **P** **V** **I** **L** **F** S **C** **T** **N** **Q** **H** **Y** **W** D **E** **K** **R**	16	4
P	261	M G **A** P **V** **I** **L** **F** S C **T** N **Q** **H** **Y** **W** D **E** **K** **R**	13	7
P	262	M **G** A P V **I** **L** **F** S C T N Q H Y **W** D E **K** **R**	7	13
R	263	**M** **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** N **Q** **H** Y **W** **D** E K R	15	5
T	264	M G A P V I **L** **F** S C T N Q H **Y** **W** D E **K** R	5	15

TABLE 19-continued

Human Klf4 Amino Acid Substitution Matrix
(Predictions Based on PMUT Analysis)

WT	Position		Number of Predicted Deleterious Mutations	Number of Predicted Neutral Mutations
C	265	M G A P V I L F S C T N Q H Y W D E K R	16	4
P	266	M G A P V I L F S C T N Q H Y W D E K R	7	13
K	267	M G A P V I L F S C T N Q H Y W D E K R	5	15
I	268	M G A P V I L F S C T N Q H Y W D E K R	12	8
K	269	M G A P V I L F S C T N Q H Y W D E K R	4	16
Q	270	M G A P V I L F S C T N Q H Y W D E K R	8	12
E	271	M G A P V I L F S C T N Q H Y W D E K R	10	10
A	272	M G A P V I L F S C T N Q H Y W D E K R	11	9
V	273	M G A P V I L F S C T N Q H Y W D E K R	6	14
S	274	M G A P V I L F S C T N Q H Y W D E K R	4	16
S	275	M G A P V I L F S C T N Q H Y W D E K R	4	16
C	276	M G A P V I L F S C T N Q H Y W D E K R	13	7
T	277	M G A P V I L F S C T N Q H Y W D E K R	14	6
H	278	M G A P V I L F S C T N Q H Y W D E K R	15	5
L	279	M G A P V I L F S C T N Q H Y W D E K R	1	19
G	280	M G A P V I L F S C T N Q H Y W D E K R	15	5
A	281	M G A P V I L F S C T N Q H Y W D E K R	7	13
G	282	M G A P V I L F S C T N Q H Y W D E K R	13	7
P	283	M G A P V I L F S C T N Q H Y W D E K R	16	4
P	284	M G A P V I L F S C T N Q H Y W D E K R	9	11
L	285	M G A P V I L F S C T N Q H Y W D E K R	3	17
S	286	M G A P V I L F S C T N Q H Y W D E K R	4	16
N	287	M G A P V I L F S C T N Q H Y W D E K R	8	12
G	288	M G A P V I L F S C T N Q H Y W D E K R	12	8
H	289	M G A P V I L F S C T N Q H Y W D E K R	12	8
R	290	M G A P V I L F S C T N Q H Y W D E K R	12	8
P	291	M G A P V I L F S C T N Q H Y W D E K R	11	9
A	292	M G A P V I L F S C T N Q H Y W D E K R	6	14
A	293	M G A P V I L F S C T N Q H Y W D E K R	11	9
H	294	M G A P V I L F S C T N Q H Y W D E K R	15	5
D	295	M G A P V I L F S C T N Q H Y W D E K R	10	10
F	296	M G A P V I L F S C T N Q H Y W D E K R	12	8
P	297	M G A P V I L F S C T N Q H Y W D E K R	7	13
L	298	M G A P V I L F S C T N Q H Y W D E K R	7	13

TABLE 19-continued

Human Klf4 Amino Acid Substitution Matrix
(Predictions Based on PMUT Analysis)

WT	Position		Number of Predicted Deleterious Mutations	Number of Predicted Neutral Mutations
G	299	**M** G A **P** **V** **I** **L** **F** S **C** **T** N **Q** **H** **Y** **W** D **E** **K** **R**	15	5
R	300	**M** **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** **N** **Q** **H** **Y** **W** **D** **E** **K** R	19	1
Q	301	M **G** A P V **I** **L** F S C T N Q H Y **W** D E **K** R	5	15
L	302	M **G** A **P** V I L F S C T **N** Q H Y **W** D E **K** R	5	15
P	303	M **G** A P **V** **I** **L** **F** S C T N **Q** **H** **Y** **W** D E **K** **R**	11	9
S	304	M G A P **V** **I** L **F** S C T N Q H **Y** **W** **D** E **K** **R**	8	12
R	305	**M** **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** N Q **H** Y **W** **D** E K R	14	6
T	306	M **G** A P V **I** **L** **F** S C T N Q H **Y** **W** D E **K** **R**	8	12
T	307	M **G** A P V I **L** **F** S C T N Q H **Y** **W** D E K **R**	6	14
P	308	M **G** A P **V** **I** **L** **F** S C T N **Q** **H** **Y** **W** D **E** **K** **R**	13	7
T	309	M G A P V I L **F** S C T N Q H **Y** **W** D **E** **K** R	5	15
L	310	M G A P V I L F S C T **N** Q H Y W **D** E K R	2	18
G	311	**M** G A **P** **V** **I** **L** **F** **S** **C** **T** **N** **Q** **H** **Y** **W** D **E** **K** **R**	17	3
L	312	**M** **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** N **Q** **H** **Y** **W** **D** **E** **K** **R**	1	19
E	313	M G A P V **I** **L** F **S** C T N Q H Y **W** D E K R	4	16
E	314	M G A P V **I** **L** **F** S C T N Q H Y **W** D E K R	4	16
V	315	M **G** A P V I **L** F S C T **N** Q **H** Y **W** **D** E **K** **R**	8	12
L	316	M **G** A **P** V I L F S C T **N** Q H Y **W** **D** E **K** R	6	14
S	317	M G A **P** **V** **I** **L** **F** S **C** T N Q H **Y** **W** D E **K** **R**	10	10
S	318	**M** G A **P** **V** **I** **L** **F** S **C** T N **Q** **H** **Y** **W** D E **K** **R**	13	7
R	319	**M** **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** N **Q** **H** Y **W** **D** E K R	15	5
D	320	**M** G A P **V** **I** **L** **F** S C T N Q H **Y** **W** D E **K** **R**	9	11
C	321	M **G** A **P** **V** **I** L **F** S C T **N** **Q** **H** **Y** **W** **D** **E** **K** **R**	14	6
H	322	**M** **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** N Q H Y **W** **D** E **K** **R**	15	5
P	323	M G A P **V** **I** **L** **F** **S** C T N Q **H** **Y** **W** D E **K** **R**	10	10
A	324	M G A **P** V I L **F** S C T **N** **Q** H **Y** **W** **D** **E** **K** **R**	10	10
L	325	M **G** A **P** V I L F S C T **N** Q H Y **W** **D** E **K** R	6	14
P	326	**M** **G** A P **V** **I** **L** **F** **S** **C** T **N** **Q** **H** **Y** **W** D E **K** R	15	5
L	327	M **G** A **P** V I L F S C T **N** Q H Y **W** **D** E **K** R	6	14
P	328	**M** **G** **A** P **V** **I** **L** **F** S **C** T **N** **Q** H **Y** **W** D E **K** **R**	14	6
P	329	M G A P V **I** **L** **F** S C T N Q **H** **Y** **W** D **E** **K** **R**	9	11
G	330	**M** G A **P** **V** **I** **L** **F** S **C** **T** **N** **Q** **H** **Y** **W** **D** **E** **K** **R**	17	3
F	331	M **G** A **P** V I L F S C **T** **N** Q H Y W **D** E K **R**	6	14
H	332	**M** **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** N Q H **Y** **W** **D** E **K** **R**	16	4

TABLE 19-continued

Human Klf4 Amino Acid Substitution Matrix
(Predictions Based on PMUT Analysis)

WT	Position		Number of Predicted Deleterious Mutations	Number of Predicted Neutral Mutations
P	333	**M G A** P **V I L F S C T N Q H Y W** D **E K R**	18	2
H	334	**M G A P V I L F S C T** N Q H **Y W D** E **K R**	16	4
P	335	M G A P V **I L F** S C T N Q H Y **W** D E **K R**	6	14
G	336	**M** G A **P V I L F S C T** N **Q H Y W** D **E K R**	16	4
P	337	M G A P V I **L F** S C T N Q H Y **W** D **E K R**	6	14
N	338	**M G** A P V **I L F** S C T N Q H **Y W** D **E** K R	8	12
Y	339	M **G A P V I** L F **S C T N** Q H Y W **D E K** R	12	8
P	340	M G A P V **I L F** S C T N **Q** H **Y W** D E **K R**	8	12
S	341	M G A **P** V **I L F** S C T N Q H **Y W** D E K **R**	7	13
F	342	M G **A P V** I L F **S C T N Q H** Y W **D E** K **R**	12	8
L	343	M **G** A **P** V I L F S C T **N** Q H Y W **D** E **K** R	5	15
P	344	M G A P V **I L F** S C T N **Q** H Y **W** D E **K R**	7	13
D	345	**M G A** P **V I L F** S C T N Q **H Y W** D E **K R**	12	8
Q	346	M **G** A **P** V **I L F S** C T N Q H Y **W** D E K R	7	13
M	347	M **G A P** V I L F **S C T N** Q H Y **W D E K R**	12	8
Q	348	M **G A P V I L F S C T** N Q H Y **W** D E K **R**	12	8
P	349	M G A P V I **L F** S C T N Q H Y **W** D E **K R**	5	15
Q	350	M G A P V **I L** F S C **T** N Q H Y **W** D E K R	4	16
V	351	M **G** A P V I L F S C **T N** Q H Y **W D** E **K R**	7	13
P	352	M **G** A P **V I L F** S C T N **Q H Y W** D E **K R**	11	9
P	353	M G A P **V I L F** S C T N Q **H Y W** D E **K** R	8	12
L	354	M **G** A **P V** I L F S C T **N** Q H Y **W D** E **K R**	8	12
H	355	M **G A P V I L F S C T** N Q H Y **W D** E **K** R	13	7
Y	356	M **G A P V I L** F **S C T N** Q **H** Y W **D E K** R	14	6
Q	357	M **G** A P V **I L** F S C **T** N Q H Y W D E K R	5	15
E	358	M **G** A P V **I L F** S **C** T N Q H **Y W** D E K R	7	13
L	359	M **G** A **P** V I L F S C T **N** Q H Y **W D** E **K** R	6	14
M	360	M G A **P** V I L F S C **T N** Q H Y W **D E K R**	7	13
P	361	**M G A** P **V I L F S** C T **N Q** H **Y W** D **E K R**	16	4
P	362	**M G A** P **V I L F S C** T **N Q H Y W** D **E K R**	17	3
G	363	**M** G A P **V I L F** S **C** T N **Q** H **Y W** D **E K R**	12	8
S	364	M G A **P V I L F** S **C** T N Q H **Y W** D E K **R**	9	11
C	365	M **G** A **P V I L F S** C T **N** Q **H Y W D E K R**	15	5
M	366	M **G** A **P** V I L F **S** C **T N** Q H Y **W D E K R**	10	10

TABLE 19-continued

Human Klf4 Amino Acid Substitution Matrix
(Predictions Based on PMUT Analysis)

WT	Position		Number of Predicted Deleterious Mutations	Number of Predicted Neutral Mutations
P	367	**M G** A P **V I L F S** C T **N Q** H **Y W** D **E K R**	14	6
E	368	**M** G A P V **I** L **F** S C T N Q H **Y W** D E K R	5	15
E	369	**M G** A **P** V **I L F** S C T N Q H **Y W** D E K **R**	9	11
P	370	M G A P V **I L F** S C T N Q H Y **W** D E **K R**	6	14
K	371	**M G A P V I L F S C T** N Q H **Y W D** E K R	14	6
P	372	M G A P **V I L F S** C T N Q **H Y W** D E **K R**	10	10
K	373	M **G** A **P V I** L F S **C** T N Q H Y **W** D E K R	6	14
R	374	**M G** A **P V I L F** S **C** T N Q H Y **W D** E K R	10	10
G	375	**M** G A **P V I L F** S **C T N Q H Y W D E K R**	17	3
R	376	**M G** A **P V I L F** S **C** T N Q **H** Y **W D** E K R	11	9
R	377	**M G A P V I L F S C T N Q H Y W D E** K R	17	3
S	378	M **G A P V I L F** S **C** T N Q H **Y W** D E K **R**	9	11
W	379	**M G A P V I L F S C T N Q H** Y W **D E K R**	2	18
P	380	**M G** A P **V I L F** S C T **N Q H Y W** D E **K R**	13	7
R	381	**M G A P V I L F S C T N Q H Y W D E** K R	18	2
K	382	M **G** A **P V I** L F S **C** T N Q H Y **W** D E K R	6	14
R	383	**M G A P V I L F S C T N Q H Y W D E** K R	18	2
T	384	M G A P V **I L F** S C T N Q H **Y W** D E K **R**	5	15
A	385	**M** G A **P** V **I L F** S C T **N Q H Y W D E K R**	14	6
T	386	**M G** A **P** V **I L F** S C T N **Q** H **Y W** D E **K R**	11	9
H	387	M **G A P V I L F S C T** N Q H Y **W D** E **K R**	14	6
T	388	**M G** A P V **I L F** S C T N Q **H Y W** D E **K R**	10	10
C	389	**M G** A **P V I L F S** C T **N Q H Y W D E K R**	17	3
D	390	**M G A** P **V I L F S** C T N **Q H Y W** D E **K R**	14	6
Y	391	M **G A P V** I L F **S C T** N Q H Y W **D E K** R	11	9
A	392	**M** G A **P** V **I L F** S C T **N Q H Y W D E K R**	14	6
G	393	**M** G A **P V I L F** S **C T** N **Q** H Y **W D E K R**	16	4
C	394	**M G A P V I L F S** C T **N Q H Y W D E K R**	18	2
G	395	**M** G A **P V I L F** S **C T** N **Q H Y W D E K R**	16	4
K	396	**M G A P V I L F S C T N** Q H **Y W D** E K R	15	5
T	397	**M G** A **P** V **I L F** S C T N **Q H Y W** D E **K R**	12	8
Y	398	M **G A P V I L** F **S C T N** Q H Y W **D E K** R	13	7
T	399	**M G** A **P** V **I L F** S C T N **Q H Y W** D E **K R**	12	8
K	400	**M G A P V I L F S C T N** Q H **Y W D** E K R	14	6

TABLE 19-continued

Human Klf4 Amino Acid Substitution Matrix
(Predictions Based on PMUT Analysis)

WT	Position		Number of Predicted Deleterious Mutations	Number of Predicted Neutral Mutations
S	401	**M** G A **P** **V** **I** **L** **F** S **C** T N **Q** **H** **Y** **W** D **E** **K** **R**	14	6
S	402	**M** G A **P** **V** **I** **L** **F** S **C** T N **Q** **H** **Y** **W** D **E** **K** **R**	14	6
H	403	**M** **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** N **Q** H **Y** **W** **D** **E** **K** **R**	18	2
L	404	M **G** A **P** V I L F **S** C T **N** **Q** H Y **W** **D** **E** **K** **R**	10	10
K	405	**M** **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** N Q H **Y** **W** **D** E K R	14	6
A	406	**M** G A **P** **V** **I** **L** **F** S C T **N** **Q** **H** **Y** **W** **D** **E** **K** **R**	15	5
H	407	**M** **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** N **Q** H **Y** **W** **D** **E** **K** **R**	18	2
L	408	M **G** A **P** V I L F S C T **N** Q H Y **W** **D** E **K** **R**	7	13
R	409	**M** **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** **N** **Q** **H** **Y** **W** **D** **E** K R	18	2
T	410	**M** **G** A **P** **V** **I** **L** **F** S C T N **Q** **H** **Y** **W** D **E** **K** **R**	14	6
H	411	**M** **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** N Q H Y **W** **D** E **K** **R**	15	5
T	412	**M** **G** A **P** V **I** **L** **F** S C T N **Q** **H** **Y** **W** D E **K** **R**	12	8
G	413	**M** G A **P** **V** **I** **L** F S **C** **T** N **Q** **H** **Y** **W** **D** **E** **K** **R**	16	4
E	414	**M** **G** **A** **P** V **I** **L** **F** S **C** **T** **N** Q H **Y** **W** D E **K** R	13	7
K	415	**M** **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** N Q H **Y** **W** **D** E K R	14	6
P	416	**M** **G** A P **V** **I** **L** **F** **S** **C** T **N** **Q** **H** **Y** **W** D E **K** **R**	15	5
Y	417	M **G** **A** **P** **V** **I** **L** F **S** **C** **T** **N** Q H Y W **D** **E** **K** R	13	7
H	418	**M** **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** N Q H Y **W** **D** E **K** **R**	15	5
C	419	**M** **G** **A** **P** **V** **I** **L** **F** **S** C T **N** **Q** **H** **Y** **W** **D** **E** **K** **R**	18	2
D	420	**M** G **A** P **V** **I** **L** **F** **S** C T **N** Q **H** **Y** **W** D E **K** **R**	13	7
W	421	**M** **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** **N** **Q** **H** Y W **D** **E** **K** **R**	18	2
D	422	**M** G **A** P **V** **I** **L** **F** S C T N Q H **Y** **W** D E **K** **R**	10	10
G	423	**M** G A **P** **V** **I** **L** **F** S **C** **T** N **Q** **H** **Y** **W** **D** **E** **K** **R**	16	4
C	424	**M** **G** **A** **P** **V** **I** **L** **F** **S** C T **N** **Q** **H** **Y** **W** **D** **E** **K** **R**	18	2
G	425	**M** G A **P** **V** **I** **L** **F** S **C** **T** N **Q** **H** **Y** **W** **D** **E** **K** **R**	16	4
W	426	**M** **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** **N** **Q** **H** Y W **D** **E** **K** **R**	18	2
K	427	**M** **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** N Q H **Y** **W** **D** E K R	14	6
F	428	M **G** **A** **P** **V** **I** **L** F **S** **C** **T** **N** **Q** **H** Y W **D** **E** K **R**	15	5
A	429	**M** G A **P** V **I** **L** **F** S C T **N** **Q** **H** **Y** **W** **D** **E** **K** **R**	14	6
R	430	**M** **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** **N** **Q** **H** **Y** **W** **D** **E** K R	18	2
S	431	**M** G A **P** **V** **I** **L** **F** S **C** T N Q **H** **Y** **W** D E **K** **R**	12	8
D	432	**M** **G** **A** **P** **V** **I** **L** **F** **S** C **T** **N** **Q** **H** **Y** **W** D E **K** **R**	17	3
E	433	**M** **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** **N** Q H **Y** **W** D E **K** **R**	16	4
L	434	M **G** A **P** V I L F **S** C T **N** **Q** H Y **W** **D** **E** **K** **R**	10	10

TABLE 19-continued

Human Klf4 Amino Acid Substitution Matrix
(Predictions Based on PMUT Analysis)

WT	Position		Number of Predicted Deleterious Mutations	Number of Predicted Neutral Mutations
T	435	**M G A P V I L F** S C T N **Q H Y W** D **E K R**	14	6
R	436	**M G A P V I L F S C T N Q H Y W D E** K R	18	2
H	437	**M G A P V I L F S C T** N **Q** H **Y W D E K R**	18	2
Y	438	M **G A P V I L** F **S C T N** Q H Y W **D E K** R	13	7
R	439	**M G A P V I L F S C T N Q H Y W D E** K R	18	2
K	440	**M G A P V I L F S C T N** Q H **Y W D E** K R	16	4
H	441	**M G A P V I L F S C T** N **Q** H **Y W D E K R**	18	2
T	442	**M G A P** V **I L F** S C T N **Q H Y W** D E **K R**	12	8
G	443	**M** G A **P V I L F** S **C T** N **Q H Y W D E K R**	16	4
H	444	**M G A P V I L F S C T** N Q H Y **W D** E **K R**	15	5
R	445	**M G A P V I L F S C T** N **Q H** Y **W D E** K R	16	4
P	446	**M G A** P **V I L F S C** T **N Q H Y W** D E **K R**	16	4
F	447	M **G A P V** I **L** F **S C T N Q H** Y W **D E** K **R**	14	6
Q	448	M **G A P V I L F** S **C T** N Q H **Y W** D E K R	11	9
C	449	**M G** A **P V I L F S** C T **N Q H Y W D E K R**	17	3
Q	450	M **G A P V I L F** S **C T** N Q **H** Y **W** D E **K** R	12	8
K	451	M **G A P V I L F S C T** N Q H **Y W** D E K R	12	8
C	452	**M G** A **P V I L F S** C T **N Q H Y W D E K R**	17	3
D	453	**M G A P V I L F S** C T N **Q H Y W** D E **K R**	15	5
R	454	**M G A P V I L F S C T N Q H Y W D E** K R	18	2
A	455	**M** G A **P** V **I L F** S C T **N Q H Y W D E K R**	14	6
F	456	M **G A P V** I L F **S C T N Q H** Y W **D E** K **R**	13	7
S	457	**M** G A **P V I L F** S **C** T N Q **H Y W** D E **K R**	12	8
R	458	**M G A P V I L F S C T N Q H Y W D E** K R	18	2
S	459	**M** G A **P V I L F** S **C** T N **Q H Y W** D **E K R**	14	6
D	460	**M G A P V I L F S** C T N **Q H Y W** D E **K R**	15	5
H	461	**M G A P V I L F S C T N Q H Y W D E K R**	18	2
L	462	M **G** A **P** V I L F **S** C T **N Q** H Y **W D E K R**	10	10
A	463	**M** G A **P V I L F** S C T **N Q H Y W D E K R**	15	5
L	464	M **G** A **P** V I L F **S** C T **N Q** H Y **W D E K R**	10	10
H	465	**M G A P V I L F S C T** N **Q** H **Y W D E K R**	18	2
M	466	M **G A P V** I L **F S C T N Q** H **Y W D E K R**	17	3
K	467	**M G A P V I L F S C T N** Q H **Y W D E** K R	16	4
R	468	**M G A P V I L F S C T N Q H Y W D E** K R	18	2

TABLE 19-continued

Human Klf4 Amino Acid Substitution Matrix
(Predictions Based on PMUT Analysis)

WT	Position		Number of Predicted Deleterious Mutations	Number of Predicted Neutral Mutations
H	469	**M G A P V I L F S C T** N Q H Y **W D E K R**	15	5
F	470	M **G A P** V I L F **S C T N Q** H Y W **D E** K **R**	11	9

TABLE 20

Human c-Myc Amino Acid Substitution Matrix
(Predictions Based on PMUT Analysis)

WT	Position		Number of Predicted Deleterious Mutations	Number of Predicted Neutral Mutations
M	1	M **G A P** V I L **F S C T N** Q H Y **W D E K R**	13	7
P	2	**M G A** P V **I L F** S C **T N Q H** Y **W** D **E K R**	14	6
L	3	M **G** A **P** V I L F S **C T N Q H** Y **W D E K R**	12	8
N	4	**M G A** P V **I L F** S C T N **Q** H **Y W** D E **K R**	11	9
V	5	M **G** A P V I L **F** S C T **N** Q H Y **W** D **E K R**	7	13
S	6	**M** G A **P** V **I** L **F** S **C** T N **Q** H Y **W** D **E K R**	10	10
F	7	M **G A P V I** L F S **C T N Q H** Y W **D** E **K R**	13	7
T	8	M G A P V I L F S C T N Q H Y W D E K R	0	20
N	9	**M G A** P V **I** L **F** S C T N Q H Y **W** D **E K** R	8	12
R	10	**M G A P** V **I L** F **S** C **T** N Q H Y **W** D E K R	9	11
N	11	**M G A** P **V I L F** S C T N **Q** H **Y W** D **E K R**	13	7
Y	12	M **G A** P **V I** L F **S C T N** Q H Y W **D** E K **R**	10	10
D	13	**M G A P V I L F S** C T N **Q H Y W** D E **K R**	16	4
L	14	M **G** A **P** V I L F S C **T N** Q H Y **W** D E **K** R	6	14
D	15	**M G A** P **V I L F S** C T N **Q** H Y **W** D E **K** R	11	9
Y	16	M **G A P V I L** F **S C T N** Q H Y W **D E K R**	14	6
D	17	**M G A P V I L F S** C T N **Q H Y W** D E **K R**	15	5
S	18	**M** G A **P V I L F** S **C** T N **Q H Y W D E K R**	16	4
V	19	M G A P V I L **F** S C T N Q H Y **W D** E **K R**	5	15
Q	20	**M G A P V I L F S C T N** Q **H Y W** D E **K R**	18	2
P	21	**M G A** P **V I L F S** C **T N Q H Y W** D **E K R**	17	3
Y	22	M **G A P V I L** F **S C T N** Q H Y W **D E K R**	14	6
F	23	**M G A P V I L** F **S C T N Q H** Y **W D E K R**	18	2
Y	24	M G **A P V I** L F **S C T N** Q H Y W **D** E **K** R	10	10
C	25	M G A P **V I** L F S C T **N** Q H **Y W** D E **K R**	7	13

TABLE 20-continued

Human c-Myc Amino Acid Substitution Matrix
(Predictions Based on PMUT Analysis)

WT	Position		Number of Predicted Deleterious Mutations	Number of Predicted Neutral Mutations
D	26	**M G A** P **V I L F** S C **T** N Q H **Y W** D E **K R**	12	8
E	27	**M G A** P **V I L F** S **C** T N Q H **Y W** D E **K** R	11	9
E	28	**M G A** P V **I L** F S C T N Q H **Y W** D E K **R**	8	12
E	29	**M G A** P **V I L** F **S C** T N Q H Y **W** D E **K** R	10	10
N	30	**M G A** P **V I L F** S C T N Q H **Y W** D E K **R**	10	10
F	31	M **G** A P V I L F S **C T N** Q H Y W D **E** K **R**	6	14
Y	32	M **G A P V I L** F S **C T N** Q **H** Y W **D E K R**	14	6
Q	33	M **G** A P V **I** L F **S** C T N Q H Y **W** D E K R	4	16
Q	34	**M G A P** V **I L F S C T N** Q H Y **W D E K R**	15	5
Q	35	M **G A P** V **I L F S C T N** Q H Y **W** D E K **R**	12	8
Q	36	M **G** A P V I L F **S C T** N Q H Y **W** D E K R	5	15
Q	37	M **G A P V I L F S** C **T** N Q **H** Y **W** D E K R	11	9
S	38	**M** G A P **V** I **L F** S C T N **Q** H **Y W** D **E K** R	9	11
E	39	**M G A P V I L F S** C **T** N Q H **Y W** D E **K** R	13	7
L	40	M **G** A P V I L F **S C** T **N Q** H Y **W D E K R**	10	10
Q	41	**M G A P** V **I L F S C T N** Q **H** Y **W** D E **K R**	16	4
P	42	**M G** A P **V** I L F S **C T** N **Q H** Y **W** D **E K R**	11	9
P	43	**M G** A P **V** I **L F** S C T **N Q** H **Y W** D **E K R**	12	8
A	44	**M** G A **P V I L F** S **C T N Q** H **Y W D E K R**	16	4
P	45	**M G A** P **V I L F S C T N Q H Y W** D **E K R**	18	2
S	46	**M** G A P V I L **F** S **C** T N Q H **Y W D E K R**	9	11
E	47	**M G A P V I** L **F S** C T N Q H Y **W** D E **K R**	11	9
D	48	**M G A** P **V I L F S** C T N **Q H Y W** D E **K R**	14	6
I	49	M **G A P** V I L **F S C** T **N** Q H **Y W D E K R**	12	8
W	50	**M G A P V I L F S C T N Q H** Y W **D E K R**	18	2
K	51	**M G A P V I L F S C T** N **Q** H **Y W D E** K R	16	4
K	52	**M G A P V I L F S C T** N **Q** H **Y W D E** K R	16	4
F	53	**M G A P V I L** F **S C T N Q H** Y **W D E K R**	18	2
E	54	**M G A** P **V I L F S** C T N Q H **Y W** D E **K** R	11	9
L	55	M G A P V I L F S C T **N Q H** Y **W D E K** R	7	13
L	56	M **G A P** V I L F S C **T N Q H** Y **W** D E **K R**	11	9
P	57	**M G** A P **V I L F** S C **T N Q H** Y **W** D **E K R**	14	6
T	58	**M G** A P **V I L F** S C T **N Q H Y W D E K R**	15	5
P	59	**M G** A P **V I L F S** C **T N Q H Y W** D **E K R**	16	4

TABLE 20-continued

Human c-Myc Amino Acid Substitution Matrix
(Predictions Based on PMUT Analysis)

WT	Position		Number of Predicted Deleterious Mutations	Number of Predicted Neutral Mutations
P	60	**M G** A P **V I L F** S C **T N Q H Y W** D **E K R**	15	5
L	61	**M G A P V I** L **F S C T** N Q H **Y W** D E K **R**	7	13
S	62	**M G** A **P V I L F** S **C** T **N Q H Y W D E K R**	17	3
P	63	**M G** A P **V I** L **F** S C **T N Q H** Y **W** D **E K R**	14	6
S	64	**M** G A **P V I L F** S **C** T N **Q H Y W D E K R**	15	5
R	65	**M G A P V I L F S C T N Q H** Y **W D E** K R	17	3
R	66	**M G A P V I** L **F S C T N Q H** Y **W** D **E** K R	15	5
S	67	**M** G A **P V I L F** S **C** T N **Q H Y W** D **E K R**	14	6
G	68	M G A P V **I L F** S **C T N Q H Y W** D **E K R**	13	7
L	69	M G A P V I L F S C **T N** Q H Y **W** D E K R	3	17
C	70	**M G** A **P V I** L **F** S C T **N Q H Y W** D **E K R**	14	6
S	71	**M** G A **P** V **I** L **F** S **C** T N **Q H Y W** D **E K R**	13	7
P	72	**M G** A P **V I** L **F S C** T **N Q H Y W** D **E K R**	15	5
S	73	M G A P V **I** L **F** S **C** T N Q H **Y W D** E K **R**	7	13
Y	74	M **G A** P **V** I L F **S** C **T** N Q H Y W D **E K R**	8	12
V	75	M G A **P** V I L F S C T **N Q H Y W** D **E K R**	9	11
A	76	M G A P **V** I L **F** S C T N **Q H Y W** D **E K R**	9	11
V	77	M G A P V I L F S C T N Q H Y W D E **K R**	2	18
T	78	M G A P V I L F S C T N Q H Y **W** D E K R	19	1
P	79	M G A P V I L **F** S C T **N** Q H Y **W** D E K R	3	17
F	80	M G **A P V** I L F **S** C **T N** Q H Y W **D** E K **R**	8	12
S	81	**M** G A **P V I L F** S C T N **Q H Y W D E K R**	14	6
L	82	M G A P V I L F S C T N Q H Y W D E **K** R	1	19
R	83	**M G A** P **V I L** F S **C T N Q H** Y **W** D E K R	12	8
G	84	**M G A** P V **I** L **F** S **C** T **N Q** H **Y W** D **E K** R	11	9
D	85	**M G A** P **V I L F** S C T N **Q** H Y **W** D E K R	9	11
N	86	M G A P V **I** L **F** S C T N Q H Y **W** D E K R	3	17
D	87	**M G A** P **V I L F** S C T N **Q H Y W** D E **K R**	13	7
G	88	**M** G A **P V I** L **F** S C T N Q H **Y W** D **E K R**	10	10
G	89	M G A **P V I** L F S C T N Q **H Y W** D E **K R**	8	12
G	90	M G A **P** V **I** L **F** S C **T N Q** H **Y W** D E **K R**	11	9
G	91	M G A **P** V I L **F** S C **T** N **Q** H **Y W** D E **K R**	8	12
S	92	M G A **P V I L F** S **C** T N **Q H Y W** D **E K R**	13	7
F	93	M G A **P** V I L F S **C T** N Q H Y W D E K **R**	4	16

TABLE 20-continued

Human c-Myc Amino Acid Substitution Matrix
(Predictions Based on PMUT Analysis)

WT	Position		Number of Predicted Deleterious Mutations	Number of Predicted Neutral Mutations
S	94	**M** G A **P** **V** **I** **L** **F** S **C** T N Q **H** **Y** **W** D **E** K **R**	12	8
T	95	**M** **G** A **P** **V** **I** **L** **F** S C T **N** **Q** **H** **Y** **W** **D** **E** **K** **R**	16	4
A	96	**M** G A **P** **V** **I** **L** **F** S **C** T **N** **Q** **H** **Y** **W** **D** **E** **K** **R**	16	4
D	97	M **G** **A** P **V** **I** **L** **F** **S** C T N **Q** H **Y** **W** D E **K** **R**	12	8
Q	98	**M** **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** **N** Q H Y **W** **D** E **K** **R**	16	4
L	99	M G A **P** V I L **F** **S** **C** **T** N **Q** **H** **Y** **W** D **E** **K** **R**	12	8
E	100	**M** **G** **A** **P** V **I** **L** **F** **S** **C** **T** N Q H **Y** **W** D E **K** **R**	14	6
M	101	M **G** **A** **P** V I L **F** **S** **C** **T** **N** **Q** H Y **W** **D** **E** **K** **R**	14	6
V	102	M **G** A **P** V I **L** **F** **S** **C** **T** **N** **Q** **H** **Y** **W** D E **K** **R**	15	5
T	103	**M** **G** A P **V** **I** **L** **F** S C T N Q **H** **Y** **W** D E **K** R	10	10
E	104	**M** **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** **N** Q H **Y** **W** D E **K** R	15	5
L	105	M **G** **A** P V I L F S **C** **T** **N** **Q** H Y **W** D **E** **K** R	9	11
L	106	M **G** **A** **P** V I L F **S** C **T** N **Q** H **Y** **W** D **E** **K** R	10	10
G	107	**M** G A **P** V **I** **L** **F** **S** **C** **T** N **Q** **H** **Y** **W** **D** **E** **K** **R**	17	3
G	108	**M** G A **P** V I L **F** S C **T** N **Q** **H** **Y** **W** D E **K** **R**	10	10
D	109	**M** **G** **A** **P** **V** **I** **L** **F** **S** C **T** **N** **Q** **H** **Y** **W** D E **K** **R**	17	3
M	110	M **G** **A** **P** V I L **F** **S** **C** **T** **N** Q H Y **W** **D** **E** **K** **R**	13	7
V	111	M **G** A **P** V I L **F** S **C** **T** **N** **Q** **H** **Y** **W** **D** **E** **K** **R**	14	6
N	112	**M** **G** **A** **P** **V** **I** **L** **F** S **C** T N **Q** **H** **Y** **W** D **E** **K** **R**	16	4
Q	113	**M** **G** **A** **P** **V** **I** **L** F S **C** **T** **N** Q **H** Y **W** **D** E **K** **R**	15	5
S	114	**M** G A **P** **V** **I** **L** **F** S **C** T N **Q** **H** **Y** **W** **D** **E** **K** **R**	15	5
F	115	M **G** A **P** **V** **I** L F **S** **C** **T** **N** **Q** **H** Y **W** **D** E K **R**	13	7
I	116	M **G** **A** **P** V I L **F** **S** **C** **T** **N** **Q** H Y **W** **D** **E** **K** **R**	14	6
C	117	**M** **G** A **P** **V** **I** **L** **F** **S** C T **N** **Q** **H** **Y** **W** D **E** **K** **R**	16	4
D	118	**M** **G** **A** P **V** **I** **L** **F** **S** C T N **Q** **H** **Y** **W** D E **K** **R**	14	6
P	119	**M** **G** A P **V** I **L** **F** S C **T** **N** Q **H** **Y** **W** D **E** **K** **R**	13	7
D	120	**M** **G** **A** P **V** **I** **L** **F** **S** C T N **Q** **H** **Y** **W** D E **K** **R**	14	6
D	121	M **G** **A** P **V** I **L** **F** S C T N Q **H** **Y** **W** D E **K** **R**	10	10
E	122	**M** **G** **A** **P** V **I** **L** **F** **S** C **T** N Q H **Y** **W** D E **K** R	12	8
T	123	M **G** A P V **I** L **F** S C T N **Q** H **Y** **W** D **E** **K** **R**	9	11
F	124	**M** **G** **A** **P** **V** **I** **L** F **S** **C** **T** **N** **Q** **H** Y W D E **K** **R**	16	4
I	125	M **G** A **P** V I L F S **C** **T** N Q H **Y** W **D** **E** **K** **R**	9	11
K	126	**M** **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** N **Q** **H** **Y** **W** **D** **E** K R	17	3
N	127	**M** **G** A P V I L **F** S C T N Q H **Y** **W** D E K **R**	6	14

TABLE 20-continued

Human c-Myc Amino Acid Substitution Matrix
(Predictions Based on PMUT Analysis)

WT	Position		Number of Predicted Deleterious Mutations	Number of Predicted Neutral Mutations
I	128	M G A P V I L F S C T N Q H Y W D E K R	14	6
I	129	M G A P V I L F S C T N Q H Y W D E K R	13	7
I	130	M G A P V I L F S C T N Q H Y W D E K R	12	8
Q	131	M G A P V I L F S C T N Q H Y W D E K R	16	4
D	132	M G A P V I L F S C T N Q H Y W D E K R	17	3
C	133	M G A P V I L F S C T N Q H Y W D E K R	17	3
M	134	M G A P V I L F S C T N Q H Y W D E K R	14	6
W	135	M G A P V I L F S C T N Q H Y W D E K R	19	1
S	136	M G A P V I L F S C T N Q H Y W D E K R	15	5
G	137	M G A P V I L F S C T N Q H Y W D E K R	18	2
F	138	M G A P V I L F S C T N Q H Y W D E K R	17	3
S	139	M G A P V I L F S C T N Q H Y W D E K R	16	4
A	140	M G A P V I L F S C T N Q H Y W D E K R	17	3
A	141	M G A P V I L F S C T N Q H Y W D E K R	16	4
A	142	M G A P V I L F S C T N Q H Y W D E K R	17	3
K	143	M G A P V I L F S C T N Q H Y W D E K R	18	2
L	144	M G A P V I L F S C T N Q H Y W D E K R	12	8
V	145	M G A P V I L F S C T N Q H Y W D E K R	15	5
S	146	M G A P V I L F S C T N Q H Y W D E K R	14	6
E	147	M G A P V I L F S C T N Q H Y W D E K R	14	6
K	148	M G A P V I L F S C T N Q H Y W D E K R	17	3
L	149	M G A P V I L F S C T N Q H Y W D E K R	14	6
A	150	M G A P V I L F S C T N Q H Y W D E K R	16	4
S	151	M G A P V I L F S C T N Q H Y W D E K R	11	9
Y	152	M G A P V I L F S C T N Q H Y W D E K R	15	5
Q	153	M G A P V I L F S C T N Q H Y W D E K R	17	3
A	154	M G A P V I L F S C T N Q H Y W D E K R	17	3
A	155	M G A P V I L F S C T N Q H Y W D E K R	12	8
R	156	M G A P V I L F S C T N Q H Y W D E K R	17	3
K	157	M G A P V I L F S C T N Q H Y W D E K R	11	9
D	158	M G A P V I L F S C T N Q H Y W D E K R	8	12
S	159	M G A P V I L F S C T N Q H Y W D E K R	9	11
G	160	M G A P V I L F S C T N Q H Y W D E K R	10	10
S	161	M G A P V I L F S C T N Q H Y W D E K R	7	13

TABLE 20-continued

Human c-Myc Amino Acid Substitution Matrix
(Predictions Based on PMUT Analysis)

WT	Position		Number of Predicted Deleterious Mutations	Number of Predicted Neutral Mutations
P	162	**M G** A P **V I L F** S C **T N Q H** Y **W** D **E K** R	13	7
N	163	M G A P V I L **F** S C T N Q H Y **W** D E K R	2	18
P	164	M **G** A P **V I L F** S C T N Q H Y **W** D E **K R**	8	12
A	165	M G A P **V** I L **F** S C T **N** Q H **Y W** D **E K R**	8	12
R	166	**M G A P V I** L **F S C T N Q H** Y **W D E** K R	16	4
G	167	**M** G A P V **I** L **F** S C T **N Q H Y W D E** K **R**	11	9
H	168	M **G A P V I L F S C T** N Q H Y **W D E K R**	14	6
S	169	M G A P V I L **F** S C T N Q H **Y W** D E K **R**	4	16
V	170	M G A P V I L **F S** C T **N** Q **H Y W D E K R**	10	10
C	171	M G A P **V I** L **F** S C T **N Q H Y W** D E **K R**	10	10
S	172	M G A **P** V **I** L **F** S **C** T N Q H **Y W D E K R**	10	10
T	173	**M** G A P V **I** L **F** S C T N **Q H Y W** D **E K R**	10	10
S	174	**M** G A **P V I L F** S C T N **Q H Y W D E K** R	13	7
S	175	M G A P **V I** L **F** S **C** T N **Q** H **Y W** D **E K R**	10	10
L	176	M G A P V I L F S C **T N Q** H Y **W** D E **K R**	6	14
Y	177	M **G A P V I** L F S C **T N** Q H Y W **D E K R**	11	9
L	178	M **G** A P V I L F **S** C **T N Q** H Y **W** D E **K R**	9	11
Q	179	M **G A P V I L F S** C **T N** Q H Y **W D** E **K** R	13	7
D	180	**M G A** P **V I L F S** C T **N Q H Y W** D E **K R**	15	5
L	181	M **G** A P V I L **F** S C **T N Q H** Y **W** D **E K R**	10	10
S	182	M G A P V **I L F** S C T N Q H **Y W D E K R**	9	11
A	183	M G A **P** V I **L F** S C T **N Q** H **Y W D E K R**	11	9
A	184	**M** G A P V **I L F** S C **T N Q H Y W D E K R**	14	6
A	185	**M** G A **P V I L F** S C T **N Q H Y W D E K R**	15	5
S	186	**M** G A **P V I L F** S **C** T N **Q H Y W D E K R**	15	5
E	187	**M G A** P V **I L** F **S** C T N Q H Y **W** D E **K R**	9	11
C	188	**M G** A **P V I L F S** C **T N Q H Y W D E K R**	18	2
I	189	M **G A P** V I L **F** S **C T N Q** H **Y W D E K R**	14	6
D	190	**M G A P V I L F S** C T **N Q H Y W** D E **K R**	16	4
P	191	**M G** A P **V I L F** S **C T N Q H Y W** D **E K R**	16	4
S	192	**M** G A **P V I L F** S **C** T N **Q H Y W D E K R**	15	5
V	193	**M G A P** V I L **F S C T N Q H Y W D E K R**	17	3
V	194	M **G** A **P** V I L **F S C T N Q H Y W D E K R**	15	5
F	195	**M G A P V I L** F **S C T N Q H** Y **W D E** K **R**	17	3

TABLE 20-continued

Human c-Myc Amino Acid Substitution Matrix
(Predictions Based on PMUT Analysis)

WT	Position		Number of Predicted Deleterious Mutations	Number of Predicted Neutral Mutations
P	196	**M G A** P **V I L F S C T N Q H Y W** D **E K R**	18	2
Y	197	**M G A P V I L** F **S C T N Q H** Y W **D E K R**	17	3
P	198	**M G A** P **V I L F S C T N Q H Y W** D **E K R**	18	2
L	199	M **G A P** V I L **F** S C **T N Q H Y W D E K R**	14	6
N	200	**M G A** P **V I L F** S C T N **Q** H **Y W** D E K **R**	11	9
D	201	**M G A** P **V I L F** S C T N Q **H Y W** D E **K R**	12	8
S	202	**M** G A P **V I L F** S C T N Q **H Y W D** E **K R**	11	9
S	203	M G A **P V** I **L F** S **C** T N Q H **Y W** D E **K R**	9	11
S	204	**M** G A P **V I L F** S **C** T N **Q** H **Y W D E K R**	13	7
P	205	**M G** A P **V I L** F S C T **N Q H Y W** D **E K R**	13	7
K	206	M **G** A **P V I L F** S C **T** N Q H **Y W D** E K R	10	10
S	207	M G A P V **I** L **F** S C T N Q H Y **W** D **E K R**	6	14
C	208	M **G** A P **V I** L **F** S C T **N Q H Y W** D **E K R**	12	8
A	209	M G A P **V** I L **F** S C T **N Q H Y W D E K R**	11	9
S	210	M G A **P V I** L **F** S **C** T N **Q** H **Y W** D **E K R**	11	9
Q	211	M G A P V I L F S C T N Q H Y **W** D E K R	1	19
D	212	**M G A** P **V I L F S** C T N **Q H Y W** D E **K R**	14	6
S	213	**M** G A P **V I L F** S **C** T N Q **H Y W D E K R**	13	7
S	214	M G A P V I L **F** S C T N **Q** H **Y W** D **E K R**	7	13
A	215	**M** G A **P V I L F** S C **T N Q H Y W D E K R**	16	4
F	216	M G A P V I L F S **C** T **N Q** H Y W **D** E **K R**	6	14
S	217	**M G** A **P V I L F** S **C** T N **Q H Y W D E K R**	16	4
P	218	**M G** A P **V I L F** S **C** T **N Q H Y W** D **E K R**	15	5
S	219	M G A **P V I** L **F** S C T N **Q H Y W** D **E K R**	11	9
S	220	M G A P V **I L F** S **C** T N Q H **Y W D E K R**	10	10
D	221	M **G A** P V **I L F** S C T **N** Q H **Y W** D E **K** R	9	11
S	222	M G A **P V** I **L F** S **C** T N **Q H Y W D E K R**	14	6
L	223	M G A P V I L F S C T **N** Q H Y **W D E K R**	6	14
L	224	M **G** A P V I L F S C T **N Q H** Y **W D E K R**	9	11
S	225	M G A **P V** I L **F** S **C** T N **Q** H **Y W D** E **K R**	10	10
S	226	M G A P **V I L F** S **C** T N Q H **Y W** D **E K R**	10	10
T	227	M **G** A P V **I L F** S C T N Q H **Y W** D E **K R**	8	12
E	228	**M G A** P V **I L F S C T** N Q H **Y W** D E K R	10	10
S	229	M G A P V I L **F** S C T N **Q** H **Y W D E K R**	8	12

TABLE 20-continued

Human c-Myc Amino Acid Substitution Matrix
(Predictions Based on PMUT Analysis)

WT	Position		Number of Predicted Deleterious Mutations	Number of Predicted Neutral Mutations
S	230	M G A **P** V **I** **L** **F** S **C** T N Q **H** **Y** **W** D **E** **K** **R**	11	9
P	231	**M** **G** A P **V** **I** **L** **F** S C T **N** **Q** **H** **Y** **W** D **E** **K** **R**	14	6
Q	232	M G **A** P V I L F S C T N Q H Y **W** D E K R	2	18
G	233	**M** G A P V **I** **L** **F** S **C** T N **Q** H **Y** **W** D **E** **K** **R**	11	9
S	234	**M** G A **P** **V** **I** **L** **F** S **C** T N Q H **Y** **W** **D** **E** **K** **R**	13	7
P	235	**M** G A P **V** **I** **L** **F** S **C** **T** **N** **Q** **H** **Y** **W** D **E** **K** **R**	15	5
E	236	**M** G **A** P V **I** **L** **F** S **C** T N Q H **Y** **W** D E **K** **R**	10	10
P	237	M **G** A P **V** **I** **L** **F** S **C** **T** N **Q** **H** **Y** **W** D **E** **K** **R**	14	6
L	238	M G A **P** V I L F S C T **N** Q H Y **W** D E **K** **R**	5	15
V	239	M **G** A P V I L **F** S C T N **Q** **H** **Y** **W** **D** E **K** **R**	10	10
L	240	M **G** **A** **P** V I L F S C **T** **N** **Q** H Y W D E **K** **R**	8	12
H	241	M **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** N Q H Y **W** **D** E **K** **R**	14	6
E	242	**M** **G** **A** **P** V **I** **L** **F** **S** **C** T N Q H **Y** **W** D E K R	11	9
E	243	**M** **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** N Q H **Y** **W** D E **K** R	14	6
T	244	**M** **G** A P **V** **I** **L** **F** S C T N **Q** **H** **Y** **W** D E **K** **R**	12	8
P	245	**M** **G** A P **V** **I** **L** **F** S **C** T **N** **Q** **H** **Y** **W** D E **K** **R**	14	6
P	246	**M** **G** A P **V** **I** **L** **F** S **C** **T** **N** **Q** **H** **Y** **W** D E **K** **R**	15	5
T	247	**M** **G** A P **V** **I** **L** **F** S C T N **Q** H **Y** **W** D E **K** **R**	11	9
Y	248	**M** **G** A P **V** **I** **L** **F** S C T N Q **H** **Y** **W** D E **K** **R**	11	9
S	249	M G A **P** **V** I **L** **F** S **C** T N Q **H** **Y** **W** D E **K** **R**	10	10
S	250	**M** G A **P** **V** **I** **L** **F** S **C** T N Q H **Y** **W** D E **K** **R**	11	9
D	251	**M** **G** **A** **P** **V** **I** **L** **F** **S** C T **N** **Q** **H** **Y** **W** D E **K** **R**	16	4
S	252	**M** G A P V **I** **L** **F** S **C** T N Q H **Y** **W** D E **K** **R**	10	10
E	253	**M** **G** **A** **P** **V** **I** **L** **F** **S** **C** T N Q H **Y** **W** D E **K** **R**	14	6
E	254	**M** **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** N Q H **Y** **W** D E **K** **R**	15	5
E	255	**M** **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** N Q H **Y** **W** D E **K** **R**	15	5
Q	256	**M** **G** **A** **P** **V** **I** **L** **F** **S** C **T** **N** Q H **Y** **W** D E **K** **R**	15	5
E	257	**M** **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** N Q H **Y** **W** D E K R	13	7
D	258	**M** **G** **A** P **V** **I** **L** **F** S C T N **Q** **H** **Y** **W** D E **K** **R**	13	7
E	259	**M** **G** **A** **P** V **I** **L** **F** **S** **C** T N Q H **Y** **W** D E **K** **R**	13	7
E	260	**M** **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** N Q H **Y** **W** D E K **R**	14	6
E	261	**M** **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** **N** Q H **Y** **W** D E **K** **R**	16	4
I	262	M **G** **A** **P** V I L **F** **S** **C** **T** **N** **Q** **H** **Y** **W** **D** **E** **K** **R**	16	4
D	263	**M** **G** **A** **P** **V** **I** **L** **F** **S** C **T** **N** **Q** **H** **Y** **W** D E **K** **R**	17	3

TABLE 20-continued

Human c-Myc Amino Acid Substitution Matrix
(Predictions Based on PMUT Analysis)

WT	Position		Number of Predicted Deleterious Mutations	Number of Predicted Neutral Mutations
V	264	M**G**A**P**V I **L** **F** **S** **C** **T** **N** **Q** **H** **Y** **W** **D** **E** **K** **R**	17	3
V	265	M**G**A**P**V I **L** **F** **S** **C** **T** **N** **Q** **H** **Y** **W** **D** **E** **K** **R**	17	3
S	266	M G A **P** V **I** **L** **F** S **C** T N Q **H** **Y** **W** **D** **E** **K** **R**	12	8
V	267	M **G** A **P** V I **L** **F** **S** **C** **T** **N** **Q** **H** **Y** **W** **D** **E** **K** **R**	16	4
E	268	**M** **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** **N** Q H **Y** **W** D E **K** **R**	16	4
K	269	**M** **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** N Q H **Y** **W** **D** **E** K R	15	5
R	270	**M** **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** **N** **Q** **H** **Y** **W** **D** **E** K R	18	2
Q	271	**M** **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** **N** Q **H** **Y** **W** D E **K** **R**	18	2
A	272	M G A P V I L **F** S C T **N** **Q** H **Y** **W** **D** E **K** **R**	8	12
P	273	M **G** A P **V** **I** **L** **F** S C T **N** **Q** **H** **Y** **W** D **E** **K** **R**	13	7
G	274	M G A P V I L **F** S **C** T N **Q** H **Y** **W** D E **K** **R**	7	13
K	275	**M** **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** N Q H **Y** **W** **D** **E** K R	15	5
R	276	**M** **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** **N** **Q** **H** **Y** **W** **D** **E** K R	18	2
S	277	M G A **P** **V** **I** **L** **F** S **C** T N Q **H** **Y** **W** D **E** **K** **R**	12	8
E	278	**M** **G** **A** **P** V **I** **L** **F** **S** C T N Q H **Y** **W** D E **K** **R**	12	8
S	279	**M** G A **P** V **I** **L** **F** S **C** T N **Q** **H** **Y** **W** D **E** **K** **R**	13	7
G	280	**M** G **A** **P** **V** **I** **L** **F** S **C** T N **Q** **H** **Y** **W** D **E** **K** **R**	15	5
S	281	M G A **P** V **I** L **F** S **C** T N **Q** **H** **Y** **W** **D** E **K** **R**	11	9
P	282	M **G** A P **V** **I** **L** **F** S C T N Q H **Y** **W** D E **K** **R**	9	11
S	283	**M** G A **P** **V** **I** **L** **F** S **C** T N Q **H** **Y** **W** **D** **E** **K** **R**	14	6
A	284	M G A **P** V **I** **L** **F** S C T **N** **Q** **H** **Y** **W** **D** **E** **K** **R**	13	7
G	285	**M** G A P V I L **F** S **C** **T** N **Q** H **Y** **W** D E **K** **R**	9	11
G	286	**M** G A **P** **V** **I** **L** **F** S **C** **T** N **Q** H **Y** **W** **D** **E** **K** **R**	15	5
H	287	M **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** N **Q** H Y **W** **D** E **K** **R**	15	5
S	288	**M** G A **P** **V** **I** **L** **F** S C T N **Q** H **Y** **W** D **E** **K** **R**	12	8
K	289	**M** **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** **N** **Q** H **Y** **W** **D** **E** K R	17	3
P	290	**M** **G** A P **V** **I** **L** **F** S **C** T **N** **Q** **H** Y **W** D **E** **K** **R**	14	6
P	291	M **G** A P **V** I **L** **F** S **C** **T** **N** Q H **Y** **W** D E **K** **R**	11	9
H	292	M **G** **A** **P** **V** **I** **L** **F** **S** **C** **T** N Q H **Y** **W** **D** E **K** **R**	15	5
S	293	**M** **G** A **P** **V** **I** **L** **F** S **C** T N **Q** **H** **Y** **W** **D** **E** **K** **R**	16	4
P	294	**M** **G** **A** P **V** **I** **L** **F** **S** **C** **T** **N** **Q** H **Y** **W** D **E** **K** **R**	17	3
L	295	M **G** **A** **P** V I L F **S** **C** **T** **N** **Q** **H** **Y** **W** **D** **E** **K** **R**	15	5
V	296	**M** **G** A **P** V I L **F** **S** **C** T **N** **Q** **H** **Y** **W** **D** **E** **K** **R**	15	5
L	297	M **G** **A** **P** V I L **F** **S** **C** **T** **N** **Q** **H** **Y** **W** **D** **E** **K** **R**	16	4

TABLE 20-continued

Human c-Myc Amino Acid Substitution Matrix
(Predictions Based on PMUT Analysis)

WT	Position		Number of Predicted Deleterious Mutations	Number of Predicted Neutral Mutations
K	298	**M G A P V I L F S C T N Q H Y W D E** K R	18	2
R	299	**M G A P V I L F S C T N Q H Y W D E K** R	19	1
C	300	**M G** A **P V I L F S** C **T N Q H Y W D E K R**	18	2
H	301	M **G A P V I L F S C T N Q** H **Y W** D E **K R**	17	3
V	302	**M G** A P V I **L F S C T N Q H Y W D E K R**	16	4
S	303	**M** G A P **V** I **L F** S **C** T N **Q H Y W** D **E K R**	12	8
T	304	**M G** A P **V** I **L F** S C T N **Q** H **Y W** D **E K R**	11	9
H	305	M **G A P V I L F S C T** N Q H **Y W D E K R**	15	5
Q	306	**M G A P V I L F S C T N** Q **H Y W** D E **K R**	18	2
H	307	**M G A P V I L F S C T** N **Q** H **Y W D E K R**	18	2
N	308	**M G A P V I L F S C T** N **Q H Y W** D **E K R**	18	2
Y	309	**M G A P V I L** F **S C T N Q H** Y **W D E K R**	18	2
A	310	**M** G A **P V I L F** S **C T N Q H Y W D E K R**	17	3
A	311	**M G** A **P V I L F** S **C T N Q H Y W D E K R**	18	2
P	312	**M G A** P **V I L F S C T N Q H Y W** D **E K R**	19	1
P	313	**M G A** P **V I L F** S **C T N Q H Y W** D **E K R**	17	3
S	314	**M** G A **P V I L F** S **C** T N **Q H Y W** D **E K R**	15	5
T	315	**M G** A **P** V **I L F** S C T N **Q H Y W** D E **K R**	12	8
R	316	**M G A P V I L F S C T N Q H** Y **W D E** K R	17	3
K	317	M **G A P** V **I L F S C T** N Q H **Y W D** E K R	12	8
D	318	**M G A P V I L F S** C T **N Q H Y W** D E **K R**	15	5
Y	319	**M G A P V I L** F **S C T N** Q **H** Y W **D E K R**	16	4
P	320	**M G A** P **V I L F S** C **T N Q H Y W** D **E K R**	17	3
A	321	**M** G A P **V I L F** S C **T N Q H Y W D E K R**	15	5
A	322	M G A **P** V I **L F** S C T **N** Q **H Y W D E K R**	11	9
K	323	**M G A P V I L F S C T** N **Q H Y W D E** K R	17	3
P	324	**M G A P V I L F S C T N Q H Y W D E** K R	18	2
V	325	M G A P V I L F **S** C T **N** Q H Y W D E **K R**	4	16
K	326	**M G A P V I L F S C T** N **Q** H **Y W D E** K R	16	4
L	327	M **G A P** V I L **F** S **C T N Q H** Y **W D E K R**	14	6
D	328	**M G A** P **V I L F S** C T **N** Q **H Y W** D E **K R**	14	6
S	329	**M** G A **P V I L F** S **C** T N **Q H Y W D E K R**	15	5
V	330	M G A P V I L F S C T **N** Q **H** Y W **D** E **K R**	5	15
R	331	**M G A P V I L F S C T N Q H Y W D E** K R	18	2

TABLE 20-continued

Human c-Myc Amino Acid Substitution Matrix
(Predictions Based on PMUT Analysis)

WT	Position		Number of Predicted Deleterious Mutations	Number of Predicted Neutral Mutations
V	332	M G A P V I L F S C T N Q H Y W D E K R	16	4
L	333	M G A P V I L F S C T N Q H Y W D E K R	11	9
R	334	M G A P V I L F S C T N Q H Y W D E K R	15	5
Q	335	M G A P V I L F S C T N Q H Y W D E K R	14	6
I	336	M G A P V I L F S C T N Q H Y W D E K R	14	6
S	337	M G A P V I L F S C T N Q H Y W D E K R	16	4
N	338	M G A P V I L F S C T N Q H Y W D E K R	13	7
N	339	M G A P V I L F S C T N Q H Y W D E K R	12	8
R	340	M G A P V I L F S C T N Q H Y W D E K R	18	2
K	341	M G A P V I L F S C T N Q H Y W D E K R	18	2
C	342	M G A P V I L F S C T N Q H Y W D E K R	18	2
T	343	M G A P V I L F S C T N Q H Y W D E K R	5	15
S	344	M G A P V I L F S C T N Q H Y W D E K R	14	6
P	345	M G A P V I L F S C T N Q H Y W D E K R	17	3
R	346	M G A P V I L F S C T N Q H Y W D E K R	19	1
S	347	M G A P V I L F S C T N Q H Y W D E K R	16	4
S	348	M G A P V I L F S C T N Q H Y W D E K R	17	3
D	349	M G A P V I L F S C T N Q H Y W D E K R	16	4
T	350	M G A P V I L F S C T N Q H Y W D E K R	11	9
E	351	M G A P V I L F S C T N Q H Y W D E K R	15	5
E	352	M G A P V I L F S C T N Q H Y W D E K R	15	5
N	353	M G A P V I L F S C T N Q H Y W D E K R	17	3
V	354	M G A P V I L F S C T N Q H Y W D E K R	1	19
K	355	M G A P V I L F S C T N Q H Y W D E K R	16	4
R	356	M G A P V I L F S C T N Q H Y W D E K R	18	2
R	357	M G A P V I L F S C T N Q H Y W D E K R	18	2
T	358	M G A P V I L F S C T N Q H Y W D E K R	16	4
H	359	M G A P V I L F S C T N Q H Y W D E K R	18	2
N	360	M G A P V I L F S C T N Q H Y W D E K R	18	2
V	361	M G A P V I L F S C T N Q H Y W D E K R	16	4
L	362	M G A P V I L F S C T N Q H Y W D E K R	16	4
E	363	M G A P V I L F S C T N Q H Y W D E K R	17	3
R	364	M G A P V I L F S C T N Q H Y W D E K R	18	2
Q	365	M G A P V I L F S C T N Q H Y W D E K R	18	2

TABLE 20-continued

Human c-Myc Amino Acid Substitution Matrix
(Predictions Based on PMUT Analysis)

WT	Position		Number of Predicted Deleterious Mutations	Number of Predicted Neutral Mutations
R	366	**M G A P V I L F S C T N Q H Y W D E** K R	18	2
R	367	**M G A P V I L F S C T N Q H Y W D E** K R	18	2
N	368	**M G A P V I L F** S C T N **Q** H **Y W** D **E K R**	15	5
E	369	**M G A P V I L F S C T** N Q H **Y W** D E **K R**	15	5
L	370	M **G A P** V I L **F S C T N Q H Y W D E K R**	16	4
K	371	**M G A P V I L F S C T N Q H Y W D E** K R	18	2
R	372	**M G A P V I L F S C T N Q H Y W D E** K R	18	2
S	373	**M G** A **P V I L F** S C T **N Q H Y W D E K R**	17	3
F	374	**M G A P V I L** F **S C T N Q H** Y **W D E K R**	18	2
F	375	**M G A P V I L** F **S C T N Q H** Y **W D E K R**	18	2
A	376	**M** G A **P V I L F** S **C T N Q H Y W D E K R**	17	3
L	377	M **G A P** V I L **F S C T N Q H Y W D E K R**	16	4
R	378	**M G A P V I L F S C T N Q H Y W D E K** R	19	1
D	379	**M G A P V I L F S** C T N **Q H Y W** D E **K R**	15	5
Q	380	**M G A P V I L F S C T N** Q **H Y W D** E **K R**	18	2
I	381	M **G A P** V I L **F S C T N Q** H **Y W D E K R**	15	5
P	382	**M G A** P **V I L F S C T N Q H Y W** D **E K R**	18	2
E	383	**M G A P V I L F S C T** N Q H **Y W** D E **K R**	15	5
L	384	M **G A P** V I L F S **C T N Q H** Y **W D E K R**	13	7
E	385	**M G** A **P** V **I L F S C T** N Q H **Y W** D E **K R**	13	7
N	386	**M G A P V I L F** S **C** T N **Q** H **Y W** D **E K R**	15	5
N	387	**M G A P V I L F** S **C** T N **Q** H **Y W** D **E K R**	15	5
E	388	**M G A P V I L F S C T** N Q H **Y W** D E **K** R	14	6
K	389	**M G A P V I L F S C T N Q H Y W D E** K R	18	2
A	390	**M** G A **P V I L F** S **C T N Q H Y W D E K R**	17	3
P	391	**M G** A P **V I L F S C T N Q H Y W** D **E K R**	17	3
K	392	**M G A P V I L F S C T N Q H Y W D E** K R	18	2
V	393	**M G A P** V I **L F S C T N Q H Y W D E K R**	18	2
V	394	**M G A P** V I **L F S C T N Q H Y W D E K R**	18	2
I	395	M **G A P** V I L **F S C T N Q H Y W D E K R**	16	4
L	396	M **G A P** V I L **F S C T N Q H Y W D E K R**	16	4
K	397	**M G A P V I L F S C T N Q H Y W D E** K R	18	2
K	398	**M G A P V I L F S C T N Q H Y W D E** K R	18	2
A	399	**M** G A **P V I L F** S **C T N Q H Y W D E K R**	17	3

TABLE 20-continued

Human c-Myc Amino Acid Substitution Matrix
(Predictions Based on PMUT Analysis)

WT	Position		Number of Predicted Deleterious Mutations	Number of Predicted Neutral Mutations
T	400	**M G** A **P V I L F** S C T **N Q H Y W D E K R**	16	4
A	401	**M** G A **P** V **I L F** S C T **N Q H Y W** D E **K R**	13	7
Y	402	M **G A P V I L** F **S C T N Q** H Y **W D E K R**	16	4
I	403	M **G A P** V I L **F S C T N Q** H **Y W D E K R**	15	5
L	404	M **G A P** V I L **F S C T N Q** H Y **W D E K R**	14	6
S	405	**M G** A **P V I L F** S **C** T N **Q H Y W D E K R**	16	4
V	406	M **G** A **P** V I L **F S** C T **N** Q **H Y W D E K R**	12	8
Q	407	**M G A P V I L F S C T N** Q **H Y W** D E K **R**	18	2
A	408	**M** G A **P V I L F** S C **T N Q H Y W D E K R**	16	4
E	409	**M G A P** V **I L F S** C T N Q H **Y W** D E K R	10	10
E	410	**M G A P V I L F S C T N** Q **H Y W** D E **K R**	17	3
Q	411	**M G A P V I L F S C T N** Q H **Y W** D E **K R**	16	4
K	412	**M G A P V I L F S C T N Q H Y W D E** K R	18	2
L	413	M **G A P** V I L **F S C T N Q H Y W D E K R**	16	4
I	414	M **G A P** V I L **F S C T N Q H Y W D E K R**	16	4
S	415	**M** G A **P V I L F** S **C** T N **Q H Y W D E K R**	15	5
E	416	**M G A P V I L F S C T N** Q **H Y W** D E **K R**	17	3
E	417	**M G A P** V **I L F** S **C** T N Q H **Y W** D E K R	10	10
D	418	**M G A P V I L F S** C **T N Q H Y W** D E **K R**	17	3
L	419	M **G A P** V I L F **S C T N** Q H **Y W D E K R**	13	7
L	420	M **G A P** V I L **F S C T N Q H Y W D E K R**	16	4
R	421	**M G A P V I L F S C T N Q H Y W D E** K R	18	2
K	422	**M G A P V I L F S C T N** Q H Y **W D E** K R	15	5
R	423	**M G A P V I L F S C T N Q H Y W D E** K R	18	2
R	424	**M G A P V I L F S C T N Q H Y W D E** K R	18	2
E	425	**M G A P V I L F S C T** N Q **H Y W** D E **K R**	16	4
Q	426	**M G A P V I L F S C T N** Q **H Y W** D E **K R**	18	2
L	427	M **G A P V** I L **F S C T N Q H Y W D E K R**	17	3
K	428	**M G A P V I L F S C T N Q H Y W D E** K R	18	2
H	429	**M G A P V I L F S C T N** Q H **Y W D E K R**	18	2
K	430	**M G A P V I L F S C T N Q H Y W D E** K R	18	2
L	431	M **G A P V** I L **F S C T N Q H Y W D E K R**	17	3
E	432	**M G A P V I L F S C T N** Q **H Y W** D E **K R**	17	3
Q	433	**M G A P V I L F S C T N** Q **H Y W D** E **K R**	18	2

TABLE 20-continued

Human c-Myc Amino Acid Substitution Matrix
(Predictions Based on PMUT Analysis)

WT	Position		Number of Predicted Deleterious Mutations	Number of Predicted Neutral Mutations
L	434	M **G A P V** I L **F S C T N Q H Y W D E K R**	17	3
R	435	**M G A P V I L F S C T N Q H Y W D E K** R	19	1
N	436	**M G A P V I L F S C T** N **Q H Y W** D **E K R**	18	2
S	437	**M G** A **P V I L F** S **C** T N **Q H Y W D E K R**	16	4
C	438	**M G A P V I L F S** C **T N Q H Y W D E K R**	19	1
A	439	**M G** A **P V I L F** S **C T N Q H Y W D E K R**	18	2

TABLE 21

Probe Sets ID, Gene Name, and Gene Description for Hierarchical Clustering Analysis (The International Stem Cell Initiative)

Probe Set ID	Gene Name	Gene Description
AFFX-HUMGAPDH/M33197_M_at	GAPDH	glyceraldehyde-3-phosphate dehydrogenase
AFFX-HUMGAPDH/M33197_5_at	GAPDH	glyceraldehyde-3-phosphate dehydrogenase
AFFX-HUMGAPDH/M33197_3_at	GAPDH	glyceraldehyde-3-phosphate dehydrogenase
40284_at	FOXA2	forkhead box A2
244849_at	SEMA3A	sema domain, immunoglobulin domain (Ig), short basicdomain, secreted, (semaphorin) 3A
244163_at	SEMA3A	sema domain, immunoglobulin domain (Ig), short basicdomain, secreted, (semaphorin) 3A
243712_at	XIST	X (inactive)-specific transcript
243692_at	GATA4	GATA binding protein 4
243161_x_at	ZFP42	zinc finger protein 42 homolog (mouse)
242622_x_at	PTEN	Phosphatase and tensin homolog (mutated in multipleadvanced cancers 1)
241861_at	SYCP3	Synaptonemal complex protein 3
241609_at	FOXD3	Forkhead box D3
237896_at	NODAL	nodal homolog (mouse)
236930_at	NUMB	Numb homolog (*Drosophila*)
236859_at	RUNX2	runt-related transcription factor 2
235795_at	PAX6	paired box gene 6 (aniridia, keratitis)
234967_at	IL6ST	interleukin 6 signal transducer (gp130, oncostatin Mreceptor)
234474_x_at	IL6ST	interleukin 6 signal transducer (gp130, oncostatin Mreceptor)
233322_at	CD9	CD9 molecule
233317_at	CD9	CD9 molecule
233314_at	PTEN	phosphatase and tensin homolog (mutated in multipleadvanced cancers 1)
233254_x_at	PTEN	phosphatase and tensin homolog (mutated in multipleadvanced cancers 1)
232809_s_at	FLT1	Fms-related tyrosine kinase 1 (vascular endothelialgrowth factor/vascular permeability factor receptor)
232231_at	RUNX2	runt-related transcription factor 2
231798_at	NOG	Noggin
231776_at	EOMES	eomesodermin homolog (*Xenopus laevis*)
231592_at	XIST	X (inactive)-specific transcript
230916_at	NODAL	nodal homolog (mouse)
230855_at	GATA4	GATA binding protein 4
230462_at	NUMB	numb homolog (*Drosophila*)
230318_at	SERPINA1	Serpin peptidase inhibitor, clade A (alpha-1antiproteinase, antitrypsin), member 1
229724_at	GABRB3	gamma-aminobutyric acid (GABA) A receptor, beta 3
229346_at	NES	nestin
229341_at	TFCP2L1	Transcription factor CP2-like 1
229282_at	GATA6	GATA binding protein 6
229259_at	GFAP	glial fibrillary acidic protein
228038_at	SOX2	SRY sex determining region Y)-box 2

TABLE 21-continued

Probe Sets ID,, Gene Name,, and Gene Descri ption for Hierarchical Clusterin gAnal ysis (The International Stem Cell Initiative)

Probe Set ID	Gene Name	Gene Description
227830_at	GABRB3	gamma-aminobutyric acid (GABA) A receptor, beta 3
227771_at	LIFR	leukemia inhibitory factor receptor alpha
227690_at	GABRB3	gamma-aminobutyric acid (GABA) A receptor, beta 3
227671_at	XIST	X (inactive)-specific transcript
227642_at	TFCP2L1	Transcription factor CP2-like 1
227469_at	PTEN	Phosphatase and tensin homolog (mutated in multipleadvanced cancers 1)
227048_at	LAMA1	laminin, alpha 1
225575_at	LIFR	leukemia inhibitory factor receptor alpha
225571_at	LIFR	leukemia inhibitory factor receptor alpha
225363_at	PTEN	phosphatase and tensin homolog (mutated in multipleadvanced cancers 1)
224590_at	XIST	X (inactive)-specific transcript
224589_at	XIST	X (inactive)-specific transcript
224588_at	XIST	X (inactive)-specific transcript
223963_s_at	IGF2BP2	insulin-like growth factor 2 mRNA binding protein 2
223679_at	CTNNB1	catenin (cadherin-associated protein), beta 1, 88 kDa
223122_s_at	SFRP2	secreted frizzled-related protein 2
223121_s_at	SFRP2	secreted frizzled-related protein 2
222346_at	LAMA1	laminin, alpha 1
222176_at	PTEN	phosphatase and tensin homolog (mutated in multipleadvanced cancers 1)
222033_s_at	FLT1	Fms-related tyrosine kinase 1 (vascular endothelialgrowth factor/vascular permeability factor receptor)
221728_x_at	XIST	X (inactive)-specific transcript
221630_s_at	DDX4	DEAD (Asp-Glu-Ala-Asp) box polypeptide 4
221283_at	RUNX2	runt-related transcription factor 2
221282_x_at	RUNX2	runt-related transcription factor 2
220668_s_at	DNMT3B	DNA (cytosine-5-)-methyltransferase 3 beta
220184_at	NANOG	Nanog homeobox
220053_at	GDF3	growth differentiation factor 3
219993_at	SOX17	SRY (sex determining region Y)-box 17
219823_at	LIN28	lin-28 homolog (*C. elegans*)
219735_s_at	TFCP2L1	transcription factor CP2-like 1
219177_at	BXDC2	brix domain containing 2
218847_at	IGF2BP2	insulin-like growth factor 2 mRNA binding protein 2
218678_at	NES	nestin
218048_at	COMMD3	COMM domain containing 3
217430_x_at	COL1A1	collagen, type I, alpha 1
217404_s_at	COL2A1	collagen, type II, alpha 1 (primary osteoarthritis, spondyloepiphyseal dysplasia, congenital)
217398_x_at	GAPDH	glyceraldehyde-3-phosphate dehydrogenase
217246_s_at	DIAPH2	diaphanous homolog 2 (*Drosophila*)
217232_x_at	HBB	hemoglobin, beta
216994_s_at	RUNX2	runt-related transcription factor 2
216953_s_at	WT1	Wilms tumor 1
216947_at	DES	desmin
216442_x_at	FN1	fibronectin 1
214702_at	FN1	fibronectin 1
214701_s_at	FN1	fibronectin 1
214614_at	HLXB9	homeobox HB9
214532_x_at	LOC642559///LOC645682/// POU5F1 ///	POU domain, class 5, transcription factor 1 /// POU domain, class 5, transcription factor 1 pseudogene 1/// POU domain, class 5, transcription factor 1 pseudogene
214413_at	TAT	Tyrosine aminotransferase
214312_at	FOXA2	forkhead box A2
214240_at	GAL	galanin
214218_s_at	XIST	X (inactive)-specific transcript
214178_s_at	SOX2	SRY (sex determining region Y)-box 2
214022_s_at	IFITM1	interferon induced transmembrane protein 1 (9-27)
213921_at	SST	somatostatin
213825_at	OLIG2	oligodendrocyte lineage transcription factor 2
213824_at	OLIG2	oligodendrocyte lineage transcription factor 2
213722_at	SOX2	SRY (sex determining region Y)-box 2
213721_at	SOX2	SRY (sex determining region Y)-box 2
213492_at	COL2A1	collagen, type II, alpha 1 (primary osteoarthritis, spondyloepiphyseal dysplasia, congenital)

TABLE 21-continued

Probe Sets ID,, Gene Name,, and Gene Descri ption for Hierarchical Clusterin gAnal ysis (The International Stem Cell Initiative)

Probe Set ID	Gene Name	Gene Description
213453_x_at	GAPDH	glyceraldehyde-3-phosphate dehydrogenase
213200_at	SYP	synaptophysin
212581_x_at	GAPDH	glyceraldehyde-3-phosphate dehydrogenase
212464_s_at	FN1	fibronectin 1
212196_at	IL6ST	Interleukin 6 signal transducer (gp130, oncostatin Mreceptor)
212195_at	IL6ST	Interleukin 6 signal transducer (gp130, oncostatin Mreceptor)
211719_x_at	FN1	fibronectin 1
211711_s_at	PTEN	phosphatase and tensin homolog (mutated in multipleadvanced cancers 1)
211696_x_at	HBB	hemoglobin, beta
211651_s_at	LAMB1	laminin, beta 1
211429_s_at	SERPINA1	serpin peptidase inhibitor, clade A (alpha-1antiproteinase, antitrypsin), member 1
211428_at	SERPINA1	serpin peptidase inhibitor, clade A (alpha-1antiproteinase, antitrypsin), member 1
211402_x_at	NR6A1	nuclear receptor subfamily 6, group A, member 1
211176_s_at	PAX4	paired box gene 4
211000_s_at	IL6ST	interleukin 6 signal transducer (gp130, oncostatin Mreceptor)
210938_at	PDX1	pancreatic and duodenal homeobox 1
210937_s_at	PDX1	pancreatic and duodenal homeobox 1
210761_s_at	GRB7	growth factor receptor-bound protein 7
210560_at	GBX2	gastrulation brain homeobox 2
210495_x_at	FN1	fibronectin 1
210392_x_at	NR6A1	nuclear receptor subfamily 6, group A, member 1
210391_at	NR6A1	nuclear receptor subfamily 6, group A, member 1
210311_at	FGF5	fibroblast growth factor 5
210310_s_at	FGF5	fibroblast growth factor 5
210287_s_at	FLT1	fms-related tyrosine kinase 1 (vascular endothelialgrowth factor/vascular permeability factor receptor)
210174_at	NR5A2	nuclear receptor subfamily 5, group A, member 2
210103_s_at	FOXA2	forkhead box A2
210002_at	GATA6	GATA binding protein 6
209957_s_at	NPPA	natriuretic peptide precursor A
209543_s_at	CD34	CD34 molecule
209116_x_at	HBB	hemoglobin, beta
209073_s_at	NUMB	numb homolog (*Drosophila*)
208983_s_at	PECAM1	platelet/endothelial cell adhesion molecule (CD31
208982_at	PECAM1	platelet/endothelial cell adhesion molecule (CD31
208981_at	PECAM1	platelet/endothelial cell adhesion molecule (CD31
208559_at	PDX1	pancreatic and duodenal homeobox 1
208500_x_at	FOXD3	forkhead box D3
208378_x_at	FGF5	fibroblast growth factor 5
208343_s_at	NR5A2	nuclear receptor subfamily 5, group A, member 2
208337_s_at	NR5A2	nuclear receptor subfamily 5, group A, member 2
208291_s_at	TH	tyrosine hydroxylase
208286_x_at	LOC642559///LOC645682/// POU5F1 ///	POU domain, class 5, transcription factor 1 /// POUdomain, class 5, transcription factor 1 pseudogene 1/// POU domain, class 5, transcription factor 1 pseudogene
208275_x_at	UTF1	undifferentiated embryonic cell transcription factor 1
207867_at	PAX4	paired box gene 4
207742_s_at	NR6A1	nuclear receptor subfamily 6, group A, member 1
207545_s_at	NUMB	numb homolog (*Drosophila*)
207466_at	GAL	galanin
207424_at	MYF5	myogenic factor 5
207199_at	TERT	telomerase reverse transcriptase
207062_at	IAPP	islet amyloid polypeptide
206916_x_at	TAT	tyrosine aminotransferase
206805_at	SEMA3A	sema domain, immunoglobulin domain (Ig), short basicdomain, secreted, (semaphorin) 3A
206783_at	FGF4	fibroblast growth factor 4 (heparin secretory transforming protein 1, Kaposi sarcoma oncogene)
206701_x_at	EDNRB	endothelin receptor type B
206657_s_at	MYOD1	myogenic differentiation 1
206647_at	HBZ	hemoglobin, zeta
206598_at	INS	insulin
206524_at	T	T, brachyury homolog (mouse)
206422_at	GCG	glucagon

TABLE 21-continued

Probe Sets ID, Gene Name, and Gene Description for Hierarchical Clustering Analysis (The International Stem Cell Initiative)

Probe Set ID	Gene Name	Gene Description
206387_at	CDX2	caudal type homeobox transcription factor 2
206286_s_at	TDGF1 ///TDGF3	teratocarcinoma-derived growth factor 1 ///teratocarcinoma-derived growth factor 3, pseudogene
206282_at	NEUROD1	neurogenic differentiation 1
206269_at	GCM1	glial cells missing homolog 1 (*Drosophila*)
206268_at	LEFTY1	left-right determination factor 1
206104_at	ISL1	ISL1 transcription factor, LIM/homeodomain, (islet-1)
206067_s_at	WT1	Wilms tumor 1
206012_at	LEFTY2	left-right determination factor 2
205900_at	KRT1	keratin 1 (epidermolytic hyperkeratosis)
205876_at	LIFR	leukemia inhibitory factor receptor alpha
205850_s_at	GABRB3	gamma-aminobutyric acid (GABA) A receptor, beta 3
205726_at	DIAPH2	diaphanous homolog 2 (*Drosophila*)
205646_s_at	PAX6	paired box gene 6 (aniridia, keratitis)
205603_s_at	DIAPH2	diaphanous homolog 2 (*Drosophila*)
205517_at	GATA4	GATA binding protein 4
205387_s_at	CGB ///CGB5 ///CGB7	chorionic gonadotropin, beta polypeptide /// chorionicgonadotropin, beta polypeptide 5 /// chorionicgonadotropin, beta polypeptide 7
205132_at	ACTC1	actin, alpha, cardiac muscle 1
205051_s_at	KIT	v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog
204864_s_at	IL6ST	interleukin 6 signal transducer (gp130, oncostatin Mreceptor)
204863_s_at	IL6ST	interleukin 6 signal transducer (gp130, oncostatin Mreceptor)
204694_at	AFP	alpha-fetoprotein
204677_at	CDH5	cadherin 5, type 2, VE-cadherin (vascular epithelium)
204535_s_at	REST	RE1-silencing transcription factor
204406_at	FLT1	fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor)
204273_at	EDNRB	endothelin receptor type B
204271_s_at	EDNRB	endothelin receptor type B
204054_at	PTEN	phosphatase and tensin homolog (mutated in multiple advanced cancers 1)
204053_x_at	PTEN	phosphatase and tensin homolog (mutated in multiple advanced cancers 1)
203540_at	GFAP	glial fibrillary acidic protein
202833_s_at	SERPINA1	serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1
202575_at	CRABP2	cellular retinoic acid binding protein 2
202312_s_at	COL1A1	collagen, type I, alpha 1
202311_s_at	COL1A1	collagen, type I, alpha 1
202310_s_at	COL1A1	collagen, type I, alpha 1
202222_s_at	DES	desmin
201601_x_at	IFITM1	interferon induced transmembrane protein 1 (9-27)
201578_at	PODXL	podocalyxin-like
201533_at	CTNNB1	catenin (cadherin-associated protein), beta 1, 88 kDa
201505_at	LAMB1	laminin, beta 1
201315_x_at	IFITM2	interferon induced transmembrane protein 2 (1-8D)
201005_at	CD9	CD9 molecule
200771_at	LAMC1	laminin, gamma 1 (formerly LAMB2)
200770_s_at	LAMC1	laminin, gamma 1 (formerly LAMB2)
1570276_a_at	GATA4	GATA binding protein 4
1562981_at	HBB	Hemoglobin, beta
1561316_at	GABRB3	Gamma-aminobutyric acid (GABA) A receptor, beta 3
1560469_at	NR5A2	nuclear receptor subfamily 5, group A, member 2
1559921_at	PECAM1	platelet/endothelial cell adhesion molecule (CD31
1558199_at	FN1	fibronectin 1
1556499_s_at	COL1A1	collagen, type I, alpha 1
1556057_s_at	NEUROD1	neurogenic differentiation 1
1555271_a_at	TERT	telomerase reverse transcriptase
1554777_at	ZFP42	zinc finger protein 42 homolog (mouse)
1554776_at	ZFP42	zinc finger protein 42 homolog (mouse)
1554411_at	CTNNB1	catenin (cadherin-associated protein), beta 1, 88 kDa
1553599_a_at	SYCP3	synaptonemal complex protein 3
1553131_a_at	GATA4	GATA binding protein 4
1552982_a_at	FGF4	fibroblast growth factor 4 (heparin secretory transforming protein 1, Kaposi sarcoma oncogene)

[0509] While preferred embodiments have been described herein, such embodiments are provided by way of example only. Numerous variations, changes, and substitutions are feasible. It should be understood that various alternatives to the embodiments of the methods and compositions described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and compositions within the scope of these claims and their equivalents be covered thereby.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 67

<210> SEQ ID NO 1
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 1

Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg
1 5 10

<210> SEQ ID NO 2
<211> LENGTH: 8
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 2

Arg Lys Lys Arg Arg Gln Arg Arg
1 5

<210> SEQ ID NO 3
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 3

Tyr Ala Arg Ala Ala Ala Arg Gln Ala Arg Ala
1 5 10

<210> SEQ ID NO 4
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 4

Thr His Arg Leu Pro Arg Arg Arg Arg Arg Arg
1 5 10

<210> SEQ ID NO 5
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 5

Gly Gly Arg Arg Ala Arg Arg Arg Arg Arg Arg
1 5 10

<210> SEQ ID NO 6

-continued

<211> LENGTH: 360
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 6

Met Ala Gly His Leu Ala Ser Asp Phe Ala Phe Ser Pro Pro Pro Gly
1 5 10 15

Gly Gly Gly Asp Gly Pro Gly Gly Pro Glu Pro Gly Trp Val Asp Pro
20 25 30

Arg Thr Trp Leu Ser Phe Gln Gly Pro Pro Gly Gly Pro Gly Ile Gly
35 40 45

Pro Gly Val Gly Pro Gly Ser Glu Val Trp Gly Ile Pro Pro Cys Pro
50 55 60

Pro Pro Tyr Glu Phe Cys Gly Gly Met Ala Tyr Cys Gly Pro Gln Val
65 70 75 80

Gly Val Gly Leu Val Pro Gln Gly Gly Leu Glu Thr Ser Gln Pro Glu
85 90 95

Gly Glu Ala Gly Val Gly Val Glu Ser Asn Ser Asp Gly Ala Ser Pro
100 105 110

Glu Pro Cys Thr Val Thr Pro Gly Ala Val Lys Leu Glu Lys Glu Lys
115 120 125

Leu Glu Gln Asn Pro Glu Glu Ser Gln Asp Ile Lys Ala Leu Gln Lys
130 135 140

Glu Leu Glu Gln Phe Ala Lys Leu Leu Lys Gln Lys Arg Ile Thr Leu
145 150 155 160

Gly Tyr Thr Gln Ala Asp Val Gly Leu Thr Leu Gly Val Leu Phe Gly
165 170 175

Lys Val Phe Ser Gln Thr Thr Ile Cys Arg Phe Glu Ala Leu Gln Leu
180 185 190

Ser Phe Lys Asn Met Cys Lys Leu Arg Pro Leu Leu Gln Lys Trp Val
195 200 205

Glu Glu Ala Asp Asn Asn Glu Asn Leu Gln Glu Ile Cys Lys Ala Glu
210 215 220

Thr Leu Val Gln Ala Arg Lys Arg Lys Arg Thr Ser Ile Glu Asn Arg
225 230 235 240

Val Arg Gly Asn Leu Glu Asn Leu Phe Leu Gln Cys Pro Lys Pro Thr
245 250 255

Leu Gln Gln Ile Ser His Ile Ala Gln Gln Leu Gly Leu Glu Lys Asp
260 265 270

Val Val Arg Val Trp Phe Cys Asn Arg Arg Gln Lys Gly Lys Arg Ser
275 280 285

Ser Ser Asp Tyr Ala Gln Arg Glu Asp Phe Glu Ala Ala Gly Ser Pro
290 295 300

Phe Ser Gly Gly Pro Val Ser Phe Pro Leu Ala Pro Gly Pro His Phe
305 310 315 320

Gly Thr Pro Gly Tyr Gly Ser Pro His Phe Thr Ala Leu Tyr Ser Ser
325 330 335

Val Pro Phe Pro Glu Gly Glu Ala Phe Pro Pro Val Ser Val Thr Thr
340 345 350

Leu Gly Ser Pro Met His Ser Asn
355 360

-continued

<210> SEQ ID NO 7
<211> LENGTH: 153
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 7

Asp Ile Lys Ala Leu Gln Lys Glu Leu Glu Gln Phe Ala Lys Leu Leu
1 5 10 15

Lys Gln Lys Arg Ile Thr Leu Gly Tyr Thr Gln Ala Asp Val Gly Leu
20 25 30

Thr Leu Gly Val Leu Phe Gly Lys Val Phe Ser Gln Thr Thr Ile Cys
35 40 45

Arg Phe Glu Ala Leu Gln Leu Ser Phe Lys Asn Met Cys Lys Leu Arg
50 55 60

Pro Leu Leu Gln Lys Trp Val Glu Glu Ala Asp Asn Asn Glu Asn Leu
65 70 75 80

Gln Glu Ile Cys Lys Ala Glu Thr Leu Val Gln Ala Arg Lys Arg Lys
85 90 95

Arg Thr Ser Ile Glu Asn Arg Val Arg Gly Asn Leu Glu Asn Leu Phe
100 105 110

Leu Gln Cys Pro Lys Pro Thr Leu Gln Gln Ile Ser His Ile Ala Gln
115 120 125

Gln Leu Gly Leu Glu Lys Asp Val Val Arg Val Trp Phe Cys Asn Arg
130 135 140

Arg Gln Lys Gly Lys Arg Ser Ser Ser
145 150

<210> SEQ ID NO 8
<211> LENGTH: 317
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 8

Met Tyr Asn Met Met Glu Thr Glu Leu Lys Pro Pro Gly Pro Gln Gln
1 5 10 15

Thr Ser Gly Gly Gly Gly Gly Asn Ser Thr Ala Ala Ala Ala Gly Gly
20 25 30

Asn Gln Lys Asn Ser Pro Asp Arg Val Lys Arg Pro Met Asn Ala Phe
35 40 45

Met Val Trp Ser Arg Gly Gln Arg Arg Lys Met Ala Gln Glu Asn Pro
50 55 60

Lys Met His Asn Ser Glu Ile Ser Lys Arg Leu Gly Ala Glu Trp Lys
65 70 75 80

Leu Leu Ser Glu Thr Glu Lys Arg Pro Phe Ile Asp Glu Ala Lys Arg
85 90 95

Leu Arg Ala Leu His Met Lys Glu His Pro Asp Tyr Lys Tyr Arg Pro
100 105 110

Arg Arg Lys Thr Lys Thr Leu Met Lys Lys Asp Lys Tyr Thr Leu Pro
115 120 125

Gly Gly Leu Leu Ala Pro Gly Gly Asn Ser Met Ala Ser Gly Val Gly
130 135 140

Val Gly Ala Gly Leu Gly Ala Gly Val Asn Gln Arg Met Asp Ser Tyr
145 150 155 160

Ala His Met Asn Gly Trp Ser Asn Gly Ser Tyr Ser Met Met Gln Asp

-continued

165 170 175

Gln Leu Gly Tyr Pro Gln His Pro Gly Leu Asn Ala His Gly Ala Ala
180 185 190

Gln Met Gln Pro Met His Arg Tyr Asp Val Ser Ala Leu Gln Tyr Asn
195 200 205

Ser Met Thr Ser Ser Gln Thr Tyr Met Asn Gly Ser Pro Thr Tyr Ser
210 215 220

Met Ser Tyr Ser Gln Gln Gly Thr Pro Gly Met Ala Leu Gly Ser Met
225 230 235 240

Gly Ser Val Val Lys Ser Glu Ala Ser Ser Ser Pro Pro Val Val Thr
245 250 255

Ser Ser Ser His Ser Arg Ala Pro Cys Gln Ala Gly Asp Leu Arg Asp
260 265 270

Met Ile Ser Met Tyr Leu Pro Gly Ala Glu Val Pro Glu Pro Ala Ala
275 280 285

Pro Ser Arg Leu His Met Ser Gln His Tyr Gln Ser Gly Pro Val Pro
290 295 300

Gly Thr Ala Ile Asn Gly Thr Leu Pro Leu Ser His Met
305 310 315

<210> SEQ ID NO 9
<211> LENGTH: 76
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 9

Arg Val Lys Arg Pro Met Asn Ala Phe Met Val Trp Ser Arg Gly Gln
1 5 10 15

Arg Arg Lys Met Ala Gln Glu Asn Pro Lys Met His Asn Ser Glu Ile
20 25 30

Ser Lys Arg Leu Gly Ala Glu Trp Lys Leu Leu Ser Glu Thr Glu Lys
35 40 45

Arg Pro Phe Ile Asp Glu Ala Lys Arg Leu Arg Ala Leu His Met Lys
50 55 60

Glu His Pro Asp Tyr Lys Tyr Arg Pro Arg Arg Lys
65 70 75

<210> SEQ ID NO 10
<211> LENGTH: 470
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 10

Met Ala Val Ser Asp Ala Leu Leu Pro Ser Phe Ser Thr Phe Ala Ser
1 5 10 15

Gly Pro Ala Gly Arg Glu Lys Thr Leu Arg Gln Ala Gly Ala Pro Asn
20 25 30

Asn Arg Trp Arg Glu Glu Leu Ser His Met Lys Arg Leu Pro Pro Val
35 40 45

Leu Pro Gly Arg Pro Tyr Asp Leu Ala Ala Ala Thr Val Ala Thr Asp
50 55 60

Leu Glu Ser Gly Gly Ala Gly Ala Ala Cys Gly Gly Ser Asn Leu Ala
65 70 75 80

Pro Leu Pro Arg Arg Glu Thr Glu Glu Phe Asn Asp Leu Leu Asp Leu

-continued

85 90 95

Asp Phe Ile Leu Ser Asn Ser Leu Thr His Pro Pro Glu Ser Val Ala
100 105 110

Ala Thr Val Ser Ser Ser Ala Ser Ala Ser Ser Ser Ser Ser Pro Ser
115 120 125

Ser Ser Gly Pro Ala Ser Ala Pro Ser Thr Cys Ser Phe Thr Tyr Pro
130 135 140

Ile Arg Ala Gly Asn Asp Pro Gly Val Ala Pro Gly Gly Thr Gly Gly
145 150 155 160

Gly Leu Leu Tyr Gly Arg Glu Ser Ala Pro Pro Pro Thr Ala Pro Phe
165 170 175

Asn Leu Ala Asp Ile Asn Asp Val Ser Pro Ser Gly Gly Phe Val Ala
180 185 190

Glu Leu Leu Arg Pro Glu Leu Asp Pro Val Tyr Ile Pro Pro Gln Gln
195 200 205

Pro Gln Pro Pro Gly Gly Gly Leu Met Gly Lys Phe Val Leu Lys Ala
210 215 220

Ser Leu Ser Ala Pro Gly Ser Glu Tyr Gly Ser Pro Ser Val Ile Ser
225 230 235 240

Val Ser Lys Gly Ser Pro Asp Gly Ser His Pro Val Val Val Ala Pro
245 250 255

Tyr Asn Gly Gly Pro Pro Arg Thr Cys Pro Lys Ile Lys Gln Glu Ala
260 265 270

Val Ser Ser Cys Thr His Leu Gly Ala Gly Pro Pro Leu Ser Asn Gly
275 280 285

His Arg Pro Ala Ala His Asp Phe Pro Leu Gly Arg Gln Leu Pro Ser
290 295 300

Arg Thr Thr Pro Thr Leu Gly Leu Glu Glu Val Leu Ser Ser Arg Asp
305 310 315 320

Cys His Pro Ala Leu Pro Leu Pro Pro Gly Phe His Pro His Pro Gly
325 330 335

Pro Asn Tyr Pro Ser Phe Leu Pro Asp Gln Met Gln Pro Gln Val Pro
340 345 350

Pro Leu His Tyr Gln Glu Leu Met Pro Pro Gly Ser Cys Met Pro Glu
355 360 365

Glu Pro Lys Pro Lys Arg Gly Arg Arg Ser Trp Pro Arg Lys Arg Thr
370 375 380

Ala Thr His Thr Cys Asp Tyr Ala Gly Cys Gly Lys Thr Tyr Thr Lys
385 390 395 400

Ser Ser His Leu Lys Ala His Leu Arg Thr His Thr Gly Glu Lys Pro
405 410 415

Tyr His Cys Asp Trp Asp Gly Cys Gly Trp Lys Phe Ala Arg Ser Asp
420 425 430

Glu Leu Thr Arg His Tyr Arg Lys His Thr Gly His Arg Pro Phe Gln
435 440 445

Cys Gln Lys Cys Asp Arg Ala Phe Ser Arg Ser Asp His Leu Ala Leu
450 455 460

His Met Lys Arg His Phe
465 470

<210> SEQ ID NO 11

-continued

<211> LENGTH: 88
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 11

Lys Arg Thr Ala Thr His Thr Cys Asp Tyr Ala Gly Cys Gly Lys Thr
1 5 10 15

Tyr Thr Lys Ser Ser His Leu Lys Ala His Leu Arg Thr His Thr Gly
20 25 30

Glu Lys Pro Tyr His Cys Asp Trp Asp Gly Cys Gly Trp Lys Phe Ala
35 40 45

Arg Ser Asp Glu Leu Thr Arg His Tyr Arg Lys His Thr Gly His Arg
50 55 60

Pro Phe Gln Cys Gln Lys Cys Asp Arg Ala Phe Ser Arg Ser Asp His
65 70 75 80

Leu Ala Leu His Met Lys Arg His
85

<210> SEQ ID NO 12
<211> LENGTH: 454
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 12

Met Asp Phe Phe Arg Val Val Glu Asn Gln Gln Pro Pro Ala Thr Met
1 5 10 15

Pro Leu Asn Val Ser Phe Thr Asn Arg Asn Tyr Asp Leu Asp Tyr Asp
20 25 30

Ser Val Gln Pro Tyr Phe Tyr Cys Asp Glu Glu Glu Asn Phe Tyr Gln
35 40 45

Gln Gln Gln Gln Ser Glu Leu Gln Pro Pro Ala Pro Ser Glu Asp Ile
50 55 60

Trp Lys Lys Phe Glu Leu Leu Pro Thr Pro Pro Leu Ser Pro Ser Arg
65 70 75 80

Arg Ser Gly Leu Cys Ser Pro Ser Tyr Val Ala Val Thr Pro Phe Ser
85 90 95

Leu Arg Gly Asp Asn Asp Gly Gly Gly Gly Ser Phe Ser Thr Ala Asp
100 105 110

Gln Leu Glu Met Val Thr Glu Leu Leu Gly Gly Asp Met Val Asn Gln
115 120 125

Ser Phe Ile Cys Asp Pro Asp Asp Glu Thr Phe Ile Lys Asn Ile Ile
130 135 140

Ile Gln Asp Cys Met Trp Ser Gly Phe Ser Ala Ala Ala Lys Leu Val
145 150 155 160

Ser Glu Lys Leu Ala Ser Tyr Gln Ala Ala Arg Lys Asp Ser Gly Ser
165 170 175

Pro Asn Pro Ala Arg Gly His Ser Val Cys Ser Thr Ser Ser Leu Tyr
180 185 190

Leu Gln Asp Leu Ser Ala Ala Ala Ser Glu Cys Ile Asp Pro Ser Val
195 200 205

Val Phe Pro Tyr Pro Leu Asn Asp Ser Ser Ser Pro Lys Ser Cys Ala
210 215 220

Ser Gln Asp Ser Ser Ala Phe Ser Pro Ser Ser Asp Ser Leu Leu Ser
225 230 235 240

-continued

```
Ser Thr Glu Ser Ser Pro Gln Gly Ser Pro Glu Pro Leu Val Leu His
245                 250                 255

Glu Glu Thr Pro Pro Thr Thr Ser Ser Asp Ser Glu Glu Glu Gln Glu
260                 265                 270

Asp Glu Glu Glu Ile Asp Val Val Ser Val Glu Lys Arg Gln Ala Pro
275                 280                 285

Gly Lys Arg Ser Glu Ser Gly Ser Pro Ser Ala Gly Gly His Ser Lys
290                 295                 300

Pro Pro His Ser Pro Leu Val Leu Lys Arg Cys His Val Ser Thr His
305                 310                 315                 320

Gln His Asn Tyr Ala Ala Pro Pro Ser Thr Arg Lys Asp Tyr Pro Ala
325                 330                 335

Ala Lys Arg Val Lys Leu Asp Ser Val Arg Val Leu Arg Gln Ile Ser
340                 345                 350

Asn Asn Arg Lys Cys Thr Ser Pro Arg Ser Ser Asp Thr Glu Glu Asn
355                 360                 365

Val Lys Arg Arg Thr His Asn Val Leu Glu Arg Gln Arg Arg Asn Glu
370                 375                 380

Leu Lys Arg Ser Phe Phe Ala Leu Arg Asp Gln Ile Pro Glu Leu Glu
385                 390                 395                 400

Asn Asn Glu Lys Ala Pro Lys Val Val Ile Leu Lys Lys Ala Thr Ala
405                 410                 415

Tyr Ile Leu Ser Val Gln Ala Glu Glu Gln Lys Leu Ile Ser Glu Glu
420                 425                 430

Asp Leu Leu Arg Lys Arg Arg Glu Gln Leu Lys His Lys Leu Glu Gln
435                 440                 445

Leu Arg Asn Ser Cys Ala
450


<210> SEQ ID NO 13
<211> LENGTH: 85
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 13

Lys Arg Arg Thr His Asn Val Leu Glu Arg Gln Arg Arg Asn Glu Leu
1               5                   10                  15

Lys Arg Ser Phe Phe Ala Leu Arg Asp Gln Ile Pro Glu Leu Glu Asn
20                  25                  30

Asn Glu Lys Ala Pro Lys Val Val Ile Leu Lys Lys Ala Thr Ala Tyr
35                  40                  45

Ile Leu Ser Val Gln Ala Glu Glu Gln Lys Leu Ile Ser Glu Glu Asp
50                  55                  60

Leu Leu Arg Lys Arg Arg Glu Gln Leu Lys His Lys Leu Glu Gln Leu
65                  70                  75                  80

Arg Asn Ser Cys Ala
85


<210> SEQ ID NO 14
<211> LENGTH: 29
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
```

-continued

primer

<400> SEQUENCE: 14

gcagccctgg gtctccagat ctggccagc 29

<210> SEQ ID NO 15
<211> LENGTH: 29
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 15

ggtggccggg gccagggcta gccacgtgc 29

<210> SEQ ID NO 16
<211> LENGTH: 263
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 16

Met Tyr Asn Met Met Glu Thr Glu Leu Lys Pro Pro Gly Pro Gln Gln
1 5 10 15

Thr Ser Gly Gly Gly Gly Gly Asn Ser Thr Ala Ala Ala Ala Gly Gly
20 25 30

Asn Gln Lys Asn Ser Pro Asp Arg Val Lys Arg Pro Met Asn Ala Phe
35 40 45

Met Val Trp Ser Arg Gly Gln Arg Arg Lys Met Ala Gln Glu Asn Pro
50 55 60

Lys Met His Asn Ser Glu Ile Ser Lys Arg Leu Gly Ala Glu Trp Lys
65 70 75 80

Leu Leu Ser Glu Thr Glu Lys Arg Pro Phe Ile Asp Glu Ala Lys Arg
85 90 95

Leu Arg Ala Leu His Met Lys Glu His Pro Asp Tyr Lys Tyr Arg Pro
100 105 110

Arg Arg Lys Thr Lys Thr Leu Met Lys Lys Asp Lys Tyr Thr Leu Pro
115 120 125

Gly Gly Leu Leu Ala Pro Gly Gly Asn Ser Met Ala Ser Gly Val Gly
130 135 140

Val Gly Ala Gly Leu Gly Ala Gly Val Asn Gln Arg Met Asp Ser Tyr
145 150 155 160

Ala His Met Asn Gly Trp Ser Asn Gly Ser Tyr Ser Met Met Gln Asp
165 170 175

Gln Leu Gly Tyr Pro Gln His Ser Thr Thr Ala Pro Ile Thr Asp Val
180 185 190

Ser Leu Gly Asp Glu Leu Arg Leu Asp Gly Glu Glu Val Asp Met Thr
195 200 205

Pro Ala Asp Ala Leu Asp Asp Phe Asp Leu Glu Met Leu Gly Asp Val
210 215 220

Glu Ser Pro Ser Pro Gly Met Thr His Asp Pro Val Ser Tyr Gly Ala
225 230 235 240

Leu Asp Val Asp Asp Phe Glu Phe Glu Gln Met Phe Thr Asp Ala Leu

-continued

245 250 255

Gly Ile Asp Asp Phe Gly Gly
260

<210> SEQ ID NO 17
<211> LENGTH: 8
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 17

Lys Lys Lys Lys Lys Lys Lys Lys
1 5

<210> SEQ ID NO 18
<211> LENGTH: 12
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic oligonucleotide

<400> SEQUENCE: 18

saccacgtgg ts 12

<210> SEQ ID NO 19
<211> LENGTH: 148
<212> TYPE: PRT
<213> ORGANISM: Human herpesvirus 2

<400> SEQUENCE: 19

Thr Lys Thr Leu Met Lys Lys Asp Lys Tyr Thr Leu Pro Gly Gly Leu
1 5 10 15

Leu Ala Pro Gly Gly Asn Ser Met Ala Ser Gly Val Gly Val Gly Ala
20 25 30

Gly Leu Gly Ala Gly Val Asn Gln Arg Met Asp Ser Tyr Ala His Met
35 40 45

Asn Gly Trp Ser Asn Gly Ser Tyr Ser Met Met Gln Asp Gln Leu Gly
50 55 60

Tyr Pro Gln His Ser Thr Thr Ala Pro Ile Thr Asp Val Ser Leu Gly
65 70 75 80

Asp Glu Leu Arg Leu Asp Gly Glu Glu Val Asp Met Thr Pro Ala Asp
85 90 95

Ala Leu Asp Asp Phe Asp Leu Glu Met Leu Gly Asp Val Glu Ser Pro
100 105 110

Ser Pro Gly Met Thr His Asp Pro Val Ser Tyr Gly Ala Leu Asp Val
115 120 125

Asp Asp Phe Glu Phe Glu Gln Met Phe Thr Asp Ala Leu Gly Ile Asp
130 135 140

Asp Phe Gly Gly
145

<210> SEQ ID NO 20
<211> LENGTH: 25
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 20

agtctggctt atatccaaca cttcg 25

<210> SEQ ID NO 21
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 21

gactttgctt tccttggtca gg 22

<210> SEQ ID NO 22
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 22

tacctcagcc tccagcagat 20

<210> SEQ ID NO 23
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 23

tgcgtcacac cattgctatt 20

<210> SEQ ID NO 24
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 24

agccagtctc accttcaacc gc 22

<210> SEQ ID NO 25
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 25

ggagtagcag agggaggccg 20

<210> SEQ ID NO 26
<211> LENGTH: 20
<212> TYPE: DNA

-continued

<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 26

aaaccccagc acatcaactc 20

<210> SEQ ID NO 27
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 27

gtcattccct gggtggttc 19

<210> SEQ ID NO 28
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 28

ttggagtgca atggtgtgat 20

<210> SEQ ID NO 29
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 29

tctgttcaca caggctccag 20

<210> SEQ ID NO 30
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 30

ggcgtccgcg ggaatgtact tc 22

<210> SEQ ID NO 31
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 31

tggcttaggg gtggtctggc c 21

<210> SEQ ID NO 32

-continued

<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 32

gcagcgacca gtcctccgac t 21

<210> SEQ ID NO 33
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 33

aacgtgggga aggcctgtgc 20

<210> SEQ ID NO 34
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 34

acagaacctg ctgcctgaat 20

<210> SEQ ID NO 35
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 35

agaaatgcct gaggaaagca 20

<210> SEQ ID NO 36
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 36

cttgacaatc gagtggctga 20

<210> SEQ ID NO 37
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 37

tcatccgtgg tgtagccata 20

-continued

<210> SEQ ID NO 38
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 38

aacctgcacg actcctcgca ca 22

<210> SEQ ID NO 39
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 39

aggatgcgca tggcgattcg 20

<210> SEQ ID NO 40
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 40

gagaaggaga agctggagca 20

<210> SEQ ID NO 41
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 41

aatagaaccc ccagggtgag 20

<210> SEQ ID NO 42
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 42

agtagacggc atcgcagctt gg 22

<210> SEQ ID NO 43
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 43

-continued

ggaagcttag ccaggtccga gg 22

<210> SEQ ID NO 44
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 44

caggagaacc ccaagatgc 19

<210> SEQ ID NO 45
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 45

gcagccgctt agcctcg 17

<210> SEQ ID NO 46
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 46

acactgcccc tctcacacat 20

<210> SEQ ID NO 47
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 47

cgggactatg gttgctgact 20

<210> SEQ ID NO 48
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 48

accctgggtc ttgaggaagt 20

<210> SEQ ID NO 49
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

-continued

<400> SEQUENCE: 49

acgatcgtct tcccctcttt 20

<210> SEQ ID NO 50
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 50

ctcaccctta ccgagtcggc g 21

<210> SEQ ID NO 51
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 51

gcagctgggg cacctgaacc 20

<210> SEQ ID NO 52
<211> LENGTH: 25
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 52

tccagcttgt acctgcagga tctga 25

<210> SEQ ID NO 53
<211> LENGTH: 25
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 53

cctccagcag aaggtgatcc agact 25

<210> SEQ ID NO 54
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 54

agtagacggc atcgcagctt gg 22

<210> SEQ ID NO 55
<211> LENGTH: 25
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic

-continued

primer

<400> SEQUENCE: 55

cctccagcag aaggtgatcc agact 25

<210> SEQ ID NO 56
<211> LENGTH: 40
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 56

aggaagagag ggaatttaag gtgtatgtat tttttatttt 40

<210> SEQ ID NO 57
<211> LENGTH: 56
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 57

cagtaatacg actcactata gggagaaggc tataacccac ccctataatc ccaata 56

<210> SEQ ID NO 58
<211> LENGTH: 35
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 58

aggaagagag gttaggttgg ttttaaattt ttgat 35

<210> SEQ ID NO 59
<211> LENGTH: 61
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 59

cagtaatacg actcactata gggagaaggc ttttataata aaaactctat caccttaaac 60

c 61

<210> SEQ ID NO 60
<211> LENGTH: 35
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 60

aggaagagag tagtagggat tttttggatt ggttt 35

<210> SEQ ID NO 61
<211> LENGTH: 58

-continued

<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 61

cagtaatacg actcactata gggagaaggc taaaactttt cccccactct tatattac 58

<210> SEQ ID NO 62
<211> LENGTH: 39
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 62

aggaagagag ggtaataaag tgagattttg ttttaaaaa 39

<210> SEQ ID NO 63
<211> LENGTH: 55
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 63

cagtaatacg actcactata gggagaaggc tccacccact aaccttaacc tctaa 55

<210> SEQ ID NO 64
<211> LENGTH: 4
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 64

Asp Glu Ala His
1

<210> SEQ ID NO 65
<211> LENGTH: 4
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic peptide

<400> SEQUENCE: 65

Asp Glu Ala Asp
1

<210> SEQ ID NO 66
<211> LENGTH: 20
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 66

-continued

```
Met Gly Ala Pro Val Ile Leu Phe Ser Cys Thr Asn Gln His Tyr Trp
1               5                  10                  15

Asp Glu Lys Arg
20


<210> SEQ ID NO 67
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 67

cttttgcatt acaatg                                                16
```

1-132. (canceled)

133. A human stem cell that is pluripotent, somatic, non-embryonic, and having the property of long-term self renewal

134. The human stem cell of claim **133**, wherein the human stem cell comprises exogenous genes encoding two or more of the following: an Oct 3/4 polypeptide, a Sox2 polypeptide, a Klf4 polypeptide, and a c-Myc polypeptide

135. The human stem cell of claim **134**, wherein the human stem cell comprises exogenous genes encoding three or more of the following: an Oct3/4 polypeptide, a Sox2 polypeptide, a Klf4 polypeptide, and a c-Myc polypeptide.

136. The human stem cell of claim **133**, comprising endogenous and exogenous genes, wherein the exogenous genes comprise a first exogenous gene encoding an Oct3/4 polypeptide, a second exogenous gene encoding a Sox2 polypeptide, and a third exogenous gene encoding a Klf4 polypeptide.

137. The human stem cell of claim **136**, wherein the exogenous genes consist essentially of the first exogenous gene, the second exogenous gene, and the third exogenous gene.

138. The human stem cell of claim **135**, wherein the human stem cell does not comprise an exogenous gene capable of inducing cancer.

139. The human stem cell of claim **138**, wherein the human stem cell does not comprise an exogenous gene encoding a c-Myc polypeptide.

140. The human stem cell of claim **136**, wherein the human stem cell further comprises an exogenous gene encoding a c-Myc polypeptide

141. The human stem cell of claim **140**, wherein the exogenous genes consist essentially of a first exogenous gene encoding an Oct3/4 polypeptide, a second exogenous gene encoding a Sox2 polypeptide, a third exogenous gene encoding a Klf4 polypeptide, and a fourth exogenous gene encoding a c-Myc polypeptide.

142. The human stem cell of claim **133**, wherein the cell was induced from a population comprising adult human skin fibroblasts, adult peripheral blood mononuclear cells, adult human bone marrow-derived mononuclear cells, neonatal human skin fibroblasts, human umbilical vein endothelial cells, human umbilical artery smooth muscle cells, human postnatal skeletal muscle cells, human postnatal adipose cells, human postnatal peripheral blood mononuclear cells, or human cord blood mononuclear cells.

143. A differentiated cell obtained by differentiating the human stem cell of claim **133**.

144. The differentiated cell of claim **143**, wherein the differentiated cell is a pancreatic beta cell, a neural stem cell, a dopaminergic neuron, an oligodendrocyte, a hepatocyte, or a cardiac muscle cell.

145. A human stem cell that is somatic, non-embryonic, alkaline phosphatase positive, and expresses two or more genes selected from the group consisting of TDGF 1, Dnmt3b, FoxD3, GDF3, Cyp26a1, TERT, zfp42, Sox2, Oct3/4, and Nanog.

146. The human stem cell of claim **145**, wherein the human stem cell is pluripotent.

147. The human stem cell of claim **145**, wherein the telomeres in the human stem cell are at least 0.25 kB shorter than telomeres in embryonic stem cell lines.

148. The human stem cell of claim **145**, wherein the human stem cell comprises exogenous genes encoding two or more of the following: an Oct 3/4 polypeptide, a Sox2 polypeptide, a Klf4 polypeptide, and a c-Myc polypeptide.

149. The human stem cell of claim **145**, wherein the human stem cell comprises exogenous genes encoding three or more of the following: an Oct3/4 polypeptide, a Sox2 polypeptide, a Klf4 polypeptide, and a c-Myc polypeptide.

150. The human stem cell of claim **149**, wherein the human stem cell comprises only three exogenous genes encoding induction factors and wherein the genes encode an Oct3/4 polypeptide, a Sox2 polypeptide, and a Klf4 polypeptide.

151. The human stem cell of claim **145**, wherein the human cell comprises four exogenous genes encoding induction factors and wherein the four exogenous genes encode the following: an Oct3/4 polypeptide, a Sox2 polypeptide, a Klf4 polypeptide, and a c-Myc polypeptide

152. The human stem cell of claim **145**, wherein the cell was induced from a population comprising adult human skin fibroblasts, adult peripheral blood mononuclear cells, adult human bone marrow-derived mononuclear cells, neonatal human skin fibroblasts, human umbilical vein endothelial cells, human umbilical artery smooth muscle cells, human postnatal skeletal muscle cells, human postnatal adipose cells, human postnatal peripheral blood mononuclear cells, or human cord blood mononuclear cells.

153. The human stem cell of claim **145**, wherein the human stem cell does not comprise exogenous genes encoding one or more of the following: a TERT polypeptide, a SV40 Large T antigen polypeptide, HPV16 E6 polypeptide, a HPV16 E7 polypeptide or a Bmi1 polypeptide.

154. The human stem cell of claim **145**, wherein, compared to a human embryonic stem cell, the human stem cell has a higher level of gene expression in 1 to 1000 genes.

155. The human stem cell of claim **154**, wherein, compared to a human embryonic stem cell, the human stem cell has a higher level of gene expression in 1 to 300 genes.

156. A differentiated cell obtained by differentiating the human stem cell of claim **145**.

157. The differentiated cell of claim **156**, wherein the differentiated cell is a pancreatic beta cell, a neural stem cell, a dopaminergic neuron, an oligodendrocyte, a hepatocyte, or a cardiac muscle cell.

158. A human stem cell generated by a method comprising forcing the expression of an Oct3/4 polypeptide, a Sox2 polypeptide, and a Klf4 polypeptide in human postnatal cells to obtain one or more colonies of cells that have a high nucleus to cytoplasm ratio and are smaller in size than cells surrounding the one or more colonies, and isolating at least one of the one or more colonies.

159. The human stem cell of claim **158**, wherein the human stem cell is pluripotent.

160. The human stem cell of claim **158**, wherein the Oct3/4 polypeptide comprises an amino acid sequence at least 70% identical to SEQ ID NO:7, the Sox2 polypeptide comprises an amino acid sequence at least 70% identical to SEQ ID NO:9, and the Klf4 polypeptide comprises an amino acid sequence at least 70% identical to SEQ ID NO: 11.

161. The human stem cell of claim **160**, wherein the Oct3/4 polypeptide comprises an amino acid sequence at least 85% identical to SEQ ID NO:7, the Sox2 polypeptide comprises an amino acid sequence at least 85% identical to SEQ ID NO:9, and the Klf4 polypeptide comprises an amino acid sequence at least 85% identical to SEQ ID NO: 11.

162. The human stem cell of claim **158**, wherein the human stem cell does not comprise an exogenous gene capable of inducing cancer.

163. The human stem cell of claim **164**, wherein the method does not comprise forcing expression of an exogenous gene encoding a c-Myc polypeptide.

164. The human stem cell of claim **164**, wherein the method does not comprise forcing expression of a c-Myc polypeptide.

165. The human stem cell of claim **158**, wherein the method further comprises forcing expression of a c-Myc polypeptide.

166. A purified population of human stem cells comprising the human stem cell of claim **158**.

167. A composition comprising the human stem cell of claim **158** and a cryopreservation medium

168. The human stem cell of claim **158**, wherein the population cells was prepared from a composition of cells that had been stored frozen and then thawed before the preparation.

169. A method for generating a human stem cell, comprising forcing expression of polypeptides in human postnatal cells, wherein the polypeptides comprise two or more of an Oct3/4 polypeptide, a Sox2 polypeptide, a Klf4 polypeptide, and a c-Myc polypeptide.

170. The method of claim **169**, wherein the method does not comprise forcing expression of a c-Myc polypeptide.

171. The method of claim **169**, wherein the method comprises forcing expression of a c-Myc polypeptide.

172. The method of claim **169**, comprising forcing expression of three or more of the polypeptides in human postnatal cells.

173. The method of claim **172**, comprising forcing expression of an Oct 3/4 polypeptide, a Sox2 polypeptide, and a Klf4 polypeptide.

174. The method of claim **172**, further comprising contacting the human postnatal cells with a histone deacetylase inhibitor.

175. The method of claims **172**, wherein the human postnatal cells are from an adult human.

176. The method of claims **172**, wherein the human postnatal cells comprise adult human bone marrow-derived mononuclear cells, neonatal human skin fibroblasts, umbilical vein endothelial cells, umbilical artery smooth muscle cells, postnatal skeletal muscle cells, postnatal adipose cells, postnatal peripheral blood mononuclear cells, cord blood mononuclear cells, or placental cells.

177. The method of claims **172**, wherein forcing the expression of the Oct3/4, Sox2, and Klf4 polypeptides, comprises introducing into the human postnatal cells one or more expression vectors encoding the Oct3/4, Sox2, and Klf4 polypeptides.

178. The method of claim **177**, wherein the one or more expression vectors comprise recombinant retroviruses, lentiviruses, or adenoviruses.

179. The method of claim **177**, wherein the one or more expression vectors are nucleic acid expression vectors.

180. The method of claim **169**, wherein forcing the expression of the Oct3/4, Sox2 polypeptide, and Klf4 polypeptides comprises contacting a human postnatal cell population with at least one of:

(i) a purified polypeptide comprising the amino acid sequence of a protein transduction domain and an Oct3/4 polypeptide;

(ii) a carrier reagent and a purified Oct3/4 polypeptide;

(iii) a purified polypeptide comprising the amino acid sequence of a protein transduction and a Sox2 polypeptide;

(iv) a carrier reagent and a purified Sox2 polypeptide;

(v) a purified polypeptide comprising the amino acid sequence of a protein transduction domain and a Klf4 polypeptide;

(vi) a carrier reagent and a purified Klf4 polypeptide;

(vii) a purified polypeptide comprising the amino acid sequence of a protein transduction domain and a c-Myc polypeptide; or

(viii) any combination of (i) to (vii).

181. A method for generating an autologous stem cell from a human subject, comprising forcing expression of an Oct3/4 polypeptide, a Sox2 polypeptide, and a Klf4 polypeptide in a cultured population of non-embryonic postnatal cells from the human subject.

182. The method of claim **181**, wherein the stem cell is capable of forming a teratoma.

183. The method of claim **181**, wherein the stem cell is pluripotent.

184. The method of claims **181**, wherein the human postnatal cells have been passaged four or fewer times after preparation from a biological sample.

185. The method of claim **181**, wherein the human postnatal cells are cultured in the presence of a serum concentration of 5% or less prior to the forced expression

186. The method of claim **181**, wherein the human postnatal cells are cultured in the presence of bFGF, FGF-2, PDGF,

EGF, IGF, insulin, TGFb-1, activin A, Noggin, BDNF, NGF, NT-1, NT-2, NT-3 or FGF-growth factor family member prior to the forced expression.

187. The method of claim **181**, further comprising isolating, after the forced expression step, one or more colonies of cells smaller in size than surrounding cells, and identifying at least one of the one or more colonies that expresses alkaline phosphatase, nanog, TDGF1, Dnmt3b, FoxD3, GDF3, CYP26A1, TERT, and zfp4.

188. A method for performing cell transplantation in a subject in need thereof, comprising:

(i) identifying a donor that is immunocompatible with the subject;

(ii) generating an induced pluripotent stem cell line from postnatal cells of the healthy donor; and

(iii) transplanting one or more cells differentiated from the induced pluripotent stem cell line into the subject.

189. The method of claim **188**, wherein the induced pluripotent stem cell line is induced from a mononuclear blood cell.

190. A method for identifying an agent that stimulates pluripotency or multipotency in a human somatic cell comprising:

(i) providing first and second cultured human somatic cells;

(ii) contacting the first cultured human somatic cell with a test agent;

(iii) contacting the second cultured human somatic cell with a negative control agent;

(iv) determining expression levels of an embryonic stem cell marker gene in the contacted first and second cultured cells; and

comparing the expression levels determined in step (iii) and indicating that the test agent stimulates pluripotency or multipotency if the embryonic stem cell marker gene expression level in the contacted first cultured cell is greater than that determined in the contacted second cultured cell, and indicating that the test agent fails to stimulate multipotency or pluripotency if the expression level of the embryonic stem cell marker gene in the contacted first cultured cell is the same or less than that determined in the contacted second cultured cell, wherein determining the expression levels of the embryonic stem cell marker gene comprises determining the expression levels of Tert or Cyp26A1.

191. The method of claim **190**, wherein the test agent comprises one or more nucleic acids.

192. The method of claim **191**, wherein the one or more nucleic acids comprises an RNAi, an RNAa, or an antisense oligonucleotide.

193. The method of claim **190**, wherein the test agent comprises a small molecule compound.

194. A composition comprising at least one of:

(i) a purified polypeptide comprising the amino acid sequence of a protein transduction domain and an Oct3/4 polypeptide;

(ii) a carrier reagent and a purified Oct3/4 polypeptide;

(iii) a purified polypeptide comprising the amino acid sequence of a protein transduction and a Sox2 polypeptide;

(iv) a carrier reagent and a purified Sox2 polypeptide;

(v) a purified polypeptide comprising the amino acid sequence of a protein transduction domain and a Klf4 polypeptide;

(vi) a carrier reagent and a purified Klf4 polypeptide;

(vii) a purified polypeptide comprising the amino acid sequence of a protein transduction domain and a c-Myc polypeptide;

(viii) a carrier reagent and a purified c-Myc; or

(ix) any combination of (i) to (viii)

195. The composition of claim **194**, comprising at least two of: (i) to (viii).

* * * * *

专利名称(译)	多能/多能细胞和方法		
公开(公告)号	US20090191159A1	公开(公告)日	2009-07-30
申请号	US12/157967	申请日	2008-06-13
[标]申请(专利权)人(译)	SAKURADA弘 MASAKI HIDEKI 石川TETABUYA 高桥俊一		
申请(专利权)人(译)	SAKURADA弘 MASAKI HIDEKI 石川TETSUYA 高桥俊一		
当前申请(专利权)人(译)	SAKURADA弘 MASAKI HIDEKI 石川TETSUYA 高桥俊一		
[标]发明人	SAKURADA KAZUHIRO MASAKI HIDEKI ISHIKAWA TETSUYA TAKAHASHI SHUNICHI		
发明人	SAKURADA, KAZUHIRO MASAKI, HIDEKI ISHIKAWA, TETSUYA TAKAHASHI, SHUNICHI		
IPC分类号	A61K45/00 C12N5/08 C12Q1/68 G01N33/53 A61P25/28 A61P3/10 C12N5/07 C12N5/0735 C12N5/074 C12N5/0775 C12N5/0789 C12N15/09 C12N15/85		
CPC分类号	C12N5/0696 C12N2501/602 C12N2501/603 C12N15/85 C12N2501/606 C12N2510/00 C12N2799/027 C12N2501/604 A61P3/10 A61P25/28 C12N5/0606 C12N5/0607 C12N5/10		
优先权	2007159382 2007-06-15 JP PCT/EP2007/010019 2007-11-20 WO 61/040646 2008-03-28 US		
其他公开文献	US8211697		
外部链接	Espacenet USPTO		

摘要(译)

本文描述了多能干细胞，例如人和其他哺乳动物多能干细胞，以及相关方法。

Fig. 1


100
Collection of Cells
(from a donor or third party)
140
Storage
110
Induction
(e.g., by forced expression of Oct3/4, Sox2, Klf4, & c-Myc)
120
Identification
of Induced Multipotent or Pluripotent Stem Cells
130
Isolation
of Induced Multipotent or Pluripotent Stem Cells
140
Storage
150
Therapeutics/
Other Uses